activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	177483	CHEMBL760350	Inhibition of PKBbeta	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ncc(C(F)(F)F)cc1Cl		CHEMBL111620	=	Activity	%	69.0	CHEMBL2431	Homo sapiens	Activity	%	69.0
	177483	CHEMBL760350	Inhibition of PKBbeta	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ncc(C(F)(F)F)cc1Cl		CHEMBL111620	=	Activity	%	69.0	CHEMBL2431	Homo sapiens	Activity	%	69.0
	178796	CHEMBL760350	Inhibition of PKBbeta	B	COCCCn1cc(C2=C(c3ccccc3O)C(=O)NC2=O)c2cccnc21		CHEMBL109944	=	Activity	%	82.0	CHEMBL2431	Homo sapiens	Activity	%	82.0
	182543	CHEMBL760350	Inhibition of PKBbeta	B	COc1ccccc1C1=C(c2cn(CCCNC(=O)OC(C)(C)C)c3ncccc23)C(=O)NC1=O		CHEMBL109981	=	Activity	%	99.0	CHEMBL2431	Homo sapiens	Activity	%	99.0
	915774	CHEMBL768271	Inhibition of Protein kinase B beta at 10 uM	B	O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCn1cc2c2cccnc21		CHEMBL340776	=	Activity	%	93.0	CHEMBL2431	Homo sapiens	Activity	%	93.0
	931235	CHEMBL768271	Inhibition of Protein kinase B beta at 10 uM	B	O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCOCCn1cc2c2cccnc21		CHEMBL337642	=	Activity	%	97.0	CHEMBL2431	Homo sapiens	Activity	%	97.0
	1034888	CHEMBL768272	Inhibition of Protein kinase B,beta at 10 uM	B	COc1ccc(C2=C(Nc3cccc(Cl)c3)C(=O)NC2=O)cc1		CHEMBL158208	=	Inhibition	%	7.0	CHEMBL2431	Homo sapiens	Inhibition	%	7.0
	1036283	CHEMBL768272	Inhibition of Protein kinase B,beta at 10 uM	B	O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1ccc(O)c(Cl)c1		CHEMBL322970	=	Inhibition	%	5.0	CHEMBL2431	Homo sapiens	Inhibition	%	5.0
	1048349	CHEMBL768272	Inhibition of Protein kinase B,beta at 10 uM	B	COc1ccccc1C1=C(N2CCc3ccccc32)C(=O)NC1=O		CHEMBL160585	=	Inhibition	%	3.0	CHEMBL2431	Homo sapiens	Inhibition	%	3.0
	1055595	CHEMBL768272	Inhibition of Protein kinase B,beta at 10 uM	B	O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160586	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	Inhibition	%	0.0
	1058281	CHEMBL768272	Inhibition of Protein kinase B,beta at 10 uM	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156379	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	Inhibition	%	0.0
	1421464	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4nc3-c3ccccc3)cc2)CC1		CHEMBL260397	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1421467	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	>	IC50	nM	2200.0	CHEMBL2431	Homo sapiens	IC50	nM	2200.0
	1421470	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	Cc1nc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)[nH]c1=O		CHEMBL178397	>	IC50	nM	20000.0	CHEMBL2431	Homo sapiens	IC50	nM	20000.0
	1421473	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	CC(C)Cc1nc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(O)nc5ccccc54)CC3)cc2)nc1O		CHEMBL178468	>	IC50	nM	20000.0	CHEMBL2431	Homo sapiens	IC50	nM	20000.0
	1421869	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4cc3-c3ccccc3)cc2)CC1		CHEMBL359864	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1421872	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3cc4ccccc4nc3-c3ccccc3)cc2)CC1		CHEMBL178349	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1421875	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	N#Cc1cnc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)c1		CHEMBL255212	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1421878	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	N#Cc1cnc(-c2ccc(CNCc3ccc(-c4csnn4)cc3)cc2)c(-c2ccccc2)c1		CHEMBL360333	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1421881	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	N#Cc1cnc(-c2ccc(CN3CCC(c4nc5cc(F)ccc5[nH]4)CC3)cc2)c(-c2ccccc2)c1		CHEMBL368010	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1421887	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	Cc1ccc2[nH]c(C3CCN(Cc4ccc(-c5ncc(C#N)cc5-c5ccccc5)cc4)CC3)nc2c1		CHEMBL181927	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1421992	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	N#Cc1cnc(-c2ccc(CN3CCC(c4nc5ccccc5[nH]4)CC3)cc2)c(-c2ccccc2)c1		CHEMBL369094	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1421995	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	N#Cc1cnc(-c2ccc(CN3CCC(n4cnc5ccccc54)CC3)cc2)c(-c2ccccc2)c1		CHEMBL361391	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1421998	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	Cc1nc2ccccc2n1C1CCN(Cc2ccc(-c3ncc(C#N)cc3-c3ccccc3)cc2)CC1		CHEMBL425338	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1422001	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3ncc(-c4nnn[nH]4)cc3-c3ccccc3)cc2)CC1		CHEMBL270847	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1422004	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	c1ccc(-c2cc(-c3nn[nH]n3)cnc2-c2ccc(CNCc3ccc(-c4csnn4)cc3)cc2)cc1		CHEMBL425155	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1422007	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	Fc1ccc2[nH]c(C3CCN(Cc4ccc(-c5ncc(-c6nn[nH]n6)cc5-c5ccccc5)cc4)CC3)nc2c1		CHEMBL181730	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1422010	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	Cc1ccc2[nH]c(C3CCN(Cc4ccc(-c5ncc(-c6nn[nH]n6)cc5-c5ccccc5)cc4)CC3)nc2c1		CHEMBL367601	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1422402	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	c1ccc(-c2cc(-c3nn[nH]n3)cnc2-c2ccc(CN3CCC(c4nc5ccccc5[nH]4)CC3)cc2)cc1		CHEMBL178872	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1422405	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	c1ccc(-c2cc(-c3nn[nH]n3)cnc2-c2ccc(CN3CCC(n4cnc5ccccc54)CC3)cc2)cc1		CHEMBL178445	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1422411	CHEMBL832703	Inhibitory concentration against Akt3 kinase	B	Cc1nc2ccccc2n1C1CCN(Cc2ccc(-c3ncc(-c4nn[nH]n4)cc3-c3ccccc3)cc2)CC1		CHEMBL369532	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1429966	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	CC(C)(N)c1ccc(-c2nc3ccccc3nc2-c2ccccc2)cc1		CHEMBL362455	=	IC50	nM	23000.0	CHEMBL2431	Homo sapiens	IC50	nM	23000.0
	1429969	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4nc3-c3ccccc3)cc2)CC1		CHEMBL260397	=	IC50	nM	2090.0	CHEMBL2431	Homo sapiens	IC50	nM	2090.0
	1429972	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	O=c1cnc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)[nH]1		CHEMBL440560	=	IC50	nM	15700.0	CHEMBL2431	Homo sapiens	IC50	nM	15700.0
	1430076	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	O=c1cnc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)[nH]1		CHEMBL577792	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1430080	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	Cc1nc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)[nH]c1=O		CHEMBL178397	=	IC50	nM	24000.0	CHEMBL2431	Homo sapiens	IC50	nM	24000.0
	1430083	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	Cc1nc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)[nH]c1=O		CHEMBL572629	=	IC50	nM	1179.0	CHEMBL2431	Homo sapiens	IC50	nM	1179.0
	1430086	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	Oc1nc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(O)nc5ccccc54)CC3)cc2)nc1Cc1ccccc1		CHEMBL180580	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1430089	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	O=c1[nH]c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)nc1Cc1ccccc1		CHEMBL3143722	=	IC50	nM	1755.0	CHEMBL2431	Homo sapiens	IC50	nM	1755.0
	1430092	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	O=c1[nH]c(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)nc1Cc1ccc(O)cc1		CHEMBL178133	=	IC50	nM	45270.0	CHEMBL2431	Homo sapiens	IC50	nM	45270.0
	1430095	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	O=c1[nH]c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)nc1Cc1ccc(O)cc1		CHEMBL3143723	=	IC50	nM	5407.0	CHEMBL2431	Homo sapiens	IC50	nM	5407.0
	1430098	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	CCC(C)c1nc(-c2ccc(CN3CCC(n4c(O)nc5ccccc54)CC3)cc2)c(-c2ccccc2)nc1O		CHEMBL428861	>	IC50	nM	50000.0	CHEMBL2431	Homo sapiens	IC50	nM	50000.0
	1430523	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	CCC(C)c1nc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)[nH]c1=O		CHEMBL3143721	=	IC50	nM	4517.0	CHEMBL2431	Homo sapiens	IC50	nM	4517.0
	1430526	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	CC(C)Cc1nc(-c2ccc(CN3CCC(n4c(O)nc5ccccc54)CC3)cc2)c(-c2ccccc2)nc1O		CHEMBL362016	=	IC50	nM	18000.0	CHEMBL2431	Homo sapiens	IC50	nM	18000.0
	1430529	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	CC(C)Cc1nc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(O)nc5ccccc54)CC3)cc2)nc1O		CHEMBL178468	=	IC50	nM	325.0	CHEMBL2431	Homo sapiens	IC50	nM	325.0
	1430533	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	O=C(O)c1ccc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)nc2c1		CHEMBL272292	=	IC50	nM	281.0	CHEMBL2431	Homo sapiens	IC50	nM	281.0
	1430637	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	O=C(O)c1ccc2nc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2c1		CHEMBL273160	=	IC50	nM	388.0	CHEMBL2431	Homo sapiens	IC50	nM	388.0
	1430640	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(-c5nn[nH]n5)cc4nc3-c3ccccc3)cc2)CC1		CHEMBL271091	=	IC50	nM	65.0	CHEMBL2431	Homo sapiens	IC50	nM	65.0
	1430643	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc(-c5nn[nH]n5)ccc4nc3-c3ccccc3)cc2)CC1		CHEMBL408151	=	IC50	nM	144.0	CHEMBL2431	Homo sapiens	IC50	nM	144.0
	1430646	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	Cn1nnc(-c2ccc3nc(-c4ccc(CN5CCC(n6c(O)nc7ccccc76)CC5)cc4)c(-c4ccccc4)nc3c2)n1		CHEMBL181419	=	IC50	nM	1877.0	CHEMBL2431	Homo sapiens	IC50	nM	1877.0
	1430649	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	Cn1nnc(-c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(n6c(O)nc7ccccc76)CC5)cc4)nc3c2)n1		CHEMBL180058	=	IC50	nM	332.0	CHEMBL2431	Homo sapiens	IC50	nM	332.0
	1430652	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5cn[nH]c5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL180231	=	IC50	nM	300.0	CHEMBL2431	Homo sapiens	IC50	nM	300.0
	1430655	CHEMBL876978	Inhibitory concentration against human Protein kinase B, Akt2	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	210.0	CHEMBL2431	Homo sapiens	IC50	nM	210.0
	1490917	CHEMBL828495	Inhibition of PKB beta	B	OCCCNc1cc(-c2ncnc(Nc3cccc(Cl)c3)n2)ccn1		CHEMBL191336	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	1697135	CHEMBL869529	Inhibition of Akt2 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL383541	=	IC50	nM	257.0	CHEMBL2431	Homo sapiens	IC50	nM	257.0
	1697136	CHEMBL869529	Inhibition of Akt2 using 10 uM ATP	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	6.5	CHEMBL2431	Homo sapiens	IC50	nM	6.5
	1704934	CHEMBL862613	Inhibition of Akt2 at 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL383541	=	IC50	nM	257.0	CHEMBL2431	Homo sapiens	IC50	nM	257.0
	1704951	CHEMBL862613	Inhibition of Akt2 at 10 uM ATP	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	6.5	CHEMBL2431	Homo sapiens	IC50	nM	6.5
	1704952	CHEMBL862613	Inhibition of Akt2 at 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	IC50	nM	6.8	CHEMBL2431	Homo sapiens	IC50	nM	6.8
	1722936	CHEMBL860187	Inhibition of AKT2	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	>	Ki	nM	8400.0	CHEMBL2431	Homo sapiens	Ki	nM	8400.0
	1722937	CHEMBL860187	Inhibition of AKT2	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	>	Ki	nM	8400.0	CHEMBL2431	Homo sapiens	Ki	nM	8400.0
	1722938	CHEMBL860187	Inhibition of AKT2	B	CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1		CHEMBL210032	>	Ki	nM	8400.0	CHEMBL2431	Homo sapiens	Ki	nM	8400.0
	1722939	CHEMBL860187	Inhibition of AKT2	B	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	>	Ki	nM	8400.0	CHEMBL2431	Homo sapiens	Ki	nM	8400.0
	1722940	CHEMBL860187	Inhibition of AKT2	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	>	Ki	nM	8400.0	CHEMBL2431	Homo sapiens	Ki	nM	8400.0
	1722941	CHEMBL860187	Inhibition of AKT2	B	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	>	Ki	nM	8400.0	CHEMBL2431	Homo sapiens	Ki	nM	8400.0
	1726438	CHEMBL861321	Inhibition of Akt2 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	IC50	nM	6.8	CHEMBL2431	Homo sapiens	IC50	nM	6.8
	1726439	CHEMBL861321	Inhibition of Akt2 at 5 uM ATP	B	Nc1cc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc2cn1		CHEMBL210390	=	IC50	nM	21.0	CHEMBL2431	Homo sapiens	IC50	nM	21.0
Not Determined	1726440	CHEMBL861321	Inhibition of Akt2 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnc(F)cc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL210246		IC50			CHEMBL2431	Homo sapiens	IC50		
	1726441	CHEMBL861321	Inhibition of Akt2 at 5 uM ATP	B	C#Cc1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2cnccc2c1		CHEMBL207544	=	IC50	nM	5.0	CHEMBL2431	Homo sapiens	IC50	nM	5.0
	1726442	CHEMBL861321	Inhibition of Akt2 at 5 uM ATP	B	N[C@H](COc1cnc(Cl)c(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL378963	=	IC50	nM	5.0	CHEMBL2431	Homo sapiens	IC50	nM	5.0
	1734130	CHEMBL854408	Residual activity at human PKBbeta at 10 uM in presence of 10 uM ATP relative to control	B	O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1		CHEMBL379156	=	Activity	%	103.0	CHEMBL2431	Homo sapiens	Activity	%	103.0
	1744521	CHEMBL865386	Inhibition of AKT2	B	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	>	Ki	nM	8400.0	CHEMBL2431	Homo sapiens	Ki	uM	8.4
	1755318	CHEMBL868046	Inhibition of AKT2	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	9.0	CHEMBL2431	Homo sapiens	IC50	nM	9.0
	1755338	CHEMBL868046	Inhibition of AKT2	B	CNc1nccc(-c2ccc(C(=O)N[C@H](CN)Cc3ccc(Cl)cc3Cl)s2)n1		CHEMBL213618	=	IC50	nM	23.0	CHEMBL2431	Homo sapiens	IC50	nM	23.0
	1769418	CHEMBL910934	Inhibition of PKBbeta	B	C[C@@H]1C[C@H]2CN1CCn1nc3c(cccc3c1O)-c1nc3c(cccc3nc1O)O2		CHEMBL215803	>	IC50	nM	1000.0	CHEMBL2431	Homo sapiens	IC50	uM	1.0
	1790011	CHEMBL854679	Percentage activity of human PKB beta in the presence of 10uM of compound and 10uM of ATP in comparison with control	B	O=C(NCc1ccc(S(=O)(=O)N2CCC(n3nnc4ccccc43)CC2)s1)c1ccc(Cl)cc1		CHEMBL383955	=	Activity	%	118.0	CHEMBL2431	Homo sapiens	Activity	%	118.0
	1790329	CHEMBL873769	Percent residual activity, relative to control, of PKB beta at 1uM concentration of inhibitor in presence of 50uM ATP	B	N=C(N)NCCC[C@@H](NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)NC(=O)CCCCCNCCNS(=O)(=O)c1cccc2cnccc12		CHEMBL413460	=	Activity	%	3.0	CHEMBL2431	Homo sapiens	Activity	%	3.0
	1790383	CHEMBL873769	Percent residual activity, relative to control, of PKB beta at 1uM concentration of inhibitor in presence of 50uM ATP	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL279185	=	Activity	%	3.0	CHEMBL2431	Homo sapiens	Activity	%	3.0
	1824474	CHEMBL913836	Inhibition of Akt2	B	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	>	Ki	nM	10000.0	CHEMBL2431	Homo sapiens	Ki	uM	10.0
	1824582	CHEMBL913836	Inhibition of Akt2	B	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	=	Ki	nM	3970.0	CHEMBL2431	Homo sapiens	Ki	uM	3.97
	1824691	CHEMBL913836	Inhibition of Akt2	B	N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2		CHEMBL373598	=	Ki	nM	1120.0	CHEMBL2431	Homo sapiens	Ki	uM	1.12
	1860901	CHEMBL919346	Inhibition of PKBbeta by radiometric filter binding assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	IC50	nM	590.0	CHEMBL2431	Homo sapiens	IC50	uM	0.59
	1860928	CHEMBL919346	Inhibition of PKBbeta by radiometric filter binding assay	B	Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1		CHEMBL228133	=	IC50	nM	20.0	CHEMBL2431	Homo sapiens	IC50	uM	0.02
	1860929	CHEMBL919346	Inhibition of PKBbeta by radiometric filter binding assay	B	CNC(c1ccc(Cl)cc1)c1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL228042	=	IC50	nM	10.0	CHEMBL2431	Homo sapiens	IC50	uM	0.01
	1860930	CHEMBL919346	Inhibition of PKBbeta by radiometric filter binding assay	B	NC(c1ccc(Cl)cc1)c1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL226712	=	IC50	nM	9.0	CHEMBL2431	Homo sapiens	IC50	uM	0.009
	1860931	CHEMBL919346	Inhibition of PKBbeta by radiometric filter binding assay	B	NC(Cc1ccccc1)c1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL227605	=	IC50	nM	430.0	CHEMBL2431	Homo sapiens	IC50	uM	0.43
	1860932	CHEMBL919346	Inhibition of PKBbeta by radiometric filter binding assay	B	NC(c1ccccc1)c1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL389176	=	IC50	nM	400.0	CHEMBL2431	Homo sapiens	IC50	uM	0.4
	1860933	CHEMBL919346	Inhibition of PKBbeta by radiometric filter binding assay	B	NCCc1cccc(-c2ncnc3[nH]cnc23)c1		CHEMBL227998	=	IC50	nM	3200.0	CHEMBL2431	Homo sapiens	IC50	uM	3.2
	1860934	CHEMBL919346	Inhibition of PKBbeta by radiometric filter binding assay	B	NCCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL227727	=	IC50	nM	9500.0	CHEMBL2431	Homo sapiens	IC50	uM	9.5
	1860935	CHEMBL919346	Inhibition of PKBbeta by radiometric filter binding assay	B	CNCc1cccc(-c2ncnc3[nH]cnc23)c1		CHEMBL375509	=	IC50	nM	1600.0	CHEMBL2431	Homo sapiens	IC50	uM	1.6
	1860936	CHEMBL919346	Inhibition of PKBbeta by radiometric filter binding assay	B	CNCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL376388	=	IC50	nM	6900.0	CHEMBL2431	Homo sapiens	IC50	uM	6.9
	1860937	CHEMBL919346	Inhibition of PKBbeta by radiometric filter binding assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	>	IC50	nM	100000.0	CHEMBL2431	Homo sapiens	IC50	uM	100.0
	1860938	CHEMBL919346	Inhibition of PKBbeta by radiometric filter binding assay	B	O=S(=O)(NCCNCCOCc1ccc(Cl)cc1)c1cccc2cnccc12		CHEMBL227381	=	IC50	nM	260.0	CHEMBL2431	Homo sapiens	IC50	uM	0.26
	1861694	CHEMBL919345	Inhibition of PKBbeta by radiometric filter binding assay	B	NC[C@H](c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL223339	=	IC50	nM	280.0	CHEMBL2431	Homo sapiens	IC50	uM	0.28
	1861696	CHEMBL919345	Inhibition of PKBbeta by radiometric filter binding assay	B	NC[C@@H](c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL227924	=	IC50	nM	34000.0	CHEMBL2431	Homo sapiens	IC50	uM	34.0
	1861697	CHEMBL919345	Inhibition of PKBbeta by radiometric filter binding assay	B	Clc1ccc(C2(c3ccc(-c4cn[nH]c4)cc3)CCNCC2)cc1		CHEMBL428462	=	IC50	nM	18000.0	CHEMBL2431	Homo sapiens	IC50	uM	18.0
	1861698	CHEMBL919345	Inhibition of PKBbeta by radiometric filter binding assay	B	NCC(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL223393	=	IC50	nM	31000.0	CHEMBL2431	Homo sapiens	IC50	uM	31.0
	1861699	CHEMBL919345	Inhibition of PKBbeta by radiometric filter binding assay	B	c1ccc(C2(c3ccc(-c4cn[nH]c4)cc3)CCNCC2)cc1		CHEMBL374742	=	IC50	nM	200.0	CHEMBL2431	Homo sapiens	IC50	uM	0.2
	1861700	CHEMBL919345	Inhibition of PKBbeta by radiometric filter binding assay	B	NCC(c1ccccc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL227029	=	IC50	nM	510.0	CHEMBL2431	Homo sapiens	IC50	uM	0.51
	1861701	CHEMBL919345	Inhibition of PKBbeta by radiometric filter binding assay	B	c1ccc(-c2cn[nH]c2)cc1		CHEMBL390066	=	IC50	nM	135000.0	CHEMBL2431	Homo sapiens	IC50	uM	135.0
	1861702	CHEMBL919345	Inhibition of PKBbeta by radiometric filter binding assay	B	NCCCc1ccc(-c2cn[nH]c2)cc1		CHEMBL226870	=	IC50	nM	3000.0	CHEMBL2431	Homo sapiens	IC50	uM	3.0
	1861703	CHEMBL919345	Inhibition of PKBbeta by radiometric filter binding assay	B	Cc1n[nH]cc1-c1ccc(CCN)cc1		CHEMBL228224	=	IC50	nM	5200.0	CHEMBL2431	Homo sapiens	IC50	uM	5.2
	1861704	CHEMBL919345	Inhibition of PKBbeta by radiometric filter binding assay	B	Cc1[nH]ncc1-c1ccc(CN)cc1		CHEMBL226766	=	IC50	nM	12000.0	CHEMBL2431	Homo sapiens	IC50	uM	12.0
	1861705	CHEMBL919345	Inhibition of PKBbeta by radiometric filter binding assay	B	Cc1n[nH]cc1-c1ccccc1		CHEMBL228114	=	IC50	nM	80000.0	CHEMBL2431	Homo sapiens	IC50	uM	80.0
	1903869	CHEMBL889499	Inhibition of AKT2	B	NC(=O)Nc1ccc2c(c1)/C(=C/c1ccc[nH]1)C(=O)N2		CHEMBL442229	=	IC50	nM	20.0	CHEMBL2431	Homo sapiens	IC50	nM	20.0
	1903871	CHEMBL889499	Inhibition of AKT2	B	C/C(=C1/C(=O)Nc2ccc(NC(N)=O)cc21)c1cc(CNC(=O)CCN2CCCCC2)c[nH]1		CHEMBL228867	=	IC50	nM	3.0	CHEMBL2431	Homo sapiens	IC50	nM	3.0
	1903872	CHEMBL889499	Inhibition of AKT2	B	C/C(=C1/C(=O)Nc2ccc(NC(N)=O)cc21)c1cc(CNC(=O)CO)c[nH]1		CHEMBL388966	=	IC50	nM	10.0	CHEMBL2431	Homo sapiens	IC50	nM	10.0
	1903873	CHEMBL889499	Inhibition of AKT2	B	C/C(=C1/C(=O)Nc2ccc(NC(N)=O)cc21)c1cc(CNC(=O)CN)c[nH]1		CHEMBL228812	=	IC50	nM	5.0	CHEMBL2431	Homo sapiens	IC50	nM	5.0
	1903874	CHEMBL889499	Inhibition of AKT2	B	C/C(=C1/C(=O)Nc2ccc(NC(N)=O)cc21)c1cc(CNC(=O)C2CNCCN2)c[nH]1		CHEMBL228811	=	IC50	nM	5.0	CHEMBL2431	Homo sapiens	IC50	nM	5.0
	1903875	CHEMBL889499	Inhibition of AKT2	B	C/C(=C1/C(=O)Nc2ccc(NC(N)=O)cc21)c1cc(CNC(=O)C2CCN(C)CC2)c[nH]1		CHEMBL228810	=	IC50	nM	4.0	CHEMBL2431	Homo sapiens	IC50	nM	4.0
	1903876	CHEMBL889499	Inhibition of AKT2	B	C/C(=C1/C(=O)Nc2ccc(NC(N)=O)cc21)c1cc(CNC(=O)C2CCNCC2)c[nH]1		CHEMBL228757	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	nM	6.0
	1903877	CHEMBL889499	Inhibition of AKT2	B	C/C(=C1/C(=O)Nc2ccc(NC(N)=O)cc21)c1cc(CNC(=O)c2cccnc2)c[nH]1		CHEMBL388739	=	IC50	nM	10.0	CHEMBL2431	Homo sapiens	IC50	nM	10.0
	1903878	CHEMBL889499	Inhibition of AKT2	B	C/C(=C1/C(=O)Nc2ccc(NC(N)=O)cc21)c1cc(CNC(=O)c2ccncc2)c[nH]1		CHEMBL228756	=	IC50	nM	5.0	CHEMBL2431	Homo sapiens	IC50	nM	5.0
	1903879	CHEMBL889499	Inhibition of AKT2	B	CC(=O)NCc1c[nH]c(/C(C)=C2\C(=O)Nc3ccc(NC(N)=O)cc32)c1		CHEMBL228755	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	nM	8.0
	1903880	CHEMBL889499	Inhibition of AKT2	B	C/C(=C1/C(=O)Nc2ccc(NC(N)=O)cc21)c1cc(CN)c[nH]1		CHEMBL228705	=	IC50	nM	10.0	CHEMBL2431	Homo sapiens	IC50	nM	10.0
	1903881	CHEMBL889499	Inhibition of AKT2	B	C/C(=C1/C(=O)Nc2ccc(NC(N)=O)cc21)c1ccc[nH]1		CHEMBL228654	=	IC50	nM	5.0	CHEMBL2431	Homo sapiens	IC50	nM	5.0
	1903882	CHEMBL889499	Inhibition of AKT2	B	NCc1cccc(-c2c[nH]c(/C=C3\C(=O)Nc4ccc(NC(N)=O)cc43)c2)c1		CHEMBL228652	=	IC50	nM	3.0	CHEMBL2431	Homo sapiens	IC50	nM	3.0
	1903883	CHEMBL889499	Inhibition of AKT2	B	CC(=O)Nc1cccc(-c2c[nH]c(/C=C3\C(=O)Nc4ccc(NC(N)=O)cc43)c2)c1		CHEMBL374611	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	nM	8.0
	1903884	CHEMBL889499	Inhibition of AKT2	B	NC(=O)Nc1ccc2c(c1)/C(=C/c1cc(-c3cccc(C(N)=O)c3)c[nH]1)C(=O)N2		CHEMBL228547	=	IC50	nM	5.0	CHEMBL2431	Homo sapiens	IC50	nM	5.0
	1903885	CHEMBL889499	Inhibition of AKT2	B	Cc1cccc(-c2c[nH]c(/C=C3\C(=O)Nc4ccc(NC(N)=O)cc43)c2)c1		CHEMBL228545	=	IC50	nM	37.0	CHEMBL2431	Homo sapiens	IC50	nM	37.0
	1903886	CHEMBL889499	Inhibition of AKT2	B	NC(=O)Nc1ccc2c(c1)/C(=C/c1cc(-c3cccc(F)c3)c[nH]1)C(=O)N2		CHEMBL437109	=	IC50	nM	51.0	CHEMBL2431	Homo sapiens	IC50	nM	51.0
	1903887	CHEMBL889499	Inhibition of AKT2	B	COc1cccc(-c2c[nH]c(/C=C3\C(=O)Nc4ccc(NC(N)=O)cc43)c2)c1		CHEMBL442227	=	IC50	nM	19.0	CHEMBL2431	Homo sapiens	IC50	nM	19.0
	1903888	CHEMBL889499	Inhibition of AKT2	B	NC(=O)Nc1ccc2c(c1)/C(=C/c1cc(-c3cccc(O)c3)c[nH]1)C(=O)N2		CHEMBL228439	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	nM	6.0
	1903889	CHEMBL889499	Inhibition of AKT2	B	NC(=O)Nc1ccc2c(c1)/C(=C/c1cc(-c3cccc(C(=O)NCCN4CCCCC4)c3)c[nH]1)C(=O)N2		CHEMBL425650	=	IC50	nM	4.0	CHEMBL2431	Homo sapiens	IC50	nM	4.0
	1903890	CHEMBL889499	Inhibition of AKT2	B	CN(C)CCNC(=O)c1cccc(-c2c[nH]c(/C=C3\C(=O)Nc4ccc(NC(N)=O)cc43)c2)c1		CHEMBL228804	=	IC50	nM	4.0	CHEMBL2431	Homo sapiens	IC50	nM	4.0
	1903891	CHEMBL889499	Inhibition of AKT2	B	NC(=O)Nc1ccc2c(c1)/C(=C/c1cc(-c3cccc(C(=O)O)c3)c[nH]1)C(=O)N2		CHEMBL228803	=	IC50	nM	45.0	CHEMBL2431	Homo sapiens	IC50	nM	45.0
	1903892	CHEMBL889499	Inhibition of AKT2	B	NC(=O)Nc1ccc2c(c1)/C(=C/c1cc(-c3cccnc3)c[nH]1)C(=O)N2		CHEMBL375236	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	nM	8.0
	1903893	CHEMBL889499	Inhibition of AKT2	B	NC(=O)Nc1ccc2c(c1)/C(=C/c1cc(-c3ccccc3)c[nH]1)C(=O)N2		CHEMBL228751	=	IC50	nM	21.0	CHEMBL2431	Homo sapiens	IC50	nM	21.0
	1903894	CHEMBL889499	Inhibition of AKT2	B	NC(=O)Nc1ccc2c(c1)/C(=C/c1cc(C(=O)NCCc3ccncc3)c[nH]1)C(=O)N2		CHEMBL228750	=	IC50	nM	17.0	CHEMBL2431	Homo sapiens	IC50	nM	17.0
	1903895	CHEMBL889499	Inhibition of AKT2	B	NC(=O)Nc1ccc2c(c1)/C(=C/c1cc(C(=O)NCCc3cnc[nH]3)c[nH]1)C(=O)N2		CHEMBL228749	=	IC50	nM	14.0	CHEMBL2431	Homo sapiens	IC50	nM	14.0
	1903896	CHEMBL889499	Inhibition of AKT2	B	CN(C)C1CCN(C(=O)c2c[nH]c(/C=C3\C(=O)Nc4ccc(NC(N)=O)cc43)c2)C1		CHEMBL388395	=	IC50	nM	31.0	CHEMBL2431	Homo sapiens	IC50	nM	31.0
	1903897	CHEMBL889499	Inhibition of AKT2	B	NC(=O)Nc1ccc2c(c1)/C(=C/c1cc(C(=O)NCCN3CCOCC3)c[nH]1)C(=O)N2		CHEMBL388184	=	IC50	nM	29.0	CHEMBL2431	Homo sapiens	IC50	nM	29.0
	1903898	CHEMBL889499	Inhibition of AKT2	B	NC(=O)Nc1ccc2c(c1)/C(=C/c1cc(C(=O)NCCN3CCCCC3)c[nH]1)C(=O)N2		CHEMBL228701	=	IC50	nM	11.0	CHEMBL2431	Homo sapiens	IC50	nM	11.0
	1903899	CHEMBL889499	Inhibition of AKT2	B	CN(C)CCNC(=O)c1c[nH]c(/C=C2\C(=O)Nc3ccc(NC(N)=O)cc32)c1		CHEMBL228700	=	IC50	nM	27.0	CHEMBL2431	Homo sapiens	IC50	nM	27.0
	1903900	CHEMBL889499	Inhibition of AKT2	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(NC(N)=O)cc32)c(C)c1CCC(=O)O		CHEMBL228699	=	IC50	nM	57.0	CHEMBL2431	Homo sapiens	IC50	nM	57.0
	1903901	CHEMBL889499	Inhibition of AKT2	B	Cc1c(CCC(=O)O)c[nH]c1/C=C1\C(=O)Nc2ccc(NC(N)=O)cc21		CHEMBL388183	=	IC50	nM	39.0	CHEMBL2431	Homo sapiens	IC50	nM	39.0
	1903902	CHEMBL889499	Inhibition of AKT2	B	Cc1c(C(=O)O)c[nH]c1/C=C1\C(=O)Nc2ccc(NC(N)=O)cc21		CHEMBL228649	=	IC50	nM	9.0	CHEMBL2431	Homo sapiens	IC50	nM	9.0
	1903903	CHEMBL889499	Inhibition of AKT2	B	NC(=O)Nc1ccc2c(c1)/C(=C/c1cc(C(=O)O)c[nH]1)C(=O)N2		CHEMBL228648	=	IC50	nM	9.0	CHEMBL2431	Homo sapiens	IC50	nM	9.0
Not Active	1910495	CHEMBL890528	Inhibition of Akt2	B	CCOC(=O)c1ccc2[nH]c3c(OC)c4[nH]c5ccc(C(=O)OCC)cc5c4cc3c2c1		CHEMBL245030		Activity			CHEMBL2431	Homo sapiens	Activity		
	1981715	CHEMBL899236	Inhibition of PKBbeta assessed as residual activity at 0.01 uM	B	N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H]1C[C@@H](O)[C@H](n2cnc3c(N)ncnc32)C1)C(N)=O		CHEMBL397521	=	Activity	%	74.0	CHEMBL2431	Homo sapiens	Activity	%	74.0
	1981716	CHEMBL899237	Inhibition of PKBbeta assessed as residual activity at 1 uM	B	N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H]1C[C@@H](O)[C@H](n2cnc3c(N)ncnc32)C1)C(N)=O		CHEMBL397521	=	Activity	%	2.0	CHEMBL2431	Homo sapiens	Activity	%	2.0
	2025176	CHEMBL887003	Inhibition of human PKBbeta at 1 uM relative to control	B	CN(C)c1cc2cc(n1)CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CCC2		CHEMBL247067	=	Inhibition	%	118.0	CHEMBL2431	Homo sapiens	Inhibition	%	118.0
	2025420	CHEMBL887003	Inhibition of human PKBbeta at 1 uM relative to control	B	CN(C)c1nc2ccc1CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CC2		CHEMBL1162963	=	Inhibition	%	86.0	CHEMBL2431	Homo sapiens	Inhibition	%	86.0
	2025421	CHEMBL887003	Inhibition of human PKBbeta at 1 uM relative to control	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1ccc(c(N3CCCC3)n1)CCCn1cc2c2ccccc21		CHEMBL396327	=	Inhibition	%	102.0	CHEMBL2431	Homo sapiens	Inhibition	%	102.0
	2025422	CHEMBL887003	Inhibition of human PKBbeta at 1 uM relative to control	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1cc(nc(N3CCCC3)c1)CCCn1cc2c2ccccc21		CHEMBL397771	=	Inhibition	%	104.0	CHEMBL2431	Homo sapiens	Inhibition	%	104.0
	2051583	CHEMBL942724	Inhibition of AKT2	B	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	=	Ki	nM	4800.0	CHEMBL2431	Homo sapiens	Ki	uM	4.8
	2080233	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCC(N)=O)cc3)nc2n1		CHEMBL276130	=	IC50	nM	1299.0	CHEMBL2431	Homo sapiens	IC50	nM	1299.0
	2080234	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCC(=O)c4ccccc4N)cc3)nc2n1		CHEMBL252456	=	IC50	nM	90.0	CHEMBL2431	Homo sapiens	IC50	nM	90.0
	2080235	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4nnc(N)s4)cc3)nc2n1		CHEMBL252455	=	IC50	nM	529.0	CHEMBL2431	Homo sapiens	IC50	nM	529.0
	2080236	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4n[nH]c(-c5ccccc5)n4)cc3)nc2n1		CHEMBL252261	=	IC50	nM	494.0	CHEMBL2431	Homo sapiens	IC50	nM	494.0
	2080237	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4n[nH]c(C)n4)cc3)nc2n1		CHEMBL403355	=	IC50	nM	1792.0	CHEMBL2431	Homo sapiens	IC50	nM	1792.0
	2080238	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN(C)CCc4cn[nH]c4)cc3)nc2n1		CHEMBL252260	=	IC50	nM	17470.0	CHEMBL2431	Homo sapiens	IC50	nM	17470.0
	2080239	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCCn4ccnc4)cc3)nc2n1		CHEMBL252259	=	IC50	nM	1514.0	CHEMBL2431	Homo sapiens	IC50	nM	1514.0
	2080240	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4cccnc4)cc3)nc2n1		CHEMBL403354	=	IC50	nM	1160.0	CHEMBL2431	Homo sapiens	IC50	nM	1160.0
	2080241	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4nccs4)cc3)nc2n1		CHEMBL252056	=	IC50	nM	1381.0	CHEMBL2431	Homo sapiens	IC50	nM	1381.0
	2080242	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4nc[nH]n4)cc3)nc2n1		CHEMBL252055	=	IC50	nM	1709.0	CHEMBL2431	Homo sapiens	IC50	nM	1709.0
	2080243	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4c[nH]cn4)cc3)nc2n1		CHEMBL252054	=	IC50	nM	1242.0	CHEMBL2431	Homo sapiens	IC50	nM	1242.0
	2080244	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCCN4CCN(C)CC4)cc3)nc2n1		CHEMBL251860	=	IC50	nM	8923.0	CHEMBL2431	Homo sapiens	IC50	nM	8923.0
	2080254	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL254099	=	IC50	nM	26.0	CHEMBL2431	Homo sapiens	IC50	nM	26.0
	2080255	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5cc(-c6ccncc6)[nH]n5)CC4)cc3)nc2n1		CHEMBL404554	=	IC50	nM	57.0	CHEMBL2431	Homo sapiens	IC50	nM	57.0
	2080256	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nc(-c6cccnc6)no5)CC4)cc3)nc2n1		CHEMBL404553	=	IC50	nM	1304.0	CHEMBL2431	Homo sapiens	IC50	nM	1304.0
	2080257	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(C(=O)Nc5ccncc5)CC4)cc3)nc2n1		CHEMBL252856	=	IC50	nM	301.0	CHEMBL2431	Homo sapiens	IC50	nM	301.0
	2080258	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(N)s5)CC4)cc3)nc2n1		CHEMBL403356	=	IC50	nM	267.0	CHEMBL2431	Homo sapiens	IC50	nM	267.0
	2080259	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(NC(=O)CNC(C)=O)CC4)cc3)nc2n1		CHEMBL252654	=	IC50	nM	5127.0	CHEMBL2431	Homo sapiens	IC50	nM	5127.0
	2080260	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(C(=O)NCCC(N)=O)CC4)cc3)nc2n1		CHEMBL252653	=	IC50	nM	2106.0	CHEMBL2431	Homo sapiens	IC50	nM	2106.0
	2080261	CHEMBL928490	Inhibition of Akt2	B	CCNC(=O)NC1CCN(Cc2ccc(-c3nc4nc(SC)ncc4cc3-c3ccccc3)cc2)CC1		CHEMBL252652	=	IC50	nM	1909.0	CHEMBL2431	Homo sapiens	IC50	nM	1909.0
	2080262	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(C(N)=O)CC4)cc3)nc2n1		CHEMBL252457	=	IC50	nM	928.0	CHEMBL2431	Homo sapiens	IC50	nM	928.0
	2080268	CHEMBL928490	Inhibition of Akt2	B	CNc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL252857	=	IC50	nM	94.4	CHEMBL2431	Homo sapiens	IC50	nM	94.4
	2080269	CHEMBL928490	Inhibition of Akt2	B	NC(=O)c1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL404556	=	IC50	nM	35.0	CHEMBL2431	Homo sapiens	IC50	nM	35.0
	2080270	CHEMBL928490	Inhibition of Akt2	B	N#Cc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL404555	=	IC50	nM	59.0	CHEMBL2431	Homo sapiens	IC50	nM	59.0
	2080271	CHEMBL928490	Inhibition of Akt2	B	COc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL404347	=	IC50	nM	107.2	CHEMBL2431	Homo sapiens	IC50	nM	107.2
	2080272	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(C(N)=O)CC4)cc3)nc2n1		CHEMBL252457	=	IC50	nM	9259.0	CHEMBL2431	Homo sapiens	IC50	nM	9259.0
	2080285	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	CNc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL252857	=	IC50	nM	899.0	CHEMBL2431	Homo sapiens	IC50	nM	899.0
	2080286	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	NC(=O)c1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL404556	=	IC50	nM	3706.0	CHEMBL2431	Homo sapiens	IC50	nM	3706.0
	2080287	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	N#Cc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL404555	=	IC50	nM	586.0	CHEMBL2431	Homo sapiens	IC50	nM	586.0
	2080288	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	COc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL404347	=	IC50	nM	2295.0	CHEMBL2431	Homo sapiens	IC50	nM	2295.0
	2080289	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL254099	=	IC50	nM	589.0	CHEMBL2431	Homo sapiens	IC50	nM	589.0
	2080290	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5cc(-c6ccncc6)[nH]n5)CC4)cc3)nc2n1		CHEMBL404554	=	IC50	nM	635.0	CHEMBL2431	Homo sapiens	IC50	nM	635.0
Not Determined	2080291	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nc(-c6cccnc6)no5)CC4)cc3)nc2n1		CHEMBL404553		IC50			CHEMBL2431	Homo sapiens	IC50		
	2080292	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(C(=O)Nc5ccncc5)CC4)cc3)nc2n1		CHEMBL252856	=	IC50	nM	1131.0	CHEMBL2431	Homo sapiens	IC50	nM	1131.0
	2080293	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(N)s5)CC4)cc3)nc2n1		CHEMBL403356	=	IC50	nM	1572.0	CHEMBL2431	Homo sapiens	IC50	nM	1572.0
Not Determined	2080294	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(NC(=O)CNC(C)=O)CC4)cc3)nc2n1		CHEMBL252654		IC50			CHEMBL2431	Homo sapiens	IC50		
Not Determined	2080295	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(C(=O)NCCC(N)=O)CC4)cc3)nc2n1		CHEMBL252653		IC50			CHEMBL2431	Homo sapiens	IC50		
	2080296	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	CCNC(=O)NC1CCN(Cc2ccc(-c3nc4nc(SC)ncc4cc3-c3ccccc3)cc2)CC1		CHEMBL252652	=	IC50	nM	5296.0	CHEMBL2431	Homo sapiens	IC50	nM	5296.0
	2080302	CHEMBL928490	Inhibition of Akt2	B	Nc1ncnc2nc(-c3ccc(CN4CCC(c5nc6ccc(F)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253457	=	IC50	nM	239.0	CHEMBL2431	Homo sapiens	IC50	nM	239.0
	2080305	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	Nc1ncnc2nc(-c3ccc(CN4CCC(c5nc6ccc(F)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253457	=	IC50	nM	1811.0	CHEMBL2431	Homo sapiens	IC50	nM	1811.0
	2080307	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253458	=	IC50	nM	468.0	CHEMBL2431	Homo sapiens	IC50	nM	468.0
	2080308	CHEMBL928490	Inhibition of Akt2	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253458	=	IC50	nM	99.0	CHEMBL2431	Homo sapiens	IC50	nM	99.0
	2080310	CHEMBL928490	Inhibition of Akt2	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)nc2n1		CHEMBL253693	=	IC50	nM	44.0	CHEMBL2431	Homo sapiens	IC50	nM	44.0
	2080312	CHEMBL928488	Inhibition of Akt2 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)nc2n1		CHEMBL253693	=	IC50	nM	828.0	CHEMBL2431	Homo sapiens	IC50	nM	828.0
	2081718	CHEMBL928795	Inhibition of Atk2 at 10 uM	B	CC[C@@H](C)Nc1nc2ccc(-c3c(-c4ccccc4F)n[nH]c3N)cc2s1		CHEMBL404115	<=	Inhibition	%	20.0	CHEMBL2431	Homo sapiens	Inhibition	%	20.0
	2092202	CHEMBL948033	Inhibition of Akt2	B	O=C(O)c1ccc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)nc2c1		CHEMBL272292	=	IC50	nM	281.0	CHEMBL2431	Homo sapiens	IC50	nM	281.0
	2092209	CHEMBL948033	Inhibition of Akt2	B	CCN(CC)CCNC(=O)c1ccc2nc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2c1		CHEMBL258696	=	IC50	nM	212.0	CHEMBL2431	Homo sapiens	IC50	nM	212.0
	2092210	CHEMBL948033	Inhibition of Akt2	B	CCN(CC)CCNC(=O)c1ccc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)nc2c1		CHEMBL270444	=	IC50	nM	359.0	CHEMBL2431	Homo sapiens	IC50	nM	359.0
	2092211	CHEMBL948033	Inhibition of Akt2	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc(-c5nn[nH]n5)ccc4nc3-c3ccccc3)cc2)CC1		CHEMBL408151	=	IC50	nM	144.0	CHEMBL2431	Homo sapiens	IC50	nM	144.0
	2092212	CHEMBL948033	Inhibition of Akt2	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(-c5nn[nH]n5)cc4nc3-c3ccccc3)cc2)CC1		CHEMBL271091	=	IC50	nM	65.0	CHEMBL2431	Homo sapiens	IC50	nM	65.0
	2092213	CHEMBL948033	Inhibition of Akt2	B	O=C(O)c1ccc2nc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2c1		CHEMBL273160	=	IC50	nM	388.0	CHEMBL2431	Homo sapiens	IC50	nM	388.0
	2092220	CHEMBL948036	Inhibition of Akt2 by cell-based IPKA assay	B	CCN(CC)CCNC(=O)c1ccc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)nc2c1		CHEMBL270444	=	IC50	nM	617.0	CHEMBL2431	Homo sapiens	IC50	nM	617.0
	2092223	CHEMBL948036	Inhibition of Akt2 by cell-based IPKA assay	B	CCN(CC)CCNC(=O)c1ccc2nc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2c1		CHEMBL258696	=	IC50	nM	276.0	CHEMBL2431	Homo sapiens	IC50	nM	276.0
	2092250	CHEMBL948033	Inhibition of Akt2	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	210.0	CHEMBL2431	Homo sapiens	IC50	nM	210.0
	2092252	CHEMBL948036	Inhibition of Akt2 by cell-based IPKA assay	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	2100.0	CHEMBL2431	Homo sapiens	IC50	nM	2100.0
	2115423	CHEMBL950113	Inhibition of human recombinant Akt2	B	N#Cc1cnc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)c1		CHEMBL255212	=	Activity	nM	3139.0	CHEMBL2431	Homo sapiens	Activity	nM	3139.0
	2115426	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	N#Cc1cnc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)c1		CHEMBL255212	>	Activity	nM	50000.0	CHEMBL2431	Homo sapiens	Activity	nM	50000.0
	2115441	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4nc[nH]n4)cc3-c3ccccc3)cc2)CC1		CHEMBL401921	=	Activity	nM	101.0	CHEMBL2431	Homo sapiens	Activity	nM	101.0
	2115442	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4ncon4)cc3-c3ccccc3)cc2)CC1		CHEMBL430217	=	Activity	nM	121.0	CHEMBL2431	Homo sapiens	Activity	nM	121.0
	2115443	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4ncccn4)cc3-c3ccccc3)cc2)CC1		CHEMBL256212	=	Activity	nM	62.0	CHEMBL2431	Homo sapiens	Activity	nM	62.0
	2115444	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4nccs4)cc3-c3ccccc3)cc2)CC1		CHEMBL271506	=	Activity	nM	64.0	CHEMBL2431	Homo sapiens	Activity	nM	64.0
	2115445	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4ccccn4)cc3-c3ccccc3)cc2)CC1		CHEMBL406858	=	Activity	nM	370.0	CHEMBL2431	Homo sapiens	Activity	nM	370.0
	2115446	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1nnc(-c2cnc(-c3ccc(CNCCC(=O)c4ccccc4N)cc3)c(-c3ccccc3)c2)s1		CHEMBL271637	=	Activity	nM	30.0	CHEMBL2431	Homo sapiens	Activity	nM	30.0
	2115447	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ncccc65)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL255129	=	Activity	nM	73.0	CHEMBL2431	Homo sapiens	Activity	nM	73.0
	2115448	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL258276	=	Activity	nM	22.0	CHEMBL2431	Homo sapiens	Activity	nM	22.0
	2115449	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5cc(-c6ccccn6)cn5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL402534	=	Activity	nM	90.0	CHEMBL2431	Homo sapiens	Activity	nM	90.0
	2115450	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL402096	=	Activity	nM	22.0	CHEMBL2431	Homo sapiens	Activity	nM	22.0
	2115451	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(c5cc(-c6ccccn6)[nH]n5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL271496	=	Activity	nM	28.0	CHEMBL2431	Homo sapiens	Activity	nM	28.0
	2115452	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(c5cc(-c6ccncc6)[nH]n5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL271887	=	Activity	nM	38.0	CHEMBL2431	Homo sapiens	Activity	nM	38.0
	2115453	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1ncnc2c1ncn2C1CCN(Cc2ccc(-c3ncc(-c4nnn[nH]4)cc3-c3ccccc3)cc2)CC1		CHEMBL404164	=	Activity	nM	105.0	CHEMBL2431	Homo sapiens	Activity	nM	105.0
	2115454	CHEMBL950113	Inhibition of human recombinant Akt2	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3ncc(-c4nnn[nH]4)cc3-c3ccccc3)cc2)CC1		CHEMBL270847	=	Activity	nM	150.0	CHEMBL2431	Homo sapiens	Activity	nM	150.0
	2115471	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4nc[nH]n4)cc3-c3ccccc3)cc2)CC1		CHEMBL401921	=	Activity	nM	666.0	CHEMBL2431	Homo sapiens	Activity	nM	666.0
	2115472	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4ncon4)cc3-c3ccccc3)cc2)CC1		CHEMBL430217	=	Activity	nM	1061.0	CHEMBL2431	Homo sapiens	Activity	nM	1061.0
	2115473	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4ncccn4)cc3-c3ccccc3)cc2)CC1		CHEMBL256212	=	Activity	nM	3459.0	CHEMBL2431	Homo sapiens	Activity	nM	3459.0
	2115474	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4nccs4)cc3-c3ccccc3)cc2)CC1		CHEMBL271506	=	Activity	nM	3239.0	CHEMBL2431	Homo sapiens	Activity	nM	3239.0
	2115475	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4ccccn4)cc3-c3ccccc3)cc2)CC1		CHEMBL406858	=	Activity	nM	8110.0	CHEMBL2431	Homo sapiens	Activity	nM	8110.0
	2115476	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CNCCC(=O)c4ccccc4N)cc3)c(-c3ccccc3)c2)s1		CHEMBL271637	=	Activity	nM	472.0	CHEMBL2431	Homo sapiens	Activity	nM	472.0
	2115477	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ncccc65)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL255129	=	Activity	nM	3957.0	CHEMBL2431	Homo sapiens	Activity	nM	3957.0
	2115478	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL258276	=	Activity	nM	416.0	CHEMBL2431	Homo sapiens	Activity	nM	416.0
	2115479	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5cc(-c6ccccn6)cn5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL402534	=	Activity	nM	1349.0	CHEMBL2431	Homo sapiens	Activity	nM	1349.0
	2115480	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL402096	=	Activity	nM	330.0	CHEMBL2431	Homo sapiens	Activity	nM	330.0
	2115481	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(c5cc(-c6ccccn6)[nH]n5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL271496	=	Activity	nM	300.0	CHEMBL2431	Homo sapiens	Activity	nM	300.0
	2115482	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(c5cc(-c6ccncc6)[nH]n5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL271887	=	Activity	nM	153.0	CHEMBL2431	Homo sapiens	Activity	nM	153.0
	2115483	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1ncnc2c1ncn2C1CCN(Cc2ccc(-c3ncc(-c4nnn[nH]4)cc3-c3ccccc3)cc2)CC1		CHEMBL404164	>	Activity	nM	50000.0	CHEMBL2431	Homo sapiens	Activity	nM	50000.0
	2115484	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3ncc(-c4nnn[nH]4)cc3-c3ccccc3)cc2)CC1		CHEMBL270847	>	Activity	nM	50000.0	CHEMBL2431	Homo sapiens	Activity	nM	50000.0
	2115489	CHEMBL950113	Inhibition of human recombinant Akt2	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5cc(-c6cnccn6)cn5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL255382	=	Activity	nM	51.0	CHEMBL2431	Homo sapiens	Activity	nM	51.0
	2115491	CHEMBL950116	Inhibition of Akt2 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5cc(-c6cnccn6)cn5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL255382	=	Activity	nM	2028.0	CHEMBL2431	Homo sapiens	Activity	nM	2028.0
	2115762	CHEMBL951086	Inhibition of human recombinant Akt2	B	CC(C)(N)c1ccc(-c2nc3ccccc3nc2-c2ccccc2)cc1		CHEMBL362455	=	IC50	nM	23000.0	CHEMBL2431	Homo sapiens	IC50	nM	23000.0
	2115763	CHEMBL951086	Inhibition of human recombinant Akt2	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253458	=	IC50	nM	99.0	CHEMBL2431	Homo sapiens	IC50	nM	99.0
	2115764	CHEMBL951086	Inhibition of human recombinant Akt2	B	Nc1ncnc2nc(-c3ccc(CN4CCC(c5cc(-c6ccncc6)[nH]n5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL255835	=	IC50	nM	85.0	CHEMBL2431	Homo sapiens	IC50	nM	85.0
	2115765	CHEMBL951086	Inhibition of human recombinant Akt2	B	Nc1ncnc2nc(-c3ccc(CN4CCC(c5nc6ccc(F)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253457	=	IC50	nM	239.0	CHEMBL2431	Homo sapiens	IC50	nM	239.0
	2115766	CHEMBL951086	Inhibition of human recombinant Akt2	B	Cc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ncnc(N)c4cc3-c3ccccc3)cc2)CC1		CHEMBL402579	=	IC50	nM	281.0	CHEMBL2431	Homo sapiens	IC50	nM	281.0
	2115767	CHEMBL951086	Inhibition of human recombinant Akt2	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5cnc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL255360	=	IC50	nM	696.0	CHEMBL2431	Homo sapiens	IC50	nM	696.0
	2115768	CHEMBL951086	Inhibition of human recombinant Akt2	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL402199	=	IC50	nM	259.0	CHEMBL2431	Homo sapiens	IC50	nM	259.0
	2115769	CHEMBL951086	Inhibition of human recombinant Akt2	B	Nc1nc(N)c2cc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2n1		CHEMBL401999	=	IC50	nM	274.0	CHEMBL2431	Homo sapiens	IC50	nM	274.0
	2115770	CHEMBL951086	Inhibition of human recombinant Akt2	B	Nc1nc(O)nc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL270815	=	IC50	nM	577.0	CHEMBL2431	Homo sapiens	IC50	nM	577.0
	2115771	CHEMBL951086	Inhibition of human recombinant Akt2	B	Nc1nn(CCc2c[nH]cn2)c2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL255348	=	IC50	nM	839.0	CHEMBL2431	Homo sapiens	IC50	nM	839.0
	2115772	CHEMBL951086	Inhibition of human recombinant Akt2	B	Nc1nn(CCO)c2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL255559	=	IC50	nM	1228.0	CHEMBL2431	Homo sapiens	IC50	nM	1228.0
	2115773	CHEMBL951086	Inhibition of human recombinant Akt2	B	Cn1nc(N)c2cc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc21		CHEMBL401622	=	IC50	nM	556.0	CHEMBL2431	Homo sapiens	IC50	nM	556.0
	2115774	CHEMBL951086	Inhibition of human recombinant Akt2	B	Nc1n[nH]c2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL270157	=	IC50	nM	7356.0	CHEMBL2431	Homo sapiens	IC50	nM	7356.0
	2115775	CHEMBL951086	Inhibition of human recombinant Akt2	B	COc1nc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)cc1C#N		CHEMBL402355	=	IC50	nM	37720.0	CHEMBL2431	Homo sapiens	IC50	nM	37720.0
	2115776	CHEMBL951086	Inhibition of human recombinant Akt2	B	CN(C)c1nc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)cc1C#N		CHEMBL257441	=	IC50	nM	15390.0	CHEMBL2431	Homo sapiens	IC50	nM	15390.0
	2115777	CHEMBL951086	Inhibition of human recombinant Akt2	B	CNc1nc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)cc1C#N		CHEMBL255772	=	IC50	nM	8141.0	CHEMBL2431	Homo sapiens	IC50	nM	8141.0
	2115778	CHEMBL951086	Inhibition of human recombinant Akt2	B	N#Cc1cc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)nc1N		CHEMBL429576	=	IC50	nM	2062.0	CHEMBL2431	Homo sapiens	IC50	nM	2062.0
	2115779	CHEMBL951086	Inhibition of human recombinant Akt2	B	N#Cc1cc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)nc1Cl		CHEMBL270388	=	IC50	nM	7356.0	CHEMBL2431	Homo sapiens	IC50	nM	7356.0
	2115780	CHEMBL951086	Inhibition of human recombinant Akt2	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	210.0	CHEMBL2431	Homo sapiens	IC50	nM	210.0
	2115789	CHEMBL951089	Inhibition of Akt2 phosphorylation in human C33a cells	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL402199	=	IC50	nM	5084.0	CHEMBL2431	Homo sapiens	IC50	nM	5084.0
	2115790	CHEMBL951089	Inhibition of Akt2 phosphorylation in human C33a cells	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253458	=	IC50	nM	468.0	CHEMBL2431	Homo sapiens	IC50	nM	468.0
	2115791	CHEMBL951089	Inhibition of Akt2 phosphorylation in human C33a cells	B	Nc1ncnc2nc(-c3ccc(CN4CCC(c5cc(-c6ccncc6)[nH]n5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL255835	=	IC50	nM	1198.0	CHEMBL2431	Homo sapiens	IC50	nM	1198.0
	2115792	CHEMBL951089	Inhibition of Akt2 phosphorylation in human C33a cells	B	Nc1ncnc2nc(-c3ccc(CN4CCC(c5nc6ccc(F)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253457	=	IC50	nM	1811.0	CHEMBL2431	Homo sapiens	IC50	nM	1811.0
	2115793	CHEMBL951089	Inhibition of Akt2 phosphorylation in human C33a cells	B	Cc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ncnc(N)c4cc3-c3ccccc3)cc2)CC1		CHEMBL402579	=	IC50	nM	344.0	CHEMBL2431	Homo sapiens	IC50	nM	344.0
Not Determined	2115794	CHEMBL951089	Inhibition of Akt2 phosphorylation in human C33a cells	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5cnc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL255360		IC50			CHEMBL2431	Homo sapiens	IC50		
	2147350	CHEMBL922036	Activity of human PKBbeta kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	104.0	CHEMBL2431	Homo sapiens	Activity	%	104.0
	2157549	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	c1nc(N2CCCCC2)c2nc[nH]c2n1		CHEMBL264666	=	IC50	nM	59000.0	CHEMBL2431	Homo sapiens	IC50	nM	59000.0
	2157553	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NC1CCN(c2ccnc3[nH]ccc23)CC1		CHEMBL264965	=	IC50	nM	880.0	CHEMBL2431	Homo sapiens	IC50	nM	880.0
	2157554	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NCC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL261249	=	IC50	nM	770.0	CHEMBL2431	Homo sapiens	IC50	nM	770.0
	2157555	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL259141	=	IC50	nM	180.0	CHEMBL2431	Homo sapiens	IC50	nM	180.0
	2157556	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NCC1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL265193	=	IC50	nM	920.0	CHEMBL2431	Homo sapiens	IC50	nM	920.0
	2157557	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NC1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL265451	=	IC50	nM	830.0	CHEMBL2431	Homo sapiens	IC50	nM	830.0
	2157558	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	Cc1nc2c(N3CCC(N)CC3)ncnc2[nH]1		CHEMBL265194	=	IC50	nM	110000.0	CHEMBL2431	Homo sapiens	IC50	nM	110000.0
	2157559	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NC1CCN(c2ncnc3[nH]cnc23)CC1		CHEMBL261260	=	IC50	nM	270.0	CHEMBL2431	Homo sapiens	IC50	nM	270.0
	2157560	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NCC1CCN(c2ncnc3[nH]cnc23)CC1		CHEMBL259356	=	IC50	nM	290.0	CHEMBL2431	Homo sapiens	IC50	nM	290.0
	2157561	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NC(=O)C1CCN(c2ncnc3[nH]cnc23)CC1		CHEMBL264667	=	IC50	nM	41000.0	CHEMBL2431	Homo sapiens	IC50	nM	41000.0
	2157589	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	nM	6.0
	2157590	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]cnc23)CC1		CHEMBL259999	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	nM	25.0
	2157591	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NC1(c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL259998	=	IC50	nM	7.0	CHEMBL2431	Homo sapiens	IC50	nM	7.0
	2157592	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NC1(c2ccc(Cl)cc2)CCN(c2ncnc3[nH]cnc23)CC1		CHEMBL407504	=	IC50	nM	7.0	CHEMBL2431	Homo sapiens	IC50	nM	7.0
	2157593	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NCC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL260000	=	IC50	nM	5.0	CHEMBL2431	Homo sapiens	IC50	nM	5.0
	2157594	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NCC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]cnc23)CC1		CHEMBL409503	=	IC50	nM	3.0	CHEMBL2431	Homo sapiens	IC50	nM	3.0
	2157595	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NCC1(c2ccc(Cl)cc2)CCN(c2ccnc3[nH]ccc23)CC1		CHEMBL260463	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	nM	25.0
	2157596	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NCC1(c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL406863	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	nM	8.0
	2157597	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NCC1(c2ccc(Cl)cc2)CCN(c2ncnc3[nH]cnc23)CC1		CHEMBL260358	=	IC50	nM	16.0	CHEMBL2431	Homo sapiens	IC50	nM	16.0
	2157598	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NC(c1ccc(Cl)cc1)C1CCN(c2ccnc3[nH]ccc23)CC1		CHEMBL260577	=	IC50	nM	12.0	CHEMBL2431	Homo sapiens	IC50	nM	12.0
	2157599	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NC(c1ccc(Cl)cc1)C1CCN(c2ncnc3[nH]cnc23)CC1		CHEMBL261034	=	IC50	nM	71.0	CHEMBL2431	Homo sapiens	IC50	nM	71.0
	2157600	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NC(c1ccc(Cl)cc1)C1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL405384	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	nM	25.0
	2157601	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	NC(c1ccccc1)C1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL261247	=	IC50	nM	246.0	CHEMBL2431	Homo sapiens	IC50	nM	246.0
	2157602	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1		CHEMBL228133	=	IC50	nM	20.0	CHEMBL2431	Homo sapiens	IC50	uM	0.02
	2157603	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	CNCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL376388	=	IC50	nM	6900.0	CHEMBL2431	Homo sapiens	IC50	uM	6.9
	2157604	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	>	IC50	nM	100000.0	CHEMBL2431	Homo sapiens	IC50	uM	100.0
	2157674	CHEMBL932635	Inhibition of PKBbeta recombinant by radiometric filter binding assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	IC50	nM	590.0	CHEMBL2431	Homo sapiens	IC50	uM	0.59
	2171147	CHEMBL937418	Inhibition of Akt2	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	210.0	CHEMBL2431	Homo sapiens	IC50	nM	210.0
	2171149	CHEMBL937420	Inhibition of Akt2 by cell-based assay	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	900.0	CHEMBL2431	Homo sapiens	IC50	nM	900.0
	2171163	CHEMBL937418	Inhibition of Akt2	B	O=C1N=CC=C2N=C(c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)C(c3ccccc3)=CC12		CHEMBL262341	=	IC50	nM	42.0	CHEMBL2431	Homo sapiens	IC50	nM	42.0
	2171164	CHEMBL937418	Inhibition of Akt2	B	c1ccc(-c2cc3ncccc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL259753	=	IC50	nM	70.0	CHEMBL2431	Homo sapiens	IC50	nM	70.0
	2171165	CHEMBL937418	Inhibition of Akt2	B	c1ccc(-c2cc3cnccc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL259967	=	IC50	nM	210.0	CHEMBL2431	Homo sapiens	IC50	nM	210.0
	2171166	CHEMBL937418	Inhibition of Akt2	B	c1ccc(-c2cc3ccncc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL259968	=	IC50	nM	160.0	CHEMBL2431	Homo sapiens	IC50	nM	160.0
	2171167	CHEMBL937418	Inhibition of Akt2	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL260670	=	IC50	nM	220.0	CHEMBL2431	Homo sapiens	IC50	nM	220.0
	2171168	CHEMBL937418	Inhibition of Akt2	B	c1ccc(-c2cc(C3CCN(Cc4ccc(-c5nc6ncccc6cc5-c5ccccc5)cc4)CC3)n[nH]2)cc1		CHEMBL429703	=	IC50	nM	1600.0	CHEMBL2431	Homo sapiens	IC50	nM	1600.0
	2171169	CHEMBL937418	Inhibition of Akt2	B	O=c1ccc(-c2cc(C3CCN(Cc4ccc(-c5nc6ncccc6cc5-c5ccccc5)cc4)CC3)n[nH]2)c[nH]1		CHEMBL260184	=	IC50	nM	83.0	CHEMBL2431	Homo sapiens	IC50	nM	83.0
	2171170	CHEMBL937418	Inhibition of Akt2	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4cc(-c5ccccn5)[nH]n4)CC3)cc2)cc1		CHEMBL259982	=	IC50	nM	280.0	CHEMBL2431	Homo sapiens	IC50	nM	280.0
	2171171	CHEMBL937418	Inhibition of Akt2	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4cc(-c5cccnc5)[nH]n4)CC3)cc2)cc1		CHEMBL407733	=	IC50	nM	900.0	CHEMBL2431	Homo sapiens	IC50	nM	900.0
	2171172	CHEMBL937418	Inhibition of Akt2	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4cc(-c5ccncc5)[nH]n4)CC3)cc2)cc1		CHEMBL261540	=	IC50	nM	260.0	CHEMBL2431	Homo sapiens	IC50	nM	260.0
	2171173	CHEMBL937418	Inhibition of Akt2	B	c1ccc(-c2nc3ccccc3nc2-c2ccc(CN3CCC(c4cc(-c5ccncc5)[nH]n4)CC3)cc2)cc1		CHEMBL261542	=	IC50	nM	1075.0	CHEMBL2431	Homo sapiens	IC50	nM	1075.0
	2171174	CHEMBL937418	Inhibition of Akt2	B	Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4nc3-c3ccccc3)cc2)CC1		CHEMBL260397	=	IC50	nM	2057.0	CHEMBL2431	Homo sapiens	IC50	nM	2057.0
	2171175	CHEMBL937418	Inhibition of Akt2	B	CCN(CC)CCNC(=O)c1ccc2nc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2c1		CHEMBL258696	=	IC50	nM	212.0	CHEMBL2431	Homo sapiens	IC50	nM	212.0
	2171187	CHEMBL937420	Inhibition of Akt2 by cell-based assay	B	O=C1N=CC=C2N=C(c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)C(c3ccccc3)=CC12		CHEMBL262341	=	IC50	nM	266.0	CHEMBL2431	Homo sapiens	IC50	nM	266.0
	2171188	CHEMBL937420	Inhibition of Akt2 by cell-based assay	B	c1ccc(-c2cc3ncccc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL259753	=	IC50	nM	1476.0	CHEMBL2431	Homo sapiens	IC50	nM	1476.0
	2171189	CHEMBL937420	Inhibition of Akt2 by cell-based assay	B	c1ccc(-c2cc3cnccc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL259967	=	IC50	nM	2679.0	CHEMBL2431	Homo sapiens	IC50	nM	2679.0
	2171190	CHEMBL937420	Inhibition of Akt2 by cell-based assay	B	c1ccc(-c2cc3ccncc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL259968	=	IC50	nM	981.0	CHEMBL2431	Homo sapiens	IC50	nM	981.0
	2171191	CHEMBL937420	Inhibition of Akt2 by cell-based assay	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL260670	=	IC50	nM	1077.0	CHEMBL2431	Homo sapiens	IC50	nM	1077.0
Not Determined	2171192	CHEMBL937420	Inhibition of Akt2 by cell-based assay	B	c1ccc(-c2cc(C3CCN(Cc4ccc(-c5nc6ncccc6cc5-c5ccccc5)cc4)CC3)n[nH]2)cc1		CHEMBL429703		IC50			CHEMBL2431	Homo sapiens	IC50		
	2171193	CHEMBL937420	Inhibition of Akt2 by cell-based assay	B	O=c1ccc(-c2cc(C3CCN(Cc4ccc(-c5nc6ncccc6cc5-c5ccccc5)cc4)CC3)n[nH]2)c[nH]1		CHEMBL260184	=	IC50	nM	613.0	CHEMBL2431	Homo sapiens	IC50	nM	613.0
	2171194	CHEMBL937420	Inhibition of Akt2 by cell-based assay	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4cc(-c5ccccn5)[nH]n4)CC3)cc2)cc1		CHEMBL259982	=	IC50	nM	995.0	CHEMBL2431	Homo sapiens	IC50	nM	995.0
Not Determined	2171195	CHEMBL937420	Inhibition of Akt2 by cell-based assay	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4cc(-c5cccnc5)[nH]n4)CC3)cc2)cc1		CHEMBL407733		IC50			CHEMBL2431	Homo sapiens	IC50		
	2171196	CHEMBL937420	Inhibition of Akt2 by cell-based assay	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4cc(-c5ccncc5)[nH]n4)CC3)cc2)cc1		CHEMBL261540	=	IC50	nM	1454.0	CHEMBL2431	Homo sapiens	IC50	nM	1454.0
	2171197	CHEMBL937420	Inhibition of Akt2 by cell-based assay	B	CCN(CC)CCNC(=O)c1ccc2nc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2c1		CHEMBL258696	=	IC50	nM	730.0	CHEMBL2431	Homo sapiens	IC50	nM	730.0
	2206997	CHEMBL966763	Inhibition of PKBeta	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	2248184	CHEMBL1012667	Inhibition of AKT2 at 5 uM	B	O=C1NC(=O)/C(=C/c2cccc(C(F)(F)F)c2)S1		CHEMBL183906	=	Inhibition	%	3.0	CHEMBL2431	Homo sapiens	INH	%	3.0
	2248214	CHEMBL1012667	Inhibition of AKT2 at 5 uM	B	CCCOc1ccc(/C=C2\SC(=O)NC2=O)cc1		CHEMBL84558	=	Inhibition	%	-1.0	CHEMBL2431	Homo sapiens	INH	%	-1.0
	2251001	CHEMBL1011052	Inhibition of PKBbeta	B	Cl.Cl.O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL1315166	=	IC50	nM	590.0	CHEMBL2431	Homo sapiens	IC50	nM	590.0
	2251055	CHEMBL1011930	Inhibition of AKT2 at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL525385	=	Inhibition	%	62.0	CHEMBL2431	Homo sapiens	INH	%	62.0
	2357001	CHEMBL964655	Inhibition of AKT2 at 1 uM relative to control	B	Cc1ccn(-c2ccc(-c3ncco3)cc2)c(=O)c1-c1ccc2nc(N)ncc2c1		CHEMBL525893	>	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	2367153	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2cncc(OC3CCNCC3)c21		CHEMBL493911	=	IC50	nM	1000.0	CHEMBL2431	Homo sapiens	IC50	uM	1.0
	2367182	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCNC[C@H](O)CO)c21		CHEMBL522351	=	IC50	nM	5.0	CHEMBL2431	Homo sapiens	IC50	uM	0.005
	2367183	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCNCCc3ccc(OC)cc3)c21		CHEMBL494060	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	uM	0.006
Not Determined	2367184	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCNC3)c21		CHEMBL521642		IC50			CHEMBL2431	Homo sapiens	IC50		
	2367185	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	IC50	nM	13.0	CHEMBL2431	Homo sapiens	IC50	uM	0.013
	2367186	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	uM	0.008
	2367187	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNC3)c21		CHEMBL494088	=	IC50	nM	13.0	CHEMBL2431	Homo sapiens	IC50	uM	0.013
	2367188	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC[C@@H](N)Cc3ccccc3)c21		CHEMBL523859	=	IC50	nM	4.0	CHEMBL2431	Homo sapiens	IC50	uM	0.004
	2367189	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCN)c21		CHEMBL453510	=	IC50	nM	20.0	CHEMBL2431	Homo sapiens	IC50	uM	0.02
	2367190	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	uM	0.008
	2367191	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCCN)c21		CHEMBL493269	=	IC50	nM	9.0	CHEMBL2431	Homo sapiens	IC50	uM	0.009
	2367192	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2cncc(CNC3CCNCC3)c21		CHEMBL188434	=	IC50	nM	741.0	CHEMBL2431	Homo sapiens	IC50	uM	0.741
	2367193	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NC3CCNCC3)c21		CHEMBL494662	=	IC50	nM	2570.0	CHEMBL2431	Homo sapiens	IC50	uM	2.57
	2367194	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2cncc(OCC3CCNCC3)c21		CHEMBL521823	=	IC50	nM	204.0	CHEMBL2431	Homo sapiens	IC50	uM	0.204
	2367195	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NC3CCCNC3)c21		CHEMBL493067	=	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	2367196	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21		CHEMBL493066	=	IC50	nM	2510.0	CHEMBL2431	Homo sapiens	IC50	uM	2.51
	2367197	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@@H](N)C3)c21		CHEMBL523695	=	IC50	nM	2340.0	CHEMBL2431	Homo sapiens	IC50	uM	2.34
	2367198	CHEMBL1028093	Inhibition of human AKT2	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	IC50	nM	3980.0	CHEMBL2431	Homo sapiens	IC50	uM	3.98
	2367358	CHEMBL1028118	Binding affinity to human AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Ki	nM	4.0	CHEMBL2431	Homo sapiens	Ki	nM	4.0
	2408770	CHEMBL959245	Inhibition of AKT2	B	NCC(NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL512135	=	IC50	nM	125.0	CHEMBL2431	Homo sapiens	IC50	nM	125.0
	2408771	CHEMBL959245	Inhibition of AKT2	B	NCC(Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL469590	=	IC50	nM	13.0	CHEMBL2431	Homo sapiens	IC50	nM	13.0
	2408772	CHEMBL959245	Inhibition of AKT2	B	NC[C@@H](Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL513728	=	IC50	nM	500.0	CHEMBL2431	Homo sapiens	IC50	nM	500.0
	2408773	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL470597	=	IC50	nM	10.0	CHEMBL2431	Homo sapiens	IC50	nM	10.0
	2408774	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](CC1CCCCC1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL470598	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	nM	25.0
	2408775	CHEMBL959245	Inhibition of AKT2	B	COc1ccc(C[C@@H](CN)NC(=O)c2cc(Br)c(-c3ccnc4[nH]ccc34)s2)cc1		CHEMBL524998	=	IC50	nM	63.0	CHEMBL2431	Homo sapiens	IC50	nM	63.0
	2408776	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1ccccc1F)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL498052	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	nM	8.0
	2408777	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1cccc(F)c1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL523586	=	IC50	nM	9.0	CHEMBL2431	Homo sapiens	IC50	nM	9.0
	2408778	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL496690	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	nM	6.0
	2409450	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1ccccc1C(F)(F)F)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL520788	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	nM	25.0
	2409451	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1cccc(C(F)(F)F)c1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL482536	=	IC50	nM	10.0	CHEMBL2431	Homo sapiens	IC50	nM	10.0
	2409452	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1ccc(C(F)(F)F)cc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL482537	=	IC50	nM	79.0	CHEMBL2431	Homo sapiens	IC50	nM	79.0
	2409453	CHEMBL959245	Inhibition of AKT2	B	NCC(NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL512135	=	Ki	nM	125.0	CHEMBL2431	Homo sapiens	Ki	nM	125.0
	2409454	CHEMBL959245	Inhibition of AKT2	B	NCC(Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL469590	=	Ki	nM	8.0	CHEMBL2431	Homo sapiens	Ki	nM	8.0
	2409455	CHEMBL959245	Inhibition of AKT2	B	NC[C@@H](Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL513728	=	Ki	nM	800.0	CHEMBL2431	Homo sapiens	Ki	nM	800.0
	2409456	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL470597	=	Ki	nM	3.0	CHEMBL2431	Homo sapiens	Ki	nM	3.0
	2409457	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](CC1CCCCC1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL470598	=	Ki	nM	6.0	CHEMBL2431	Homo sapiens	Ki	nM	6.0
	2409458	CHEMBL959245	Inhibition of AKT2	B	COc1ccc(C[C@@H](CN)NC(=O)c2cc(Br)c(-c3ccnc4[nH]ccc34)s2)cc1		CHEMBL524998	=	Ki	nM	40.0	CHEMBL2431	Homo sapiens	Ki	nM	40.0
	2409459	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1cccc(F)c1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL523586	=	Ki	nM	0.63	CHEMBL2431	Homo sapiens	Ki	nM	0.63
	2409460	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL496690	=	Ki	nM	2.0	CHEMBL2431	Homo sapiens	Ki	nM	2.0
	2409461	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1ccccc1C(F)(F)F)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL520788	=	Ki	nM	4.0	CHEMBL2431	Homo sapiens	Ki	nM	4.0
	2409462	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1cccc(C(F)(F)F)c1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL482536	=	Ki	nM	4.0	CHEMBL2431	Homo sapiens	Ki	nM	4.0
	2409463	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1ccc(C(F)(F)F)cc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL482537	=	Ki	nM	16.0	CHEMBL2431	Homo sapiens	Ki	nM	16.0
	2409539	CHEMBL959245	Inhibition of AKT2	B	NC[C@H](Cc1ccncc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL498051	=	Ki	nM	40.0	CHEMBL2431	Homo sapiens	Ki	nM	40.0
	2418052	CHEMBL1018812	Inhibition of AKT2 at 1 uM	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O		CHEMBL2216825	=	Inhibition	%	99.0	CHEMBL2431	Homo sapiens	INH	%	99.0
	2445332	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	c1ccc(-c2cc3cnc(-n4ccnc4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL448926	=	IC50	nM	684.0	CHEMBL2431	Homo sapiens	IC50	nM	684.0
	2445333	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CN(C)C1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL454859	=	IC50	nM	70.0	CHEMBL2431	Homo sapiens	IC50	nM	70.0
	2445334	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	O[C@@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CCN1		CHEMBL499683	=	IC50	nM	421.0	CHEMBL2431	Homo sapiens	IC50	nM	421.0
	2445335	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CN(C)CCNc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL505758	=	IC50	nM	223.0	CHEMBL2431	Homo sapiens	IC50	nM	223.0
	2445336	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)[C@H](C)CN1		CHEMBL454210	=	IC50	nM	199.0	CHEMBL2431	Homo sapiens	IC50	nM	199.0
	2445337	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL504251	=	IC50	nM	52.0	CHEMBL2431	Homo sapiens	IC50	nM	52.0
	2445338	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CCN1		CHEMBL508754	=	IC50	nM	125.0	CHEMBL2431	Homo sapiens	IC50	nM	125.0
	2445339	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	C[C@@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CCN1		CHEMBL503980	=	IC50	nM	44.0	CHEMBL2431	Homo sapiens	IC50	nM	44.0
	2445340	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)C[C@@H](C)N1		CHEMBL450545	=	IC50	nM	101.0	CHEMBL2431	Homo sapiens	IC50	nM	101.0
	2445341	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)C[C@@H](C)O1		CHEMBL448826	=	IC50	nM	184.0	CHEMBL2431	Homo sapiens	IC50	nM	184.0
	2445342	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	OC1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL500993	=	IC50	nM	168.0	CHEMBL2431	Homo sapiens	IC50	nM	168.0
	2445343	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	c1ccc(-c2cc3cnc(N4CCOCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL488654	=	IC50	nM	243.0	CHEMBL2431	Homo sapiens	IC50	nM	243.0
	2445344	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	c1ccc(-c2cc3cnc(N4CCCCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL442718	=	IC50	nM	229.0	CHEMBL2431	Homo sapiens	IC50	nM	229.0
	2445345	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	FC1(F)CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)C1		CHEMBL451961	=	IC50	nM	462.0	CHEMBL2431	Homo sapiens	IC50	nM	462.0
	2445346	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCC(=O)c4ccccc4N)cc3)nc2n1		CHEMBL252456	=	IC50	nM	388.0	CHEMBL2431	Homo sapiens	IC50	nM	388.0
Not Active	2445348	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CN1CCN(c2nccc3nc(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)c(-c4ccccc4)cc23)CC1		CHEMBL506434		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Active	2445349	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CN1CCN(c2nccc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc23)CC1		CHEMBL443633		Activity			CHEMBL2431	Homo sapiens	Activity		
	2447588	CHEMBL947432	Inhibition of Akt2	B	Nc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)cn1		CHEMBL502393	=	IC50	nM	33.0	CHEMBL2431	Homo sapiens	IC50	nM	33.0
	2447589	CHEMBL947432	Inhibition of Akt2	B	O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5nnc(-c6cnccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL444136	=	IC50	nM	21.0	CHEMBL2431	Homo sapiens	IC50	nM	21.0
	2447590	CHEMBL947432	Inhibition of Akt2	B	O=C1NCCc2nc(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc21		CHEMBL446134	=	IC50	nM	26.0	CHEMBL2431	Homo sapiens	IC50	nM	26.0
	2447592	CHEMBL947432	Inhibition of Akt2	B	COc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)cn1		CHEMBL446966	=	IC50	nM	16.0	CHEMBL2431	Homo sapiens	IC50	nM	16.0
	2447593	CHEMBL947432	Inhibition of Akt2	B	O=c1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)c[nH]1		CHEMBL488428	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	nM	8.0
	2447594	CHEMBL947432	Inhibition of Akt2	B	O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5nnc(-c6ncccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL447114	=	IC50	nM	44.0	CHEMBL2431	Homo sapiens	IC50	nM	44.0
	2447595	CHEMBL947432	Inhibition of Akt2	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL443661	=	IC50	nM	4.0	CHEMBL2431	Homo sapiens	IC50	nM	4.0
	2447630	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	O=C1NCCc2nc(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc21		CHEMBL446134	=	IC50	nM	224.0	CHEMBL2431	Homo sapiens	IC50	nM	224.0
	2447631	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN1CCN(c2ccc3nc(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)c(-c4ccccc4)nc3n2)CC1		CHEMBL452823	=	IC50	nM	827.0	CHEMBL2431	Homo sapiens	IC50	nM	827.0
	2447632	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	Nc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6nc(N7CCN(CCO)CC7)ccc6nc5-c5ccccc5)cc4)CC3)[nH]2)cn1		CHEMBL447558	=	IC50	nM	230.0	CHEMBL2431	Homo sapiens	IC50	nM	230.0
	2447633	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(N)nc7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL499961	=	IC50	nM	225.0	CHEMBL2431	Homo sapiens	IC50	nM	225.0
	2447634	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN(C)CCN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL506827	=	IC50	nM	116.0	CHEMBL2431	Homo sapiens	IC50	nM	116.0
	2447635	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	OCCN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL501612	=	IC50	nM	190.0	CHEMBL2431	Homo sapiens	IC50	nM	190.0
	2447636	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL508098	=	IC50	nM	192.0	CHEMBL2431	Homo sapiens	IC50	nM	192.0
	2447637	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN(C)CCN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL499554	=	IC50	nM	43.0	CHEMBL2431	Homo sapiens	IC50	nM	43.0
	2447638	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	OCCN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL449989	=	IC50	nM	48.0	CHEMBL2431	Homo sapiens	IC50	nM	48.0
	2447639	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL443620	=	IC50	nM	92.0	CHEMBL2431	Homo sapiens	IC50	nM	92.0
	2447640	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7cc[n+]([O-])cc7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL455071	=	IC50	nM	68.0	CHEMBL2431	Homo sapiens	IC50	nM	68.0
	2447641	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	[O-][n+]1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6nc(N7CCN(CCO)CC7)ncc6cc5-c5ccccc5)cc4)CC3)[nH]2)cc1		CHEMBL449200	=	IC50	nM	146.0	CHEMBL2431	Homo sapiens	IC50	nM	146.0
	2447642	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7cc[n+]([O-])cc7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL507204	=	IC50	nM	185.0	CHEMBL2431	Homo sapiens	IC50	nM	185.0
	2447643	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(=O)[nH]c7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL503652	=	IC50	nM	98.0	CHEMBL2431	Homo sapiens	IC50	nM	98.0
	2447644	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	O=c1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6nc(N7CCN(CCO)CC7)ncc6cc5-c5ccccc5)cc4)CC3)[nH]2)c[nH]1		CHEMBL502113	=	IC50	nM	284.0	CHEMBL2431	Homo sapiens	IC50	nM	284.0
	2447645	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(=O)[nH]c7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL450266	=	IC50	nM	188.0	CHEMBL2431	Homo sapiens	IC50	nM	188.0
	2447646	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(N)nc7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL503270	=	IC50	nM	140.0	CHEMBL2431	Homo sapiens	IC50	nM	140.0
	2447647	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	Nc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6nc(N7CCN(CCO)CC7)ncc6cc5-c5ccccc5)cc4)CC3)[nH]2)cn1		CHEMBL503810	=	IC50	nM	180.0	CHEMBL2431	Homo sapiens	IC50	nM	180.0
	2447648	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(N)nc7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL445212	=	IC50	nM	84.0	CHEMBL2431	Homo sapiens	IC50	nM	84.0
	2447649	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL505848	=	IC50	nM	130.0	CHEMBL2431	Homo sapiens	IC50	nM	130.0
	2447650	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	OCCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL455226	=	IC50	nM	80.0	CHEMBL2431	Homo sapiens	IC50	nM	80.0
	2447651	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL453288	=	IC50	nM	40.0	CHEMBL2431	Homo sapiens	IC50	nM	40.0
	2447652	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	COc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)cn1		CHEMBL446966	=	IC50	nM	159.0	CHEMBL2431	Homo sapiens	IC50	nM	159.0
	2447653	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5nnc(-c6cnccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL444136	=	IC50	nM	405.0	CHEMBL2431	Homo sapiens	IC50	nM	405.0
	2447654	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	Nc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)cn1		CHEMBL502393	=	IC50	nM	165.0	CHEMBL2431	Homo sapiens	IC50	nM	165.0
	2447655	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	O=c1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)c[nH]1		CHEMBL488428	=	IC50	nM	284.0	CHEMBL2431	Homo sapiens	IC50	nM	284.0
	2447656	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5nnc(-c6ncccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL447114	=	IC50	nM	69.0	CHEMBL2431	Homo sapiens	IC50	nM	69.0
	2447657	CHEMBL947434	Inhibition of Akt2 by cellular assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL443661	=	IC50	nM	39.0	CHEMBL2431	Homo sapiens	IC50	nM	39.0
	2465574	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CNc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL252857	=	IC50	nM	94.0	CHEMBL2431	Homo sapiens	IC50	nM	94.0
	2465576	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CNc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL252857	=	IC50	nM	899.0	CHEMBL2431	Homo sapiens	IC50	nM	899.0
	2465604	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CN1CCN(c2cc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3cn2)CC1		CHEMBL448196	=	IC50	nM	59.0	CHEMBL2431	Homo sapiens	IC50	nM	59.0
	2465605	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CN1CCN(c2nccc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc23)CC1		CHEMBL443633	=	IC50	nM	3570.0	CHEMBL2431	Homo sapiens	IC50	nM	3570.0
	2465606	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CN1CCN(c2nccc3nc(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)c(-c4ccccc4)cc23)CC1		CHEMBL506434	=	IC50	nM	539.0	CHEMBL2431	Homo sapiens	IC50	nM	539.0
	2465607	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CN1CC(N2CCN(c3ncc4cc(-c5ccccc5)c(-c5ccc(CN6CCC(c7nnc(-c8ccccn8)[nH]7)CC6)cc5)nc4n3)CC2)C1		CHEMBL448991	=	IC50	nM	9.0	CHEMBL2431	Homo sapiens	IC50	nM	9.0
	2465608	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL443661	=	IC50	nM	4.0	CHEMBL2431	Homo sapiens	IC50	nM	4.0
	2465609	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	OCCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL453995	=	IC50	nM	31.0	CHEMBL2431	Homo sapiens	IC50	nM	31.0
	2465610	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	c1ccc(-c2cc3cnc(N4CCn5cnnc5C4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL447044	=	IC50	nM	138.0	CHEMBL2431	Homo sapiens	IC50	nM	138.0
	2465611	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CN(C)CC(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL447168	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	nM	6.0
	2465612	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CN(C)C(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL447348	=	IC50	nM	40.0	CHEMBL2431	Homo sapiens	IC50	nM	40.0
	2465613	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CS(=O)(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL502426	=	IC50	nM	23.0	CHEMBL2431	Homo sapiens	IC50	nM	23.0
	2465614	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CC(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL453586	=	IC50	nM	16.0	CHEMBL2431	Homo sapiens	IC50	nM	16.0
	2465615	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	c1ccc(-c2cc3cnc(-n4ccnc4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL448926	=	IC50	nM	73.0	CHEMBL2431	Homo sapiens	IC50	nM	73.0
	2465616	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CN(C)C1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL454859	=	IC50	nM	22.0	CHEMBL2431	Homo sapiens	IC50	nM	22.0
	2465617	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	O[C@@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CCN1		CHEMBL499683	=	IC50	nM	67.0	CHEMBL2431	Homo sapiens	IC50	nM	67.0
	2465618	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CN(C)CCNc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL505758	=	IC50	nM	154.0	CHEMBL2431	Homo sapiens	IC50	nM	154.0
	2465619	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)[C@H](C)CN1		CHEMBL454210	=	IC50	nM	29.0	CHEMBL2431	Homo sapiens	IC50	nM	29.0
	2465620	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL504251	=	IC50	nM	27.0	CHEMBL2431	Homo sapiens	IC50	nM	27.0
	2465621	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CCN1		CHEMBL508754	=	IC50	nM	47.0	CHEMBL2431	Homo sapiens	IC50	nM	47.0
	2465622	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	C[C@@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CCN1		CHEMBL503980	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	nM	25.0
	2465623	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)C[C@@H](C)N1		CHEMBL450545	=	IC50	nM	77.0	CHEMBL2431	Homo sapiens	IC50	nM	77.0
	2465624	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	O=S1(=O)CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL450772	=	IC50	nM	297.0	CHEMBL2431	Homo sapiens	IC50	nM	297.0
	2465625	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)C[C@@H](C)O1		CHEMBL448826	=	IC50	nM	102.0	CHEMBL2431	Homo sapiens	IC50	nM	102.0
	2465626	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	OC1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL500993	=	IC50	nM	45.0	CHEMBL2431	Homo sapiens	IC50	nM	45.0
	2465627	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	c1ccc(-c2cc3cnc(N4CCOCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL488654	=	IC50	nM	43.0	CHEMBL2431	Homo sapiens	IC50	nM	43.0
	2465628	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	c1ccc(-c2cc3cnc(N4CCCCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL442718	=	IC50	nM	93.0	CHEMBL2431	Homo sapiens	IC50	nM	93.0
	2465629	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	FC1(F)CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)C1		CHEMBL451961	=	IC50	nM	252.0	CHEMBL2431	Homo sapiens	IC50	nM	252.0
	2465630	CHEMBL951578	Inhibition of Akt2 phosphorylation by HTRF assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCC(=O)c4ccccc4N)cc3)nc2n1		CHEMBL252456	=	IC50	nM	90.0	CHEMBL2431	Homo sapiens	IC50	nM	90.0
	2465658	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CN1CCN(c2cc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3cn2)CC1		CHEMBL448196	=	IC50	nM	133.0	CHEMBL2431	Homo sapiens	IC50	nM	133.0
	2465659	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CN1CC(N2CCN(c3ncc4cc(-c5ccccc5)c(-c5ccc(CN6CCC(c7nnc(-c8ccccn8)[nH]7)CC6)cc5)nc4n3)CC2)C1		CHEMBL448991	=	IC50	nM	27.0	CHEMBL2431	Homo sapiens	IC50	nM	27.0
	2465660	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL443661	=	IC50	nM	39.0	CHEMBL2431	Homo sapiens	IC50	nM	39.0
	2465661	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	OCCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL453995	=	IC50	nM	41.0	CHEMBL2431	Homo sapiens	IC50	nM	41.0
	2465662	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	c1ccc(-c2cc3cnc(N4CCn5cnnc5C4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL447044	=	IC50	nM	735.0	CHEMBL2431	Homo sapiens	IC50	nM	735.0
	2465663	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CN(C)CC(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL447168	=	IC50	nM	19.0	CHEMBL2431	Homo sapiens	IC50	nM	19.0
	2465664	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CN(C)C(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL447348	=	IC50	nM	177.0	CHEMBL2431	Homo sapiens	IC50	nM	177.0
	2465665	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CS(=O)(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL502426	=	IC50	nM	196.0	CHEMBL2431	Homo sapiens	IC50	nM	196.0
	2465666	CHEMBL951580	Inhibition of Akt2 phosphorylation in human by C33a cells by IPKA assay	B	CC(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL453586	=	IC50	nM	145.0	CHEMBL2431	Homo sapiens	IC50	nM	145.0
	2470104	CHEMBL1032246	Inhibition of AKT2 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL2431	Homo sapiens	INH	%	10.0
Not Evaluated	2476690	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1		CHEMBL514582		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2476893	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2		CHEMBL233000		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2478732	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2479587	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1		CHEMBL516312		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2479790	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2480587	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2480789	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878		Activity			CHEMBL2431	Homo sapiens	Activity		
	2504326	CHEMBL939834	Inhibition of Akt2 by cell based assay	B	Nc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(n6cnc(-c7ccccn7)c6)CC5)cc4)nc3ccn12		CHEMBL508794	=	IC50	nM	74.8	CHEMBL2431	Homo sapiens	IC50	nM	74.8
	2504327	CHEMBL939834	Inhibition of Akt2 by cell based assay	B	OCCNCc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL442919	=	IC50	nM	251.4	CHEMBL2431	Homo sapiens	IC50	nM	251.4
	2504328	CHEMBL939834	Inhibition of Akt2 by cell based assay	B	CN1CCN(Cc2nnc3c4cc(-c5ccccc5)c(-c5ccc(CN6CCC(c7n[nH]c(-c8ccccn8)n7)CC6)cc5)nc4ccn23)CC1		CHEMBL446779	=	IC50	nM	376.1	CHEMBL2431	Homo sapiens	IC50	nM	376.1
	2504329	CHEMBL939834	Inhibition of Akt2 by cell based assay	B	ClCc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL508861	=	IC50	nM	483.3	CHEMBL2431	Homo sapiens	IC50	nM	483.3
	2504330	CHEMBL939834	Inhibition of Akt2 by cell based assay	B	Cc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL445464	=	IC50	nM	176.5	CHEMBL2431	Homo sapiens	IC50	nM	176.5
	2504331	CHEMBL939834	Inhibition of Akt2 by cell based assay	B	c1ccc(-c2cc3c(ccn4cnnc34)nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL447328	=	IC50	nM	41.0	CHEMBL2431	Homo sapiens	IC50	nM	41.0
	2504332	CHEMBL939834	Inhibition of Akt2 by cell based assay	B	NC(=O)Nc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL509747	=	IC50	nM	1213.0	CHEMBL2431	Homo sapiens	IC50	nM	1213.0
	2504333	CHEMBL939834	Inhibition of Akt2 by cell based assay	B	Sc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL502854	=	IC50	nM	107.6	CHEMBL2431	Homo sapiens	IC50	nM	107.6
	2504334	CHEMBL939834	Inhibition of Akt2 by cell based assay	B	Oc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL506077	=	IC50	nM	167.7	CHEMBL2431	Homo sapiens	IC50	nM	167.7
	2504335	CHEMBL939834	Inhibition of Akt2 by cell based assay	B	Nc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL499555	=	IC50	nM	47.7	CHEMBL2431	Homo sapiens	IC50	nM	47.7
	2504346	CHEMBL939832	Inhibition of human cloned Akt2 expressed in Drosophila S2 cells by HTRF assay	B	Nc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(n6cnc(-c7ccccn7)c6)CC5)cc4)nc3ccn12		CHEMBL508794	=	IC50	nM	2.8	CHEMBL2431	Homo sapiens	IC50	nM	2.8
	2504347	CHEMBL939832	Inhibition of human cloned Akt2 expressed in Drosophila S2 cells by HTRF assay	B	OCCNCc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL442919	=	IC50	nM	77.9	CHEMBL2431	Homo sapiens	IC50	nM	77.9
	2504348	CHEMBL939832	Inhibition of human cloned Akt2 expressed in Drosophila S2 cells by HTRF assay	B	CN1CCN(Cc2nnc3c4cc(-c5ccccc5)c(-c5ccc(CN6CCC(c7n[nH]c(-c8ccccn8)n7)CC6)cc5)nc4ccn23)CC1		CHEMBL446779	=	IC50	nM	55.1	CHEMBL2431	Homo sapiens	IC50	nM	55.1
	2504349	CHEMBL939832	Inhibition of human cloned Akt2 expressed in Drosophila S2 cells by HTRF assay	B	ClCc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL508861	=	IC50	nM	10.5	CHEMBL2431	Homo sapiens	IC50	nM	10.5
	2504350	CHEMBL939832	Inhibition of human cloned Akt2 expressed in Drosophila S2 cells by HTRF assay	B	Cc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL445464	=	IC50	nM	14.6	CHEMBL2431	Homo sapiens	IC50	nM	14.6
	2504351	CHEMBL939832	Inhibition of human cloned Akt2 expressed in Drosophila S2 cells by HTRF assay	B	c1ccc(-c2cc3c(ccn4cnnc34)nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL447328	=	IC50	nM	10.0	CHEMBL2431	Homo sapiens	IC50	nM	10.0
	2504352	CHEMBL939832	Inhibition of human cloned Akt2 expressed in Drosophila S2 cells by HTRF assay	B	NC(=O)Nc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL509747	=	IC50	nM	24.1	CHEMBL2431	Homo sapiens	IC50	nM	24.1
	2504353	CHEMBL939832	Inhibition of human cloned Akt2 expressed in Drosophila S2 cells by HTRF assay	B	Sc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL502854	=	IC50	nM	10.4	CHEMBL2431	Homo sapiens	IC50	nM	10.4
	2504354	CHEMBL939832	Inhibition of human cloned Akt2 expressed in Drosophila S2 cells by HTRF assay	B	Oc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL506077	=	IC50	nM	6.7	CHEMBL2431	Homo sapiens	IC50	nM	6.7
	2504355	CHEMBL939832	Inhibition of human cloned Akt2 expressed in Drosophila S2 cells by HTRF assay	B	Nc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL499555	=	IC50	nM	9.4	CHEMBL2431	Homo sapiens	IC50	nM	9.4
	2506969	CHEMBL942624	Inhibition of PKB beta at 10 uM	B	COc1cc(O)ccc1-c1ccc2c(-c3nc4c(N5CCN(C)CC5)cccc4[nH]3)n[nH]c2c1		CHEMBL474619	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	2506970	CHEMBL942624	Inhibition of PKB beta at 10 uM	B	CN1CCN(c2cccc3nc(-c4n[nH]c5cc(-c6ccc(N)cc6)ccc45)[nH]c23)CC1		CHEMBL480391	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	2511943	CHEMBL969687	Inhibition of human PKBbeta at 1 uM assessed as residual enzyme activity	B	O=C(Nc1ccccc1Cl)c1ccc(Nc2nc(Nc3ccc(O)cc3)ncc2F)cc1		CHEMBL521949	=	Activity	%	103.0	CHEMBL2431	Homo sapiens	Activity	%	103.0
Not Evaluated	2577411	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1		CHEMBL511337		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2593616	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL249097		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2593819	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL478649		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2593882	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1		CHEMBL450519		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2594085	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL515466		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2595028	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL1964275		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2596225	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1		CHEMBL282342		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2596428	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1		CHEMBL408019		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2597697	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Evaluated	2597900	CHEMBL988962	Binding affinity to human AKT2 at 10 uM relative to control	B	CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C		CHEMBL526901		Activity			CHEMBL2431	Homo sapiens	Activity		
	2635192	CHEMBL1000631	Inhibition of PKBbeta at 1 uM relative to control	B	CSc1cc(Oc2ccnc3[nH]c(=O)[nH]c23)ccc1NC(=O)Nc1cccc(C(F)(F)F)c1		CHEMBL496009	=	Residual_activity	%	100.0	CHEMBL2431	Homo sapiens	Residual_activity	%	100.0
	2635935	CHEMBL1000631	Inhibition of PKBbeta at 1 uM relative to control	B	O=C(Nc1cc(C(F)(F)F)ccc1F)Nc1ccc(Oc2ccnc3[nH]c(=O)[nH]c23)c2ccccc12		CHEMBL498112	=	Residual_activity	%	100.0	CHEMBL2431	Homo sapiens	Residual_activity	%	100.0
	2636003	CHEMBL1000631	Inhibition of PKBbeta at 1 uM relative to control	B	CC(C)(C)c1cccc(NC(=O)Nc2ccc(Oc3ccnc4[nH]c(=O)[nH]c34)c3ccccc23)c1		CHEMBL496073	=	Residual_activity	%	75.0	CHEMBL2431	Homo sapiens	Residual_activity	%	75.0
Not Active	2705272	CHEMBL1061588	Inhibition of AKT2 at 50 uM by FRET based assay	B	Clc1ccc(C2(c3ccc(-c4cn[nH]c4)cc3)CCNCC2)cc1		CHEMBL428462		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Active	2705273	CHEMBL1061588	Inhibition of AKT2 at 50 uM by FRET based assay	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Active	2705274	CHEMBL1061588	Inhibition of AKT2 at 50 uM by FRET based assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Active	2705275	CHEMBL1061589	Inhibition of AKT2 at 25 uM by FRET based assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Active	2705276	CHEMBL1061589	Inhibition of AKT2 at 25 uM by FRET based assay	B	Clc1ccc(C2(c3ccc(-c4cn[nH]c4)cc3)CCNCC2)cc1		CHEMBL428462		Activity			CHEMBL2431	Homo sapiens	Activity		
Not Active	2705277	CHEMBL1061589	Inhibition of AKT2 at 25 uM by FRET based assay	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300		Activity			CHEMBL2431	Homo sapiens	Activity		
	2705279	CHEMBL1061586	Inhibition of AKT2 by FRET based assay	B	O=C1COc2ccc(-c3cc(-c4ccccc4)cc(-c4ccc5oc(=O)[nH]c5c4)n3)cc2N1		CHEMBL564972	=	IC50	nM	1500.0	CHEMBL2431	Homo sapiens	IC50	uM	1.5
	2705282	CHEMBL1061586	Inhibition of AKT2 by FRET based assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	IC50	nM	300.0	CHEMBL2431	Homo sapiens	IC50	uM	0.3
	2721690	CHEMBL1054317	Inhibition of PKBbeta at 1 uM	B	C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F		CHEMBL551079	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	2894008	CHEMBL1061915	Percentage PKBbeta activity remaining in the presence of 0.01uM inhibitor	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Activity	%	113.0	CHEMBL2431	Homo sapiens	Activity	%	113.0
Antagonist	2894009	CHEMBL1061915	Percentage PKBbeta activity remaining in the presence of 0.01uM inhibitor	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Activity	%	17.0	CHEMBL2431	Homo sapiens	Activity	%	17.0
	2894010	CHEMBL1061915	Percentage PKBbeta activity remaining in the presence of 0.01uM inhibitor	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Activity	%	77.0	CHEMBL2431	Homo sapiens	Activity	%	77.0
	2894011	CHEMBL1061182	Percentage PKBbeta activity remaining in the presence of 0.1uM inhibitor	B	CC(C)CCN1c2nc(Nc3cc(F)c(O)c(F)c3)ncc2N(C)C(=O)C1C		CHEMBL573107	=	Activity	%	102.0	CHEMBL2431	Homo sapiens	Activity	%	102.0
	2894012	CHEMBL1061182	Percentage PKBbeta activity remaining in the presence of 0.1uM inhibitor	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Activity	%	97.0	CHEMBL2431	Homo sapiens	Activity	%	97.0
Antagonist	2894013	CHEMBL1061182	Percentage PKBbeta activity remaining in the presence of 0.1uM inhibitor	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Activity	%	2.0	CHEMBL2431	Homo sapiens	Activity	%	2.0
	2894014	CHEMBL1061182	Percentage PKBbeta activity remaining in the presence of 0.1uM inhibitor	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Activity	%	92.0	CHEMBL2431	Homo sapiens	Activity	%	92.0
	2894015	CHEMBL1061182	Percentage PKBbeta activity remaining in the presence of 0.1uM inhibitor	B	Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL6291	=	Activity	%	60.0	CHEMBL2431	Homo sapiens	Activity	%	60.0
	2894016	CHEMBL1061182	Percentage PKBbeta activity remaining in the presence of 0.1uM inhibitor	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Activity	%	81.0	CHEMBL2431	Homo sapiens	Activity	%	81.0
	2894017	CHEMBL1061182	Percentage PKBbeta activity remaining in the presence of 0.1uM inhibitor	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Activity	%	83.0	CHEMBL2431	Homo sapiens	Activity	%	83.0
	2894018	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	=	Activity	%	80.0	CHEMBL2431	Homo sapiens	Activity	%	80.0
	2894019	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	=	Activity	%	116.0	CHEMBL2431	Homo sapiens	Activity	%	116.0
	2894020	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Activity	%	86.0	CHEMBL2431	Homo sapiens	Activity	%	86.0
	2894021	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br		CHEMBL573108	=	Activity	%	80.0	CHEMBL2431	Homo sapiens	Activity	%	80.0
	2894022	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Activity	%	88.0	CHEMBL2431	Homo sapiens	Activity	%	88.0
	2894023	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	=	Activity	%	93.0	CHEMBL2431	Homo sapiens	Activity	%	93.0
	2894024	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Activity	%	81.0	CHEMBL2431	Homo sapiens	Activity	%	81.0
	2894025	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Activity	%	51.0	CHEMBL2431	Homo sapiens	Activity	%	51.0
	2894026	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	CC(=O)c1c(O)c(C)c(O)c(Cc2c(O)c3c(c(C(=O)/C=C/c4ccccc4)c2O)OC(C)(C)C=C3)c1O		CHEMBL34241	=	Activity	%	92.0	CHEMBL2431	Homo sapiens	Activity	%	92.0
	2894027	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	C[C@H]1CNCCN1S(=O)(=O)c1cccc2cnccc12		CHEMBL1233654	=	Activity	%	81.0	CHEMBL2431	Homo sapiens	Activity	%	81.0
	2894028	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1ccc(O)c(Cl)c1		CHEMBL322970	=	Activity	%	85.0	CHEMBL2431	Homo sapiens	Activity	%	85.0
	2894029	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	CNCCNS(=O)(=O)c1cccc2cnccc12		CHEMBL148333	=	Activity	%	64.0	CHEMBL2431	Homo sapiens	Activity	%	64.0
	2894030	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Activity	%	75.0	CHEMBL2431	Homo sapiens	Activity	%	75.0
	2894031	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Activity	%	86.0	CHEMBL2431	Homo sapiens	Activity	%	86.0
	2894032	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	NC(=O)c1sc(-c2ccsc2)cc1N		CHEMBL193093	=	Activity	%	103.0	CHEMBL2431	Homo sapiens	Activity	%	103.0
	2894033	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21		CHEMBL264406	=	Activity	%	89.0	CHEMBL2431	Homo sapiens	Activity	%	89.0
	2894034	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Activity	%	92.0	CHEMBL2431	Homo sapiens	Activity	%	92.0
	2894035	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	Cc1ccc(NC(=O)c2cccc(N(C)C)c2)cc1NC(=O)c1ccc(O)cc1		CHEMBL186526	=	Activity	%	63.0	CHEMBL2431	Homo sapiens	Activity	%	63.0
	2894036	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	=	Activity	%	83.0	CHEMBL2431	Homo sapiens	Activity	%	83.0
	2894037	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H]1OC(C)=O		CHEMBL240954	=	Activity	%	99.0	CHEMBL2431	Homo sapiens	Activity	%	99.0
	2894038	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	O=C(Nc1cc(Cl)cc2c1[nH]c1cnccc12)c1cccnc1		CHEMBL79004	=	Activity	%	101.0	CHEMBL2431	Homo sapiens	Activity	%	101.0
	2894039	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	O=C(NOC[C@@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl.O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL540501	=	Activity	%	91.0	CHEMBL2431	Homo sapiens	Activity	%	91.0
	2894040	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	N#CC(=C(/N)Sc1ccccc1N)/C(C#N)=C(\N)Sc1ccccc1N		CHEMBL34704	=	Activity	%	98.0	CHEMBL2431	Homo sapiens	Activity	%	98.0
	2894041	CHEMBL1062855	Percentage PKBbeta activity remaining in the presence of 10uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	87.0	CHEMBL2431	Homo sapiens	Activity	%	87.0
	2894042	CHEMBL1051301	Percentage PKBbeta activity remaining in the presence of 25uM inhibitor	B	COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1		CHEMBL576349	=	Activity	%	90.0	CHEMBL2431	Homo sapiens	Activity	%	90.0
	2894043	CHEMBL1051301	Percentage PKBbeta activity remaining in the presence of 25uM inhibitor	B	NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12		CHEMBL489157	=	Activity	%	89.0	CHEMBL2431	Homo sapiens	Activity	%	89.0
	2894044	CHEMBL1061916	Percentage PKBbeta activity remaining in the presence of 2uM inhibitor	B	Cn1cc(C2=C(c3ccc(Cl)cc3Cl)C(=O)NC2=O)c2ccccc21		CHEMBL102714	=	Activity	%	96.0	CHEMBL2431	Homo sapiens	Activity	%	96.0
	2894045	CHEMBL1061173	Percentage PKBbeta activity remaining in the presence of 3uM inhibitor	B	Cc1ccc(-c2c(C(=O)CF)n(CCCO)c3ncnc(N)c23)cc1		CHEMBL515414	=	Activity	%	97.0	CHEMBL2431	Homo sapiens	Activity	%	97.0
	2894046	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	Activity	%	89.0	CHEMBL2431	Homo sapiens	Activity	%	89.0
	2894047	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	=	Activity	%	80.0	CHEMBL2431	Homo sapiens	Activity	%	80.0
	2894048	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Activity	%	77.0	CHEMBL2431	Homo sapiens	Activity	%	77.0
	2894049	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br		CHEMBL573108	=	Activity	%	104.0	CHEMBL2431	Homo sapiens	Activity	%	104.0
	2894050	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Activity	%	102.0	CHEMBL2431	Homo sapiens	Activity	%	102.0
	2894051	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	=	Activity	%	95.0	CHEMBL2431	Homo sapiens	Activity	%	95.0
	2894052	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Activity	%	90.0	CHEMBL2431	Homo sapiens	Activity	%	90.0
	2894053	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Activity	%	90.0	CHEMBL2431	Homo sapiens	Activity	%	90.0
	2894054	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Activity	%	91.0	CHEMBL2431	Homo sapiens	Activity	%	91.0
	2894055	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O		CHEMBL428496	=	Activity	%	90.0	CHEMBL2431	Homo sapiens	Activity	%	90.0
	2894056	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	Activity	%	83.0	CHEMBL2431	Homo sapiens	Activity	%	83.0
	2894057	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Activity	%	88.0	CHEMBL2431	Homo sapiens	Activity	%	88.0
	2894058	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Activity	%	90.0	CHEMBL2431	Homo sapiens	Activity	%	90.0
	2894059	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	CC(=O)O.O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL265470	=	Activity	%	107.0	CHEMBL2431	Homo sapiens	Activity	%	107.0
	2894060	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Activity	%	92.0	CHEMBL2431	Homo sapiens	Activity	%	92.0
	2894061	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Activity	%	95.0	CHEMBL2431	Homo sapiens	Activity	%	95.0
	2894062	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	COc1ccc2c(c1)[nH]c1c(C)nccc12		CHEMBL269538	=	Activity	%	90.0	CHEMBL2431	Homo sapiens	Activity	%	90.0
	2894063	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	CC1=NCCc2c1[nH]c1cc(O)ccc21		CHEMBL129177	=	Activity	%	81.0	CHEMBL2431	Homo sapiens	Activity	%	81.0
	2894064	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	Cc1nccc2c1[nH]c1ccccc12		CHEMBL12014	=	Activity	%	91.0	CHEMBL2431	Homo sapiens	Activity	%	91.0
	2894065	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	COc1ccc2c3c([nH]c2c1)C(C)=NCC3		CHEMBL340807	=	Activity	%	105.0	CHEMBL2431	Homo sapiens	Activity	%	105.0
	2894066	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	Oc1c(Br)cc(C=C2c3cc(I)ccc3NC2O)cc1Br		CHEMBL1794051	=	Activity	%	82.0	CHEMBL2431	Homo sapiens	Activity	%	82.0
Antagonist	2894067	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	CNCCNS(=O)(=O)c1cccc2cnccc12		CHEMBL148333	=	Activity	%	21.0	CHEMBL2431	Homo sapiens	Activity	%	21.0
	2894068	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12		CHEMBL406821	=	Activity	%	86.0	CHEMBL2431	Homo sapiens	Activity	%	86.0
	2894069	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Activity	%	65.0	CHEMBL2431	Homo sapiens	Activity	%	65.0
	2894070	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21		CHEMBL264406	=	Activity	%	96.0	CHEMBL2431	Homo sapiens	Activity	%	96.0
	2894071	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	=	Activity	%	90.0	CHEMBL2431	Homo sapiens	Activity	%	90.0
	2894072	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Activity	%	98.0	CHEMBL2431	Homo sapiens	Activity	%	98.0
	2894073	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Activity	%	85.0	CHEMBL2431	Homo sapiens	Activity	%	85.0
	2894074	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Activity	%	86.0	CHEMBL2431	Homo sapiens	Activity	%	86.0
	2894878	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	CCCCCCOC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608532	=	Activity	%	96.0	CHEMBL2431	Homo sapiens	Activity	%	96.0
	2894879	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Activity	%	86.0	CHEMBL2431	Homo sapiens	Activity	%	86.0
	2894880	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	92.0	CHEMBL2431	Homo sapiens	Activity	%	92.0
	2894881	CHEMBL1061917	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	B	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	=	Activity	%	97.0	CHEMBL2431	Homo sapiens	Activity	%	97.0
	2897715	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897716	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897717	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897718	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897719	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897720	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897721	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897722	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897723	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897724	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897725	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897726	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897727	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897728	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897729	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897730	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897731	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897732	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897733	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897734	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897735	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897736	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897737	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897738	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897739	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897740	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	780.0	CHEMBL2431	Homo sapiens	Kd	nM	780.0
	2897741	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897742	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897743	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897744	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897745	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897746	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897747	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	44.0	CHEMBL2431	Homo sapiens	Kd	nM	44.0
	2897748	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897749	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	2700.0	CHEMBL2431	Homo sapiens	Kd	nM	2700.0
	2897750	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897751	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2897752	CHEMBL1062832	Binding constant for AKT2 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	2921443	CHEMBL1057568	Inhibition of AKT2 assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	88.0	CHEMBL2431	Homo sapiens	Activity	%	88.0
	2924721	CHEMBL1056853	Inhibition of PKBbeta assessed as residual enzyme activity at 10 uM relative to untreated control	B	c1ccc2c(c1)[nH]c1c3cc[nH]c3ccc21		CHEMBL567173	=	Activity	%	107.0	CHEMBL2431	Homo sapiens	Activity	%	107.0
	2924722	CHEMBL1056853	Inhibition of PKBbeta assessed as residual enzyme activity at 10 uM relative to untreated control	B	c1ccc2c(c1)[nH]c1c2ccc2cc[nH]c21		CHEMBL584980	=	Activity	%	107.0	CHEMBL2431	Homo sapiens	Activity	%	107.0
	2924723	CHEMBL1056853	Inhibition of PKBbeta assessed as residual enzyme activity at 10 uM relative to untreated control	B	O=Cc1c[nH]c2ccc3c4ccccc4[nH]c3c12		CHEMBL575754	=	Activity	%	107.0	CHEMBL2431	Homo sapiens	Activity	%	107.0
	2924724	CHEMBL1056853	Inhibition of PKBbeta assessed as residual enzyme activity at 10 uM relative to untreated control	B	O=Cc1c[nH]c2c1ccc1c3ccccc3[nH]c12		CHEMBL583972	=	Activity	%	98.0	CHEMBL2431	Homo sapiens	Activity	%	98.0
	2926201	CHEMBL1049415	Inhibition of PKBbeta assessed as remaining enzyme activity at 3 uM relative to DMSO	B	COc1ccccc1-n1c(-c2ccccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL574236	=	Activity	%	104.0	CHEMBL2431	Homo sapiens	Activity	%	104.0
	2926295	CHEMBL1057679	Inhibition of PKBbeta assessed as remaining enzyme activity at 1 uM relative to DMSO	B	COc1ccccc1-n1c(-c2cc(O)ccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL566515	=	Activity	%	104.0	CHEMBL2431	Homo sapiens	Activity	%	104.0
	2938533	CHEMBL1040495	Inhibition of AKT2 at 1 uM	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
Not Active	2938591	CHEMBL1040604	Inhibition of AKT2 at 10 uM	B	O=C1OC(/C=C/c2ccccc2)=N/C1=C\c1cccnc1		CHEMBL565286		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	2998993	CHEMBL1041965	Inhibition of PKBbeta assessed as residual activity at 10 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	CC(C)c1onc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL220227	=	Activity	%	101.0	CHEMBL2431	Homo sapiens	Activity	%	101.0
	2999783	CHEMBL1041965	Inhibition of PKBbeta assessed as residual activity at 10 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	CC(C)c1noc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL375428	=	Activity	%	104.0	CHEMBL2431	Homo sapiens	Activity	%	104.0
	2999860	CHEMBL1048105	Inhibition of PKBbeta assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL569114	=	Activity	%	98.0	CHEMBL2431	Homo sapiens	Activity	%	98.0
	2999936	CHEMBL1048105	Inhibition of PKBbeta assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c([S+](C)[O-])nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL572006	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	3052524	CHEMBL1047775	Residual activity of AKT2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	113.0	CHEMBL2431	Homo sapiens	Residual activity	%	113.0
	3052776	CHEMBL1046509	Residual activity of AKT2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	167.0	CHEMBL2431	Homo sapiens	Residual activity	%	167.0
	3054085	CHEMBL1066603	Residual activity of AKT2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	97.0	CHEMBL2431	Homo sapiens	Residual activity	%	97.0
	3055372	CHEMBL1047775	Residual activity of AKT2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	83.0	CHEMBL2431	Homo sapiens	Residual activity	%	83.0
	3055624	CHEMBL1046509	Residual activity of AKT2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	175.0	CHEMBL2431	Homo sapiens	Residual activity	%	175.0
	3056929	CHEMBL1066603	Residual activity of AKT2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	102.0	CHEMBL2431	Homo sapiens	Residual activity	%	102.0
	3058249	CHEMBL1047775	Residual activity of AKT2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	91.0	CHEMBL2431	Homo sapiens	Residual activity	%	91.0
	3058501	CHEMBL1046509	Residual activity of AKT2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	119.0	CHEMBL2431	Homo sapiens	Residual activity	%	119.0
	3062439	CHEMBL1048632	Binding affinity to human AKT2 at 200 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CSSC[C@@H](C(=O)NCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL595545	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	3063574	CHEMBL1045160	Binding affinity to human AKT2 at 500 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL595546	=	Activity	%	37.0	CHEMBL2431	Homo sapiens	Activity	%	37.0
	3063664	CHEMBL1038875	Binding affinity to human AKT2 at 50 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CNC(=O)C[C@@H](C(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL609010	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	3065845	CHEMBL1068651	Inhibition of AKT2 at 10 uM	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	3066911	CHEMBL1068651	Inhibition of AKT2 at 10 uM	B	O=C1Nc2ccccc2/C1=C1\C(=O)N(CCCc2ccccc2)c2ccccc21		CHEMBL607196	=	Inhibition	%	35.0	CHEMBL2431	Homo sapiens	INH	%	35.0
	3072847	CHEMBL1066603	Residual activity of AKT2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	108.0	CHEMBL2431	Homo sapiens	Residual activity	%	108.0
	3076641	CHEMBL1072611	Inhibition of human AKT2	B	Cc1occc1-c1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1		CHEMBL596583	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	uM	0.025
	3076647	CHEMBL1072611	Inhibition of human AKT2	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2[nH]nc(C)c2c1		CHEMBL593374	=	IC50	nM	15.0	CHEMBL2431	Homo sapiens	IC50	uM	0.015
	3076653	CHEMBL1072611	Inhibition of human AKT2	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2c1		CHEMBL593375	=	IC50	nM	15.0	CHEMBL2431	Homo sapiens	IC50	uM	0.015
	3076659	CHEMBL1072611	Inhibition of human AKT2	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1		CHEMBL595944	=	IC50	nM	19.0	CHEMBL2431	Homo sapiens	IC50	uM	0.019
	3076665	CHEMBL1072611	Inhibition of human AKT2	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cc2c(C)n[nH]c2cn1		CHEMBL595459	=	IC50	nM	13.0	CHEMBL2431	Homo sapiens	IC50	uM	0.013
	3076671	CHEMBL1072611	Inhibition of human AKT2	B	Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c(C#N)nc3-c3ccoc3)nc12		CHEMBL606467	=	IC50	nM	250.0	CHEMBL2431	Homo sapiens	IC50	uM	0.25
	3076677	CHEMBL1072611	Inhibition of human AKT2	B	Cc1nc(-c2ccoc2)c(-c2cnc3[nH]nc(C)c3n2)cc1OC[C@@H](N)Cc1c[nH]c2ccccc12		CHEMBL594523	=	IC50	nM	63.0	CHEMBL2431	Homo sapiens	IC50	uM	0.063
	3076683	CHEMBL1072611	Inhibition of human AKT2	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2ccccc2)cc1-c1cnc2[nH]nc(C)c2n1		CHEMBL594755	=	IC50	nM	130.0	CHEMBL2431	Homo sapiens	IC50	uM	0.13
	3076689	CHEMBL1072611	Inhibition of human AKT2	B	CCNc1nc(-c2ccoc2)c(-c2cnc3[nH]nc(C)c3n2)cc1OC[C@@H](N)Cc1ccccc1		CHEMBL593573	=	IC50	nM	6300.0	CHEMBL2431	Homo sapiens	IC50	uM	6.3
	3076695	CHEMBL1072611	Inhibition of human AKT2	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(Cl)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1		CHEMBL593813	=	IC50	nM	12.0	CHEMBL2431	Homo sapiens	IC50	uM	0.012
	3076701	CHEMBL1072611	Inhibition of human AKT2	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(C#N)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1		CHEMBL605410	=	IC50	nM	7.0	CHEMBL2431	Homo sapiens	IC50	uM	0.007
	3076707	CHEMBL1072611	Inhibition of human AKT2	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(C(N)=O)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1		CHEMBL594072	=	IC50	nM	15.0	CHEMBL2431	Homo sapiens	IC50	uM	0.015
	3084412	CHEMBL1072691	Inhibition of AKT2	B	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	=	IC50	nM	4200.0	CHEMBL2431	Homo sapiens	IC50	uM	4.2
	3086985	CHEMBL1069942	Inhibition of AKT2	B	Cc1[nH]nc2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12		CHEMBL593490	=	IC50	nM	12.0	CHEMBL2431	Homo sapiens	IC50	uM	0.012
	3086986	CHEMBL1069942	Inhibition of AKT2	B	Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12		CHEMBL596290	=	IC50	nM	39.0	CHEMBL2431	Homo sapiens	IC50	uM	0.039
	3086987	CHEMBL1069942	Inhibition of AKT2	B	Cc1n[nH]c2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12		CHEMBL603197	=	IC50	nM	31.0	CHEMBL2431	Homo sapiens	IC50	uM	0.031
	3086988	CHEMBL1069942	Inhibition of AKT2	B	Cc1n[nH]c2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12		CHEMBL594933	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	uM	0.006
	3094749	CHEMBL1069049	Inhibition of AKT2 at 1 uM by microfluidic substrate phosphorylation assay	B	NC(=O)c1ccc(-c2cc(-c3cccc4c3OCO4)cnc2N)cc1		CHEMBL590335	=	Inhibition	%	-2.0	CHEMBL2431	Homo sapiens	INH	%	-2.0
	3094758	CHEMBL1069049	Inhibition of AKT2 at 1 uM by microfluidic substrate phosphorylation assay	B	NCCNC(=O)c1cc(-c2ccsc2)cnc1N		CHEMBL610226	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	3094764	CHEMBL1069049	Inhibition of AKT2 at 1 uM by microfluidic substrate phosphorylation assay	B	NCCNC(=O)c1cc(-c2scc3c2OCCO3)cnc1N		CHEMBL599171	=	Inhibition	%	1.0	CHEMBL2431	Homo sapiens	INH	%	1.0
	3094775	CHEMBL1069049	Inhibition of AKT2 at 1 uM by microfluidic substrate phosphorylation assay	B	NC(=O)c1ccc(-c2cc(-c3scc4c3OCCO4)cnc2N)cc1		CHEMBL602931	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	3126357	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	IC50	nM	2.2	CHEMBL2431	Homo sapiens	IC50	nM	2.2
	3126359	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)NCc2ccc(Cl)cc2F)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597600	=	IC50	nM	4.0	CHEMBL2431	Homo sapiens	IC50	nM	4.0
	3126360	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)NCc2ccc(Cl)cc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL599849	=	IC50	nM	4.9	CHEMBL2431	Homo sapiens	IC50	nM	4.9
	3126361	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]c(=O)[nH]c23)CC1		CHEMBL598842	=	IC50	nM	5.0	CHEMBL2431	Homo sapiens	IC50	nM	5.0
	3126362	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ccnc3[nH]ccc23)CC1		CHEMBL596991	=	IC50	nM	5.5	CHEMBL2431	Homo sapiens	IC50	nM	5.5
	3126363	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)NCc2ccc(Cl)c(Cl)c2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598206	=	IC50	nM	5.7	CHEMBL2431	Homo sapiens	IC50	nM	5.7
	3126364	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	nM	6.0
	3126367	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2ccc3ccccc3c2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL603882	=	IC50	nM	7.0	CHEMBL2431	Homo sapiens	IC50	nM	7.0
	3126368	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)NCc2cccc(Cl)c2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL604910	=	IC50	nM	7.0	CHEMBL2431	Homo sapiens	IC50	nM	7.0
	3126371	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(COCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597793	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	nM	8.0
	3126372	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)NCc2ccc(F)cc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL604507	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	nM	8.0
	3126373	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2ccc(Cl)cc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597414	=	IC50	nM	8.5	CHEMBL2431	Homo sapiens	IC50	nM	8.5
	3126375	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)NCc2ccc(C(F)(F)F)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL599847	=	IC50	nM	11.0	CHEMBL2431	Homo sapiens	IC50	nM	11.0
	3126376	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)NCc2ccc(F)cc2F)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598207	=	IC50	nM	11.0	CHEMBL2431	Homo sapiens	IC50	nM	11.0
	3126378	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ccnc3[nH]ccc23)CC1		CHEMBL599448	=	IC50	nM	12.0	CHEMBL2431	Homo sapiens	IC50	nM	12.0
	3126379	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ccnc3[nH]ncc23)CC1		CHEMBL598013	=	IC50	nM	12.0	CHEMBL2431	Homo sapiens	IC50	nM	12.0
	3126384	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)NCc2ccc(F)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597183	=	IC50	nM	14.0	CHEMBL2431	Homo sapiens	IC50	nM	14.0
	3126385	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	COc1cccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)c1		CHEMBL597819	=	IC50	nM	15.0	CHEMBL2431	Homo sapiens	IC50	nM	15.0
	3126387	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2cc(Cl)ccc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL604917	=	IC50	nM	16.0	CHEMBL2431	Homo sapiens	IC50	nM	16.0
	3126388	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2ccc(Cl)c(Cl)c2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL603680	=	IC50	nM	18.0	CHEMBL2431	Homo sapiens	IC50	nM	18.0
	3126390	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2cccc(OC(F)(F)F)c2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597818	=	IC50	nM	19.0	CHEMBL2431	Homo sapiens	IC50	nM	19.0
	3126391	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2c(Cl)cccc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597415	=	IC50	nM	20.0	CHEMBL2431	Homo sapiens	IC50	nM	20.0
	3126394	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2cccc3ccccc23)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598448	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	nM	25.0
	3126395	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	CN(Cc1ccc(Cl)cc1)C(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597803	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	nM	25.0
	3126396	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1		CHEMBL597211	=	IC50	nM	27.0	CHEMBL2431	Homo sapiens	IC50	nM	27.0
	3126397	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)NCc2ccc(OC(F)(F)F)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL599848	=	IC50	nM	29.0	CHEMBL2431	Homo sapiens	IC50	nM	29.0
	3126399	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	CC(C)(C)c1ccc(CC2(N)CCN(c3ccnc4[nH]ccc34)CC2)cc1		CHEMBL603262	=	IC50	nM	31.0	CHEMBL2431	Homo sapiens	IC50	nM	31.0
	3126402	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2ccc(OC(F)(F)F)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597817	=	IC50	nM	35.0	CHEMBL2431	Homo sapiens	IC50	nM	35.0
	3126403	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2cccc(Cl)c2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597212	=	IC50	nM	35.0	CHEMBL2431	Homo sapiens	IC50	nM	35.0
	3126404	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)NCc2ccccc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL600646	=	IC50	nM	36.0	CHEMBL2431	Homo sapiens	IC50	nM	36.0
	3126405	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2ccccc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598439	=	IC50	nM	44.0	CHEMBL2431	Homo sapiens	IC50	nM	44.0
	3126408	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2cccc(Cl)c2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598438	=	IC50	nM	46.0	CHEMBL2431	Homo sapiens	IC50	nM	46.0
	3127114	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2ccc(Cl)cc2Cl)CCN(c2ncnc3[nH]c(=O)[nH]c23)CC1		CHEMBL590957	=	IC50	nM	52.0	CHEMBL2431	Homo sapiens	IC50	nM	52.0
	3127120	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	CC(C)(C)c1ccc(CC2(N)CCN(c3ccnc4[nH]ncc34)CC2)cc1		CHEMBL603675	=	IC50	nM	58.0	CHEMBL2431	Homo sapiens	IC50	nM	58.0
	3127123	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(CNC(=O)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL603244	=	IC50	nM	69.0	CHEMBL2431	Homo sapiens	IC50	nM	69.0
	3127125	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]c(=O)[nH]c34)CC2)cc1		CHEMBL598841	=	IC50	nM	70.0	CHEMBL2431	Homo sapiens	IC50	nM	70.0
	3127128	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2ccccc2OC(F)(F)F)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL602236	=	IC50	nM	84.0	CHEMBL2431	Homo sapiens	IC50	nM	84.0
	3127130	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(Cc2ccc(F)cc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL605212	=	IC50	nM	90.0	CHEMBL2431	Homo sapiens	IC50	nM	90.0
	3127139	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	CC(C)(C)c1ccc(CNC(=O)C2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1		CHEMBL606200	=	IC50	nM	210.0	CHEMBL2431	Homo sapiens	IC50	nM	210.0
	3127140	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)N2CCc3ccccc3C2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL596990	=	IC50	nM	250.0	CHEMBL2431	Homo sapiens	IC50	nM	250.0
	3127148	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	NC1(C(=O)N2CCCC2c2ccccc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL605326	=	IC50	nM	680.0	CHEMBL2431	Homo sapiens	IC50	nM	680.0
	3127160	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	COc1ccccc1CC1(N)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597008	>	IC50	nM	1000.0	CHEMBL2431	Homo sapiens	IC50	nM	1000.0
	3127254	CHEMBL1072809	Inhibition of PKBbeta by radiometric filter binding assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	IC50	nM	590.0	CHEMBL2431	Homo sapiens	IC50	nM	590.0
	3130786	CHEMBL1065107	Inhibition of PKBbeta at 3 to 6 uM relative to control	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1OC		CHEMBL604087	>	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3131776	CHEMBL1065780	Inhibition of PKBbeta at 3 uM relative to control	B	NC(=O)c1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1		CHEMBL600852	>	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3186230	CHEMBL1111478	Inhibition of Akt2	B	c1ccc(-c2cc3c(ccn4cnnc34)nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL447328	=	IC50	nM	10.0	CHEMBL2431	Homo sapiens	IC50	nM	10.0
	3186237	CHEMBL1111478	Inhibition of Akt2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCNC3)c21		CHEMBL521642	=	IC50	nM	13.0	CHEMBL2431	Homo sapiens	IC50	nM	13.0
	3186271	CHEMBL1111478	Inhibition of Akt2	B	Cn1nnnc1-c1cnc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)c1		CHEMBL182101	=	IC50	nM	157.0	CHEMBL2431	Homo sapiens	IC50	nM	157.0
	3186273	CHEMBL1111478	Inhibition of Akt2	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	210.0	CHEMBL2431	Homo sapiens	IC50	nM	210.0
	3186285	CHEMBL1111478	Inhibition of Akt2	B	CCn1c(-c2nonc2N)nc2cncc(OC3CCNCC3)c21		CHEMBL493911	=	IC50	nM	1000.0	CHEMBL2431	Homo sapiens	IC50	nM	1000.0
	3186295	CHEMBL1111478	Inhibition of Akt2	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	=	IC50	nM	12.0	CHEMBL2431	Homo sapiens	IC50	nM	12.0
	3213871	CHEMBL1111287	Inhibition of AKT2 at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	-1.0	CHEMBL2431	Homo sapiens	INH	%	-1.0
	3219687	CHEMBL1110438	Inhibition of PKBbeta at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1ccc(-c2ccnc(N)n2)s1)C(N)=O		CHEMBL1077375	=	Inhibition	%	80.0	CHEMBL2431	Homo sapiens	INH	%	80.0
	3224748	CHEMBL1102595	Inhibition of AKT2 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3225003	CHEMBL1102595	Inhibition of AKT2 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3240787	CHEMBL1108838	Inhibition of AKT2	B	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1		CHEMBL1090360	>	IC50	nM	1000.0	CHEMBL2431	Homo sapiens	IC50	uM	1.0
	3260080	CHEMBL1116009	Inhibition of PKBbeta at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2nccc(Nc3cccc(Br)c3)c2c1		CHEMBL1089524	=	Activity	%	61.0	CHEMBL2431	Homo sapiens	Activity	%	61.0
	3261393	CHEMBL1116009	Inhibition of PKBbeta at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL1088901	=	Activity	%	80.0	CHEMBL2431	Homo sapiens	Activity	%	80.0
	3262266	CHEMBL1113460	Inhibition of AKT2 at 10 uM	B	O=C1OC(c2ccccc2)=N/C1=C\c1cccnc1		CHEMBL579387	=	Inhibition	%	13.0	CHEMBL2431	Homo sapiens	INH	%	13.0
	3262267	CHEMBL1113460	Inhibition of AKT2 at 10 uM	B	Cc1cccc(C2=N/C(=C\c3cccnc3)C(=O)O2)c1		CHEMBL1091786	=	Inhibition	%	6.0	CHEMBL2431	Homo sapiens	INH	%	6.0
	3262268	CHEMBL1113460	Inhibition of AKT2 at 10 uM	B	O=C1OC(c2ccc(Cl)cc2)=N/C1=C\c1cccnc1		CHEMBL1091787	=	Inhibition	%	17.0	CHEMBL2431	Homo sapiens	INH	%	17.0
	3262269	CHEMBL1113460	Inhibition of AKT2 at 10 uM	B	O=C1OC(/C=C/c2ccccc2)=N/C1=C\c1cccnc1		CHEMBL565286	=	Inhibition	%	17.0	CHEMBL2431	Homo sapiens	INH	%	17.0
	3262270	CHEMBL1113460	Inhibition of AKT2 at 10 uM	B	O=C1OC(c2ccc(F)c(F)c2)=N/C1=C\c1cccnc1		CHEMBL1091764	=	Inhibition	%	18.0	CHEMBL2431	Homo sapiens	INH	%	18.0
	3262271	CHEMBL1113460	Inhibition of AKT2 at 10 uM	B	Cc1cc(C2=N/C(=C\c3cccnc3)C(=O)O2)ccc1Br		CHEMBL1091766	=	Inhibition	%	28.0	CHEMBL2431	Homo sapiens	INH	%	28.0
	3269008	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@H](CN)c3ccccc3)cc21		CHEMBL1099296	=	Ki	nM	17.0	CHEMBL2431	Homo sapiens	Ki	nM	17.0
	3269009	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)Cc3ccccc3)cc21		CHEMBL1098938	=	Ki	nM	2.0	CHEMBL2431	Homo sapiens	Ki	nM	2.0
	3269010	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21		CHEMBL1099276	=	Ki	nM	5.0	CHEMBL2431	Homo sapiens	Ki	nM	5.0
	3269011	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCCN)cc21		CHEMBL1096292	=	Ki	nM	646.0	CHEMBL2431	Homo sapiens	Ki	nM	646.0
	3269012	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCN)cc21		CHEMBL1096291	=	Ki	nM	39.0	CHEMBL2431	Homo sapiens	Ki	nM	39.0
	3269013	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Ki	nM	4.0	CHEMBL2431	Homo sapiens	Ki	nM	4.0
	3269053	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	IC50	nM	13.0	CHEMBL2431	Homo sapiens	IC50	nM	13.0
	3269054	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN)cc21		CHEMBL1098241	=	IC50	nM	63.0	CHEMBL2431	Homo sapiens	IC50	nM	63.0
	3269055	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CCN)cc21		CHEMBL1095624	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	nM	25.0
	3269056	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CCCN)cc21		CHEMBL1097974	=	IC50	nM	40.0	CHEMBL2431	Homo sapiens	IC50	nM	40.0
	3269057	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CNC)cc21		CHEMBL1098316	=	IC50	nM	16.0	CHEMBL2431	Homo sapiens	IC50	nM	16.0
	3269058	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN(C)C)cc21		CHEMBL1099290	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	nM	25.0
	3269059	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	IC50	nM	200.0	CHEMBL2431	Homo sapiens	IC50	nM	200.0
	3269060	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCN)cc21		CHEMBL1096291	=	IC50	nM	40.0	CHEMBL2431	Homo sapiens	IC50	nM	40.0
	3269061	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCCN)cc21		CHEMBL1096292	=	IC50	nM	200.0	CHEMBL2431	Homo sapiens	IC50	nM	200.0
	3269062	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCCCN)cc21		CHEMBL1096636	=	IC50	nM	316.0	CHEMBL2431	Homo sapiens	IC50	nM	316.0
	3269063	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21		CHEMBL1098943	=	IC50	nM	79.0	CHEMBL2431	Homo sapiens	IC50	nM	79.0
	3269064	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](C)N)cc21		CHEMBL1098944	=	IC50	nM	50.0	CHEMBL2431	Homo sapiens	IC50	nM	50.0
	3269065	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](C)N)cc21		CHEMBL1099281	=	IC50	nM	63.0	CHEMBL2431	Homo sapiens	IC50	nM	63.0
	3269066	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	IC50	nM	20.0	CHEMBL2431	Homo sapiens	IC50	nM	20.0
	3269067	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	IC50	nM	20.0	CHEMBL2431	Homo sapiens	IC50	nM	20.0
	3269068	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)Cc3ccccc3)cc21		CHEMBL1098938	=	IC50	nM	10.0	CHEMBL2431	Homo sapiens	IC50	nM	10.0
	3269069	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)Cc3ccccc3)cc21		CHEMBL1098939	=	IC50	nM	20.0	CHEMBL2431	Homo sapiens	IC50	nM	20.0
	3269070	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21		CHEMBL1099276	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	nM	25.0
	3269071	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@H](CN)c3ccccc3)cc21		CHEMBL1099296	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	nM	25.0
	3269072	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CCN)c3ccccc3)cc21		CHEMBL1099297	=	IC50	nM	16.0	CHEMBL2431	Homo sapiens	IC50	nM	16.0
	3269073	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@H](CCN)c3ccccc3)cc21		CHEMBL1099298	=	IC50	nM	50.0	CHEMBL2431	Homo sapiens	IC50	nM	50.0
	3269525	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CCN)c3ccccc3)cc21		CHEMBL1099297	=	Ki	nM	1.0	CHEMBL2431	Homo sapiens	Ki	nM	1.0
	3269526	CHEMBL1109953	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@H](CCN)c3ccccc3)cc21		CHEMBL1099298	=	Ki	nM	105.0	CHEMBL2431	Homo sapiens	Ki	nM	105.0
Not Active	3271724	CHEMBL1112897	Inhibition of AKT2	B	COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1		CHEMBL576349		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	3271725	CHEMBL1112897	Inhibition of AKT2	B	COc1ccccc1/C=C1/C(=O)Nc2ccccc21		CHEMBL444673		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	3271726	CHEMBL1112897	Inhibition of AKT2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1F		CHEMBL1088391		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	3271727	CHEMBL1112897	Inhibition of AKT2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1[N+](=O)[O-]		CHEMBL1088392		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	3271728	CHEMBL1112897	Inhibition of AKT2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1S(=O)(=O)O		CHEMBL1088529		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	3271729	CHEMBL1112897	Inhibition of AKT2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccc2c(c1)OCO2		CHEMBL1086669		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	3271730	CHEMBL1112897	Inhibition of AKT2	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1cc(F)cc(F)c1		CHEMBL1086670		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	3271731	CHEMBL1112897	Inhibition of AKT2	B	NC(=O)Cc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL1086795		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	3271732	CHEMBL1112897	Inhibition of AKT2	B	COc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1OC		CHEMBL1086796		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	3271733	CHEMBL1112897	Inhibition of AKT2	B	COc1cc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc(OC)c1OC		CHEMBL383871		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	3271734	CHEMBL1112897	Inhibition of AKT2	B	COc1cc(OC)c(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1		CHEMBL1086939	<	Inhibition	%	20.0	CHEMBL2431	Homo sapiens	INH	%	20.0
Not Active	3271735	CHEMBL1112897	Inhibition of AKT2	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	3306912	CHEMBL1117937	Inhibition of PKBbeta at 3 uM	B	O=C(Nc1cc2cc[nH]c(=O)c2cc1Cl)C(NC1CC1)c1ccccc1		CHEMBL1084106	=	Inhibition	%	39.0	CHEMBL2431	Homo sapiens	INH	%	39.0
	3331823	CHEMBL1168782	Inhibition of AKT2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3333238	CHEMBL1168782	Inhibition of AKT2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3334643	CHEMBL1168782	Inhibition of AKT2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3336063	CHEMBL1168782	Inhibition of AKT2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3337449	CHEMBL1168782	Inhibition of AKT2 at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3337697	CHEMBL1168782	Inhibition of AKT2 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3339028	CHEMBL1168782	Inhibition of AKT2 at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3339284	CHEMBL1168782	Inhibition of AKT2 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3340591	CHEMBL1168782	Inhibition of AKT2 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3342007	CHEMBL1168782	Inhibition of AKT2 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	3354474	CHEMBL1173998	Inhibition of AKT2 at 10 uM by mobility shift assay	B	c1ccc(-c2cnc3cnc(-c4cc[nH]n4)cn23)cc1		CHEMBL1170750	=	Inhibition	%	-7.0	CHEMBL2431	Homo sapiens	INH	%	-7.0
	3354475	CHEMBL1173998	Inhibition of AKT2 at 10 uM by mobility shift assay	B	c1ccc(-c2cnc3cnc(-c4cn[nH]c4)cn23)cc1		CHEMBL1172464	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	3354476	CHEMBL1173998	Inhibition of AKT2 at 10 uM by mobility shift assay	B	c1ccc(-c2cnc3cnc(-c4ccncc4)cn23)cc1	Outside typical range	CHEMBL1170317	=	Inhibition	%	-11.0	CHEMBL2431	Homo sapiens	INH	%	-11.0
	3354477	CHEMBL1173998	Inhibition of AKT2 at 10 uM by mobility shift assay	B	c1n[nH]cc1-c1cnc2ncc(-c3cn[nH]c3)n2c1		CHEMBL1171532	=	Inhibition	%	-5.0	CHEMBL2431	Homo sapiens	INH	%	-5.0
	3354478	CHEMBL1173998	Inhibition of AKT2 at 10 uM by mobility shift assay	B	Cn1cc(-c2cnc3ncc(-c4cn[nH]c4)cn23)cn1		CHEMBL1171533	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	3354479	CHEMBL1173998	Inhibition of AKT2 at 10 uM by mobility shift assay	B	c1cc(-c2cnc3ncc(-c4cn[nH]c4)cn23)n[nH]1		CHEMBL1171534	=	Inhibition	%	-2.0	CHEMBL2431	Homo sapiens	INH	%	-2.0
	3354480	CHEMBL1173998	Inhibition of AKT2 at 10 uM by mobility shift assay	B	OCc1cccc(-c2cnc3ncc(-c4cn[nH]c4)cn23)c1		CHEMBL1171699	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	3354481	CHEMBL1173998	Inhibition of AKT2 at 10 uM by mobility shift assay	B	c1ccc2c(-c3cnc4cnc(-c5cn[nH]c5)cn34)c[nH]c2c1		CHEMBL1170126	=	Inhibition	%	14.0	CHEMBL2431	Homo sapiens	INH	%	14.0
	3354482	CHEMBL1173998	Inhibition of AKT2 at 10 uM by mobility shift assay	B	NCc1ccc(-c2cn3c(-c4cn[nH]c4)cnc3cn2)cc1		CHEMBL1170747	=	Inhibition	%	5.0	CHEMBL2431	Homo sapiens	INH	%	5.0
	3354483	CHEMBL1173998	Inhibition of AKT2 at 10 uM by mobility shift assay	B	OCc1cccc(-c2cn3c(-c4cn[nH]c4)cnc3cn2)c1		CHEMBL1170748	=	Inhibition	%	2.0	CHEMBL2431	Homo sapiens	INH	%	2.0
	3354484	CHEMBL1173998	Inhibition of AKT2 at 10 uM by mobility shift assay	B	OCc1ccc(-c2cn3c(-c4cn[nH]c4)cnc3cn2)cc1		CHEMBL1170749	=	Inhibition	%	-8.0	CHEMBL2431	Homo sapiens	INH	%	-8.0
	3354941	CHEMBL1173998	Inhibition of AKT2 at 10 uM by mobility shift assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Inhibition	%	84.0	CHEMBL2431	Homo sapiens	INH	%	84.0
	3358450	CHEMBL1174064	Inhibition of AKT2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	30.0	CHEMBL2431	Homo sapiens	INH	%	30.0
	3358892	CHEMBL1174064	Inhibition of AKT2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	4.6	CHEMBL2431	Homo sapiens	INH	%	4.6
	3368283	CHEMBL1176582	Inhibition of AKT2 after 90 mins by IMAP assay	B	CCc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4F)C3)c12		CHEMBL1171647	=	IC50	nM	9.0	CHEMBL2431	Homo sapiens	IC50	nM	9.0
	3370104	CHEMBL1176705	Inhibition of AKT2 at 10 uM	B	COc1ccc(NC(=O)Nc2ccc3c(c2)NC(=O)/C3=C\c2[nH]cc(C(=O)O)c2C)cc1		CHEMBL1173411	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	3439168	CHEMBL1247990	Inhibition of PKBbeta by HTRF assay	B	CNc1nccc(-c2cccnc2Oc2ccc(Nc3nnc(-c4ccc(F)cc4)c4ccccc34)cc2)n1		CHEMBL1243326	>	IC50	nM	25000.0	CHEMBL2431	Homo sapiens	IC50	nM	25000.0
	3443337	CHEMBL1243989	Inhibition of AKT2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	1.0	CHEMBL2431	Homo sapiens	INH	%	1.0
	3443554	CHEMBL1243989	Inhibition of AKT2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	3.0	CHEMBL2431	Homo sapiens	INH	%	3.0
	3444709	CHEMBL1243989	Inhibition of AKT2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	3.0	CHEMBL2431	Homo sapiens	INH	%	3.0
	3445024	CHEMBL1244720	Binding affinity to AKT2	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	2100.0	CHEMBL2431	Homo sapiens	Kd	nM	2100.0
	3445333	CHEMBL1243989	Inhibition of AKT2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	1.0	CHEMBL2431	Homo sapiens	INH	%	1.0
	3445550	CHEMBL1243989	Inhibition of AKT2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	6.0	CHEMBL2431	Homo sapiens	INH	%	6.0
	3445768	CHEMBL1243989	Inhibition of AKT2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	13.0	CHEMBL2431	Homo sapiens	INH	%	13.0
	3445958	CHEMBL1243989	Inhibition of AKT2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	3447713	CHEMBL1250015	Inhibition of Akt2	B	CC(C)Cc1nc(-c2ccc(CN3CCC(n4c(O)nc5ccccc54)CC3)cc2)c(-c2ccccc2)nc1O		CHEMBL362016	=	Ki	nM	325.0	CHEMBL2431	Homo sapiens	Ki	nM	325.0
	3448877	CHEMBL1244720	Binding affinity to AKT2	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	780.0	CHEMBL2431	Homo sapiens	Kd	nM	780.0
	3449392	CHEMBL1244720	Binding affinity to AKT2	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	2700.0	CHEMBL2431	Homo sapiens	Kd	nM	2700.0
	3449556	CHEMBL1244720	Binding affinity to AKT2	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	3449981	CHEMBL1244720	Binding affinity to AKT2	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	3450910	CHEMBL1244720	Binding affinity to AKT2	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	3451200	CHEMBL1244720	Binding affinity to AKT2	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	uM	10.0
	3462679	CHEMBL1252173	Inhibition of myristoylated wild type AKT2 expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	IC50	nM	30.0	CHEMBL2431	Homo sapiens	IC50	nM	30.0
	3462680	CHEMBL1252173	Inhibition of myristoylated wild type AKT2 expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	nM	10000.0
	3462681	CHEMBL1252173	Inhibition of myristoylated wild type AKT2 expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	B	CC(C)(C)n1nc(Cc2cccc(I)c2)c2c(N)ncnc21		CHEMBL1254115	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	nM	10000.0
	3463170	CHEMBL1251630	Inhibition of AKT2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	94.0	CHEMBL2431	Homo sapiens	INH	%	94.0
	3463389	CHEMBL1251630	Inhibition of AKT2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	12.0	CHEMBL2431	Homo sapiens	INH	%	12.0
	3463933	CHEMBL1251630	Inhibition of AKT2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	9.0	CHEMBL2431	Homo sapiens	INH	%	9.0
	3502272	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	N[C@H](Cc1ccccc1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258329	=	IC50	nM	8362.0	CHEMBL2431	Homo sapiens	IC50	nM	8362.0
	3502273	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258330	=	IC50	nM	118.0	CHEMBL2431	Homo sapiens	IC50	nM	118.0
	3502274	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	N#Cc1ccc(C[C@@H](N)C(=O)N2CCN(c3ncnc4ccccc34)CC2)cc1		CHEMBL1258441	=	IC50	nM	4371.0	CHEMBL2431	Homo sapiens	IC50	nM	4371.0
	3502275	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	N[C@H](Cc1ccc(F)cc1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258442	=	IC50	nM	1288.0	CHEMBL2431	Homo sapiens	IC50	nM	1288.0
	3502276	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	COc1ccc(C[C@@H](N)C(=O)N2CCN(c3ncnc4ccccc34)CC2)cc1		CHEMBL1258550	=	IC50	nM	1485.0	CHEMBL2431	Homo sapiens	IC50	nM	1485.0
	3502277	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	Cc1ccc(C[C@@H](N)C(=O)N2CCN(c3ncnc4ccccc34)CC2)cc1		CHEMBL1258551	=	IC50	nM	630.0	CHEMBL2431	Homo sapiens	IC50	nM	630.0
	3502278	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	N[C@H](Cc1ccc(Br)cc1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258662	=	IC50	nM	279.0	CHEMBL2431	Homo sapiens	IC50	nM	279.0
	3502279	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	N[C@H](Cc1ccccc1Cl)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258663	=	IC50	nM	26500.0	CHEMBL2431	Homo sapiens	IC50	nM	26500.0
	3502280	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	N[C@H](Cc1cccc(Cl)c1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258778	=	IC50	nM	5586.0	CHEMBL2431	Homo sapiens	IC50	nM	5586.0
	3502281	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1Cl)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258779	=	IC50	nM	1067.0	CHEMBL2431	Homo sapiens	IC50	nM	1067.0
	3502282	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	N[C@H](Cc1ccc(Cl)c(Cl)c1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258898	=	IC50	nM	433.0	CHEMBL2431	Homo sapiens	IC50	nM	433.0
	3502283	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	N[C@H](Cc1ccc(F)c(F)c1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258899	=	IC50	nM	872.0	CHEMBL2431	Homo sapiens	IC50	nM	872.0
	3502284	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	N[C@H](Cc1ccc(C(F)(F)F)cc1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1257163	=	IC50	nM	707.0	CHEMBL2431	Homo sapiens	IC50	nM	707.0
	3502285	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	N[C@H](Cc1ccc(-c2ccccc2)cc1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1257164	=	IC50	nM	37826.0	CHEMBL2431	Homo sapiens	IC50	nM	37826.0
	3502286	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	N[C@H](Cc1cc(F)cc(F)c1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1257280	=	IC50	nM	5027.0	CHEMBL2431	Homo sapiens	IC50	nM	5027.0
	3502287	CHEMBL1259575	Inhibition of AKT2 by IMAP assay	B	COc1cc(C[C@@H](N)C(=O)N2CCN(c3ncnc4ccccc34)CC2)cc(OC)c1		CHEMBL1257281	=	IC50	nM	4951.0	CHEMBL2431	Homo sapiens	IC50	nM	4951.0
	3515242	CHEMBL1273368	Binding affinity to Akt2	B	Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O		CHEMBL14249	=	Km	nM	254000.0	CHEMBL2431	Homo sapiens	Km	uM	254.0
	3556536	CHEMBL1285569	Inhibition of AKT2 at 1 uM	B	CN1C[C@@H]2C[C@H]1CN2c1cc(F)c(-c2ccnc3c(-c4cccc5[nH]ncc45)c(-c4ccncc4)nn23)c(F)c1		CHEMBL1276179	=	Inhibition	%	9.0	CHEMBL2431	Homo sapiens	INH	%	9.0
	5120437	CHEMBL1648675	Inhibition of human PKBbeta at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	110.0	CHEMBL2431	Homo sapiens	INH	%	110.0
	5133690	CHEMBL1648722	Inhibition of PKBbeta assessed as residual activity at 10 uM	B	CN(C)C/C=C/C(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641990	=	Activity	%	37.0	CHEMBL2431	Homo sapiens	Activity	%	37.0
	5133785	CHEMBL1648722	Inhibition of PKBbeta assessed as residual activity at 10 uM	B	CN(C)CCCC(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641989	=	Activity	%	85.0	CHEMBL2431	Homo sapiens	Activity	%	85.0
	5133886	CHEMBL1648722	Inhibition of PKBbeta assessed as residual activity at 10 uM	B	CN1CCN(CCC(=O)Nc2ccc3c(C#N)cnc(Nc4cccc(Br)c4)c3c2)CC1		CHEMBL1641992	=	Activity	%	87.0	CHEMBL2431	Homo sapiens	Activity	%	87.0
	5191355	CHEMBL1663979	Inhibition of PKBbeta at 1 uM	B	COc1cc2nc(-c3cc(F)ccc3O)nc(N[C@@H]3CNC[C@H]3C(C)(C)O)c2cc1OC		CHEMBL1236782	=	Inhibition	%	-6.0	CHEMBL2431	Homo sapiens	INH	%	-6.0
	5191356	CHEMBL1663979	Inhibition of PKBbeta at 1 uM	B	CC(C)(O)[C@@H]1CNC[C@H]1Nc1nc(-c2cc(-c3cc[nH]n3)ccc2O)nc2ccccc12		CHEMBL1650131	=	Inhibition	%	75.0	CHEMBL2431	Homo sapiens	INH	%	75.0
	5243751	CHEMBL1685855	Inhibition of PKBbeta at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCN(Cc6ccccc6)CC5)cc34)[nH]c2c1		CHEMBL1684543	=	Inhibition	%	103.0	CHEMBL2431	Homo sapiens	INH	%	103.0
	5243859	CHEMBL1686071	Inhibition of PKBbeta at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCN(Cc6ccccc6)CC5)cc34)[nH]c2c1		CHEMBL1684543	=	Inhibition	%	85.0	CHEMBL2431	Homo sapiens	INH	%	85.0
	5243972	CHEMBL1685855	Inhibition of PKBbeta at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCNC5)cc34)[nH]c2c1		CHEMBL1684654	=	Inhibition	%	107.0	CHEMBL2431	Homo sapiens	INH	%	107.0
	5244080	CHEMBL1686071	Inhibition of PKBbeta at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCNC5)cc34)[nH]c2c1		CHEMBL1684654	=	Inhibition	%	88.0	CHEMBL2431	Homo sapiens	INH	%	88.0
	5244953	CHEMBL1685855	Inhibition of PKBbeta at 0.1 uM	B	O=C(Cc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1)c1ccccc1		CHEMBL1684662	=	Inhibition	%	109.0	CHEMBL2431	Homo sapiens	INH	%	109.0
	5245061	CHEMBL1686071	Inhibition of PKBbeta at 1 uM	B	O=C(Cc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1)c1ccccc1		CHEMBL1684662	=	Inhibition	%	95.0	CHEMBL2431	Homo sapiens	INH	%	95.0
	5245212	CHEMBL1685855	Inhibition of PKBbeta at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NS(=O)(=O)c5ncn(C)c5C)cc34)[nH]c2c1		CHEMBL1684525	=	Inhibition	%	102.0	CHEMBL2431	Homo sapiens	INH	%	102.0
	5246042	CHEMBL1686071	Inhibition of PKBbeta at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NS(=O)(=O)c5ncn(C)c5C)cc34)[nH]c2c1		CHEMBL1684525	=	Inhibition	%	104.0	CHEMBL2431	Homo sapiens	INH	%	104.0
Active	6161825	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	COCCN(CC(O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761067		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6161826	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	Cc1noc(C)c1S(=O)(=O)N(Cc1ccccc1)CC(O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1		CHEMBL1761068		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6161827	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	COCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761069		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6161828	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	COCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761069		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6161829	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	COCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761069		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6161830	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	COCCN(C[C@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761070		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6161831	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761071		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162463	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	Cc1noc(C)c1S(=O)(=O)N(CCOC(C)C)C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1		CHEMBL1761072		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162464	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCCCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761073		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162465	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	Cc1noc(C)c1S(=O)(=O)N(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)C1CCCCC1		CHEMBL1761074		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162466	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1cccc(Cl)c1		CHEMBL1761075		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162467	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccc(Cl)cc1		CHEMBL1761076		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162468	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1Cl		CHEMBL1761077		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162469	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1OC		CHEMBL1761078		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162470	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1F		CHEMBL1761079		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162471	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1C#N		CHEMBL1761080		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162472	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1C(F)(F)F		CHEMBL1761081		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162473	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1C		CHEMBL1761082		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162474	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761083		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162475	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761084		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162476	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761085		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162477	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(F)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761086		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162478	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(C#N)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761087		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162479	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(C(N)=O)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761088		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162480	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc4c(cc3O2)CNC4=O)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761089		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	6162481	CHEMBL1764867	Inhibition of AKT2 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3c(ccc4[nH]ncc34)O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761090		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	6218882	CHEMBL1787680	Inhibition of human PKBbeta using gamma-33P-ATP as substrate assessed as enzyme functional activity at 1 uM by scintillation counting relative to untreated control	B	c1ccc(Cc2cnc(N3CCN(c4ncnc5ccccc45)CC3)nc2)cc1		CHEMBL1782075	=	Activity	%	89.0	CHEMBL2431	Homo sapiens	Activity	%	89.0
Not Determined	6218894	CHEMBL1787716	Inhibition of human PKBbeta using gamma-33P-ATP as substrate by scintillation counting	B	c1ccc(Cc2cnc(N3CCN(c4ncnc5ccccc45)CC3)nc2)cc1		CHEMBL1782075		IC50			CHEMBL2431	Homo sapiens	IC50		
	6219060	CHEMBL1787680	Inhibition of human PKBbeta using gamma-33P-ATP as substrate assessed as enzyme functional activity at 1 uM by scintillation counting relative to untreated control	B	CCc1cnc(N2CCN(C(=O)c3ccc(CNc4ncnc5ccccc45)cc3)CC2)nc1		CHEMBL1783929	=	Activity	%	82.0	CHEMBL2431	Homo sapiens	Activity	%	82.0
	6220409	CHEMBL1787680	Inhibition of human PKBbeta using gamma-33P-ATP as substrate assessed as enzyme functional activity at 1 uM by scintillation counting relative to untreated control	B	O=C(c1cccc(Nc2ncnc3ccccc23)c1)N1CCN(c2ncc(Cc3ccccc3)cn2)CC1		CHEMBL1783930	=	Activity	%	83.0	CHEMBL2431	Homo sapiens	Activity	%	83.0
	6230420	CHEMBL1786949	Inhibition of AKT2	B	O=C(c1cccs1)N1N=C(c2cccnc2)CC1c1ccccc1O		CHEMBL1782188	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	6230421	CHEMBL1786949	Inhibition of AKT2	B	O=C(c1ccc[nH]1)N1N=C(c2cccnc2)CC1c1ccccc1O		CHEMBL1782187	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	6230422	CHEMBL1786949	Inhibition of AKT2	B	CCOc1cccc2cc(C(=O)N3N=C(c4cccnc4)CC3c3ccccc3O)oc12		CHEMBL1782186	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	6230423	CHEMBL1786949	Inhibition of AKT2	B	O=C(c1ccc(Br)o1)N1N=C(c2cccnc2)CC1c1ccccc1O		CHEMBL1782185	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	6230424	CHEMBL1786949	Inhibition of AKT2	B	O=C(c1cccc(-n2cccn2)c1)N1N=C(c2cccnc2)CC1c1ccccc1O		CHEMBL1782182	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	6264906	CHEMBL1799789	Inhibition of AKT2 at 1 uM	B	COCCN1CCc2cc(Nc3ncc(Cl)c(N[C@@H]4CCCC[C@H]4NS(C)(=O)=O)n3)c(OC)cc2CC1		CHEMBL1796254	<	Inhibition	%	65.0	CHEMBL2431	Homo sapiens	INH	%	65.0
	6265630	CHEMBL1799789	Inhibition of AKT2 at 1 uM	B	COCCN1CCc2cc(Nc3ncc(Cl)c(N[C@@H]4CCCC[C@H]4N(C)S(C)(=O)=O)n3)c(OC)cc2CC1		CHEMBL1796257	<	Inhibition	%	65.0	CHEMBL2431	Homo sapiens	INH	%	65.0
	6317655	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2[nH]nc(N)c2c(=O)[nH]1		CHEMBL1813604	=	Inhibition	%	8.0	CHEMBL2431	Homo sapiens	INH	%	8.0
	6317656	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2cc(-c3cccnc3)[nH]c(=O)c12		CHEMBL1813606	=	Inhibition	%	8.0	CHEMBL2431	Homo sapiens	INH	%	8.0
	6317657	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2cc(-c3ccccn3)[nH]c(=O)c12		CHEMBL1813607	=	Inhibition	%	8.0	CHEMBL2431	Homo sapiens	INH	%	8.0
	6317658	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2cc(-c3ccncc3)[nH]c(=O)c12		CHEMBL1813608	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	6317659	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	COc1cccc(-c2cc3[nH]nc(N)c3c(=O)[nH]2)c1		CHEMBL1813609	=	Inhibition	%	2.0	CHEMBL2431	Homo sapiens	INH	%	2.0
	6317660	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	COc1ccc(-c2cc3[nH]nc(N)c3c(=O)[nH]2)cc1		CHEMBL1813610	=	Inhibition	%	11.0	CHEMBL2431	Homo sapiens	INH	%	11.0
	6317661	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	CN1CCN(c2ccc(-c3cc4[nH]nc(N)c4c(=O)[nH]3)cc2)CC1		CHEMBL1813611	=	Inhibition	%	6.0	CHEMBL2431	Homo sapiens	INH	%	6.0
	6317662	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2cc(-c3cccs3)[nH]c(=O)c12		CHEMBL1813612	=	Inhibition	%	5.0	CHEMBL2431	Homo sapiens	INH	%	5.0
	6317663	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	CC(C)(C)c1cc2[nH]nc(N)c2c(=O)[nH]1		CHEMBL1813613	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	6317664	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2cc(-c3ccc(N4CCOCC4)cc3)[nH]c(=O)c12		CHEMBL1813614	=	Inhibition	%	7.0	CHEMBL2431	Homo sapiens	INH	%	7.0
	6317665	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2cc(CC3CCNCC3)[nH]c(=O)c12		CHEMBL1813615	=	Inhibition	%	6.0	CHEMBL2431	Homo sapiens	INH	%	6.0
	6317666	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2c3c([nH]c(=O)c12)CCCC3		CHEMBL1813617	=	Inhibition	%	-1.0	CHEMBL2431	Homo sapiens	INH	%	-1.0
	6317667	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2[nH]nc(N)c2c(N2CCCCC2)n1		CHEMBL1813618	=	Inhibition	%	11.0	CHEMBL2431	Homo sapiens	INH	%	11.0
	6317668	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2[nH]nc(N)c2c(N2CCOCC2)n1		CHEMBL1813619	=	Inhibition	%	7.0	CHEMBL2431	Homo sapiens	INH	%	7.0
	6317669	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(c(N)nn2C)c(=O)[nH]1		CHEMBL1813620	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	6317670	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cn1nc(N)c2c(=O)[nH]c(-c3ccccc3)cc21		CHEMBL1813621	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	6317671	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cn1nc(N)c2c(=O)[nH]c(-c3ccccn3)cc21		CHEMBL1813622	=	Inhibition	%	10.0	CHEMBL2431	Homo sapiens	INH	%	10.0
	6317672	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	COc1ccc(-c2cc3c(c(N)nn3C)c(=O)[nH]2)cc1		CHEMBL1813623	=	Inhibition	%	-8.0	CHEMBL2431	Homo sapiens	INH	%	-8.0
	6317673	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	COc1cccc(-c2cc3c(c(N)nn3C)c(=O)[nH]2)c1		CHEMBL1813624	=	Inhibition	%	1.0	CHEMBL2431	Homo sapiens	INH	%	1.0
	6317674	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	CN1CCN(c2ccc(-c3cc4c(c(N)nn4C)c(=O)[nH]3)cc2)CC1		CHEMBL1813625	=	Inhibition	%	-1.0	CHEMBL2431	Homo sapiens	INH	%	-1.0
	6317675	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	COC(=O)CCc1c(C)[nH]c(=O)c2c(N)nn(C)c12		CHEMBL1813627	=	Inhibition	%	3.0	CHEMBL2431	Homo sapiens	INH	%	3.0
	6317676	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	COc1ccc(-c2c(C)[nH]c(=O)c3c(N)nn(C)c23)cc1		CHEMBL1813628	=	Inhibition	%	25.0	CHEMBL2431	Homo sapiens	INH	%	25.0
	6317677	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(c(NC(=O)Nc3ccccc3)nn2C)c(=O)[nH]1		CHEMBL1813630	=	Inhibition	%	11.0	CHEMBL2431	Homo sapiens	INH	%	11.0
	6317678	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	CC(=O)Nc1nn(C)c2cc(-c3ccccc3)[nH]c(=O)c12		CHEMBL1813777	=	Inhibition	%	40.0	CHEMBL2431	Homo sapiens	INH	%	40.0
	6317679	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(c(NS(C)(=O)=O)nn2C)c(=O)[nH]1		CHEMBL1813778	=	Inhibition	%	16.0	CHEMBL2431	Homo sapiens	INH	%	16.0
	6317680	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	COc1ccc(S(=O)(=O)Nc2nn(C)c3cc(C)[nH]c(=O)c23)c(OC)c1		CHEMBL1813779	=	Inhibition	%	6.0	CHEMBL2431	Homo sapiens	INH	%	6.0
	6317681	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	CC(=O)Nc1nn(C)c2cc(-c3ccc(N4CCN(C)CC4)cc3)[nH]c(=O)c12		CHEMBL1813780	=	Inhibition	%	-1.0	CHEMBL2431	Homo sapiens	INH	%	-1.0
	6317682	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(c(N)nn2C)c(N2CCCCC2)n1		CHEMBL1813781	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	6317683	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(c(N)nn2C)c(N2CCOCC2)n1		CHEMBL1813782	=	Inhibition	%	12.0	CHEMBL2431	Homo sapiens	INH	%	12.0
	6317684	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(c(N)nn2C)c(N2CC[C@H](O)C2)n1		CHEMBL1813784	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	6317685	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	COCCNc1nc(C)cc2c1c(N)nn2C		CHEMBL1813785	=	Inhibition	%	-3.0	CHEMBL2431	Homo sapiens	INH	%	-3.0
	6317686	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	COCCNc1nc(-c2ccccc2)cc2c1c(N)nn2C		CHEMBL1813786	=	Inhibition	%	-1.0	CHEMBL2431	Homo sapiens	INH	%	-1.0
	6317687	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	COCCNc1nc(C)cc2nn(-c3ccccc3)c(N)c12		CHEMBL1813787	=	Inhibition	%	2.0	CHEMBL2431	Homo sapiens	INH	%	2.0
	6317688	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2nn(-c3ccccc3)c(N)c2c(=O)[nH]1		CHEMBL1813788	=	Inhibition	%	1.0	CHEMBL2431	Homo sapiens	INH	%	1.0
	6317689	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	CC(C)(C)c1cc2nn(-c3ccccc3)c(N)c2c(=O)[nH]1		CHEMBL1813789	=	Inhibition	%	3.0	CHEMBL2431	Homo sapiens	INH	%	3.0
	6317690	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Nc1c2c(=O)[nH]c(-c3ccccc3)cc2nn1-c1ccccc1		CHEMBL1813790	=	Inhibition	%	-1.0	CHEMBL2431	Homo sapiens	INH	%	-1.0
	6317691	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Nc1c2c(=O)[nH]c(-c3ccccn3)cc2nn1-c1ccccc1		CHEMBL1813791	=	Inhibition	%	8.0	CHEMBL2431	Homo sapiens	INH	%	8.0
	6317692	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	COc1ccccc1-c1cc2nn(-c3ccccc3)c(N)c2c(=O)[nH]1		CHEMBL1813792	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	6317693	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	COc1ccc(-c2cc3nn(-c4ccccc4)c(N)c3c(=O)[nH]2)cc1		CHEMBL1813793	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	6317694	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	CN1CCN(c2ccc(-c3cc4nn(-c5ccccc5)c(N)c4c(=O)[nH]3)cc2)CC1		CHEMBL1813795	=	Inhibition	%	10.0	CHEMBL2431	Homo sapiens	INH	%	10.0
	6317695	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Nc1c2c(=O)[nH]c(-c3ccccc3)cc2nn1-c1ccccn1		CHEMBL1813796	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	6317696	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2nn(-c3ccccc3)c(N)c2c(N2CCCCC2)n1		CHEMBL1813797	=	Inhibition	%	-7.0	CHEMBL2431	Homo sapiens	INH	%	-7.0
	6317697	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1[nH]c(=O)c2c(N)n(-c3ccccc3)nc2c1-c1ccccc1		CHEMBL1813798	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	6317698	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cn1nc2c3c(nc(-c4ccccc4)cc31)NCC(=O)N2		CHEMBL1813799	=	Inhibition	%	1.0	CHEMBL2431	Homo sapiens	INH	%	1.0
	6317699	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cn1nc(N)c2cnc(-c3ccccc3)cc21		CHEMBL1813800	=	Inhibition	%	6.0	CHEMBL2431	Homo sapiens	INH	%	6.0
	6317700	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(cn1)c(N)nn2C		CHEMBL1813801	=	Inhibition	%	-2.0	CHEMBL2431	Homo sapiens	INH	%	-2.0
	6317701	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Nc1c2cnc(-c3ccccc3)cc2nn1-c1ccccc1		CHEMBL1813802	=	Inhibition	%	3.0	CHEMBL2431	Homo sapiens	INH	%	3.0
	6317702	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2[nH]nc(N)c2cn1		CHEMBL1813803	=	Inhibition	%	-3.0	CHEMBL2431	Homo sapiens	INH	%	-3.0
	6317703	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2[nH]ncc2c(=O)[nH]1		CHEMBL1813804	=	Inhibition	%	1.0	CHEMBL2431	Homo sapiens	INH	%	1.0
	6317704	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2nc(N)nc(N)c2c(=O)[nH]1		CHEMBL1813805	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	6317705	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2nc(-c3ccccc3)nc(N)c2c(=O)[nH]1		CHEMBL1813806	=	Inhibition	%	2.0	CHEMBL2431	Homo sapiens	INH	%	2.0
	6317706	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	Cc1nc(N)c2c(=O)[nH]c(C)cc2n1		CHEMBL1813807	=	Inhibition	%	2.0	CHEMBL2431	Homo sapiens	INH	%	2.0
	6317707	CHEMBL1815736	Inhibition of AKT2 at 30 uM by microfluidic mobility shift assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Inhibition	%	82.0	CHEMBL2431	Homo sapiens	INH	%	82.0
	6325303	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Nc1ncnc2[nH]cnc12		CHEMBL226345	=	Inhibition	%	7.0	CHEMBL2431	Homo sapiens	INH	%	7.0
	6325332	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	c1ccc(Nc2ncccn2)cc1		CHEMBL1650061	=	Inhibition	%	16.0	CHEMBL2431	Homo sapiens	INH	%	16.0
	6325364	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	=	Inhibition	%	19.0	CHEMBL2431	Homo sapiens	INH	%	19.0
	6325396	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	c1ccc2[nH]ncc2c1		CHEMBL86795	=	Inhibition	%	12.0	CHEMBL2431	Homo sapiens	INH	%	12.0
	6325428	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Nc1ncccc1OCc1ccccc1		CHEMBL194009	=	Inhibition	%	25.0	CHEMBL2431	Homo sapiens	INH	%	25.0
	6325457	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Nc1[nH]nc2ccccc12		CHEMBL1331627	=	Inhibition	%	16.0	CHEMBL2431	Homo sapiens	INH	%	16.0
	6325487	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Nc1n[nH]c2ncccc12		CHEMBL1817865	=	Inhibition	%	14.0	CHEMBL2431	Homo sapiens	INH	%	14.0
	6325515	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	c1n[nH]c2c1CCCC2		CHEMBL1817866	=	Inhibition	%	13.0	CHEMBL2431	Homo sapiens	INH	%	13.0
	6325545	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Nc1ccc2ncc(-c3ccccc3)n2n1		CHEMBL1817867	=	Inhibition	%	39.0	CHEMBL2431	Homo sapiens	INH	%	39.0
	6325888	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	c1ccc(-c2cnc3nccnn23)cc1		CHEMBL1817868	=	Inhibition	%	8.0	CHEMBL2431	Homo sapiens	INH	%	8.0
	6325918	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Cc1ccc(NC(=O)Nc2cc(C(C)(C)C)nn2-c2ccccc2)cc1		CHEMBL1817869	=	Inhibition	%	12.0	CHEMBL2431	Homo sapiens	INH	%	12.0
	6325947	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccccc2)no1		CHEMBL292785	=	Inhibition	%	15.0	CHEMBL2431	Homo sapiens	INH	%	15.0
	6325976	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Cc1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)cc1		CHEMBL1817870	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	6326005	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	O=C(Nc1ccccc1)Nc1cccc(C(F)(F)F)c1		CHEMBL1605296	=	Inhibition	%	6.0	CHEMBL2431	Homo sapiens	INH	%	6.0
	6326034	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	O=C(Nc1ccccc1)Nc1ccccc1		CHEMBL354676	=	Inhibition	%	16.0	CHEMBL2431	Homo sapiens	INH	%	16.0
	6326064	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Cc1ccc(C(=O)NC2CC2)cc1F		CHEMBL1817871	=	Inhibition	%	9.0	CHEMBL2431	Homo sapiens	INH	%	9.0
	6326092	CHEMBL1819982	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	c1ccc(Nc2ccccc2)cc1		CHEMBL38688	=	Inhibition	%	9.0	CHEMBL2431	Homo sapiens	INH	%	9.0
	6340996	CHEMBL1827582	Activity of AKT2 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	99.0	CHEMBL2431	Homo sapiens	Activity	%	99.0
	6352265	CHEMBL1825913	Inhibition of PKBbeta assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	B	Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1		CHEMBL215205	=	Activity	%	56.0	CHEMBL2431	Homo sapiens	Activity	%	56.0
	6384584	CHEMBL1837738	Inhibition of human AKT2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCCc2ccccc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1		CHEMBL1834114	<	Inhibition	%	35.0	CHEMBL2431	Homo sapiens	INH	%	35.0
	6384585	CHEMBL1837738	Inhibition of human AKT2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CCCC1		CHEMBL1834318	<	Inhibition	%	35.0	CHEMBL2431	Homo sapiens	INH	%	35.0
	6384586	CHEMBL1837738	Inhibition of human AKT2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	C[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834323	<	Inhibition	%	35.0	CHEMBL2431	Homo sapiens	INH	%	35.0
	6384587	CHEMBL1837738	Inhibition of human AKT2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	CC(C)[C@@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834324	<	Inhibition	%	35.0	CHEMBL2431	Homo sapiens	INH	%	35.0
	6384588	CHEMBL1837738	Inhibition of human AKT2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCCC1)CO2		CHEMBL1834330	<	Inhibition	%	35.0	CHEMBL2431	Homo sapiens	INH	%	35.0
	7567234	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7567693	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7568164	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7569207	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7569667	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7570139	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7570160	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7570587	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	2700.0	CHEMBL2431	Homo sapiens	Kd	nM	2700.0
	7571183	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7571640	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7572137	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7572553	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7573164	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7573655	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7574124	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	780.0	CHEMBL2431	Homo sapiens	Kd	nM	780.0
	7574532	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7575142	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7575161	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7575632	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7576097	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7576505	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7577133	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7577611	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7578081	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7578486	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7578682	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	Kd	nM	2900.0	CHEMBL2431	Homo sapiens	Kd	nM	2900.0
	7579056	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7579506	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7579980	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7580449	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7580852	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7581040	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7581425	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7581870	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7582341	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7582805	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7583205	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7583386	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7583783	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7584228	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7584699	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Kd	nM	8700.0	CHEMBL2431	Homo sapiens	Kd	nM	8700.0
	7585716	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7586124	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7586570	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7587053	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7587677	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7588096	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	2100.0	CHEMBL2431	Homo sapiens	Kd	nM	2100.0
	7588549	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7588578	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7589029	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7589642	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7590066	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7590565	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7591016	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7591615	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7592067	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7592540	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7592993	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7593575	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7594047	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Kd	nM	2.1	CHEMBL2431	Homo sapiens	Kd	nM	2.1
	7594520	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7594972	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7595108	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7595552	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7596026	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7596497	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7596944	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	44.0	CHEMBL2431	Homo sapiens	Kd	nM	44.0
	7597080	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7597533	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7598006	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7598476	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7598918	CHEMBL1908536	Binding constant for AKT2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	10000.0	CHEMBL2431	Homo sapiens	Kd	nM	10000.0
	7959665	CHEMBL1932323	Inhibition of AKT2	B	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O		CHEMBL1929238	>	IC50	nM	30000.0	CHEMBL2431	Homo sapiens	IC50	uM	30.0
	7959666	CHEMBL1932323	Inhibition of AKT2	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	IC50	nM	30000.0	CHEMBL2431	Homo sapiens	IC50	uM	30.0
	7969782	CHEMBL1929883	Inhibition of PKBbeta assessed as residual activity at 10 uM using [33P-ATP] by radiometric filter binding assay	B	Cc1ccc(F)cc1-c1nc2[nH]nc(N)c2c2c1CCCC2		CHEMBL1927262	=	Activity	%	77.0	CHEMBL2431	Homo sapiens	Activity	%	77.0
	7970411	CHEMBL1930206	Inhibition of AKT2 at 10 uM	B	NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O		CHEMBL1929247	=	Inhibition	%	8.0	CHEMBL2431	Homo sapiens	INH	%	8.0
	8046163	CHEMBL1960377	Inhibition of AKT2	B	COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1		CHEMBL1957085	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	8047309	CHEMBL1960792	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21		CHEMBL220241	=	IC50	nM	1350.0	CHEMBL2431	Homo sapiens	IC50	nM	1350.0
	8047310	CHEMBL1960792	Inhibition of AKT2	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21		CHEMBL1956071	=	IC50	nM	1950.0	CHEMBL2431	Homo sapiens	IC50	nM	1950.0
	8061219	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	-1.18	CHEMBL2431	Homo sapiens	Inhibition	%	-1.18
	8061396	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-1.08	CHEMBL2431	Homo sapiens	Inhibition	%	-1.08
	8061620	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	1.16	CHEMBL2431	Homo sapiens	Inhibition	%	1.16
	8061727	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	0.8	CHEMBL2431	Homo sapiens	Inhibition	%	0.8
	8062142	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	1.6	CHEMBL2431	Homo sapiens	Inhibition	%	1.6
	8062258	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	2.48	CHEMBL2431	Homo sapiens	Inhibition	%	2.48
	8062644	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	1.56	CHEMBL2431	Homo sapiens	Inhibition	%	1.56
	8062966	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	Inhibition	%	0.0
	8063098	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	-0.26	CHEMBL2431	Homo sapiens	Inhibition	%	-0.26
	8063489	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.96	CHEMBL2431	Homo sapiens	Inhibition	%	0.96
	8063597	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	1.27	CHEMBL2431	Homo sapiens	Inhibition	%	1.27
	8063821	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	1.16	CHEMBL2431	Homo sapiens	Inhibition	%	1.16
	8064003	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	2.75	CHEMBL2431	Homo sapiens	Inhibition	%	2.75
	8064118	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	1.66	CHEMBL2431	Homo sapiens	Inhibition	%	1.66
	8064342	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	0.71	CHEMBL2431	Homo sapiens	Inhibition	%	0.71
	8064552	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-1.02	CHEMBL2431	Homo sapiens	Inhibition	%	-1.02
	8064690	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	-0.16	CHEMBL2431	Homo sapiens	Inhibition	%	-0.16
	8064914	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	0.11	CHEMBL2431	Homo sapiens	Inhibition	%	0.11
	8065080	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.33	CHEMBL2431	Homo sapiens	Inhibition	%	0.33
	8065420	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	1.35	CHEMBL2431	Homo sapiens	Inhibition	%	1.35
	8065595	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	1.12	CHEMBL2431	Homo sapiens	Inhibition	%	1.12
	8065934	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	8.4	CHEMBL2431	Homo sapiens	Inhibition	%	8.4
	8066144	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	0.34	CHEMBL2431	Homo sapiens	Inhibition	%	0.34
	8066504	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	0.16	CHEMBL2431	Homo sapiens	Inhibition	%	0.16
	8066670	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.37	CHEMBL2431	Homo sapiens	Inhibition	%	0.37
	8067018	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	1.01	CHEMBL2431	Homo sapiens	Inhibition	%	1.01
	8067193	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	1.6	CHEMBL2431	Homo sapiens	Inhibition	%	1.6
	8067538	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	0.35	CHEMBL2431	Homo sapiens	Inhibition	%	0.35
	8067748	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	1.71	CHEMBL2431	Homo sapiens	Inhibition	%	1.71
	8068107	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	0.1	CHEMBL2431	Homo sapiens	Inhibition	%	0.1
	8068271	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	0.15	CHEMBL2431	Homo sapiens	Inhibition	%	0.15
	8068495	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	0.75	CHEMBL2431	Homo sapiens	Inhibition	%	0.75
	8068620	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.36	CHEMBL2431	Homo sapiens	Inhibition	%	0.36
	8068794	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	1.74	CHEMBL2431	Homo sapiens	Inhibition	%	1.74
	8069018	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	1.34	CHEMBL2431	Homo sapiens	Inhibition	%	1.34
	8069143	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	1.43	CHEMBL2431	Homo sapiens	Inhibition	%	1.43
	8069438	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	0.87	CHEMBL2431	Homo sapiens	Inhibition	%	0.87
	8069823	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	0.6	CHEMBL2431	Homo sapiens	Inhibition	%	0.6
	8069949	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.77	CHEMBL2431	Homo sapiens	Inhibition	%	0.77
	8070345	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	1.69	CHEMBL2431	Homo sapiens	Inhibition	%	1.69
	8070470	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	-0.03	CHEMBL2431	Homo sapiens	Inhibition	%	-0.03
	8070694	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.06	CHEMBL2431	Homo sapiens	Inhibition	%	0.06
	8070768	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	1.56	CHEMBL2431	Homo sapiens	Inhibition	%	1.56
	8070992	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-0.46	CHEMBL2431	Homo sapiens	Inhibition	%	-0.46
	8071149	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	1.11	CHEMBL2431	Homo sapiens	Inhibition	%	1.11
	8071275	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.56	CHEMBL2431	Homo sapiens	Inhibition	%	0.56
	8071499	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-0.22	CHEMBL2431	Homo sapiens	Inhibition	%	-0.22
	8071672	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	2.1	CHEMBL2431	Homo sapiens	Inhibition	%	2.1
	8072021	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-0.14	CHEMBL2431	Homo sapiens	Inhibition	%	-0.14
	8072102	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	2.19	CHEMBL2431	Homo sapiens	Inhibition	%	2.19
	8072335	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-0.62	CHEMBL2431	Homo sapiens	Inhibition	%	-0.62
	8072492	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	1.44	CHEMBL2431	Homo sapiens	Inhibition	%	1.44
	8072841	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-0.31	CHEMBL2431	Homo sapiens	Inhibition	%	-0.31
	8073008	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	2.15	CHEMBL2431	Homo sapiens	Inhibition	%	2.15
	8073357	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-0.64	CHEMBL2431	Homo sapiens	Inhibition	%	-0.64
	8073700	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-0.04	CHEMBL2431	Homo sapiens	Inhibition	%	-0.04
	8073933	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	10.01	CHEMBL2431	Homo sapiens	Inhibition	%	10.01
	8074085	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	1.16	CHEMBL2431	Homo sapiens	Inhibition	%	1.16
	8074309	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	1.52	CHEMBL2431	Homo sapiens	Inhibition	%	1.52
	8074439	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	0.45	CHEMBL2431	Homo sapiens	Inhibition	%	0.45
	8074596	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	1.23	CHEMBL2431	Homo sapiens	Inhibition	%	1.23
	8074820	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	0.29	CHEMBL2431	Homo sapiens	Inhibition	%	0.29
	8074947	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	-0.9	CHEMBL2431	Homo sapiens	Inhibition	%	-0.9
	8075282	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.74	CHEMBL2431	Homo sapiens	Inhibition	%	0.74
	8075519	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	55.48	CHEMBL2431	Homo sapiens	Inhibition	%	55.48
	8075884	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	0.7	CHEMBL2431	Homo sapiens	Inhibition	%	0.7
	8076026	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.92	CHEMBL2431	Homo sapiens	Inhibition	%	-0.92
	8076398	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	1.52	CHEMBL2431	Homo sapiens	Inhibition	%	1.52
	8076532	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	-0.32	CHEMBL2431	Homo sapiens	Inhibition	%	-0.32
	8076858	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.26	CHEMBL2431	Homo sapiens	Inhibition	%	0.26
	8077105	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	94.2	CHEMBL2431	Homo sapiens	Inhibition	%	94.2
	8077457	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	0.76	CHEMBL2431	Homo sapiens	Inhibition	%	0.76
	8077608	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.19	CHEMBL2431	Homo sapiens	Inhibition	%	-0.19
	8077832	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-0.48	CHEMBL2431	Homo sapiens	Inhibition	%	-0.48
	8077975	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.89	CHEMBL2431	Homo sapiens	Inhibition	%	0.89
	8078114	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-3.37	CHEMBL2431	Homo sapiens	Inhibition	%	-3.37
	8078338	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-1.69	CHEMBL2431	Homo sapiens	Inhibition	%	-1.69
	8078440	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	0.72	CHEMBL2431	Homo sapiens	Inhibition	%	0.72
	8078690	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	96.15	CHEMBL2431	Homo sapiens	Inhibition	%	96.15
	8078914	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	0.67	CHEMBL2431	Homo sapiens	Inhibition	%	0.67
	8079030	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	0.57	CHEMBL2431	Homo sapiens	Inhibition	%	0.57
	8079412	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-0.32	CHEMBL2431	Homo sapiens	Inhibition	%	-0.32
	8079554	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	2.53	CHEMBL2431	Homo sapiens	Inhibition	%	2.53
	8079917	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	2.13	CHEMBL2431	Homo sapiens	Inhibition	%	2.13
	8080022	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	-1.73	CHEMBL2431	Homo sapiens	Inhibition	%	-1.73
	8080246	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	0.32	CHEMBL2431	Homo sapiens	Inhibition	%	0.32
	8080498	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	1.73	CHEMBL2431	Homo sapiens	Inhibition	%	1.73
	8080613	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	0.26	CHEMBL2431	Homo sapiens	Inhibition	%	0.26
	8081001	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-2.1	CHEMBL2431	Homo sapiens	Inhibition	%	-2.1
	8081136	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	0.9	CHEMBL2431	Homo sapiens	Inhibition	%	0.9
	8081360	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	1.03	CHEMBL2431	Homo sapiens	Inhibition	%	1.03
	8081504	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	1.62	CHEMBL2431	Homo sapiens	Inhibition	%	1.62
	8081831	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	-0.16	CHEMBL2431	Homo sapiens	Inhibition	%	-0.16
	8082083	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	1.24	CHEMBL2431	Homo sapiens	Inhibition	%	1.24
	8082196	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	0.34	CHEMBL2431	Homo sapiens	Inhibition	%	0.34
	8082420	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.39	CHEMBL2431	Homo sapiens	Inhibition	%	0.39
	8082593	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-2.04	CHEMBL2431	Homo sapiens	Inhibition	%	-2.04
	8082940	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	1.6	CHEMBL2431	Homo sapiens	Inhibition	%	1.6
	8083096	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	2.05	CHEMBL2431	Homo sapiens	Inhibition	%	2.05
	8083419	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	0.26	CHEMBL2431	Homo sapiens	Inhibition	%	0.26
	8083673	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	22.41	CHEMBL2431	Homo sapiens	Inhibition	%	22.41
	8084007	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.66	CHEMBL2431	Homo sapiens	Inhibition	%	0.66
	8084192	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	1.6	CHEMBL2431	Homo sapiens	Inhibition	%	1.6
	8084534	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	2.07	CHEMBL2431	Homo sapiens	Inhibition	%	2.07
	8084695	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	2.17	CHEMBL2431	Homo sapiens	Inhibition	%	2.17
	8084919	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	-1.35	CHEMBL2431	Homo sapiens	Inhibition	%	-1.35
	8085017	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	0.15	CHEMBL2431	Homo sapiens	Inhibition	%	0.15
	8085273	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-3.56	CHEMBL2431	Homo sapiens	Inhibition	%	-3.56
	8085605	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	0.63	CHEMBL2431	Homo sapiens	Inhibition	%	0.63
	8085794	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	2.48	CHEMBL2431	Homo sapiens	Inhibition	%	2.48
	8086018	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	1.08	CHEMBL2431	Homo sapiens	Inhibition	%	1.08
	8086133	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	1.16	CHEMBL2431	Homo sapiens	Inhibition	%	1.16
	8086519	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	-1.57	CHEMBL2431	Homo sapiens	Inhibition	%	-1.57
	8086618	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	0.98	CHEMBL2431	Homo sapiens	Inhibition	%	0.98
	8086842	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	1.01	CHEMBL2431	Homo sapiens	Inhibition	%	1.01
	8087053	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	-2.77	CHEMBL2431	Homo sapiens	Inhibition	%	-2.77
	8087211	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.4	CHEMBL2431	Homo sapiens	Inhibition	%	2.4
	8087549	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	0.6	CHEMBL2431	Homo sapiens	Inhibition	%	0.6
	8087687	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	4.18	CHEMBL2431	Homo sapiens	Inhibition	%	4.18
	8087911	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	-2.98	CHEMBL2431	Homo sapiens	Inhibition	%	-2.98
	8088053	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	2.21	CHEMBL2431	Homo sapiens	Inhibition	%	2.21
	8088425	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	1.28	CHEMBL2431	Homo sapiens	Inhibition	%	1.28
	8088553	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	1.65	CHEMBL2431	Homo sapiens	Inhibition	%	1.65
	8088870	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	2.24	CHEMBL2431	Homo sapiens	Inhibition	%	2.24
	8089222	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	2.04	CHEMBL2431	Homo sapiens	Inhibition	%	2.04
	8089370	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	0.76	CHEMBL2431	Homo sapiens	Inhibition	%	0.76
	8089714	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	0.22	CHEMBL2431	Homo sapiens	Inhibition	%	0.22
	8089894	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.01	CHEMBL2431	Homo sapiens	Inhibition	%	0.01
	8090118	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	-0.63	CHEMBL2431	Homo sapiens	Inhibition	%	-0.63
	8090283	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	3.18	CHEMBL2431	Homo sapiens	Inhibition	%	3.18
	8090450	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	0.45	CHEMBL2431	Homo sapiens	Inhibition	%	0.45
	8090674	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	2.03	CHEMBL2431	Homo sapiens	Inhibition	%	2.03
	8090813	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	0.51	CHEMBL2431	Homo sapiens	Inhibition	%	0.51
	8091018	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	0.5	CHEMBL2431	Homo sapiens	Inhibition	%	0.5
	8091379	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	1.3	CHEMBL2431	Homo sapiens	Inhibition	%	1.3
	8091534	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	1.7	CHEMBL2431	Homo sapiens	Inhibition	%	1.7
	8091758	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	0.99	CHEMBL2431	Homo sapiens	Inhibition	%	0.99
	8091874	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	2.82	CHEMBL2431	Homo sapiens	Inhibition	%	2.82
	8092235	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%		CHEMBL2431	Homo sapiens	Inhibition	%	
	8092386	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	0.7	CHEMBL2431	Homo sapiens	Inhibition	%	0.7
	8092758	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-0.49	CHEMBL2431	Homo sapiens	Inhibition	%	-0.49
	8092887	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	1.94	CHEMBL2431	Homo sapiens	Inhibition	%	1.94
	8093111	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	-2.65	CHEMBL2431	Homo sapiens	Inhibition	%	-2.65
	8093199	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	1.9	CHEMBL2431	Homo sapiens	Inhibition	%	1.9
	8093423	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	0.18	CHEMBL2431	Homo sapiens	Inhibition	%	0.18
	8093563	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	61.23	CHEMBL2431	Homo sapiens	Inhibition	%	61.23
	8093702	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	0.93	CHEMBL2431	Homo sapiens	Inhibition	%	0.93
	8093926	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-3.47	CHEMBL2431	Homo sapiens	Inhibition	%	-3.47
	8094046	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	0.16	CHEMBL2431	Homo sapiens	Inhibition	%	0.16
	8094450	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	0.09	CHEMBL2431	Homo sapiens	Inhibition	%	0.09
	8094625	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	1.62	CHEMBL2431	Homo sapiens	Inhibition	%	1.62
	8095005	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	-0.99	CHEMBL2431	Homo sapiens	Inhibition	%	-0.99
	8095145	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	1.22	CHEMBL2431	Homo sapiens	Inhibition	%	1.22
	8095348	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	1.64	CHEMBL2431	Homo sapiens	Inhibition	%	1.64
	8095572	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.14	CHEMBL2431	Homo sapiens	Inhibition	%	0.14
	8095713	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	1.5	CHEMBL2431	Homo sapiens	Inhibition	%	1.5
	8096085	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	1.0	CHEMBL2431	Homo sapiens	Inhibition	%	1.0
	8096202	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	2.55	CHEMBL2431	Homo sapiens	Inhibition	%	2.55
	8096426	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	3.94	CHEMBL2431	Homo sapiens	Inhibition	%	3.94
	8096565	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.29	CHEMBL2431	Homo sapiens	Inhibition	%	0.29
	8096721	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	1.93	CHEMBL2431	Homo sapiens	Inhibition	%	1.93
	8096945	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	0.41	CHEMBL2431	Homo sapiens	Inhibition	%	0.41
	8097092	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	0.01	CHEMBL2431	Homo sapiens	Inhibition	%	0.01
	8097623	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	1.22	CHEMBL2431	Homo sapiens	Inhibition	%	1.22
	8097773	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	91.13	CHEMBL2431	Homo sapiens	Inhibition	%	91.13
	8098130	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-2.42	CHEMBL2431	Homo sapiens	Inhibition	%	-2.42
	8098250	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%		CHEMBL2431	Homo sapiens	Inhibition	%	
	8098474	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	2.81	CHEMBL2431	Homo sapiens	Inhibition	%	2.81
	8098654	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-0.87	CHEMBL2431	Homo sapiens	Inhibition	%	-0.87
	8098839	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	3.68	CHEMBL2431	Homo sapiens	Inhibition	%	3.68
	8099207	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	1.09	CHEMBL2431	Homo sapiens	Inhibition	%	1.09
	8099349	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	0.85	CHEMBL2431	Homo sapiens	Inhibition	%	0.85
	8099573	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	1.16	CHEMBL2431	Homo sapiens	Inhibition	%	1.16
	8099767	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.78	CHEMBL2431	Homo sapiens	Inhibition	%	0.78
	8099914	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	1.76	CHEMBL2431	Homo sapiens	Inhibition	%	1.76
	8100284	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	-3.63	CHEMBL2431	Homo sapiens	Inhibition	%	-3.63
	8100624	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	0.99	CHEMBL2431	Homo sapiens	Inhibition	%	0.99
	8100764	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	1.29	CHEMBL2431	Homo sapiens	Inhibition	%	1.29
	8101148	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	2.06	CHEMBL2431	Homo sapiens	Inhibition	%	2.06
	8101290	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	-2.18	CHEMBL2431	Homo sapiens	Inhibition	%	-2.18
	8101699	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	-2.8	CHEMBL2431	Homo sapiens	Inhibition	%	-2.8
	8101952	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	-0.06	CHEMBL2431	Homo sapiens	Inhibition	%	-0.06
	8102107	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	-3.71	CHEMBL2431	Homo sapiens	Inhibition	%	-3.71
	8102331	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	-1.08	CHEMBL2431	Homo sapiens	Inhibition	%	-1.08
	8102462	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	0.37	CHEMBL2431	Homo sapiens	Inhibition	%	0.37
	8102806	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	1.8	CHEMBL2431	Homo sapiens	Inhibition	%	1.8
	8102984	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.43	CHEMBL2431	Homo sapiens	Inhibition	%	0.43
	8103180	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	75.26	CHEMBL2431	Homo sapiens	Inhibition	%	75.26
	8103404	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	91.99	CHEMBL2431	Homo sapiens	Inhibition	%	91.99
	8103542	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	0.22	CHEMBL2431	Homo sapiens	Inhibition	%	0.22
	8103916	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	0.84	CHEMBL2431	Homo sapiens	Inhibition	%	0.84
	8104101	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	-0.4	CHEMBL2431	Homo sapiens	Inhibition	%	-0.4
	8104249	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	1.75	CHEMBL2431	Homo sapiens	Inhibition	%	1.75
	8104473	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	1.73	CHEMBL2431	Homo sapiens	Inhibition	%	1.73
	8104619	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	-1.8	CHEMBL2431	Homo sapiens	Inhibition	%	-1.8
	8104957	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	3.57	CHEMBL2431	Homo sapiens	Inhibition	%	3.57
	8105097	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.02	CHEMBL2431	Homo sapiens	Inhibition	%	0.02
	8105321	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.86	CHEMBL2431	Homo sapiens	Inhibition	%	0.86
	8105487	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	-4.17	CHEMBL2431	Homo sapiens	Inhibition	%	-4.17
	8105625	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	-1.88	CHEMBL2431	Homo sapiens	Inhibition	%	-1.88
	8105849	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	1.9	CHEMBL2431	Homo sapiens	Inhibition	%	1.9
	8105905	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	1.58	CHEMBL2431	Homo sapiens	Inhibition	%	1.58
	8106129	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	1.24	CHEMBL2431	Homo sapiens	Inhibition	%	1.24
	8106294	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	-2.07	CHEMBL2431	Homo sapiens	Inhibition	%	-2.07
	8106674	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	-0.31	CHEMBL2431	Homo sapiens	Inhibition	%	-0.31
	8106803	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	0.18	CHEMBL2431	Homo sapiens	Inhibition	%	0.18
	8107148	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	3.99	CHEMBL2431	Homo sapiens	Inhibition	%	3.99
	8107320	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	-0.81	CHEMBL2431	Homo sapiens	Inhibition	%	-0.81
	8107544	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.47	CHEMBL2431	Homo sapiens	Inhibition	%	0.47
	8107745	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	2.46	CHEMBL2431	Homo sapiens	Inhibition	%	2.46
	8107880	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	0.58	CHEMBL2431	Homo sapiens	Inhibition	%	0.58
	8108262	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	2.06	CHEMBL2431	Homo sapiens	Inhibition	%	2.06
	8108437	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.5	CHEMBL2431	Homo sapiens	Inhibition	%	0.5
	8108808	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	2.79	CHEMBL2431	Homo sapiens	Inhibition	%	2.79
	8108950	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	0.2	CHEMBL2431	Homo sapiens	Inhibition	%	0.2
	8109174	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	1.21	CHEMBL2431	Homo sapiens	Inhibition	%	1.21
	8109288	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	1.92	CHEMBL2431	Homo sapiens	Inhibition	%	1.92
	8109642	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-3.59	CHEMBL2431	Homo sapiens	Inhibition	%	-3.59
	8109813	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	-2.31	CHEMBL2431	Homo sapiens	Inhibition	%	-2.31
	8110169	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	2.08	CHEMBL2431	Homo sapiens	Inhibition	%	2.08
	8110448	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.52	CHEMBL2431	Homo sapiens	Inhibition	%	1.52
	8110614	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	-3.03	CHEMBL2431	Homo sapiens	Inhibition	%	-3.03
	8110996	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	12.79	CHEMBL2431	Homo sapiens	Inhibition	%	12.79
	8111119	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	1.23	CHEMBL2431	Homo sapiens	Inhibition	%	1.23
	8111343	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	1.45	CHEMBL2431	Homo sapiens	Inhibition	%	1.45
	8111470	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	79.65	CHEMBL2431	Homo sapiens	Inhibition	%	79.65
	8111860	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	-1.39	CHEMBL2431	Homo sapiens	Inhibition	%	-1.39
	8112065	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	2.97	CHEMBL2431	Homo sapiens	Inhibition	%	2.97
	8112202	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-0.34	CHEMBL2431	Homo sapiens	Inhibition	%	-0.34
	8112426	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	0.3	CHEMBL2431	Homo sapiens	Inhibition	%	0.3
	8112594	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	0.29	CHEMBL2431	Homo sapiens	Inhibition	%	0.29
	8112766	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-0.24	CHEMBL2431	Homo sapiens	Inhibition	%	-0.24
	8112990	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	0.41	CHEMBL2431	Homo sapiens	Inhibition	%	0.41
	8113142	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	33.15	CHEMBL2431	Homo sapiens	Inhibition	%	33.15
	8113502	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	0.26	CHEMBL2431	Homo sapiens	Inhibition	%	0.26
	8113626	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	3.53	CHEMBL2431	Homo sapiens	Inhibition	%	3.53
	8113966	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-1.1	CHEMBL2431	Homo sapiens	Inhibition	%	-1.1
	8114142	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	0.73	CHEMBL2431	Homo sapiens	Inhibition	%	0.73
	8114366	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	1.64	CHEMBL2431	Homo sapiens	Inhibition	%	1.64
	8114498	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	0.95	CHEMBL2431	Homo sapiens	Inhibition	%	0.95
	8114774	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.72	CHEMBL2431	Homo sapiens	Inhibition	%	1.72
	8114940	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	1.35	CHEMBL2431	Homo sapiens	Inhibition	%	1.35
	8115164	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	0.45	CHEMBL2431	Homo sapiens	Inhibition	%	0.45
	8115329	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-1.3	CHEMBL2431	Homo sapiens	Inhibition	%	-1.3
	8115673	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	0.07	CHEMBL2431	Homo sapiens	Inhibition	%	0.07
	8115806	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%		CHEMBL2431	Homo sapiens	Inhibition	%	
	8116189	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	0.25	CHEMBL2431	Homo sapiens	Inhibition	%	0.25
	8116392	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	85.15	CHEMBL2431	Homo sapiens	Inhibition	%	85.15
	8116750	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-0.37	CHEMBL2431	Homo sapiens	Inhibition	%	-0.37
	8116922	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	2.33	CHEMBL2431	Homo sapiens	Inhibition	%	2.33
	8117317	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	-0.35	CHEMBL2431	Homo sapiens	Inhibition	%	-0.35
	8117475	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	75.28	CHEMBL2431	Homo sapiens	Inhibition	%	75.28
	8117829	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	0.32	CHEMBL2431	Homo sapiens	Inhibition	%	0.32
	8117967	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	-3.3	CHEMBL2431	Homo sapiens	Inhibition	%	-3.3
	8118191	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	-2.56	CHEMBL2431	Homo sapiens	Inhibition	%	-2.56
	8118307	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	2.77	CHEMBL2431	Homo sapiens	Inhibition	%	2.77
	8118703	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	0.95	CHEMBL2431	Homo sapiens	Inhibition	%	0.95
	8118839	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	1.84	CHEMBL2431	Homo sapiens	Inhibition	%	1.84
	8119110	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	0.81	CHEMBL2431	Homo sapiens	Inhibition	%	0.81
	8119493	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	2.4	CHEMBL2431	Homo sapiens	Inhibition	%	2.4
	8119660	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-0.21	CHEMBL2431	Homo sapiens	Inhibition	%	-0.21
	8120003	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	1.1	CHEMBL2431	Homo sapiens	Inhibition	%	1.1
	8120142	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.5	CHEMBL2431	Homo sapiens	Inhibition	%	1.5
	8120366	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.65	CHEMBL2431	Homo sapiens	Inhibition	%	1.65
	8120526	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-0.56	CHEMBL2431	Homo sapiens	Inhibition	%	-0.56
	8120727	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	95.45	CHEMBL2431	Homo sapiens	Inhibition	%	95.45
	8121079	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	0.73	CHEMBL2431	Homo sapiens	Inhibition	%	0.73
	8121251	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	0.98	CHEMBL2431	Homo sapiens	Inhibition	%	0.98
	8121475	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	1.79	CHEMBL2431	Homo sapiens	Inhibition	%	1.79
	8121642	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	0.27	CHEMBL2431	Homo sapiens	Inhibition	%	0.27
	8121805	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	0.68	CHEMBL2431	Homo sapiens	Inhibition	%	0.68
	8122029	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	3.59	CHEMBL2431	Homo sapiens	Inhibition	%	3.59
	8122150	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-1.97	CHEMBL2431	Homo sapiens	Inhibition	%	-1.97
	8122512	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	2.08	CHEMBL2431	Homo sapiens	Inhibition	%	2.08
	8122632	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	1.74	CHEMBL2431	Homo sapiens	Inhibition	%	1.74
	8122856	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	1.23	CHEMBL2431	Homo sapiens	Inhibition	%	1.23
	8123023	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	2.49	CHEMBL2431	Homo sapiens	Inhibition	%	2.49
	8123165	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	-2.6	CHEMBL2431	Homo sapiens	Inhibition	%	-2.6
	8123389	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	-2.54	CHEMBL2431	Homo sapiens	Inhibition	%	-2.54
	8123443	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	1.17	CHEMBL2431	Homo sapiens	Inhibition	%	1.17
	8123667	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	0.47	CHEMBL2431	Homo sapiens	Inhibition	%	0.47
	8123817	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	-2.91	CHEMBL2431	Homo sapiens	Inhibition	%	-2.91
	8123984	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	-3.57	CHEMBL2431	Homo sapiens	Inhibition	%	-3.57
	8124208	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	-4.73	CHEMBL2431	Homo sapiens	Inhibition	%	-4.73
	8124327	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	1.17	CHEMBL2431	Homo sapiens	Inhibition	%	1.17
	8124690	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	-0.56	CHEMBL2431	Homo sapiens	Inhibition	%	-0.56
	8124855	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-0.1	CHEMBL2431	Homo sapiens	Inhibition	%	-0.1
	8125056	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	2.05	CHEMBL2431	Homo sapiens	Inhibition	%	2.05
	8125280	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	3.62	CHEMBL2431	Homo sapiens	Inhibition	%	3.62
	8125410	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	-0.56	CHEMBL2431	Homo sapiens	Inhibition	%	-0.56
	8125802	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	1.43	CHEMBL2431	Homo sapiens	Inhibition	%	1.43
	8125966	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-1.1	CHEMBL2431	Homo sapiens	Inhibition	%	-1.1
	8126354	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	-2.76	CHEMBL2431	Homo sapiens	Inhibition	%	-2.76
	8126469	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-2.44	CHEMBL2431	Homo sapiens	Inhibition	%	-2.44
	8126829	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	2.38	CHEMBL2431	Homo sapiens	Inhibition	%	2.38
	8127175	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	1.51	CHEMBL2431	Homo sapiens	Inhibition	%	1.51
	8127342	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	0.44	CHEMBL2431	Homo sapiens	Inhibition	%	0.44
	8127708	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	1.75	CHEMBL2431	Homo sapiens	Inhibition	%	1.75
	8127996	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	1.85	CHEMBL2431	Homo sapiens	Inhibition	%	1.85
	8128148	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	2.14	CHEMBL2431	Homo sapiens	Inhibition	%	2.14
	8128539	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	0.21	CHEMBL2431	Homo sapiens	Inhibition	%	0.21
	8128658	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	0.61	CHEMBL2431	Homo sapiens	Inhibition	%	0.61
	8128882	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.17	CHEMBL2431	Homo sapiens	Inhibition	%	0.17
	8129019	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	1.26	CHEMBL2431	Homo sapiens	Inhibition	%	1.26
	8129190	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-0.71	CHEMBL2431	Homo sapiens	Inhibition	%	-0.71
	8129414	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-0.42	CHEMBL2431	Homo sapiens	Inhibition	%	-0.42
	8129603	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	-0.33	CHEMBL2431	Homo sapiens	Inhibition	%	-0.33
	8129742	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.1	CHEMBL2431	Homo sapiens	Inhibition	%	0.1
	8129966	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-0.81	CHEMBL2431	Homo sapiens	Inhibition	%	-0.81
	8130127	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.42	CHEMBL2431	Homo sapiens	Inhibition	%	0.42
	8130299	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-0.35	CHEMBL2431	Homo sapiens	Inhibition	%	-0.35
	8130683	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	-2.22	CHEMBL2431	Homo sapiens	Inhibition	%	-2.22
	8130799	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	1.2	CHEMBL2431	Homo sapiens	Inhibition	%	1.2
	8131023	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	2.26	CHEMBL2431	Homo sapiens	Inhibition	%	2.26
	8131162	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	2.55	CHEMBL2431	Homo sapiens	Inhibition	%	2.55
	8131506	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	-2.94	CHEMBL2431	Homo sapiens	Inhibition	%	-2.94
	8131673	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	3.48	CHEMBL2431	Homo sapiens	Inhibition	%	3.48
	8132038	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	2.15	CHEMBL2431	Homo sapiens	Inhibition	%	2.15
	8132324	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-3.1	CHEMBL2431	Homo sapiens	Inhibition	%	-3.1
	8132471	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	0.78	CHEMBL2431	Homo sapiens	Inhibition	%	0.78
	8132695	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	1.11	CHEMBL2431	Homo sapiens	Inhibition	%	1.11
	8132863	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	0.07	CHEMBL2431	Homo sapiens	Inhibition	%	0.07
	8133208	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	-0.27	CHEMBL2431	Homo sapiens	Inhibition	%	-0.27
	8133346	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	-1.36	CHEMBL2431	Homo sapiens	Inhibition	%	-1.36
	8133742	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-1.71	CHEMBL2431	Homo sapiens	Inhibition	%	-1.71
	8133922	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	1.06	CHEMBL2431	Homo sapiens	Inhibition	%	1.06
	8134294	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-0.64	CHEMBL2431	Homo sapiens	Inhibition	%	-0.64
	8134454	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.88	CHEMBL2431	Homo sapiens	Inhibition	%	0.88
	8134638	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-3.92	CHEMBL2431	Homo sapiens	Inhibition	%	-3.92
	8134862	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-2.28	CHEMBL2431	Homo sapiens	Inhibition	%	-2.28
	8135022	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	0.53	CHEMBL2431	Homo sapiens	Inhibition	%	0.53
	8135361	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.35	CHEMBL2431	Homo sapiens	Inhibition	%	1.35
	8135502	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	1.54	CHEMBL2431	Homo sapiens	Inhibition	%	1.54
	8135726	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	3.72	CHEMBL2431	Homo sapiens	Inhibition	%	3.72
	8135847	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	-3.14	CHEMBL2431	Homo sapiens	Inhibition	%	-3.14
	8136015	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	2.42	CHEMBL2431	Homo sapiens	Inhibition	%	2.42
	8136239	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	1.51	CHEMBL2431	Homo sapiens	Inhibition	%	1.51
	8136383	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	0.93	CHEMBL2431	Homo sapiens	Inhibition	%	0.93
	8136673	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-2.1	CHEMBL2431	Homo sapiens	Inhibition	%	-2.1
	8137032	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	1.63	CHEMBL2431	Homo sapiens	Inhibition	%	1.63
	8137195	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	0.22	CHEMBL2431	Homo sapiens	Inhibition	%	0.22
	8137539	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-3.43	CHEMBL2431	Homo sapiens	Inhibition	%	-3.43
	8137687	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	0.79	CHEMBL2431	Homo sapiens	Inhibition	%	0.79
	8137911	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	-0.91	CHEMBL2431	Homo sapiens	Inhibition	%	-0.91
	8138077	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-1.01	CHEMBL2431	Homo sapiens	Inhibition	%	-1.01
	8138256	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	-0.39	CHEMBL2431	Homo sapiens	Inhibition	%	-0.39
	8138628	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-4.74	CHEMBL2431	Homo sapiens	Inhibition	%	-4.74
	8138786	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	1.23	CHEMBL2431	Homo sapiens	Inhibition	%	1.23
	8139010	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.06	CHEMBL2431	Homo sapiens	Inhibition	%	1.06
	8139195	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	1.72	CHEMBL2431	Homo sapiens	Inhibition	%	1.72
	8139354	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	1.57	CHEMBL2431	Homo sapiens	Inhibition	%	1.57
	8139692	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	2.2	CHEMBL2431	Homo sapiens	Inhibition	%	2.2
	8140057	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	3.57	CHEMBL2431	Homo sapiens	Inhibition	%	3.57
	8140180	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	1.18	CHEMBL2431	Homo sapiens	Inhibition	%	1.18
	8140563	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	1.23	CHEMBL2431	Homo sapiens	Inhibition	%	1.23
	8140706	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	2.21	CHEMBL2431	Homo sapiens	Inhibition	%	2.21
	8140930	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	2.21	CHEMBL2431	Homo sapiens	Inhibition	%	2.21
	8141008	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	0.6	CHEMBL2431	Homo sapiens	Inhibition	%	0.6
	8141362	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	0.45	CHEMBL2431	Homo sapiens	Inhibition	%	0.45
	8141522	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	-0.08	CHEMBL2431	Homo sapiens	Inhibition	%	-0.08
	8141746	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	0.5	CHEMBL2431	Homo sapiens	Inhibition	%	0.5
	8141865	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-4.29	CHEMBL2431	Homo sapiens	Inhibition	%	-4.29
	8142250	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	-0.18	CHEMBL2431	Homo sapiens	Inhibition	%	-0.18
	8142418	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	-1.9	CHEMBL2431	Homo sapiens	Inhibition	%	-1.9
	8142594	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	0.39	CHEMBL2431	Homo sapiens	Inhibition	%	0.39
	8142818	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	0.28	CHEMBL2431	Homo sapiens	Inhibition	%	0.28
	8142967	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-3.0	CHEMBL2431	Homo sapiens	Inhibition	%	-3.0
	8143346	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.24	CHEMBL2431	Homo sapiens	Inhibition	%	1.24
	8143533	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	1.1	CHEMBL2431	Homo sapiens	Inhibition	%	1.1
	8143692	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	0.8	CHEMBL2431	Homo sapiens	Inhibition	%	0.8
	8143916	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	2.31	CHEMBL2431	Homo sapiens	Inhibition	%	2.31
	8144030	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-3.3	CHEMBL2431	Homo sapiens	Inhibition	%	-3.3
	8144393	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	1.29	CHEMBL2431	Homo sapiens	Inhibition	%	1.29
	8144523	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	0.93	CHEMBL2431	Homo sapiens	Inhibition	%	0.93
	8144747	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	2.45	CHEMBL2431	Homo sapiens	Inhibition	%	2.45
	8144900	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	1.37	CHEMBL2431	Homo sapiens	Inhibition	%	1.37
	8145261	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	3.29	CHEMBL2431	Homo sapiens	Inhibition	%	3.29
	8145350	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.42	CHEMBL2431	Homo sapiens	Inhibition	%	1.42
	8145574	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	0.76	CHEMBL2431	Homo sapiens	Inhibition	%	0.76
	8145698	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	0.89	CHEMBL2431	Homo sapiens	Inhibition	%	0.89
	8146083	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	2.1	CHEMBL2431	Homo sapiens	Inhibition	%	2.1
	8146203	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-0.16	CHEMBL2431	Homo sapiens	Inhibition	%	-0.16
	8146587	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	2.64	CHEMBL2431	Homo sapiens	Inhibition	%	2.64
	8146754	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	-0.71	CHEMBL2431	Homo sapiens	Inhibition	%	-0.71
	8147147	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	1.31	CHEMBL2431	Homo sapiens	Inhibition	%	1.31
	8147289	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	0.62	CHEMBL2431	Homo sapiens	Inhibition	%	0.62
	8147666	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.23	CHEMBL2431	Homo sapiens	Inhibition	%	1.23
	8147853	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	0.67	CHEMBL2431	Homo sapiens	Inhibition	%	0.67
	8148235	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	0.54	CHEMBL2431	Homo sapiens	Inhibition	%	0.54
	8148349	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-3.04	CHEMBL2431	Homo sapiens	Inhibition	%	-3.04
	8148573	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	1.01	CHEMBL2431	Homo sapiens	Inhibition	%	1.01
	8148712	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	2.02	CHEMBL2431	Homo sapiens	Inhibition	%	2.02
	8149074	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	1.86	CHEMBL2431	Homo sapiens	Inhibition	%	1.86
	8149233	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	-3.4	CHEMBL2431	Homo sapiens	Inhibition	%	-3.4
	8149591	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	3.28	CHEMBL2431	Homo sapiens	Inhibition	%	3.28
	8149913	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	1.15	CHEMBL2431	Homo sapiens	Inhibition	%	1.15
	8150038	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	-3.05	CHEMBL2431	Homo sapiens	Inhibition	%	-3.05
	8150422	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	Inhibition	%	0.0
	8150542	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-0.51	CHEMBL2431	Homo sapiens	Inhibition	%	-0.51
	8150766	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.2	CHEMBL2431	Homo sapiens	Inhibition	%	0.2
	8150931	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	0.91	CHEMBL2431	Homo sapiens	Inhibition	%	0.91
	8151094	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-3.64	CHEMBL2431	Homo sapiens	Inhibition	%	-3.64
	8151318	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-3.23	CHEMBL2431	Homo sapiens	Inhibition	%	-3.23
	8151495	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	-0.16	CHEMBL2431	Homo sapiens	Inhibition	%	-0.16
	8151633	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	1.58	CHEMBL2431	Homo sapiens	Inhibition	%	1.58
	8151857	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	0.57	CHEMBL2431	Homo sapiens	Inhibition	%	0.57
	8152011	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.84	CHEMBL2431	Homo sapiens	Inhibition	%	1.84
	8152199	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	1.05	CHEMBL2431	Homo sapiens	Inhibition	%	1.05
	8152423	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	-2.93	CHEMBL2431	Homo sapiens	Inhibition	%	-2.93
	8152581	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	2.99	CHEMBL2431	Homo sapiens	Inhibition	%	2.99
	8152919	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	2.53	CHEMBL2431	Homo sapiens	Inhibition	%	2.53
	8153058	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	1.77	CHEMBL2431	Homo sapiens	Inhibition	%	1.77
	8153419	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	2.91	CHEMBL2431	Homo sapiens	Inhibition	%	2.91
	8153576	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	-2.91	CHEMBL2431	Homo sapiens	Inhibition	%	-2.91
	8153800	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	0.22	CHEMBL2431	Homo sapiens	Inhibition	%	0.22
	8153933	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	10.54	CHEMBL2431	Homo sapiens	Inhibition	%	10.54
	8154254	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	0.69	CHEMBL2431	Homo sapiens	Inhibition	%	0.69
	8154380	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	-2.64	CHEMBL2431	Homo sapiens	Inhibition	%	-2.64
	8154604	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	1.14	CHEMBL2431	Homo sapiens	Inhibition	%	1.14
	8154763	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	0.98	CHEMBL2431	Homo sapiens	Inhibition	%	0.98
	8155107	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.66	CHEMBL2431	Homo sapiens	Inhibition	%	0.66
	8155283	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-0.52	CHEMBL2431	Homo sapiens	Inhibition	%	-0.52
	8155668	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	1.31	CHEMBL2431	Homo sapiens	Inhibition	%	1.31
	8155846	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	0.84	CHEMBL2431	Homo sapiens	Inhibition	%	0.84
	8156208	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	1.35	CHEMBL2431	Homo sapiens	Inhibition	%	1.35
	8156420	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	1.6	CHEMBL2431	Homo sapiens	Inhibition	%	1.6
	8156794	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	0.78	CHEMBL2431	Homo sapiens	Inhibition	%	0.78
	8156937	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	1.95	CHEMBL2431	Homo sapiens	Inhibition	%	1.95
	8157281	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	1.11	CHEMBL2431	Homo sapiens	Inhibition	%	1.11
	8157422	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	1.62	CHEMBL2431	Homo sapiens	Inhibition	%	1.62
	8157646	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	1.52	CHEMBL2431	Homo sapiens	Inhibition	%	1.52
	8157776	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	2.59	CHEMBL2431	Homo sapiens	Inhibition	%	2.59
	8158161	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	-3.19	CHEMBL2431	Homo sapiens	Inhibition	%	-3.19
	8158411	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	3.72	CHEMBL2431	Homo sapiens	Inhibition	%	3.72
	8158569	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	-1.55	CHEMBL2431	Homo sapiens	Inhibition	%	-1.55
	8158962	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	1.89	CHEMBL2431	Homo sapiens	Inhibition	%	1.89
	8159097	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	2.23	CHEMBL2431	Homo sapiens	Inhibition	%	2.23
	8159321	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	2.72	CHEMBL2431	Homo sapiens	Inhibition	%	2.72
	8159441	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	-2.67	CHEMBL2431	Homo sapiens	Inhibition	%	-2.67
	8159796	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	1.85	CHEMBL2431	Homo sapiens	Inhibition	%	1.85
	8159937	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	0.83	CHEMBL2431	Homo sapiens	Inhibition	%	0.83
	8160298	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	1.0	CHEMBL2431	Homo sapiens	Inhibition	%	1.0
	8160448	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-2.08	CHEMBL2431	Homo sapiens	Inhibition	%	-2.08
	8160672	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-1.44	CHEMBL2431	Homo sapiens	Inhibition	%	-1.44
	8160742	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	1.7	CHEMBL2431	Homo sapiens	Inhibition	%	1.7
	8161116	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	0.37	CHEMBL2431	Homo sapiens	Inhibition	%	0.37
	8161259	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	2.29	CHEMBL2431	Homo sapiens	Inhibition	%	2.29
	8161483	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	1.47	CHEMBL2431	Homo sapiens	Inhibition	%	1.47
	8161608	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	1.74	CHEMBL2431	Homo sapiens	Inhibition	%	1.74
	8161970	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	3.5	CHEMBL2431	Homo sapiens	Inhibition	%	3.5
	8162100	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	2.36	CHEMBL2431	Homo sapiens	Inhibition	%	2.36
	8162324	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	2.18	CHEMBL2431	Homo sapiens	Inhibition	%	2.18
	8162484	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	-0.85	CHEMBL2431	Homo sapiens	Inhibition	%	-0.85
	8162737	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	13.26	CHEMBL2431	Homo sapiens	Inhibition	%	13.26
	8162885	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	2.3	CHEMBL2431	Homo sapiens	Inhibition	%	2.3
	8163109	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	2.59	CHEMBL2431	Homo sapiens	Inhibition	%	2.59
	8163278	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	1.74	CHEMBL2431	Homo sapiens	Inhibition	%	1.74
	8163636	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	1.94	CHEMBL2431	Homo sapiens	Inhibition	%	1.94
	8163759	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	-1.63	CHEMBL2431	Homo sapiens	Inhibition	%	-1.63
	8164117	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	1.92	CHEMBL2431	Homo sapiens	Inhibition	%	1.92
	8164257	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	-0.58	CHEMBL2431	Homo sapiens	Inhibition	%	-0.58
	8164481	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	0.6	CHEMBL2431	Homo sapiens	Inhibition	%	0.6
	8164636	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	1.11	CHEMBL2431	Homo sapiens	Inhibition	%	1.11
	8165004	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	1.58	CHEMBL2431	Homo sapiens	Inhibition	%	1.58
	8165074	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	2.81	CHEMBL2431	Homo sapiens	Inhibition	%	2.81
	8165298	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	2.14	CHEMBL2431	Homo sapiens	Inhibition	%	2.14
	8165439	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	0.71	CHEMBL2431	Homo sapiens	Inhibition	%	0.71
	8165806	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	1.95	CHEMBL2431	Homo sapiens	Inhibition	%	1.95
	8165932	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	1.48	CHEMBL2431	Homo sapiens	Inhibition	%	1.48
	8166294	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	2.66	CHEMBL2431	Homo sapiens	Inhibition	%	2.66
	8166648	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	2.47	CHEMBL2431	Homo sapiens	Inhibition	%	2.47
	8166749	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	1.19	CHEMBL2431	Homo sapiens	Inhibition	%	1.19
	8167061	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	2.69	CHEMBL2431	Homo sapiens	Inhibition	%	2.69
	8167426	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	2.13	CHEMBL2431	Homo sapiens	Inhibition	%	2.13
	8167590	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	2.41	CHEMBL2431	Homo sapiens	Inhibition	%	2.41
	8167947	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	2.93	CHEMBL2431	Homo sapiens	Inhibition	%	2.93
	8168071	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	0.33	CHEMBL2431	Homo sapiens	Inhibition	%	0.33
	8168295	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	1.45	CHEMBL2431	Homo sapiens	Inhibition	%	1.45
	8168436	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	1.62	CHEMBL2431	Homo sapiens	Inhibition	%	1.62
	8168796	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-4.21	CHEMBL2431	Homo sapiens	Inhibition	%	-4.21
	8168960	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	1.66	CHEMBL2431	Homo sapiens	Inhibition	%	1.66
	8169326	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	4.27	CHEMBL2431	Homo sapiens	Inhibition	%	4.27
	8169630	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	3.41	CHEMBL2431	Homo sapiens	Inhibition	%	3.41
	8169764	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	1.42	CHEMBL2431	Homo sapiens	Inhibition	%	1.42
	8170133	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	2.09	CHEMBL2431	Homo sapiens	Inhibition	%	2.09
	8170258	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	2.18	CHEMBL2431	Homo sapiens	Inhibition	%	2.18
	8170482	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	1.39	CHEMBL2431	Homo sapiens	Inhibition	%	1.39
	8170622	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	74.19	CHEMBL2431	Homo sapiens	Inhibition	%	74.19
	8170981	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	1.28	CHEMBL2431	Homo sapiens	Inhibition	%	1.28
	8171178	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	0.52	CHEMBL2431	Homo sapiens	Inhibition	%	0.52
	8171395	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	7.74	CHEMBL2431	Homo sapiens	Inhibition	%	7.74
	8171760	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	2.14	CHEMBL2431	Homo sapiens	Inhibition	%	2.14
	8171913	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	-2.03	CHEMBL2431	Homo sapiens	Inhibition	%	-2.03
	8172137	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	-2.75	CHEMBL2431	Homo sapiens	Inhibition	%	-2.75
	8172269	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	1.75	CHEMBL2431	Homo sapiens	Inhibition	%	1.75
	8172621	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	-0.98	CHEMBL2431	Homo sapiens	Inhibition	%	-0.98
	8172763	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	1.08	CHEMBL2431	Homo sapiens	Inhibition	%	1.08
	8173123	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-1.31	CHEMBL2431	Homo sapiens	Inhibition	%	-1.31
	8173288	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	1.42	CHEMBL2431	Homo sapiens	Inhibition	%	1.42
	8173512	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	-0.44	CHEMBL2431	Homo sapiens	Inhibition	%	-0.44
	8173653	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	1.49	CHEMBL2431	Homo sapiens	Inhibition	%	1.49
	8173964	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	1.59	CHEMBL2431	Homo sapiens	Inhibition	%	1.59
	8174096	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	1.09	CHEMBL2431	Homo sapiens	Inhibition	%	1.09
	8174320	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	1.16	CHEMBL2431	Homo sapiens	Inhibition	%	1.16
	8174468	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.68	CHEMBL2431	Homo sapiens	Inhibition	%	1.68
	8174814	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	3.39	CHEMBL2431	Homo sapiens	Inhibition	%	3.39
	8174957	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	89.35	CHEMBL2431	Homo sapiens	Inhibition	%	89.35
	8175181	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	2.42	CHEMBL2431	Homo sapiens	Inhibition	%	2.42
	8175317	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	1.13	CHEMBL2431	Homo sapiens	Inhibition	%	1.13
	8175573	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	0.9	CHEMBL2431	Homo sapiens	Inhibition	%	0.9
	8175736	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	1.6	CHEMBL2431	Homo sapiens	Inhibition	%	1.6
	8175960	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	2.15	CHEMBL2431	Homo sapiens	Inhibition	%	2.15
	8176113	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	3.5	CHEMBL2431	Homo sapiens	Inhibition	%	3.5
	8176486	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	0.75	CHEMBL2431	Homo sapiens	Inhibition	%	0.75
	8176618	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	2.21	CHEMBL2431	Homo sapiens	Inhibition	%	2.21
	8176972	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	0.73	CHEMBL2431	Homo sapiens	Inhibition	%	0.73
	8177114	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	-1.95	CHEMBL2431	Homo sapiens	Inhibition	%	-1.95
	8177338	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	-2.32	CHEMBL2431	Homo sapiens	Inhibition	%	-2.32
	8177476	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	1.45	CHEMBL2431	Homo sapiens	Inhibition	%	1.45
	8177864	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	2.24	CHEMBL2431	Homo sapiens	Inhibition	%	2.24
	8178004	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	2.84	CHEMBL2431	Homo sapiens	Inhibition	%	2.84
	8178316	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.82	CHEMBL2431	Homo sapiens	Inhibition	%	1.82
	8178667	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	2.0	CHEMBL2431	Homo sapiens	Inhibition	%	2.0
	8178816	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.73	CHEMBL2431	Homo sapiens	Inhibition	%	1.73
	8179163	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	2.59	CHEMBL2431	Homo sapiens	Inhibition	%	2.59
	8179531	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	1.92	CHEMBL2431	Homo sapiens	Inhibition	%	1.92
	8179668	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	1.03	CHEMBL2431	Homo sapiens	Inhibition	%	1.03
	8179925	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	3.48	CHEMBL2431	Homo sapiens	Inhibition	%	3.48
	8180303	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	-2.34	CHEMBL2431	Homo sapiens	Inhibition	%	-2.34
	8180459	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	15.12	CHEMBL2431	Homo sapiens	Inhibition	%	15.12
	8180831	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	1.06	CHEMBL2431	Homo sapiens	Inhibition	%	1.06
	8180964	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	2.36	CHEMBL2431	Homo sapiens	Inhibition	%	2.36
	8181188	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	1.9	CHEMBL2431	Homo sapiens	Inhibition	%	1.9
	8181319	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	-3.63	CHEMBL2431	Homo sapiens	Inhibition	%	-3.63
	8181683	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	1.2	CHEMBL2431	Homo sapiens	Inhibition	%	1.2
	8181822	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	2.54	CHEMBL2431	Homo sapiens	Inhibition	%	2.54
	8182046	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	1.56	CHEMBL2431	Homo sapiens	Inhibition	%	1.56
	8182209	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	2.19	CHEMBL2431	Homo sapiens	Inhibition	%	2.19
	8182349	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	0.91	CHEMBL2431	Homo sapiens	Inhibition	%	0.91
	8182573	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	1.4	CHEMBL2431	Homo sapiens	Inhibition	%	1.4
	8182665	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.59	CHEMBL2431	Homo sapiens	Inhibition	%	1.59
	8183011	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	1.56	CHEMBL2431	Homo sapiens	Inhibition	%	1.56
	8183160	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	1.41	CHEMBL2431	Homo sapiens	Inhibition	%	1.41
	8183384	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	0.82	CHEMBL2431	Homo sapiens	Inhibition	%	0.82
	8183513	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	0.17	CHEMBL2431	Homo sapiens	Inhibition	%	0.17
	8183879	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	3.01	CHEMBL2431	Homo sapiens	Inhibition	%	3.01
	8184015	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	0.88	CHEMBL2431	Homo sapiens	Inhibition	%	0.88
	8184239	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	-3.17	CHEMBL2431	Homo sapiens	Inhibition	%	-3.17
	8184281	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	1.57	CHEMBL2431	Homo sapiens	Inhibition	%	1.57
	8184505	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.25	CHEMBL2431	Homo sapiens	Inhibition	%	3.25
	8184652	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	-1.49	CHEMBL2431	Homo sapiens	Inhibition	%	-1.49
	8184809	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	1.99	CHEMBL2431	Homo sapiens	Inhibition	%	1.99
	8185033	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	1.14	CHEMBL2431	Homo sapiens	Inhibition	%	1.14
	8185182	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-0.39	CHEMBL2431	Homo sapiens	Inhibition	%	-0.39
	8185537	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	-0.89	CHEMBL2431	Homo sapiens	Inhibition	%	-0.89
	8185668	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	-0.17	CHEMBL2431	Homo sapiens	Inhibition	%	-0.17
	8185892	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	1.96	CHEMBL2431	Homo sapiens	Inhibition	%	1.96
	8186031	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	1.68	CHEMBL2431	Homo sapiens	Inhibition	%	1.68
	8186396	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	1.42	CHEMBL2431	Homo sapiens	Inhibition	%	1.42
	8186560	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	2.65	CHEMBL2431	Homo sapiens	Inhibition	%	2.65
	8186923	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	1.42	CHEMBL2431	Homo sapiens	Inhibition	%	1.42
	8187021	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.8	CHEMBL2431	Homo sapiens	Inhibition	%	1.8
	8187245	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.63	CHEMBL2431	Homo sapiens	Inhibition	%	1.63
	8187369	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	2.41	CHEMBL2431	Homo sapiens	Inhibition	%	2.41
	8187741	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	2.06	CHEMBL2431	Homo sapiens	Inhibition	%	2.06
	8187870	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	0.25	CHEMBL2431	Homo sapiens	Inhibition	%	0.25
	8188094	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	0.92	CHEMBL2431	Homo sapiens	Inhibition	%	0.92
	8188237	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	2.43	CHEMBL2431	Homo sapiens	Inhibition	%	2.43
	8188596	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	-2.73	CHEMBL2431	Homo sapiens	Inhibition	%	-2.73
	8188870	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	1.52	CHEMBL2431	Homo sapiens	Inhibition	%	1.52
	8189018	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	0.47	CHEMBL2431	Homo sapiens	Inhibition	%	0.47
	8189398	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	1.32	CHEMBL2431	Homo sapiens	Inhibition	%	1.32
	8189547	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	0.71	CHEMBL2431	Homo sapiens	Inhibition	%	0.71
	8189771	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-3.12	CHEMBL2431	Homo sapiens	Inhibition	%	-3.12
	8189903	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	-2.09	CHEMBL2431	Homo sapiens	Inhibition	%	-2.09
	8190259	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	2.36	CHEMBL2431	Homo sapiens	Inhibition	%	2.36
	8190399	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	1.93	CHEMBL2431	Homo sapiens	Inhibition	%	1.93
	8190760	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	1.3	CHEMBL2431	Homo sapiens	Inhibition	%	1.3
	8190924	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	1.87	CHEMBL2431	Homo sapiens	Inhibition	%	1.87
	8191148	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	1.49	CHEMBL2431	Homo sapiens	Inhibition	%	1.49
	8191286	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	0.96	CHEMBL2431	Homo sapiens	Inhibition	%	0.96
	8191606	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	1.39	CHEMBL2431	Homo sapiens	Inhibition	%	1.39
	8191728	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	1.51	CHEMBL2431	Homo sapiens	Inhibition	%	1.51
	8191952	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	1.38	CHEMBL2431	Homo sapiens	Inhibition	%	1.38
	8192101	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	1.3	CHEMBL2431	Homo sapiens	Inhibition	%	1.3
	8192454	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	1.2	CHEMBL2431	Homo sapiens	Inhibition	%	1.2
	8192598	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	2.41	CHEMBL2431	Homo sapiens	Inhibition	%	2.41
	8192958	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	0.01	CHEMBL2431	Homo sapiens	Inhibition	%	0.01
	8193230	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	1.95	CHEMBL2431	Homo sapiens	Inhibition	%	1.95
	8193375	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	-1.58	CHEMBL2431	Homo sapiens	Inhibition	%	-1.58
	8193599	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	-0.21	CHEMBL2431	Homo sapiens	Inhibition	%	-0.21
	8193756	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	1.98	CHEMBL2431	Homo sapiens	Inhibition	%	1.98
	8194129	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-0.45	CHEMBL2431	Homo sapiens	Inhibition	%	-0.45
	8194260	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	1.99	CHEMBL2431	Homo sapiens	Inhibition	%	1.99
	8194615	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	1.7	CHEMBL2431	Homo sapiens	Inhibition	%	1.7
	8194758	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	2.56	CHEMBL2431	Homo sapiens	Inhibition	%	2.56
	8194982	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	2.3	CHEMBL2431	Homo sapiens	Inhibition	%	2.3
	8195115	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	1.3	CHEMBL2431	Homo sapiens	Inhibition	%	1.3
	8195503	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	0.98	CHEMBL2431	Homo sapiens	Inhibition	%	0.98
	8195642	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	2.08	CHEMBL2431	Homo sapiens	Inhibition	%	2.08
	8195964	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	1.43	CHEMBL2431	Homo sapiens	Inhibition	%	1.43
	8196305	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	1.4	CHEMBL2431	Homo sapiens	Inhibition	%	1.4
	8196455	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	2.02	CHEMBL2431	Homo sapiens	Inhibition	%	2.02
	8196807	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	-1.63	CHEMBL2431	Homo sapiens	Inhibition	%	-1.63
	8196948	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	2.34	CHEMBL2431	Homo sapiens	Inhibition	%	2.34
	8197172	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	1.46	CHEMBL2431	Homo sapiens	Inhibition	%	1.46
	8197309	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	0.53	CHEMBL2431	Homo sapiens	Inhibition	%	0.53
	8197584	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	2.01	CHEMBL2431	Homo sapiens	Inhibition	%	2.01
	8197948	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	0.92	CHEMBL2431	Homo sapiens	Inhibition	%	0.92
	8198105	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	-1.68	CHEMBL2431	Homo sapiens	Inhibition	%	-1.68
	8198467	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	1.68	CHEMBL2431	Homo sapiens	Inhibition	%	1.68
	8198597	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	1.77	CHEMBL2431	Homo sapiens	Inhibition	%	1.77
	8198821	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	2.55	CHEMBL2431	Homo sapiens	Inhibition	%	2.55
	8198952	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	2.85	CHEMBL2431	Homo sapiens	Inhibition	%	2.85
	8199324	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	2.71	CHEMBL2431	Homo sapiens	Inhibition	%	2.71
	8199458	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	1.28	CHEMBL2431	Homo sapiens	Inhibition	%	1.28
	8199845	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	1.75	CHEMBL2431	Homo sapiens	Inhibition	%	1.75
	8199983	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	2.51	CHEMBL2431	Homo sapiens	Inhibition	%	2.51
	8200207	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	2.69	CHEMBL2431	Homo sapiens	Inhibition	%	2.69
	8200311	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	0.64	CHEMBL2431	Homo sapiens	Inhibition	%	0.64
	8200650	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	1.01	CHEMBL2431	Homo sapiens	Inhibition	%	1.01
	8200800	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	1.95	CHEMBL2431	Homo sapiens	Inhibition	%	1.95
	8201024	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	3.2	CHEMBL2431	Homo sapiens	Inhibition	%	3.2
	8201154	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	-2.73	CHEMBL2431	Homo sapiens	Inhibition	%	-2.73
	8201513	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	1.66	CHEMBL2431	Homo sapiens	Inhibition	%	1.66
	8201646	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-0.6	CHEMBL2431	Homo sapiens	Inhibition	%	-0.6
	8201870	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-0.29	CHEMBL2431	Homo sapiens	Inhibition	%	-0.29
	8201925	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	2.87	CHEMBL2431	Homo sapiens	Inhibition	%	2.87
	8202149	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	0.73	CHEMBL2431	Homo sapiens	Inhibition	%	0.73
	8202289	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-2.78	CHEMBL2431	Homo sapiens	Inhibition	%	-2.78
	8202456	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	-1.83	CHEMBL2431	Homo sapiens	Inhibition	%	-1.83
	8202680	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	1.85	CHEMBL2431	Homo sapiens	Inhibition	%	1.85
	8202805	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	2.45	CHEMBL2431	Homo sapiens	Inhibition	%	2.45
	8203159	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	2.42	CHEMBL2431	Homo sapiens	Inhibition	%	2.42
	8203290	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	-2.16	CHEMBL2431	Homo sapiens	Inhibition	%	-2.16
	8203514	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	-3.49	CHEMBL2431	Homo sapiens	Inhibition	%	-3.49
	8203660	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	1.29	CHEMBL2431	Homo sapiens	Inhibition	%	1.29
	8203794	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	1.61	CHEMBL2431	Homo sapiens	Inhibition	%	1.61
	8204018	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	2.54	CHEMBL2431	Homo sapiens	Inhibition	%	2.54
	8204184	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	0.98	CHEMBL2431	Homo sapiens	Inhibition	%	0.98
	8204545	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	2.45	CHEMBL2431	Homo sapiens	Inhibition	%	2.45
	8204650	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.15	CHEMBL2431	Homo sapiens	Inhibition	%	1.15
	8204874	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	0.25	CHEMBL2431	Homo sapiens	Inhibition	%	0.25
	8204989	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	0.76	CHEMBL2431	Homo sapiens	Inhibition	%	0.76
	8205362	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	2.75	CHEMBL2431	Homo sapiens	Inhibition	%	2.75
	8205498	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	1.97	CHEMBL2431	Homo sapiens	Inhibition	%	1.97
	8205722	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	1.44	CHEMBL2431	Homo sapiens	Inhibition	%	1.44
	8205861	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	1.47	CHEMBL2431	Homo sapiens	Inhibition	%	1.47
	8206217	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-3.94	CHEMBL2431	Homo sapiens	Inhibition	%	-3.94
	8206493	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	0.03	CHEMBL2431	Homo sapiens	Inhibition	%	0.03
	8206636	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-0.83	CHEMBL2431	Homo sapiens	Inhibition	%	-0.83
	8207040	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	3.82	CHEMBL2431	Homo sapiens	Inhibition	%	3.82
	8207166	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	1.97	CHEMBL2431	Homo sapiens	Inhibition	%	1.97
	8207520	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	2.21	CHEMBL2431	Homo sapiens	Inhibition	%	2.21
	8207876	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	1.79	CHEMBL2431	Homo sapiens	Inhibition	%	1.79
	8208021	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	1.85	CHEMBL2431	Homo sapiens	Inhibition	%	1.85
	8208377	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	1.95	CHEMBL2431	Homo sapiens	Inhibition	%	1.95
	8208543	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	0.74	CHEMBL2431	Homo sapiens	Inhibition	%	0.74
	8208900	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	2.53	CHEMBL2431	Homo sapiens	Inhibition	%	2.53
	8209229	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	0.43	CHEMBL2431	Homo sapiens	Inhibition	%	0.43
	8209345	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	1.1	CHEMBL2431	Homo sapiens	Inhibition	%	1.1
	8209569	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	1.5	CHEMBL2431	Homo sapiens	Inhibition	%	1.5
	8209719	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.38	CHEMBL2431	Homo sapiens	Inhibition	%	1.38
	8210079	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	2.49	CHEMBL2431	Homo sapiens	Inhibition	%	2.49
	8210220	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	1.58	CHEMBL2431	Homo sapiens	Inhibition	%	1.58
	8210580	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-1.99	CHEMBL2431	Homo sapiens	Inhibition	%	-1.99
	8210839	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	-2.39	CHEMBL2431	Homo sapiens	Inhibition	%	-2.39
	8210983	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	2.35	CHEMBL2431	Homo sapiens	Inhibition	%	2.35
	8211207	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	1.5	CHEMBL2431	Homo sapiens	Inhibition	%	1.5
	8211377	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	1.89	CHEMBL2431	Homo sapiens	Inhibition	%	1.89
	8211500	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	2.05	CHEMBL2431	Homo sapiens	Inhibition	%	2.05
	8211724	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	0.2	CHEMBL2431	Homo sapiens	Inhibition	%	0.2
	8211853	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	3.12	CHEMBL2431	Homo sapiens	Inhibition	%	3.12
	8212209	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.65	CHEMBL2431	Homo sapiens	Inhibition	%	2.65
	8212350	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	1.62	CHEMBL2431	Homo sapiens	Inhibition	%	1.62
	8212574	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	1.6	CHEMBL2431	Homo sapiens	Inhibition	%	1.6
	8212707	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	2.63	CHEMBL2431	Homo sapiens	Inhibition	%	2.63
	8212877	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	1.1	CHEMBL2431	Homo sapiens	Inhibition	%	1.1
	8213101	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	0.18	CHEMBL2431	Homo sapiens	Inhibition	%	0.18
	8213230	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	5.04	CHEMBL2431	Homo sapiens	Inhibition	%	5.04
	8213558	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-2.06	CHEMBL2431	Homo sapiens	Inhibition	%	-2.06
	8213895	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	1.02	CHEMBL2431	Homo sapiens	Inhibition	%	1.02
	8214042	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	0.67	CHEMBL2431	Homo sapiens	Inhibition	%	0.67
	8214403	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	2.19	CHEMBL2431	Homo sapiens	Inhibition	%	2.19
	8214537	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	-1.66	CHEMBL2431	Homo sapiens	Inhibition	%	-1.66
	8214761	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	-2.15	CHEMBL2431	Homo sapiens	Inhibition	%	-2.15
	8214913	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-0.23	CHEMBL2431	Homo sapiens	Inhibition	%	-0.23
	8215164	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	2.52	CHEMBL2431	Homo sapiens	Inhibition	%	2.52
	8215541	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	2.07	CHEMBL2431	Homo sapiens	Inhibition	%	2.07
	8215705	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	1.81	CHEMBL2431	Homo sapiens	Inhibition	%	1.81
	8216048	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	-1.3	CHEMBL2431	Homo sapiens	Inhibition	%	-1.3
	8216167	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	2.44	CHEMBL2431	Homo sapiens	Inhibition	%	2.44
	8216391	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	2.18	CHEMBL2431	Homo sapiens	Inhibition	%	2.18
	8216527	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	1.86	CHEMBL2431	Homo sapiens	Inhibition	%	1.86
	8216889	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	-2.31	CHEMBL2431	Homo sapiens	Inhibition	%	-2.31
	8217023	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	1.84	CHEMBL2431	Homo sapiens	Inhibition	%	1.84
	8217421	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	0.15	CHEMBL2431	Homo sapiens	Inhibition	%	0.15
	8217552	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	2.07	CHEMBL2431	Homo sapiens	Inhibition	%	2.07
	8217776	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	1.33	CHEMBL2431	Homo sapiens	Inhibition	%	1.33
	8217877	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-1.58	CHEMBL2431	Homo sapiens	Inhibition	%	-1.58
	8218216	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	0.67	CHEMBL2431	Homo sapiens	Inhibition	%	0.67
	8218343	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	1.29	CHEMBL2431	Homo sapiens	Inhibition	%	1.29
	8218567	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	-2.95	CHEMBL2431	Homo sapiens	Inhibition	%	-2.95
	8218710	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	3.21	CHEMBL2431	Homo sapiens	Inhibition	%	3.21
	8219065	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	1.71	CHEMBL2431	Homo sapiens	Inhibition	%	1.71
	8219225	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-0.3	CHEMBL2431	Homo sapiens	Inhibition	%	-0.3
	8219475	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	0.79	CHEMBL2431	Homo sapiens	Inhibition	%	0.79
	8219860	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	1.94	CHEMBL2431	Homo sapiens	Inhibition	%	1.94
	8220029	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	1.59	CHEMBL2431	Homo sapiens	Inhibition	%	1.59
	8220382	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	2.82	CHEMBL2431	Homo sapiens	Inhibition	%	2.82
	8220720	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	1.33	CHEMBL2431	Homo sapiens	Inhibition	%	1.33
	8220858	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	4.03	CHEMBL2431	Homo sapiens	Inhibition	%	4.03
	8221218	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	2.15	CHEMBL2431	Homo sapiens	Inhibition	%	2.15
	8221351	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	1.27	CHEMBL2431	Homo sapiens	Inhibition	%	1.27
	8221575	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	1.08	CHEMBL2431	Homo sapiens	Inhibition	%	1.08
	8221740	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-0.23	CHEMBL2431	Homo sapiens	Inhibition	%	-0.23
	8222095	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	1.52	CHEMBL2431	Homo sapiens	Inhibition	%	1.52
	8222193	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	0.96	CHEMBL2431	Homo sapiens	Inhibition	%	0.96
	8222417	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	2.41	CHEMBL2431	Homo sapiens	Inhibition	%	2.41
	8222551	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	2.08	CHEMBL2431	Homo sapiens	Inhibition	%	2.08
	8222893	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	0.84	CHEMBL2431	Homo sapiens	Inhibition	%	0.84
	8223037	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	2.57	CHEMBL2431	Homo sapiens	Inhibition	%	2.57
	8223390	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	1.18	CHEMBL2431	Homo sapiens	Inhibition	%	1.18
	8223551	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	0.33	CHEMBL2431	Homo sapiens	Inhibition	%	0.33
	8223775	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-0.17	CHEMBL2431	Homo sapiens	Inhibition	%	-0.17
	8223801	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	2.93	CHEMBL2431	Homo sapiens	Inhibition	%	2.93
	8224025	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	2.26	CHEMBL2431	Homo sapiens	Inhibition	%	2.26
	8224187	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	-1.45	CHEMBL2431	Homo sapiens	Inhibition	%	-1.45
	8224357	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	2.74	CHEMBL2431	Homo sapiens	Inhibition	%	2.74
	8224581	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	1.23	CHEMBL2431	Homo sapiens	Inhibition	%	1.23
	8224716	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	2.46	CHEMBL2431	Homo sapiens	Inhibition	%	2.46
	8225054	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	3.66	CHEMBL2431	Homo sapiens	Inhibition	%	3.66
	8225188	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	1.64	CHEMBL2431	Homo sapiens	Inhibition	%	1.64
	8225412	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	3.28	CHEMBL2431	Homo sapiens	Inhibition	%	3.28
	8225550	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	0.67	CHEMBL2431	Homo sapiens	Inhibition	%	0.67
	8225909	CHEMBL1961876	GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	1.56	CHEMBL2431	Homo sapiens	Inhibition	%	1.56
	8226067	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.22	CHEMBL2431	Homo sapiens	Inhibition	%	0.22
	8226416	CHEMBL1961877	GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	1.54	CHEMBL2431	Homo sapiens	Inhibition	%	1.54
inactive	9575086	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(-c2[nH]c(-c3ccnc(N)n3)cc2C(N)=O)c1C		CHEMBL1964290	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575087	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)c(OC)c1		CHEMBL2003768	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575088	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc2onc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL213505	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575089	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)c1		CHEMBL1982880	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575090	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575091	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1		CHEMBL1987034	=	Ki	nM	1258.93	CHEMBL2431	Homo sapiens	pKi		5.9
inactive	9575092	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1993941	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575093	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575094	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1		CHEMBL578061	<	Ki	nM	19952.62	CHEMBL2431	Homo sapiens	pKi		4.7
inactive	9575095	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12		CHEMBL2005886	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575096	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL481491	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575097	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682345	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9575098	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=O)Nc1c(C(N)=O)sc2ccc(Cl)c(Cl)c12		CHEMBL1973142	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575099	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4nc(N)nc(N)c34)cc2)c1		CHEMBL1973145	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575100	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982924	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575101	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCC(=O)Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL2005936	=	Ki	nM	3162.28	CHEMBL2431	Homo sapiens	pKi		5.5
active	9575102	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC1CCC(Nc2nccc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1966628	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9575103	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc(C(N)=O)c3)cc2)c1		CHEMBL1971141	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575104	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC1CCCCC1Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL1995813	=	Ki	nM	1584.89	CHEMBL2431	Homo sapiens	pKi		5.8
inactive	9575105	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1c(C)n(Cc2ccccc2)c2ccc(C(=O)Nc3nc[nH]n3)cc12		CHEMBL1979718	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575106	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1		CHEMBL1993781	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575107	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH][nH]c2cccc(-c3ccccc3)c12		CHEMBL1989834	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9575108	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL523823	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575109	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC1(C)CC2=Nc3cc(Cl)ccc3SC2=C(O)C1		CHEMBL1562756	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575110	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL244378	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575111	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2		CHEMBL362558	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575112	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(OCC(F)(F)F)nccn23)n1		CHEMBL2001957	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575113	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COCCNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1969372	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575114	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnn2ccc(C(=O)Nc3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1990583	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575115	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	5011.87	CHEMBL2431	Homo sapiens	pKi		5.3
inactive	9575116	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc(Nc2ncnc3ccccc23)cc1		CHEMBL289959	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
active	9575117	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nc2ccc(NS(=O)(=O)c3ccc(N)cc3)cc2nc1C		CHEMBL2006263	=	Ki	nM	794.33	CHEMBL2431	Homo sapiens	pKi		6.1
active	9575118	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1993584	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575119	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O		CHEMBL1986263	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575120	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CSc1c[nH]c2ncnc(NCCCO)c12		CHEMBL2000114	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575121	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575122	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cccc12		CHEMBL1975647	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575123	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1968380	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575124	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1		CHEMBL1964644	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575125	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NCc1ccc(Cl)c(Cl)c1)Nc1ccc2[nH]ncc2c1		CHEMBL1981782	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575126	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC(=O)c1cc2c(-c3ccccc3F)n[nH]c2s1		CHEMBL1977681	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575127	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC(=O)C(C)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(C)cc5)cc4)csc23)cn1		CHEMBL1970142	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575128	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575129	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OCCNc1cc2cc(-c3cccnc3)ccc2cn1		CHEMBL1990912	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575130	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575131	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(-c4ccccc4)c3n2)c1		CHEMBL1988163	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575132	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(O)ccc1-n1c2cc(Cl)ccc2c(=O)c2c(N)nc(N)nc21		CHEMBL1995592	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575133	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	=	Ki	nM	2511.89	CHEMBL2431	Homo sapiens	pKi		5.6
inactive	9575134	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1CCCc2oc3cc(C(F)(F)F)ccc3c(=O)c21		CHEMBL2006493	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575135	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(OC)c(CNC(=O)c2cc(N)c(C#N)c(OC(C)C)n2)c1		CHEMBL1982541	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575136	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Clc1cc2nn[nH]c2cc1Cl		CHEMBL1996923	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575137	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1C		CHEMBL1983449	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575138	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]cnc2c1oc1ccc(Cl)cc12		CHEMBL1992323	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575139	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(Cl)nccn23)n1		CHEMBL1969735	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575140	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCc1nc2c(c3cc(OC)c(OC)cc13)C(=O)NC2=O		CHEMBL2003524	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575141	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2		CHEMBL2002649	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575142	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc2c(c1)Cc1c[nH]nc1-2		CHEMBL1989423	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
active	9575143	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCn1c(C2CCNCC2)nc(-c2ccc(Cl)c(Cl)c2)c1-c1ccnc(NC2CCCCC2)n1		CHEMBL437747	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575144	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Brc1ccc2c(c1)-c1[nH]ncc1C2		CHEMBL1995172	<	Ki	nM	50118.72	CHEMBL2431	Homo sapiens	pKi		4.3
inactive	9575145	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL507936	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575146	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=S(=O)(NCCNCC=Cc1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL1987756	=	Ki	nM	398.11	CHEMBL2431	Homo sapiens	pKi		6.4
inactive	9575147	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCNS(C)(=O)=O)cnc(N)c34)cc2)c1		CHEMBL1994321	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575148	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1NCCc2[nH]c(-c3ccnc(C=Cc4ccccc4)c3)cc21		CHEMBL1997129	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575149	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL1974870	=	Ki	nM	10.0	CHEMBL2431	Homo sapiens	pKi		8.0
inactive	9575150	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cc(Cl)cc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1984788	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575151	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	FC(F)(F)c1ccc(-c2nnc3ccc(NC4CC4)nn23)cc1		CHEMBL451964	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575152	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL1964307	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575153	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Fc1ccc(-c2nc3sccn3c2-c2ccncc2)cc1		CHEMBL2000508	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575154	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCCNc1n[s+]([O-])nc1Nc1ccc(F)cc1		CHEMBL1971694	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575155	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2001547	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575156	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575157	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1F		CHEMBL1994361	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575158	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(-n4cccn4)cc3)s2)no1		CHEMBL1986603	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575159	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575160	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(COc1cncc(-c2cc3cnccc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1972840	=	Ki	nM	1584.89	CHEMBL2431	Homo sapiens	pKi		5.8
inactive	9575161	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CCO)c5)cnc(N)c34)cc2)cc1		CHEMBL1977148	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575162	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(C=C2SC(=O)NC2=O)ccc1O		CHEMBL2003286	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575163	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccn1		CHEMBL1992306	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575164	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL2002165	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575165	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]cc(I)c2nc(-c3ccccc3)cn12		CHEMBL2001668	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575166	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2c1C(c1ccccc1I)C(C#N)=C(N)O2		CHEMBL1979318	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575167	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1989518	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575168	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1998585	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575169	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cn1cncc1C(OCc1c(-c2ccc(OC(F)(F)F)cc2)cc(C#N)c(=O)n1C)c1ccc(C#N)cc1		CHEMBL127898	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575170	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2C		CHEMBL519697	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575171	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(F)c2)c1		CHEMBL2004934	=	Ki	nM	1258.93	CHEMBL2431	Homo sapiens	pKi		5.9
inactive	9575172	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(O)c1cc(-c2cccs2)n2nccc2n1		CHEMBL1977619	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
active	9575173	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	=	Ki	nM	2511.89	CHEMBL2431	Homo sapiens	pKi		5.6
inactive	9575174	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)C1CCCN(C(=O)c2cc(-c3ccc4[nH]ncc4c3)on2)C1		CHEMBL1970369	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575175	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C(C)C(=O)N(C)C)c5)cnc(N)c34)cc2)cc1		CHEMBL2001485	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575176	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575177	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(C)c2c(n1)sc1c(N)ncnc12		CHEMBL504950	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575178	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C)CCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1966425	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9575179	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL1984363	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575180	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1		CHEMBL1978099	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575181	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COC(=O)c1c(-c2ccc(NC(=O)Nc3ccccc3)cc2)c2c(N)ncnn2c1C		CHEMBL1977041	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575182	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cccc2c1Nc1nnc(Cl)cc1C(=O)N2		CHEMBL1968070	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575183	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=O)Nc1cccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)c1		CHEMBL1988608	=	Ki	nM	1995.26	CHEMBL2431	Homo sapiens	pKi		5.7
inactive	9575184	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)cc1C		CHEMBL184847	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575185	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C)c1ccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)cc1		CHEMBL1984367	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575186	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCOCC1)CC2		CHEMBL178737	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575187	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2cnc(-c3cncc(OCC(N)Cc4cccc(C(F)(F)F)c4)c3)cc12		CHEMBL1998159	=	Ki	nM	6.31	CHEMBL2431	Homo sapiens	pKi		8.2
inactive	9575188	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COCC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(C)nccn23)n1		CHEMBL1982563	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575189	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1CCCN1Cc1ccc2c(c1)[nH]c(=O)c1cccn12		CHEMBL539474	=	Ki	nM	316.23	CHEMBL2431	Homo sapiens	pKi		6.5
active	9575190	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(COc1cncc(-c2ccc3[nH]c(=O)oc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1987679	=	Ki	nM	100.0	CHEMBL2431	Homo sapiens	pKi		7.0
active	9575191	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(OC(F)F)cc5)cc4)csc23)cn1		CHEMBL1988387	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575192	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1		CHEMBL1997759	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575193	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575194	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575195	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]c2cc(Cl)cc(Cl)c2c(-c2cc(Cl)ccc2O)c1O		CHEMBL1974803	=	Ki	nM	3162.28	CHEMBL2431	Homo sapiens	pKi		5.5
inactive	9575196	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL1970074	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575197	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1NCc2c(Br)cccc21		CHEMBL1984500	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9575198	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COCCN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1986970	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575199	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC1=NN(c2cccc(Br)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL2005112	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575200	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1cc(-c2ccncc2)nc(NC2CCCCC2)[nH]1		CHEMBL1958401	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575201	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCN(CC)CCOc1ccc(-c2nc3c(C(N)=O)cccc3[nH]2)cc1		CHEMBL1984044	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575202	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]c2cc(-c3ccccc3)cnc2[nH]1		CHEMBL2003456	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575203	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)cccc12		CHEMBL1966816	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575204	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575205	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575206	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1		CHEMBL560813	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575207	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCOn1c2ccc(Cl)cc2c(=O)c2c(C)nn(C)c21		CHEMBL207253	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575208	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=NNC(=O)c1nnn(-c2nonc2N)c1-c1ccccc1)c1ccco1		CHEMBL1890036	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575209	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CC(CN2CCCC2)C1		CHEMBL1968791	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575210	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1CC(c2ccc(Cl)cc2Cl)Cc2nc3cc(Cl)ccc3c(O)c21		CHEMBL326282	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575211	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(Cl)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)NCCOCCOCCN)[nH]c12		CHEMBL2002682	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575212	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOc1ccccc1C=NNC(=O)c1nnn(-c2nonc2N)c1N1CCCC1		CHEMBL1992732	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575213	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Fc1ccc(-c2nc3occn3c2-c2ccnc(NC3CCNCC3)n2)cc1		CHEMBL1971186	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575214	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Cc1ccc(Cl)cc1)Nc1[nH]nc2c1CCC2		CHEMBL2003482	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575215	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=O)Nc1cc2ccccn2n1		CHEMBL1976872	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9575216	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1nccc2cnc(-c3ccccc3)n12		CHEMBL1969156	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9575217	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCCC5)cnc(N)c34)cc2)c1		CHEMBL1973211	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575218	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1984700	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575219	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575220	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CCC(N2CCCC2)CC1		CHEMBL2007151	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575221	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(c1ccc2[nH]ncc2c1)c1c(NCc2ccc(Cl)cc2Cl)c(=O)c1=O		CHEMBL1987899	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575222	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1		CHEMBL1972125	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575223	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1ccc2[nH]ncc2c1)c1cccc(F)c1		CHEMBL1461728	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575224	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575225	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1cc2cc(-c3ccc4cn[nH]c4c3)cnc2[nH]1		CHEMBL1976134	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575226	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(C(=O)Nc2c(C(N)=O)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL1965131	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575227	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCCOc1cccc(Nc2ccnc(N)n2)c1		CHEMBL1995448	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575228	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL1972158	=	Ki	nM	1584.89	CHEMBL2431	Homo sapiens	pKi		5.8
inactive	9575229	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1974457	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575230	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575231	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Oc1ccc(Nc2ncnc3scc(Cl)c23)cc1		CHEMBL2006580	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575232	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1Cl		CHEMBL2006581	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575233	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCCC1		CHEMBL2006481	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575234	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCC#N)c2)n1		CHEMBL1979855	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575235	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575236	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575237	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCNc1nc2cc(Cl)c(OC)cc2nc1NCC		CHEMBL1995927	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575238	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21		CHEMBL1975534	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575239	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(Cc4ccccc4)c3n2)c1		CHEMBL1993424	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575240	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2c1C(c1ccccc1F)C1=C(CC(C)(C)CC1=O)N2		CHEMBL1966703	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575241	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)N(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1969561	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575242	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	=	Ki	nM	2511.89	CHEMBL2431	Homo sapiens	pKi		5.6
inactive	9575243	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C)c1cc2sncc2cc1NC(=O)C(=O)O		CHEMBL1997023	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575244	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(C)cc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1964687	=	Ki	nM	5011.87	CHEMBL2431	Homo sapiens	pKi		5.3
active	9575245	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943	=	Ki	nM	1000.0	CHEMBL2431	Homo sapiens	pKi		6.0
inactive	9575246	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cc2c(-c3ccc(Br)c(F)c3F)cncc2s1		CHEMBL1999918	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575247	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1974254	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575248	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(C(=O)N2c3ccccc3Sc3c(Cl)cncc32)cc1		CHEMBL1988537	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575249	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(C)c2)c1		CHEMBL1969049	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
active	9575250	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)cc1		CHEMBL2005828	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575251	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccc3ccccc3c2)n1		CHEMBL2002240	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575252	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1		CHEMBL363648	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575253	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(-n2nc(C)c3c(=O)c4cc(Cl)ccc4n(O)c32)cc1		CHEMBL1991143	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575254	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575255	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1sc2c(Br)ccc(Cl)c2c1N		CHEMBL1998611	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575256	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2CCC(N)=O		CHEMBL485556	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575257	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1c(NCc2ccc(Cl)c(Cl)c2)c(Nc2ccncc2)c1=O		CHEMBL1975900	=	Ki	nM	1258.93	CHEMBL2431	Homo sapiens	pKi		5.9
inactive	9575258	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(C=C2SC(=S)NC2=O)ccc1O		CHEMBL1973098	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575259	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(=O)CC)c3c2)cc1		CHEMBL1972221	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575260	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC(=O)C=Cc1cnc(N)c2c(-c3cc(F)c4[nH]c(C)cc4c3)csc12		CHEMBL2006778	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575261	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575262	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1c(F)cccc1F		CHEMBL1996979	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575263	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cccc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1997025	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575264	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1968406	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575265	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)csc12		CHEMBL1982476	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575266	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1C(=NNc2cccc3c(=O)[nH][nH]c(=O)c23)C(c2ccccc2)=NN1c1ccccc1		CHEMBL1984274	=	Ki	nM	2511.89	CHEMBL2431	Homo sapiens	pKi		5.6
inactive	9575267	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1998545	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575268	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1csc(NC(=O)c2sc3nc(-c4ccncc4)ccc3c2N)n1		CHEMBL1986869	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575269	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)c(Cl)ccc12		CHEMBL2006010	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9575270	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682558	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575271	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575272	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1n[nH]c2cc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)ccc12		CHEMBL1997623	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575273	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccc(Cl)cc5o4)cc3)c1)CNC2=O		CHEMBL2002479	=	Ki	nM	501.19	CHEMBL2431	Homo sapiens	pKi		6.3
inactive	9575274	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C		CHEMBL1472492	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575275	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCN(C)CCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1993166	=	Ki	nM	1995.26	CHEMBL2431	Homo sapiens	pKi		5.7
inactive	9575276	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NCc1ccc(Cl)cc1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL1967094	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575277	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1		CHEMBL1966035	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575278	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NC(CO)c1cc(Cl)cc(Cl)c1)c1ccc(-c2ccncc2)cc1		CHEMBL2003341	=	Ki	nM	6309.57	CHEMBL2431	Homo sapiens	pKi		5.2
inactive	9575279	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc(-c2n[nH]cc2-c2ccncc2)cc1		CHEMBL1992644	<	Ki	nM	19952.62	CHEMBL2431	Homo sapiens	pKi		4.7
inactive	9575280	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NS(=O)(=O)c1ccc(NCCSc2ccc(O)cc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1		CHEMBL1992645	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575281	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Oc1cccc(Nc2ncnc3scc(Cl)c23)c1		CHEMBL1982992	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575282	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(-c2ccccc2)n(-c2cc(NN=Cc3ccco3)ncn2)n1		CHEMBL1999590	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575283	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1F		CHEMBL1981079	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575284	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCN(CC)CCCNc1cccc(-c2nc3c(C(N)=O)cccc3[nH]2)n1		CHEMBL1972276	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575285	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1c(NCc2ccc(Cl)cc2)c(Nc2ccncc2)c1=O		CHEMBL1980489	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575286	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCc4cccc(F)c4)cc2NC3=O)ccc1O		CHEMBL2000832	=	Ki	nM	1584.89	CHEMBL2431	Homo sapiens	pKi		5.8
active	9575287	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)c1		CHEMBL1967116	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9575288	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nn(C)c2c1c(=O)c1cc(Cl)ccc1n2OCC(C)C		CHEMBL1977814	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575289	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nc2ccccn2c1-c1csc(Nc2ccc(O)cc2)n1		CHEMBL513846	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575290	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NCc1ccc(Br)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL1970709	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575291	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575292	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(-c2cc3nccn3c(Nc3ccccc3C(N)=O)n2)cc1OC		CHEMBL1998112	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575293	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)n1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)cc21		CHEMBL1969126	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575294	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc2sc(Br)c(-c3ccc(NC(=O)Cc4cccc(Cl)c4)cc3)c12		CHEMBL1980896	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575295	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=O)NC1CCN(c2nc3[nH]cc(C(=O)O)c(=O)c3c(C)c2F)C1		CHEMBL1975208	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575296	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575297	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1		CHEMBL1991429	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575298	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cc2c(Oc3cccc(F)c3)cncc2s1		CHEMBL1964777	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575299	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)C(=O)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1971149	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575300	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc2c(c1)NC(=O)c1ccccc1N2		CHEMBL1999714	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575301	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Cc1ccccc1Cl)Nc1ccc2cn[nH]c2c1		CHEMBL1987533	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575302	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(O)CNc1nccc(-c2c(-c3ccc(F)cc3F)nc3c(CC4CC4)nccn23)n1		CHEMBL1994040	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575303	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	10.0	CHEMBL2431	Homo sapiens	pKi		8.0
active	9575304	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL1967302	=	Ki	nM	251.19	CHEMBL2431	Homo sapiens	pKi		6.6
inactive	9575305	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575306	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc2cnc3c(c2cc1OC)C(=O)NC3=O		CHEMBL1982506	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575307	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCN(CC)CCNC(=O)C=Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2004716	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575308	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1		CHEMBL1968127	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575309	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(C)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1975233	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575310	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cccc(F)c3F)cc12		CHEMBL1985406	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575311	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cn1nc(C(F)(F)F)c2c(=O)c3cc(Cl)ccc3n(O)c21		CHEMBL207400	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575312	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(O)ccc1-n1cc(C(=O)NN)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL2000894	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575313	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccccc1NC(=O)Nc1ccc2c(c1)CCc1sc3ncnc(N)c3c1-2		CHEMBL1982135	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575314	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc2c1sc1ncnc(N)c12		CHEMBL1976090	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575315	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12		CHEMBL1993243	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575316	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OCC(CO)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1992922	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575317	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3o2)cc1		CHEMBL2004771	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575318	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CC(CN2CCCC2)C1		CHEMBL1988370	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575319	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1997597	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9575320	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4		CHEMBL1969537	=	Ki	nM	3162.28	CHEMBL2431	Homo sapiens	pKi		5.5
inactive	9575321	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1976093	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9575322	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1		CHEMBL210032	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9578900	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(COc1cncc(-c2ccc(F)cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1996543	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578901	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1cccs1		CHEMBL1975256	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578902	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cnc4c(-c5cnn(C)c5)cnn4c3N)cc2)c1		CHEMBL508928	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578903	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(-c2cc3c(=O)[nH]c4ccccc4n3c2)c1		CHEMBL1991356	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578904	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(C(=O)Nc2nc3ccc(Cl)cc3s2)c(OC)c1		CHEMBL1983309	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578905	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL2004892	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578906	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC1=NN(c2ccccc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL1999126	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578907	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)Oc1ccc(-c2noc(-c3ccc(NC4CCC(C(=O)O)C4)cc3)n2)cc1Cl		CHEMBL1997503	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578908	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cc2c(Oc3ccc(Br)cc3)cncc2s1		CHEMBL116070	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578909	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(C)c(C)c(OCCCc2c(C(=O)O)[nH]c3c(-c4ccccc4C)cccc23)c1		CHEMBL1990821	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578910	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cc(-c2cccc(N)c2)cc2cccnc12		CHEMBL1970314	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578911	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OCCCn1cnc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL2004871	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578912	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncn3)cc2)c1		CHEMBL2004872	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578913	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1Nc2ccccc2Nc2ccccc21		CHEMBL1727312	<	Ki	nM	50118.72	CHEMBL2431	Homo sapiens	pKi		4.3
inactive	9578914	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC1CCN(C(=O)CO)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL1969879	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578915	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cnccn1)Nc1ccnc2ccccc12		CHEMBL1981720	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9578916	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(N)COc1cnc(Cl)c(C=Cc2ccncc2)c1		CHEMBL1993548	=	Ki	nM	5011.87	CHEMBL2431	Homo sapiens	pKi		5.3
inactive	9578917	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3nsc4ncnc(N)c34)cc2)c1		CHEMBL262433	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578918	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578919	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nn(C)c2sc(C(N)=O)cc12		CHEMBL1986588	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
active	9578920	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NNC(=S)Nc1ccc(Cl)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1966722	=	Ki	nM	1258.93	CHEMBL2431	Homo sapiens	pKi		5.9
inactive	9578921	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O		CHEMBL1975500	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578922	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4snc(N)c34)cc2)c1		CHEMBL1976328	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578923	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ccnc(N)c34)cc2)c1		CHEMBL394619	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578924	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)cc1OC		CHEMBL1964399	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9578925	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(O)c1c2c(nc3ccccc13)C(=C1CCCC1)CC2		CHEMBL1996831	=	Ki	nM	1000.0	CHEMBL2431	Homo sapiens	pKi		6.0
inactive	9578926	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc1)CCN2		CHEMBL411903	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578927	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN)cnc(N)c34)cc2)c1		CHEMBL1965988	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578928	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578929	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL1989646	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578930	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc(Cc2cc(-c3ccc4[nH]ncc4c3)on2)cc1		CHEMBL1682357	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578931	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578932	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOc1nc(C(=O)NCc2cccnc2)cc(N)c1C#N		CHEMBL209534	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578933	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nccn2c(-c3ccnc(NCCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1978200	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578934	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578935	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C)S(=O)(=O)c1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O		CHEMBL2006631	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578936	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(C=C2SC(=Nc3ccccc3)NC2=O)ccc1O		CHEMBL1970522	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578937	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578938	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1n[nH]c2nc3ccccc3cc12)c1ccncc1		CHEMBL1990415	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578939	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	C(=Cc1cncc(OC2CCNC2)c1)c1ccncc1		CHEMBL1966087	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578940	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cncc21		CHEMBL1964692	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578941	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NC(CO)Cc1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1		CHEMBL1996931	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578942	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	FC(F)(F)c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C(F)(F)F)c1		CHEMBL1964413	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578943	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL1973483	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578944	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C)c1		CHEMBL1984432	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578945	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL1970735	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578946	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL219722	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578947	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCC(O)C1		CHEMBL1997340	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9578948	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOC(=O)C1=C(N)n2c(sc(=Cc3cccs3)c2=O)=C(C(N)=O)C1c1cccs1		CHEMBL2004365	=	Ki	nM	6309.57	CHEMBL2431	Homo sapiens	pKi		5.2
inactive	9578949	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(Nc2ncnc3ccccc23)c1		CHEMBL117697	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578950	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578951	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cn1cc(-c2ccncn2)c(-c2ccc(F)cc2)n1		CHEMBL1989474	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578952	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1		CHEMBL1090360	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578953	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1nc2ccccc2n1CCCO)c1cccc([N+](=O)[O-])c1		CHEMBL210887	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578954	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578955	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C(F)(F)F)c2)c1		CHEMBL1971021	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9578956	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(OC(F)(F)F)c4)c3)cc12		CHEMBL1965836	=	Ki	nM	15.85	CHEMBL2431	Homo sapiens	pKi		7.8
inactive	9578957	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12		CHEMBL583144	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578958	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1		CHEMBL1974310	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578959	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578960	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc2sc3c(c12)-c1ccc(NC(=O)Nc2ccccc2)cc1CC3		CHEMBL1994693	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578961	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cccc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982957	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578962	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9578963	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc(CNc2cc(-c3c[nH]c4ncccc34)ncn2)cc1		CHEMBL2002346	=	Ki	nM	3162.28	CHEMBL2431	Homo sapiens	pKi		5.5
active	9578964	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1975138	=	Ki	nM	1000.0	CHEMBL2431	Homo sapiens	pKi		6.0
inactive	9578965	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578966	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC1=NN(c2ccc(C(=O)O)cc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL2006836	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578967	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#Cc5cccnc5)cnc(N)c34)cc2)c1		CHEMBL1971947	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578968	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578969	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578970	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc2nnc(SCc3cn4ccccc4n3)n2c2ccccc12		CHEMBL1980704	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578971	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1sc2ccc(Cl)c(Cl)c2c1NC(=O)c1ccc(Cl)cc1		CHEMBL2003271	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578972	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1cc2nc(-c3ccccc3)cn2cn1		CHEMBL1972365	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9578973	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccncc4)nn12)CCCC3		CHEMBL1966808	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578974	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(C)c1n[nH]c2c1C(c1ccccc1F)C(C#N)=C(N)O2		CHEMBL2004447	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578975	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578976	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OCCNc1cc2cc(-c3ccsc3)ccc2cn1		CHEMBL1973860	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578977	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NCc1ccc(Cl)cc1)Nc1cccc2[nH]ncc12		CHEMBL1977713	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578978	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL260135	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9578979	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21		CHEMBL220241	=	Ki	nM	630.96	CHEMBL2431	Homo sapiens	pKi		6.2
active	9578980	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=S(=O)(O)c1ccc(NCc2ccc3c(c2)OCO3)c2c(O)cccc12		CHEMBL2004544	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9578981	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]cc(I)c2nc(-c3cccc(Cl)c3)cn12		CHEMBL1982610	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578982	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(C2(c3cccc(C)c3)CC2C(=O)Nc2ccncc2)c1		CHEMBL1999496	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578983	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc2c(c1)C(=O)Nc1ccccc1N2		CHEMBL1970873	<	Ki	nM	50118.72	CHEMBL2431	Homo sapiens	pKi		4.3
inactive	9578984	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CSc1cnc2c(ccc3cnccc32)c1O		CHEMBL2006933	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578985	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ccc(-c2csc3c(C=Cc4nc5ccccc5[nH]4)cnc(N)c23)cc1		CHEMBL1988300	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578986	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578987	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578988	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCCNc1ccc2c3c(cccc13)C(=O)N(CCNCCO)C2=O		CHEMBL1987359	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9578989	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=NNC(=N)N)c1cc(NC(=O)c2cccc(C(=O)Nc3cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c3)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL2000685	=	Ki	nM	199.53	CHEMBL2431	Homo sapiens	pKi		6.7
active	9578990	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	=	Ki	nM	3162.28	CHEMBL2431	Homo sapiens	pKi		5.5
inactive	9578991	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(CO)ccc4F)cc3)c12		CHEMBL1985311	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578992	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)cc3n21		CHEMBL1989265	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578993	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578994	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC1CCN(c2nc3[nH]cc(C(=O)O)c(=O)c3c(C)c2Br)C1		CHEMBL2004647	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9578995	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23		CHEMBL1969502	=	Ki	nM	398.11	CHEMBL2431	Homo sapiens	pKi		6.4
inactive	9578996	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CCC(N2CCCC2)CC1		CHEMBL1965910	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9578997	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682553	=	Ki	nM	2511.89	CHEMBL2431	Homo sapiens	pKi		5.6
inactive	9578998	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(-c2c(-c3ccncc3)nc(NCC(N)Cc3ccccc3)n(C)c2=O)c1		CHEMBL1971430	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9578999	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)cc1		CHEMBL1997764	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579000	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)c1		CHEMBL1983963	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579001	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(CN)Cc4ccccc4)c3)cc12		CHEMBL2000271	=	Ki	nM	501.19	CHEMBL2431	Homo sapiens	pKi		6.3
inactive	9579002	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]cnc2ccc(Br)cc12		CHEMBL562488	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9579003	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Oc1ccc(-c2n[nH]c(Nc3cccc(Cl)c3)c2-c2ccc(O)cc2)cc1		CHEMBL1985092	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579004	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1ccccc1		CHEMBL2004692	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579005	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL1981410	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579006	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC1(O)CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1		CHEMBL1996234	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579007	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(C=C2C(=O)ON=C2c2ccc(Br)cc2)cc1OC		CHEMBL1991434	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579008	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C)c1cccc2c(S(=O)(=O)N(CCN)c3cncc(-c4ccc5cnccc5c4)c3)cccc12		CHEMBL1967544	=	Ki	nM	2511.89	CHEMBL2431	Homo sapiens	pKi		5.6
active	9579009	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9579010	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579011	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cn(-c2ccc(O)cc2Cl)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL340384	=	Ki	nM	1995.26	CHEMBL2431	Homo sapiens	pKi		5.7
inactive	9579012	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1996587	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579013	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CS(=O)(=O)NCCOc1cncc(-c2ccc3cnccc3c2)c1		CHEMBL1964804	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579014	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(-c2cnc3c(Br)cnn3c2)cc1		CHEMBL443962	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579015	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O		CHEMBL2000354	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579016	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1965507	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579017	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cn1ncc2c1CCCC2=O		CHEMBL1981107	<	Ki	nM	19952.62	CHEMBL2431	Homo sapiens	pKi		4.7
inactive	9579018	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579019	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCC(=O)Nc1n[nH]c2nc3ccccc3cc12		CHEMBL1967564	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579020	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	=	Ki	nM	1995.26	CHEMBL2431	Homo sapiens	pKi		5.7
inactive	9579021	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OCCCNc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL2000071	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579022	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc2c(NC(=O)Nc3cc(C(F)(F)F)ccn3)ccnc2c1		CHEMBL1979176	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579023	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1970317	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579024	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc2c(C)n1		CHEMBL2000408	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579025	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	=	Ki	nM	5011.87	CHEMBL2431	Homo sapiens	pKi		5.3
inactive	9579026	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN1CCC(C(=O)n2nc(N)c3cc(-c4cn(Cc5ccccc5)nn4)ccc32)CC1		CHEMBL1978014	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579027	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cnccn1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1994538	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579028	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCN(CC)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1983195	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9579029	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1975490	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579030	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1964444	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579031	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OCCNc1cc2cc(-c3ccccc3)ccc2cn1		CHEMBL1989957	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579032	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccsc2)n1		CHEMBL2006567	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579033	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Clc1csc2ncnc(Nc3ccccc3)c12		CHEMBL1986139	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579034	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(Cc1cccc2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1985580	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579035	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)cccc12		CHEMBL1980540	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579036	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN(C)C)cnc(N)c34)cc2)c1		CHEMBL1979883	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579037	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1984162	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579038	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Fc1cnc(Nc2ccccc2)nc1Nc1ccccc1		CHEMBL491758	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579039	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C(C)(C)C		CHEMBL1986186	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579040	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1cc2[nH]ncc2cc1-c1cc(CN2CCCCC2)no1		CHEMBL1682360	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579041	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]c2ccc(Br)cc2n1-c1cc(Cl)c(O)cc1O		CHEMBL1996473	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579042	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2c1C(c1ccccc1Cl)C(C#N)=C(N)O2		CHEMBL1970189	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579043	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc2c1c(I)nn2C1CCC(O)CC1		CHEMBL1996791	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579044	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3c(C)sc4ncnc(N)c34)cc2)c1		CHEMBL371206	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579045	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC		CHEMBL1974664	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579046	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579047	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NC(CO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1974288	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9579048	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1		CHEMBL196363	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579049	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nn(C)c2sc(C(N)=O)c(N)c12		CHEMBL1996837	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9579050	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(-c2cc3nccn3c(Nc3ncccc3C(N)=O)n2)cc1OC		CHEMBL1190711	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579051	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1n[nH]c2cccc(-c3ccc(Br)cc3)c12		CHEMBL1990346	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579052	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579053	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL404367	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579054	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1		CHEMBL1966343	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579055	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2ccc(-c3cncc(OCCN)c3)cc12		CHEMBL1967887	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579056	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579057	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)cc1C		CHEMBL2000335	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9579058	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)c(F)c3n21		CHEMBL1977604	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579059	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1n[nH]c2c(Cl)cccc12		CHEMBL1980161	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9579060	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579061	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cn1cc(-c2cnn3c(N)c(-c4ccc(NC(=O)Nc5cccc(C(F)(F)F)c5)cc4)cnc23)cn1		CHEMBL1988717	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579062	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579063	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579064	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579065	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1ccccc1)Nc1ccccn1		CHEMBL143703	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9579066	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1ccc2[nH]ncc2c1)c1ccc(Cl)cc1		CHEMBL1973808	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579067	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2000429	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579068	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)cc1		CHEMBL1972576	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9579069	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NN=Cc1ccc(Sc2nc3ccccc3[nH]2)o1)c1cccc([N+](=O)[O-])c1		CHEMBL1992555	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579070	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	=	Ki	nM	398.11	CHEMBL2431	Homo sapiens	pKi		6.4
inactive	9579071	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1992342	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579072	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(Cl)ccc1NC(=S)NNC(=O)C(O)(c1ccccc1)c1ccccc1		CHEMBL1988173	=	Ki	nM	79.43	CHEMBL2431	Homo sapiens	pKi		7.1
inactive	9579073	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	C(=NNc1nc2ccccc2[nH]1)c1c[nH]c2ccccc12		CHEMBL535331	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579074	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#CC1=C(N)n2c(sc(=Cc3ccco3)c2=O)=C(C(N)=O)C1c1ccco1		CHEMBL1989805	=	Ki	nM	6309.57	CHEMBL2431	Homo sapiens	pKi		5.2
inactive	9579075	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579076	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)=C(C)c1cccc2c(CCCOc3cccc(Cl)c3Cl)c(C(=O)O)[nH]c12		CHEMBL1982980	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579077	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL1965423	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579078	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCC(N)(C#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12)CC		CHEMBL1983025	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579079	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	=	Ki	nM	630.96	CHEMBL2431	Homo sapiens	pKi		6.2
inactive	9579080	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1977135	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579081	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21		CHEMBL2001920	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579082	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cc2c(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cncc2s1		CHEMBL2002322	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579083	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(F)c(-c2ccc3nnc(N)n3c2)c1		CHEMBL2002323	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579084	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC		CHEMBL1241473	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579085	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	=	Ki	nM	79.43	CHEMBL2431	Homo sapiens	pKi		7.1
inactive	9579086	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COC(=O)c1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O		CHEMBL2004513	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579087	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1972258	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579088	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCN(CC)CC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2001257	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579089	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(Cl)cc4Cl)c(=O)c3=O)ccc21		CHEMBL2005548	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579090	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccccc1-c1c(C(=O)O)n(CCCOc2cccc3ccccc23)c2ccccc12		CHEMBL1987793	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9579091	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)cc1		CHEMBL1992536	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579092	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCN1CCN(CCCC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1		CHEMBL1992740	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579093	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OCCCn1cnc(-c2ccccc2)c1-c1ccncc1		CHEMBL2002373	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579094	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1cccc(Cl)c1		CHEMBL1973348	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579095	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2NCCCN)c1		CHEMBL2006188	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9579096	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1967531	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579097	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCC(=O)Nc1nn(C(=O)CC)c2nc3ccccc3cc12		CHEMBL1970913	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579098	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1		CHEMBL1973893	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579099	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOC(=O)c1cccc2[nH]c(-c3ccc(N4CCC(N)C4)cc3)nc12		CHEMBL1995736	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579100	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579101	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C(C)NC(=O)c2cc(C)c(-c3ccc4[nH]nc(C)c4c3)s2)c1		CHEMBL1997534	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579102	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579103	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)Cn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL1985095	=	Ki	nM	2511.89	CHEMBL2431	Homo sapiens	pKi		5.6
inactive	9579104	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(O)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1998551	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579105	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1977374	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579106	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COCc1nnn(-c2nonc2N)c1C(=O)NN=C(C)c1ccc(O)cc1O		CHEMBL1991180	=	Ki	nM	501.19	CHEMBL2431	Homo sapiens	pKi		6.3
inactive	9579107	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579108	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1		CHEMBL1682540	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579109	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1c(O)cccc1NC(=O)c1cnn2c(-c3ccccc3)ccnc12		CHEMBL1978656	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579110	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579111	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1		CHEMBL1994864	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579112	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCO)c(Cl)cc1NC(=O)N2		CHEMBL413779	=	Ki	nM	1000.0	CHEMBL2431	Homo sapiens	pKi		6.0
inactive	9579113	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOCC5CC5)c4)n[nH]c2-3)CC1		CHEMBL2002446	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579114	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1nc(-c2cc3c(Oc4ccc(I)cc4)cncc3s2)[nH]o1		CHEMBL497151	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579115	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1		CHEMBL246970	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579116	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(O)ccc1-n1cc(C(N)=O)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL340921	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579117	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2		CHEMBL373598	=	Ki	nM	1000.0	CHEMBL2431	Homo sapiens	pKi		6.0
inactive	9579118	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#Cc1ccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)nc1		CHEMBL1999718	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579119	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL1973540	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9579120	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1Nc2ccccc2Nc2nnc(I)cc21		CHEMBL1977346	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579121	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL1971649	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579122	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2003657	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579123	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579124	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OCCNc1cc2cc(-c3ccncc3)ccc2cn1		CHEMBL1998435	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579125	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579126	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)N(C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1)C(C)C		CHEMBL2006156	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579127	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(-c2ccc(NC(=O)Nc3cc(F)cc(F)c3)cc2)c2c(N)noc12		CHEMBL1969190	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579128	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)n[nH]c12		CHEMBL1973937	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579129	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579130	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579131	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579132	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	FC(F)(F)Oc1ccc(-c2ccc3[nH]cc(C4=CCNCC4)c3c2)cc1		CHEMBL1987982	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579133	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1984842	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579134	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1		CHEMBL1969102	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9579135	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1682346	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9579136	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCN(CC)CC#Cc1ccc2c(c1)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL2007044	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582713	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC(=O)N1CCN(CCCOc2ccc3c(c2)-c2[nH]nc(-c4ccc(C#N)nc4)c2C3)CC1		CHEMBL2001998	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582714	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(C=C(C#N)c2nc3ccccc3[nH]2)c(Br)cc1O		CHEMBL1994241	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582715	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582716	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1ccc(Cl)cc1		CHEMBL1998829	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582717	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582718	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1		CHEMBL1988838	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582719	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCN1CCN(c2ccc(Nc3nccc(-c4c(-c5cccc(C(=O)Nc6ccccc6F)c5)nc5ccccn45)n3)cc2)CC1		CHEMBL1981725	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582720	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]ncc34)cc2)c1		CHEMBL375284	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582721	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COCCn1cc(-c2ccncn2)c(-c2ccc(Cl)cc2)n1		CHEMBL1982866	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582722	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2005792	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582723	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc(CSc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL1968926	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582724	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOc1nc(C(=O)NCc2ccncc2)cc(N)c1C#N		CHEMBL1984206	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582725	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL462120	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582726	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C1CCCCC1		CHEMBL1991577	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582727	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1n[nH]c2nc(Cl)sc12		CHEMBL1991867	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9582728	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)c12		CHEMBL1965570	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582729	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3		CHEMBL2007592	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582730	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582731	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cncc2cccc(S(=O)(=O)N3CCCNCC3C)c12		CHEMBL1082440	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582732	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3F)c2-c2ccncn2)CC1		CHEMBL1614705	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582733	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1		CHEMBL1972362	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582734	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)s2)c1		CHEMBL1984633	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582735	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582736	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2007372	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582737	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C(C)NC(=O)N2CC=C(c3c[nH]c4ncccc34)CC2)c1		CHEMBL1965845	=	Ki	nM	2511.89	CHEMBL2431	Homo sapiens	pKi		5.6
inactive	9582738	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(OC)c(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1		CHEMBL1982167	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582739	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1)c1c(F)cccc1F		CHEMBL2006715	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582740	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cccc2[nH]c(-c3ccc(NC(=O)c4cccc(S(=O)(=O)N5CCOCC5)c4)cc3)nc12		CHEMBL1986597	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582741	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1971017	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582742	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cccc2[nH]c(-c3ccncc3)nc12		CHEMBL1990482	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582743	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Fc1ccc(-c2nc3cnccn3c2-c2ccnc(NCC3CC3)n2)cc1		CHEMBL1990904	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582744	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582745	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NCC1CCCCC1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL2005475	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582746	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1		CHEMBL2000104	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582747	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582748	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC1=NN(c2ccc(Cl)c(Cl)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL1997349	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9582749	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2C)c1		CHEMBL183844	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582750	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL220057	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582751	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682545	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582752	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1974935	=	Ki	nM	125.89	CHEMBL2431	Homo sapiens	pKi		6.9
inactive	9582753	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(OC2CCCC2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL2001224	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582754	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582755	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(O)Cc1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1976732	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582756	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(S(N)(=O)=O)cc4)c(=O)c3=O)ccc21		CHEMBL1969506	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582757	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NC(CO)c1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1964937	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582758	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1		CHEMBL1980163	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582759	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	=	Ki	nM	3162.28	CHEMBL2431	Homo sapiens	pKi		5.5
inactive	9582760	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(-c2nn(C3CCC(N4CCN(C(C)=O)CC4)CC3)c3ncnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1970879	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582761	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1c(C=O)c(O)n2c(nc3ccccc32)c1C#N		CHEMBL1989856	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582762	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=O)N(c1ccncc1)c1c(NC(C)C(C)(C)C)c(=O)c1=O		CHEMBL2005899	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582763	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)c(NC3CCCCC3)n2c1		CHEMBL1682552	=	Ki	nM	5011.87	CHEMBL2431	Homo sapiens	pKi		5.3
inactive	9582764	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582765	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cncc(C=Cc2ccncc2)c1		CHEMBL1972568	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582766	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN1CCC1COc1cncc(CCc2ccncc2)c1		CHEMBL1996155	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582767	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL1974870	=	Ki	nM	10.0	CHEMBL2431	Homo sapiens	pKi		8.0
inactive	9582768	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1682359	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582769	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(C)c(C=C2C(=O)Nc3ccccc32)[nH]1		CHEMBL2002702	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582770	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1ccccc1		CHEMBL1991846	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582771	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)c1		CHEMBL1969523	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582772	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1ccccc1)Nc1ccccc1		CHEMBL354676	<	Ki	nM	50118.72	CHEMBL2431	Homo sapiens	pKi		4.3
inactive	9582773	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(C=O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL207995	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582774	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1988995	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582775	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1Nc2cc(CCOc3ccc(N4CCOCC4)cc3)ccc2Nc2cc(-c3cn(Cc4cc(F)c(F)c(F)c4)c4cnccc34)ccc21		CHEMBL2001923	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582776	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=O)N1CCC(Nc2nccc(-c3c(-c4ccc(F)cc4)nc4occn34)n2)CC1		CHEMBL1986781	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582777	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1nc(-c2ccc3[nH]ncc3c2)cc(-c2ccccc2)[nH]1		CHEMBL526133	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582778	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21		CHEMBL1230122	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582779	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nn(C)c2sc3c(=O)[nH]cnc3c12		CHEMBL1967538	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9582780	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3[nH]2)cc1		CHEMBL1979057	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582781	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1OCC(O)CO		CHEMBL1981045	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582782	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1		CHEMBL387971	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582783	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc(Cn2nnc(-c3ccc4[nH]ncc4c3)c2C2CC2)cc1		CHEMBL1975418	=	Ki	nM	5011.87	CHEMBL2431	Homo sapiens	pKi		5.3
inactive	9582784	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]c2ccc(Cl)cc2c(-c2ccccc2)c1C1=NNC(c2ccccc2)C1		CHEMBL1992796	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582785	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1999428	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582786	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCC(O)CO)c(Cl)cc1NC(=O)N2		CHEMBL223257	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582787	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCN1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1967560	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582788	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582789	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3noc4ncnc(N)c34)cc2)c1		CHEMBL211378	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582790	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1982465	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582791	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1		CHEMBL2003420	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582792	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccccc1NC(=O)Nc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL1984586	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582793	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1c(Cl)c(N2CCC(CN)C2)nc2[nH]cc(C(=O)O)c(=O)c12		CHEMBL1999774	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582794	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1c(O)ccc2c1CCCC2=NNC(=O)Cc1cccc2ccccc12		CHEMBL1972659	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582795	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OC1CCN(c2ncnc3[nH]cc(-c4ccccc4)c23)CC1		CHEMBL1973395	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582796	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(NC(=O)Nc2ccc(-c3cccc4onc(N)c34)cc2)cc1Cl		CHEMBL272453	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582797	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1nnc2ccc(-c3ccccc3)cn12		CHEMBL1987143	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
active	9582798	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3C)cc2)c1		CHEMBL1970217	=	Ki	nM	1258.93	CHEMBL2431	Homo sapiens	pKi		5.9
inactive	9582799	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1Nc2ccccc2Nc2nnccc21		CHEMBL1971801	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582800	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1Nc2ccccc2Nc2nnc(Cl)cc21		CHEMBL1968850	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582801	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOC(=O)c1ccc2[nH]c3c(c2c1)CCNC3=O		CHEMBL2005528	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582802	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)c1		CHEMBL185569	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582803	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1		CHEMBL1969843	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582804	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(-c2ccc3[nH]nc(C(=O)Nc4ccccc4)c3c2)ccc1O		CHEMBL2007002	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582805	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	=	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582806	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN1CCC(NC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)CC1		CHEMBL1987007	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582807	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Clc1cc(-c2c[nH]c3ncccc23)cc(NCc2ccccc2)n1		CHEMBL1969588	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582808	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(Nc2nccc(Nc3cc(C4CCCCC4)no3)n2)cc(OC)c1OC		CHEMBL1984711	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582809	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582810	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)cc1Cl		CHEMBL1990212	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582811	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	=	Ki	nM	251.19	CHEMBL2431	Homo sapiens	pKi		6.6
inactive	9582812	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL484390	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582813	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1c(NCc2cccc(C(F)(F)F)c2)c(Nc2ccncc2)c1=O		CHEMBL1979252	=	Ki	nM	2511.89	CHEMBL2431	Homo sapiens	pKi		5.6
inactive	9582814	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc(Cc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682341	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582815	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582816	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12		CHEMBL1986499	=	Ki	nM	6309.57	CHEMBL2431	Homo sapiens	pKi		5.2
inactive	9582817	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C=C2SC(=Nc3ccccc3)NC2=O)c1		CHEMBL1972937	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582818	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	C#Cc1cc2c(cc1OC)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL1972250	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582819	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1C1CCOc2c(F)cccc21		CHEMBL2000393	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582820	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL2004072	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582821	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C)c2)c1		CHEMBL2004311	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582822	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Brc1cnc2[nH]cc(-c3ccccc3)c2c1		CHEMBL1992634	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582823	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1242373	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582824	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCNNc1cc(C)c(C#N)c2nc3ccccc3n12		CHEMBL2000433	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582825	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL1974157	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582826	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Fc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL316264	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582827	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1988075	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582828	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc2c(Nc3cc(OCc4ccccc4Br)ccc3Sc3ccc(O)cc3)ncnc2n1		CHEMBL2001520	=	Ki	nM	1995.26	CHEMBL2431	Homo sapiens	pKi		5.7
inactive	9582829	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582830	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc(Nc2cc(CNC(=O)C(F)(F)F)c(O)c(-c3ccc(Cl)cc3)c2)n1		CHEMBL2001239	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9582831	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc2scc(C(=O)Nc3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1988594	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582832	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc2c1c(I)nn2C1OC(CO)C(O)C1O		CHEMBL2001288	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582833	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL260092	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582834	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582835	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12		CHEMBL1999811	=	Ki	nM	3162.28	CHEMBL2431	Homo sapiens	pKi		5.5
inactive	9582836	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2ncc(C#N)c(-c3ccccc3)c12		CHEMBL1965495	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582837	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CSc1ccc2nc3c(c(Cl)c2c1)CCNC3=O		CHEMBL1985074	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582838	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc2n1CC1CC1		CHEMBL1982874	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582839	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL2000481	=	Ki	nM	5011.87	CHEMBL2431	Homo sapiens	pKi		5.3
inactive	9582840	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1		CHEMBL1173055	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582841	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C)CC(=O)NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1991725	=	Ki	nM	6309.57	CHEMBL2431	Homo sapiens	pKi		5.2
inactive	9582842	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4sncc34)cc2)c1		CHEMBL1992242	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582843	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2007296	=	Ki	nM	2511.89	CHEMBL2431	Homo sapiens	pKi		5.6
inactive	9582844	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582845	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1		CHEMBL396523	=	Ki	nM	5011.87	CHEMBL2431	Homo sapiens	pKi		5.3
inactive	9582846	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1NC(=O)C(Nc2ccccc2)=C1Cl		CHEMBL2007138	<	Ki	nM	19952.62	CHEMBL2431	Homo sapiens	pKi		4.7
inactive	9582847	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1970203	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582848	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(c1cc(Cc2n[nH]c(=O)c3c2CCCC3)ccc1F)N1CCN(c2ncccn2)CC1		CHEMBL1986530	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582849	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(C=NNc2cc(N3CCOCC3)nc(OCCc3ccccn3)n2)c1		CHEMBL1965351	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582850	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1c(NCCc2ccc(Oc3ccccc3)cc2)c(Nc2ccncc2)c1=O		CHEMBL1999321	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582851	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1cnc2[nH]cc(-c3ccnc(NC4CCCCC4)n3)c2c1		CHEMBL385478	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582852	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4sc(C)nc4c3)csc12		CHEMBL1968590	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582853	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(Nc2ncnc3ccc(-c4ccc(CN5CC6C(CO)C6C5)cc4)cc23)ccc1Oc1ccccc1		CHEMBL1999749	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582854	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCCCC4)cc3OC)nc2N1C1CCCC1		CHEMBL2005375	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582855	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Clc1ccc(-c2n[nH]cc2-c2ccncn2)cc1Cl		CHEMBL1984191	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582856	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(C(=O)O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1983006	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582857	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN1CCCC1COc1cncc(CCc2ccccc2)c1		CHEMBL1972183	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582858	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br		CHEMBL1971029	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582859	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)Nc1n[nH]c2ccc(N)cc12		CHEMBL1995391	<	Ki	nM	19952.62	CHEMBL2431	Homo sapiens	pKi		4.7
inactive	9582860	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL394790	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582861	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21		CHEMBL226471	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582862	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nc2c(sc3c(Br)ccc(Cl)c32)c(=O)o1		CHEMBL1974702	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582863	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1996111	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582864	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1965589	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582865	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NCCCCCCNC(=O)Nc1cccnc1)Nc1cccnc1		CHEMBL1998193	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582866	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)O)s3)c2cc1OC		CHEMBL474432	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582867	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1cc2c(s1)CCc1cn[nH]c1-2		CHEMBL2001539	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9582868	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nnc(-c2cc3c(Oc4ccc(C(F)(F)F)cc4)cncc3s2)o1		CHEMBL1988153	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582869	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582870	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582871	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1999556	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582872	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582873	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(COc1cc(C=Cc2ccncc2)cnc1Cl)Cc1c[nH]c2ccccc12		CHEMBL1968245	=	Ki	nM	794.33	CHEMBL2431	Homo sapiens	pKi		6.1
active	9582874	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCCC(C(=O)Nc1ccc2[nH]ncc2c1)c1ccc(Cl)c(Cl)c1		CHEMBL1998121	=	Ki	nM	19.95	CHEMBL2431	Homo sapiens	pKi		7.7
inactive	9582875	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CC(C)(C)N)cnc(N)c34)cc2)c1		CHEMBL1979577	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582876	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CC4CC4)nccn23)n1		CHEMBL1991800	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582877	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1CC#N		CHEMBL1985566	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582878	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL52387	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582879	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nn(-c2ccccc2)c2c1c(=O)c1cc(Cl)ccc1n2O		CHEMBL379835	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582880	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cn1cc(C(CN)c2cncc(C=Cc3ccncc3)c2)c2ccccc21		CHEMBL1979357	=	Ki	nM	3162.28	CHEMBL2431	Homo sapiens	pKi		5.5
inactive	9582881	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#Cc1ncc2nc1OCC(O)C(O)COc1ccc(Cl)cc1NC(=O)N2		CHEMBL1980802	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582882	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1c(NCc2ccc(Cl)cc2Cl)c(Nc2ccc3[nH]ncc3c2)c1=O		CHEMBL1979554	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582883	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCCOc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1996817	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582884	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2ccncc2)c1-c1ccccc1		CHEMBL1419458	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582885	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOc1nc(C(=O)NCc2ccc(S(N)(=O)=O)cc2)cc(N)c1C#N		CHEMBL2004355	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582886	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582887	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCn1c2cc(Cl)c(F)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL468280	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582888	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(C)c2oc(Nc3ccc(-c4cccc(C(N)=O)c4N)cc3F)nc2c1		CHEMBL1990884	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582889	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582890	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL256835	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582891	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1980142	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582892	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL41783	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582893	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12		CHEMBL2004438	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582894	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc2c1Nc1cc(Nc3ccncc3)ccc1C(=O)N2		CHEMBL2006276	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582895	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)noc12		CHEMBL271381	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582896	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(C(=O)Nc2c(C#N)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL2006785	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582897	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1982466	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582898	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(-c2ccc3c(c2)Nc2ccc([N+](=O)[O-])cc2NC3=O)ccc1O		CHEMBL1995740	=	Ki	nM	2511.89	CHEMBL2431	Homo sapiens	pKi		5.6
inactive	9582899	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1996390	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582900	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	5011.87	CHEMBL2431	Homo sapiens	pKi		5.3
inactive	9582901	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582902	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1995832	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582903	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2sc(C(=O)NCCc3ccc(Cl)cc3)cc12		CHEMBL1998414	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582904	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Oc1ccc(Nc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1		CHEMBL1969042	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582905	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(C=C(C#N)c2nc3cc(C)ccc3[nH]2)c(Br)cc1O		CHEMBL2000345	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582906	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1		CHEMBL1999931	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
active	9582907	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]sc2c1c(=O)c1cc(F)c(NCc3ccccc3)c(F)c1n2C1CC1		CHEMBL1991640	=	Ki	nM	1584.89	CHEMBL2431	Homo sapiens	pKi		5.8
inactive	9582908	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1375418	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582909	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582910	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL2007064	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582911	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582912	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccc(Cl)c(Cl)c4)c3)cc12		CHEMBL1991063	=	Ki	nM	12.59	CHEMBL2431	Homo sapiens	pKi		7.9
active	9582913	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C(CN)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1976240	=	Ki	nM	316.23	CHEMBL2431	Homo sapiens	pKi		6.5
inactive	9582914	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc(-c2ccc(NC(=O)Nc3ccc(F)c(C)c3)cc2)c2c(N)noc12		CHEMBL1979093	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582915	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]c2sccc2c2nc(-c3ccncc3)nn12		CHEMBL1968151	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582916	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Clc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1381197	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582917	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)c1		CHEMBL1987009	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582918	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccccc4)c3)cc12		CHEMBL2002726	=	Ki	nM	501.19	CHEMBL2431	Homo sapiens	pKi		6.3
inactive	9582919	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cnccn1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL2003817	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582920	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ncccc2N1		CHEMBL336961	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582921	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1nnc(-c2cc3c(Oc4ccc(Cl)cc4)cncc3s2)o1		CHEMBL1994830	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582922	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(Cl)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1987054	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582923	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncc(-c2ccncc2)c2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1970083	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582924	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21		CHEMBL226403	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582925	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cc(C)ccc4F)cc3)csc12		CHEMBL2005631	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582926	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncc(C=CC(=O)NCCCn2ccnc2)c2scc(-c3ccc(Br)cc3)c12		CHEMBL1994938	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582927	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582928	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1977223	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582929	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(C)C(=O)Oc1ccc2c(c1)nc(NC(=O)c1cccc([N+](=O)[O-])c1)n2CCCO		CHEMBL1236126	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582930	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NCCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL1966279	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582931	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	=	Ki	nM	5011.87	CHEMBL2431	Homo sapiens	pKi		5.3
inactive	9582932	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)Cn1c(N)nc2c(F)cc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2004419	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582933	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCCCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1991728	=	Ki	nM	794.33	CHEMBL2431	Homo sapiens	pKi		6.1
inactive	9582934	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cc2c(-c3ccc(F)cc3F)cncc2s1		CHEMBL1975787	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582935	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(C=C(C#N)c2n[nH]c(N)c2C#N)ccc1O		CHEMBL2002407	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582936	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1ccc2cn[nH]c2c1)c1ccc(Cl)cc1		CHEMBL1972489	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582937	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Brc1ccc2[nH]nc(-c3ccccc3)c2c1		CHEMBL1994074	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582938	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582939	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1cccc2cn[nH]c12		CHEMBL451401	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9582940	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cccc(N2CCOCC2)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1972119	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582941	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1986328	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9582942	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL95692	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582943	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1		CHEMBL1090356	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582944	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(C(F)(F)F)cc12		CHEMBL1976455	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582945	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582946	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9582947	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc(CNc2nc3ccc(-c4ccncc4)cc3s2)cc1		CHEMBL1983534	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9582948	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1c(NCc2ccccc2F)c(Nc2ccncc2)c1=O		CHEMBL1982361	=	Ki	nM	3162.28	CHEMBL2431	Homo sapiens	pKi		5.5
inactive	9582949	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1		CHEMBL1999112	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9586510	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	OCCC(Nc1nc2ccc(-c3ccncc3)cc2s1)c1ccccc1		CHEMBL1982122	=	Ki	nM	630.96	CHEMBL2431	Homo sapiens	pKi		6.2
inactive	9586511	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1ccc(-c2cccc3sncc23)cc1)Nc1ccc(F)c(C(F)(F)F)c1		CHEMBL2000801	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586512	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682546	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586513	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1991395	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586514	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN1CCN(c2cccc(Nc3nccc(-c4c(C(N)=O)nc5ccccn45)n3)c2)CC1		CHEMBL1971245	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586515	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1987648	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586516	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOC(=O)c1cn(-c2ccc(O)cc2C)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL1996780	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586517	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NCc1ccccc1)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL1972142	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586518	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1966514	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9586519	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCCCCCCCCCCOc1ccc(NC(=N)N)cc1NC(=N)N		CHEMBL1980715	=	Ki	nM	6309.57	CHEMBL2431	Homo sapiens	pKi		5.2
active	9586520	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(F)c1		CHEMBL2003638	=	Ki	nM	3981.07	CHEMBL2431	Homo sapiens	pKi		5.4
inactive	9586521	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586522	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#Cc1ccc2nc(N)n(-c3nc(-c4ccccc4)cs3)c2c1		CHEMBL1996066	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9586523	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(COc1cncc(-c2cc3ccncc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1966524	=	Ki	nM	199.53	CHEMBL2431	Homo sapiens	pKi		6.7
inactive	9586524	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(C(=O)O)ccc4F)cc3)c12		CHEMBL1993722	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586525	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=c1[nH]c2sc3c(c2c2nc(-c4cccnc4)nn12)CCCC3		CHEMBL1970806	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586526	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nc(COc2ccccc2Cl)sc1-c1ccnc(N)n1		CHEMBL1375640	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586527	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL1979970	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586528	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCN4CCOCC4)cc2-3)cn1		CHEMBL249282	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586529	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(C)NC(=O)c1ccc2nc3[nH]c4ccccc4c3nc2c1		CHEMBL1969264	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9586530	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	N#Cc1c(O)[nH]c(=O)c2c(=N)oc3ccc(Cl)cc3c12		CHEMBL1973711	=	Ki	nM	3162.28	CHEMBL2431	Homo sapiens	pKi		5.5
inactive	9586531	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN1CCN(CCCNc2cccc(-c3nc4c(C(N)=O)cccc4[nH]3)n2)CC1		CHEMBL2006237	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586532	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(C(N)=O)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1967720	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586533	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12		CHEMBL1624529	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586534	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1nccn2c(C3CC(CN4CCCC4)C3)nc(-c3cccc(OCc4ccccc4)c3)c12		CHEMBL1991138	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586535	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1F		CHEMBL1969755	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586536	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1979516	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586537	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586538	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(O)c1ccc(N2C(=O)c3ccccc3C2=O)cc1O		CHEMBL1972820	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586539	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NNc1cc(N2CCOCC2)nc(OCCc2ccccn2)n1		CHEMBL1996208	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586540	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12		CHEMBL1989029	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586541	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1		CHEMBL392642	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586542	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586543	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1965631	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9586544	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccccc1NC(=O)Nc1ccc(NC(=O)c2csc3ncnc(N)c23)cc1		CHEMBL1980144	=	Ki	nM	1995.26	CHEMBL2431	Homo sapiens	pKi		5.7
inactive	9586545	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2OC)c1		CHEMBL1991188	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586546	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1972849	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586547	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586548	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586549	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL231209	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586550	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(C)OC(=O)n1cc(-c2cncn2C2CCCCC2)c2ccccc21		CHEMBL1975357	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586551	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c12		CHEMBL1976220	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586552	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL259922	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
active	9586553	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CN1CCN(C2CCC(n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1997617	=	Ki	nM	3162.28	CHEMBL2431	Homo sapiens	pKi		5.5
inactive	9586554	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CCN)nccn23)n1		CHEMBL1982383	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586555	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CCCCn1c(NC(=O)c2cccc(C#N)c2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL1969301	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586556	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CSc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17370	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586557	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4ccccc4C(F)(F)F)cc3)c12		CHEMBL1987910	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586558	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1ccc2c(NC(=O)Nc3cccc(Br)n3)ccnc2c1		CHEMBL1983932	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586559	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586560	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	NC(=O)c1csc2c1NCCC2=O		CHEMBL1973399	<	Ki	nM	79432.82	CHEMBL2431	Homo sapiens	pKi		4.1
inactive	9586561	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	c1ccc2c(c1)nnn2Cc1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL1966069	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586562	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586563	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc(OCC2CCC(C(=O)O)C2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL1991285	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586564	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1cc2cc(-c3csc4c(-c5cccc(S(C)(=O)=O)c5)cnc(N)c34)ccc2[nH]1		CHEMBL1997822	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586565	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1		CHEMBL243088	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586566	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586567	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586568	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1cccc(F)c1F		CHEMBL1974416	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586569	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	CSc1nn(-c2ccccn2)c(N)c1C(N)=O		CHEMBL2004615	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586570	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	Cc1nn(C)c(C)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)O)[nH]c12		CHEMBL1984039	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586571	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
inactive	9586572	CHEMBL1963739	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT2	F	O=C(c1cccc(-c2cnc3[nH]ccc3c2)c1)N1CCOCC1		CHEMBL1997872	<	Ki	nM	7943.28	CHEMBL2431	Homo sapiens	pKi		5.1
	10838644	CHEMBL2014522	Inhibition of AKT2 at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	10839610	CHEMBL2015796	Inhibition of PKBbeta assessed as residual activity at 10 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	76.0	CHEMBL2431	Homo sapiens	Activity	%	76.0
	10840403	CHEMBL2016320	Inhibition of PKBbeta assessed as residual activity at 1 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	82.0	CHEMBL2431	Homo sapiens	Activity	%	82.0
	10840585	CHEMBL2014741	Inhibition of Akt2	B	CCc1n[nH]c2ncnc(N3CCN(c4cc(Cl)cc(NCCN(C)C)c4C)CC3)c12		CHEMBL2012701	=	IC50	nM	3021.0	CHEMBL2431	Homo sapiens	IC50	nM	3021.0
	10840586	CHEMBL2014741	Inhibition of Akt2	B	Cc1c(NCCN(C)C)cc(Cl)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2012702	=	IC50	nM	311.0	CHEMBL2431	Homo sapiens	IC50	nM	311.0
	10840587	CHEMBL2014741	Inhibition of Akt2	B	Cc1c(NCCN(C)C)cc(Cl)cc1N1CCN(c2ncnc3[nH]nc(C(F)(F)F)c23)CC1		CHEMBL2012703	=	IC50	nM	477.0	CHEMBL2431	Homo sapiens	IC50	nM	477.0
	10889039	CHEMBL2032476	Inhibition of PKBbeta	B	COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1		CHEMBL460472	=	IC50	nM	25000.0	CHEMBL2431	Homo sapiens	IC50	uM	25.0
	10889066	CHEMBL2032476	Inhibition of PKBbeta	B	COc1cc2nccc(Oc3ccc(NC(=O)c4c(C)n(C)n(-c5ccccc5)c4=O)cc3F)c2cc1OC		CHEMBL2031893	=	IC50	nM	25000.0	CHEMBL2431	Homo sapiens	IC50	uM	25.0
	10923980	CHEMBL2044303	Inhibition of AKT2 at 1 uM incubated for 30 mins prior to substrate addition study done at apparent ATP Km for enzyme	B	C[C@H](/C=C\C(F)(F)F)Oc1cc(-c2cc(-c3cc(CN(C)C)cs3)cnc2N)ccc1C(N)=O		CHEMBL2042135	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
Not Active	11011589	CHEMBL2091232	Inhibition of AKT2 at 10 uM by luciferase assay	B	O=C1NC(=O)c2c1c(-c1ccccc1)cc1[nH]c3ccc(O)cc3c21		CHEMBL214253		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	11011613	CHEMBL2091232	Inhibition of AKT2 at 10 uM by luciferase assay	B	Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1		CHEMBL238125	>	Inhibition	%	25.0	CHEMBL2431	Homo sapiens	INH	%	25.0
Not Active	11011655	CHEMBL2091232	Inhibition of AKT2 at 10 uM by luciferase assay	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21		CHEMBL268368		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	12046237	CHEMBL2157257	Inhibition of AKT2 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	6.2	CHEMBL2431	Homo sapiens	INH	%	6.2
	12060917	CHEMBL2157049	Binding affinity to AKT2 at 1 uM by high throughput binding assay relative to control	B	Nc1cc(NS(=O)(=O)c2cccc(C(F)(F)F)c2)cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)c1		CHEMBL2152288	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	12074616	CHEMBL2161013	Inhibition of Akt2 at 1 uM	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL1908842	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	12074695	CHEMBL2161416	Inhibition of PKBbeta at 1 uM	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL1908842	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	12143224	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177837	=	IC50	nM	80.0	CHEMBL2431	Homo sapiens	IC50	uM	0.08
	12143225	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177836	=	IC50	nM	18.0	CHEMBL2431	Homo sapiens	IC50	uM	0.018
	12143226	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177835	=	IC50	nM	35.0	CHEMBL2431	Homo sapiens	IC50	uM	0.035
	12143227	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5ccccc5)cc4)c3n2)c1		CHEMBL2177834	=	IC50	nM	47.0	CHEMBL2431	Homo sapiens	IC50	uM	0.047
	12143228	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177832	=	IC50	nM	32.0	CHEMBL2431	Homo sapiens	IC50	uM	0.032
	12143229	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177829	=	IC50	nM	25.0	CHEMBL2431	Homo sapiens	IC50	uM	0.025
	12143230	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177828	=	IC50	nM	24.0	CHEMBL2431	Homo sapiens	IC50	uM	0.024
	12143231	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5ccccc5)cc4)c3n2)c1		CHEMBL2177827	=	IC50	nM	15.0	CHEMBL2431	Homo sapiens	IC50	uM	0.015
	12143240	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177837	=	Delta Tm	degrees C	5.7	CHEMBL2431	Homo sapiens	deltaTm	degrees C	5.7
	12143241	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177836	=	Delta Tm	degrees C	7.7	CHEMBL2431	Homo sapiens	deltaTm	degrees C	7.7
	12143242	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177835	=	Delta Tm	degrees C	6.4	CHEMBL2431	Homo sapiens	deltaTm	degrees C	6.4
	12143243	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5ccccc5)cc4)c3n2)c1		CHEMBL2177834	=	Delta Tm	degrees C	6.7	CHEMBL2431	Homo sapiens	deltaTm	degrees C	6.7
	12143244	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177832	=	Delta Tm	degrees C	4.0	CHEMBL2431	Homo sapiens	deltaTm	degrees C	4.0
	12143245	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177829	=	Delta Tm	degrees C	5.1	CHEMBL2431	Homo sapiens	deltaTm	degrees C	5.1
	12143246	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177828	=	Delta Tm	degrees C	6.7	CHEMBL2431	Homo sapiens	deltaTm	degrees C	6.7
	12143247	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5ccccc5)cc4)c3n2)c1		CHEMBL2177827	=	Delta Tm	degrees C	6.5	CHEMBL2431	Homo sapiens	deltaTm	degrees C	6.5
	12143283	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cc(-c3ccccc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177830	=	IC50	nM	51000.0	CHEMBL2431	Homo sapiens	IC50	uM	51.0
	12143326	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177833	=	Delta Tm	degrees C	5.4	CHEMBL2431	Homo sapiens	deltaTm	degrees C	5.4
	12143328	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177831	=	Delta Tm	degrees C	4.8	CHEMBL2431	Homo sapiens	deltaTm	degrees C	4.8
	12143335	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	Nc1ncccc1-c1nc2cc(C3CCCC3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177826	=	Delta Tm	degrees C	3.3	CHEMBL2431	Homo sapiens	deltaTm	degrees C	3.3
	12143340	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	Nc1ncccc1-c1nc2cc(Br)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177825	=	Delta Tm	degrees C	3.0	CHEMBL2431	Homo sapiens	deltaTm	degrees C	3.0
	12143364	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	=	Delta Tm	degrees C	1.3	CHEMBL2431	Homo sapiens	deltaTm	degrees C	1.3
	12143370	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	Nc1ncccc1-c1nc2cc(-c3ccccc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177830	=	Delta Tm	degrees C	1.2	CHEMBL2431	Homo sapiens	deltaTm	degrees C	1.2
	12143371	CHEMBL2186221	Binding affinity to Akt2 (1 to 481) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	=	Delta Tm	degrees C	1.2	CHEMBL2431	Homo sapiens	deltaTm	degrees C	1.2
	12143382	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cc(C3CCCC3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177826	=	IC50	nM	800.0	CHEMBL2431	Homo sapiens	IC50	uM	0.8
	12143385	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	=	IC50	nM	700.0	CHEMBL2431	Homo sapiens	IC50	uM	0.7
	12143389	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	=	IC50	nM	660.0	CHEMBL2431	Homo sapiens	IC50	uM	0.66
	12143418	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cc(Br)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177825	=	IC50	nM	130.0	CHEMBL2431	Homo sapiens	IC50	uM	0.13
	12143449	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177831	=	IC50	nM	30.0	CHEMBL2431	Homo sapiens	IC50	uM	0.03
	12143452	CHEMBL2186224	Inhibition of Akt2 (1 to 481) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177833	=	IC50	nM	27.0	CHEMBL2431	Homo sapiens	IC50	uM	0.027
	12149876	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC4CCOCC4)c4ccc(Cl)c(F)c4)CC3)c21		CHEMBL2177362	=	IC50	nM	24.0	CHEMBL2431	Homo sapiens	IC50	nM	24.0
	12149877	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCC4CC4)c4ccc(C(F)(F)F)c(F)c4)CC3)c21		CHEMBL2177361	=	IC50	nM	3.0	CHEMBL2431	Homo sapiens	IC50	nM	3.0
	12149878	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC(C)(C)CO)c4ccc(C(F)(F)F)c(F)c4)CC3)c21		CHEMBL2178598	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	nM	6.0
	12149879	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC(C)(C)C)c4ccc(C(F)(F)F)c(F)c4)CC3)c21		CHEMBL2178597	=	IC50	nM	5.0	CHEMBL2431	Homo sapiens	IC50	nM	5.0
	12149880	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)c(F)c1		CHEMBL2177372	=	IC50	nM	17.0	CHEMBL2431	Homo sapiens	IC50	nM	17.0
	12149881	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CN)c4ccc(C(F)(F)F)cc4)CC3)c21		CHEMBL2177371	=	IC50	nM	30.0	CHEMBL2431	Homo sapiens	IC50	nM	30.0
	12149882	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@@H](c4ccc(Cl)cc4)[C@@H]4COCCN4)CC3)c21		CHEMBL2177370	=	IC50	nM	29.0	CHEMBL2431	Homo sapiens	IC50	nM	29.0
	12149883	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@@H](c4ccc(Cl)cc4)[C@@H]4CCCCN4)CC3)c21		CHEMBL2177369	=	IC50	nM	22.0	CHEMBL2431	Homo sapiens	IC50	nM	22.0
	12149884	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCC4CCOCC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177368	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	nM	6.0
	12149885	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CO[C@H]1CC[C@H](NC[C@@H](C(=O)N2CCN(c3ncnc4c3[C@H](C)C[C@H]4O)CC2)c2ccc(Cl)cc2)CC1		CHEMBL2177367	=	IC50	nM	10.0	CHEMBL2431	Homo sapiens	IC50	nM	10.0
	12149886	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC4CCOCC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177366	=	IC50	nM	15.0	CHEMBL2431	Homo sapiens	IC50	nM	15.0
	12149887	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@@H](c4ccc(Cl)cc4)[C@@H]4CCCN4)CC3)c21		CHEMBL2177379	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	nM	6.0
	12149888	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)N(C)C[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177365	=	IC50	nM	31.0	CHEMBL2431	Homo sapiens	IC50	nM	31.0
	12149889	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC4CCCCC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177364	=	IC50	nM	18.0	CHEMBL2431	Homo sapiens	IC50	nM	18.0
	12149890	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CN4CCC(F)CC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177363	=	IC50	nM	11.0	CHEMBL2431	Homo sapiens	IC50	nM	11.0
	12149891	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC(C)(C)CO)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177378	=	IC50	nM	4.0	CHEMBL2431	Homo sapiens	IC50	nM	4.0
	12149892	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	COCCNC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177377	=	IC50	nM	17.0	CHEMBL2431	Homo sapiens	IC50	nM	17.0
	12149893	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCC(F)(F)F)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177376	=	IC50	nM	2005.0	CHEMBL2431	Homo sapiens	IC50	nM	2005.0
	12149894	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCCF)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177375	=	IC50	nM	33.0	CHEMBL2431	Homo sapiens	IC50	nM	33.0
	12149895	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCC4CC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177374	=	IC50	nM	12.0	CHEMBL2431	Homo sapiens	IC50	nM	12.0
	12149896	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CN)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177373	=	IC50	nM	66.0	CHEMBL2431	Homo sapiens	IC50	nM	66.0
	12151726	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)CC3(F)F)CC1)c1ccc(Cl)cc1		CHEMBL2177383	=	IC50	nM	4177.0	CHEMBL2431	Homo sapiens	IC50	nM	4177.0
	12151727	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@@H]3F)CC1)c1ccc(Cl)cc1		CHEMBL2177382	=	IC50	nM	35.0	CHEMBL2431	Homo sapiens	IC50	nM	35.0
	12151728	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3F)CC1)c1ccc(Cl)cc1		CHEMBL2177381	=	IC50	nM	14.0	CHEMBL2431	Homo sapiens	IC50	nM	14.0
	12151729	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177380	=	IC50	nM	249.0	CHEMBL2431	Homo sapiens	IC50	nM	249.0
	12151730	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177390	=	IC50	nM	18.0	CHEMBL2431	Homo sapiens	IC50	nM	18.0
	12151731	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](CO)CC3)CC1)c1ccc(Cl)cc1		CHEMBL2177389	=	IC50	nM	356.0	CHEMBL2431	Homo sapiens	IC50	nM	356.0
	12151732	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](CF)CC3)CC1)c1ccc(Cl)cc1		CHEMBL2177388	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	nM	6.0
	12151733	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C=C[C@@H]1CCc2ncnc(N3CCN(C(=O)[C@H](CNC(C)C)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177387	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	nM	6.0
	12151734	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2C(C)(C)CC3)CC1)c1ccc(Cl)cc1		CHEMBL2177386	>	IC50	nM	2000.0	CHEMBL2431	Homo sapiens	IC50	nM	2000.0
	12151735	CHEMBL2188025	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt2 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)CC3)CC1)c1ccc(Cl)cc1		CHEMBL2177385	=	IC50	nM	12.0	CHEMBL2431	Homo sapiens	IC50	nM	12.0
	12166141	CHEMBL2211614	Binding affinity to AKT2 at 1 uM	B	Cc1nc(N)nc(-c2cc(Cl)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1		CHEMBL2206921	<	Activity	%	50.0	CHEMBL2431	Homo sapiens	Activity	%	50.0
	12170749	CHEMBL2209470	Inhibition of PKBb assessed as residual activity at 1 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	95.0	CHEMBL2431	Homo sapiens	Activity	%	95.0
	12170880	CHEMBL2213199	Inhibition of PKBb assessed as residual activity at 10 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	85.0	CHEMBL2431	Homo sapiens	Activity	%	85.0
	12173742	CHEMBL2212080	Inhibition of AKT2 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	12195476	CHEMBL2210934	Inhibition of recombinant AKT2 after 1 hr by scintillation counter analysis in presence of gamma-[33P]ATP	B	CC(C)(C)Nc1c(Nc2ccnc(Nc3ccc(-c4ccncc4)cc3)n2)c(=O)c1=O		CHEMBL2205426	>	Ki	nM	8000.0	CHEMBL2431	Homo sapiens	Ki	nM	8000.0
	12257033	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	147.0	CHEMBL2431	Homo sapiens	Residual Activity	%	147.0
	12257034	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	95.0	CHEMBL2431	Homo sapiens	Residual Activity	%	95.0
	12257035	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	118.0	CHEMBL2431	Homo sapiens	Residual Activity	%	118.0
	12257036	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	145.0	CHEMBL2431	Homo sapiens	Residual Activity	%	145.0
	12257037	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	127.0	CHEMBL2431	Homo sapiens	Residual Activity	%	127.0
	12257038	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	139.0	CHEMBL2431	Homo sapiens	Residual Activity	%	139.0
	12257039	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	128.0	CHEMBL2431	Homo sapiens	Residual Activity	%	128.0
	12257040	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	128.0	CHEMBL2431	Homo sapiens	Residual Activity	%	128.0
	12257041	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	118.0	CHEMBL2431	Homo sapiens	Residual Activity	%	118.0
	12257042	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	137.0	CHEMBL2431	Homo sapiens	Residual Activity	%	137.0
	12257043	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	103.0	CHEMBL2431	Homo sapiens	Residual Activity	%	103.0
	12257044	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	141.0	CHEMBL2431	Homo sapiens	Residual Activity	%	141.0
	12257045	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	135.0	CHEMBL2431	Homo sapiens	Residual Activity	%	135.0
	12257046	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	106.0	CHEMBL2431	Homo sapiens	Residual Activity	%	106.0
	12257047	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	101.0	CHEMBL2431	Homo sapiens	Residual Activity	%	101.0
	12257048	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	142.0	CHEMBL2431	Homo sapiens	Residual Activity	%	142.0
	12257049	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	91.0	CHEMBL2431	Homo sapiens	Residual Activity	%	91.0
	12257050	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	90.0	CHEMBL2431	Homo sapiens	Residual Activity	%	90.0
	12257051	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	122.0	CHEMBL2431	Homo sapiens	Residual Activity	%	122.0
	12257052	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	146.0	CHEMBL2431	Homo sapiens	Residual Activity	%	146.0
	12257053	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	136.0	CHEMBL2431	Homo sapiens	Residual Activity	%	136.0
	12257054	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	116.0	CHEMBL2431	Homo sapiens	Residual Activity	%	116.0
	12257055	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	111.0	CHEMBL2431	Homo sapiens	Residual Activity	%	111.0
	12257056	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	140.0	CHEMBL2431	Homo sapiens	Residual Activity	%	140.0
	12257057	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	130.0	CHEMBL2431	Homo sapiens	Residual Activity	%	130.0
	12257058	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	125.0	CHEMBL2431	Homo sapiens	Residual Activity	%	125.0
	12257059	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	92.0	CHEMBL2431	Homo sapiens	Residual Activity	%	92.0
	12257060	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	100.0	CHEMBL2431	Homo sapiens	Residual Activity	%	100.0
	12257061	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	100.0	CHEMBL2431	Homo sapiens	Residual Activity	%	100.0
	12257062	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	129.0	CHEMBL2431	Homo sapiens	Residual Activity	%	129.0
	12257063	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	106.0	CHEMBL2431	Homo sapiens	Residual Activity	%	106.0
	12257064	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	105.0	CHEMBL2431	Homo sapiens	Residual Activity	%	105.0
	12257065	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	121.0	CHEMBL2431	Homo sapiens	Residual Activity	%	121.0
	12257066	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	133.0	CHEMBL2431	Homo sapiens	Residual Activity	%	133.0
	12257067	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	88.0	CHEMBL2431	Homo sapiens	Residual Activity	%	88.0
	12257068	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	111.0	CHEMBL2431	Homo sapiens	Residual Activity	%	111.0
	12257069	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	96.0	CHEMBL2431	Homo sapiens	Residual Activity	%	96.0
	12257070	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	114.0	CHEMBL2431	Homo sapiens	Residual Activity	%	114.0
	12257071	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	115.0	CHEMBL2431	Homo sapiens	Residual Activity	%	115.0
	12257072	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	112.0	CHEMBL2431	Homo sapiens	Residual Activity	%	112.0
	12257073	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	111.0	CHEMBL2431	Homo sapiens	Residual Activity	%	111.0
	12257074	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	134.0	CHEMBL2431	Homo sapiens	Residual Activity	%	134.0
	12257075	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	100.0	CHEMBL2431	Homo sapiens	Residual Activity	%	100.0
	12257076	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	131.0	CHEMBL2431	Homo sapiens	Residual Activity	%	131.0
	12257077	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	131.0	CHEMBL2431	Homo sapiens	Residual Activity	%	131.0
	12257078	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	121.0	CHEMBL2431	Homo sapiens	Residual Activity	%	121.0
	12257079	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	133.0	CHEMBL2431	Homo sapiens	Residual Activity	%	133.0
	12257080	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	114.0	CHEMBL2431	Homo sapiens	Residual Activity	%	114.0
	12257081	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	133.0	CHEMBL2431	Homo sapiens	Residual Activity	%	133.0
	12257082	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	130.0	CHEMBL2431	Homo sapiens	Residual Activity	%	130.0
	12257083	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	133.0	CHEMBL2431	Homo sapiens	Residual Activity	%	133.0
	12257084	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	133.0	CHEMBL2431	Homo sapiens	Residual Activity	%	133.0
	12257085	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	128.0	CHEMBL2431	Homo sapiens	Residual Activity	%	128.0
	12257086	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	149.0	CHEMBL2431	Homo sapiens	Residual Activity	%	149.0
	12257087	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	120.0	CHEMBL2431	Homo sapiens	Residual Activity	%	120.0
	12257088	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	115.0	CHEMBL2431	Homo sapiens	Residual Activity	%	115.0
	12257089	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	138.0	CHEMBL2431	Homo sapiens	Residual Activity	%	138.0
	12257090	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	104.0	CHEMBL2431	Homo sapiens	Residual Activity	%	104.0
	12257091	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	123.0	CHEMBL2431	Homo sapiens	Residual Activity	%	123.0
	12257092	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	132.0	CHEMBL2431	Homo sapiens	Residual Activity	%	132.0
	12257093	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	117.0	CHEMBL2431	Homo sapiens	Residual Activity	%	117.0
	12257094	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	80.0	CHEMBL2431	Homo sapiens	Residual Activity	%	80.0
	12257095	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	118.0	CHEMBL2431	Homo sapiens	Residual Activity	%	118.0
	12257096	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	104.0	CHEMBL2431	Homo sapiens	Residual Activity	%	104.0
	12257097	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	99.0	CHEMBL2431	Homo sapiens	Residual Activity	%	99.0
	12257098	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	112.0	CHEMBL2431	Homo sapiens	Residual Activity	%	112.0
	12257099	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	96.0	CHEMBL2431	Homo sapiens	Residual Activity	%	96.0
	12257100	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	98.0	CHEMBL2431	Homo sapiens	Residual Activity	%	98.0
	12257101	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	84.0	CHEMBL2431	Homo sapiens	Residual Activity	%	84.0
	12257102	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	85.0	CHEMBL2431	Homo sapiens	Residual Activity	%	85.0
	12257103	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	97.0	CHEMBL2431	Homo sapiens	Residual Activity	%	97.0
	12257104	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	97.0	CHEMBL2431	Homo sapiens	Residual Activity	%	97.0
	12257105	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	107.0	CHEMBL2431	Homo sapiens	Residual Activity	%	107.0
	12257106	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	122.0	CHEMBL2431	Homo sapiens	Residual Activity	%	122.0
	12257107	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	91.0	CHEMBL2431	Homo sapiens	Residual Activity	%	91.0
	12257108	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	106.0	CHEMBL2431	Homo sapiens	Residual Activity	%	106.0
	12257109	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	89.0	CHEMBL2431	Homo sapiens	Residual Activity	%	89.0
	12257110	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	91.0	CHEMBL2431	Homo sapiens	Residual Activity	%	91.0
	12257111	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	111.0	CHEMBL2431	Homo sapiens	Residual Activity	%	111.0
	12257112	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	4.0	CHEMBL2431	Homo sapiens	Residual Activity	%	4.0
	12257113	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	120.0	CHEMBL2431	Homo sapiens	Residual Activity	%	120.0
	12257114	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	116.0	CHEMBL2431	Homo sapiens	Residual Activity	%	116.0
	12257115	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	102.0	CHEMBL2431	Homo sapiens	Residual Activity	%	102.0
	12257116	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	93.0	CHEMBL2431	Homo sapiens	Residual Activity	%	93.0
	12257117	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	109.0	CHEMBL2431	Homo sapiens	Residual Activity	%	109.0
	12257118	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	106.0	CHEMBL2431	Homo sapiens	Residual Activity	%	106.0
	12257119	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	131.0	CHEMBL2431	Homo sapiens	Residual Activity	%	131.0
	12257120	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	107.0	CHEMBL2431	Homo sapiens	Residual Activity	%	107.0
	12257121	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	106.0	CHEMBL2431	Homo sapiens	Residual Activity	%	106.0
	12257122	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	98.0	CHEMBL2431	Homo sapiens	Residual Activity	%	98.0
	12257123	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	100.0	CHEMBL2431	Homo sapiens	Residual Activity	%	100.0
	12257124	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	108.0	CHEMBL2431	Homo sapiens	Residual Activity	%	108.0
	12257125	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	103.0	CHEMBL2431	Homo sapiens	Residual Activity	%	103.0
	12257126	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	111.0	CHEMBL2431	Homo sapiens	Residual Activity	%	111.0
	12257127	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	114.0	CHEMBL2431	Homo sapiens	Residual Activity	%	114.0
	12257128	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	109.0	CHEMBL2431	Homo sapiens	Residual Activity	%	109.0
	12257129	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	108.0	CHEMBL2431	Homo sapiens	Residual Activity	%	108.0
	12257130	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	120.0	CHEMBL2431	Homo sapiens	Residual Activity	%	120.0
	12257131	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	106.0	CHEMBL2431	Homo sapiens	Residual Activity	%	106.0
	12257132	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	111.0	CHEMBL2431	Homo sapiens	Residual Activity	%	111.0
	12257133	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	96.0	CHEMBL2431	Homo sapiens	Residual Activity	%	96.0
	12257134	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	67.0	CHEMBL2431	Homo sapiens	Residual Activity	%	67.0
	12257135	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	114.0	CHEMBL2431	Homo sapiens	Residual Activity	%	114.0
	12257136	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	101.0	CHEMBL2431	Homo sapiens	Residual Activity	%	101.0
	12257137	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	115.0	CHEMBL2431	Homo sapiens	Residual Activity	%	115.0
	12257138	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	115.0	CHEMBL2431	Homo sapiens	Residual Activity	%	115.0
	12257139	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	100.0	CHEMBL2431	Homo sapiens	Residual Activity	%	100.0
	12257140	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	94.0	CHEMBL2431	Homo sapiens	Residual Activity	%	94.0
	12257141	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	90.0	CHEMBL2431	Homo sapiens	Residual Activity	%	90.0
	12257142	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	89.0	CHEMBL2431	Homo sapiens	Residual Activity	%	89.0
	12257143	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	101.0	CHEMBL2431	Homo sapiens	Residual Activity	%	101.0
	12257144	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	89.0	CHEMBL2431	Homo sapiens	Residual Activity	%	89.0
	12257145	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	98.0	CHEMBL2431	Homo sapiens	Residual Activity	%	98.0
	12257146	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	92.0	CHEMBL2431	Homo sapiens	Residual Activity	%	92.0
	12257147	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	85.0	CHEMBL2431	Homo sapiens	Residual Activity	%	85.0
	12257148	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	93.0	CHEMBL2431	Homo sapiens	Residual Activity	%	93.0
	12257149	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	95.0	CHEMBL2431	Homo sapiens	Residual Activity	%	95.0
	12257150	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	87.0	CHEMBL2431	Homo sapiens	Residual Activity	%	87.0
	12257151	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	103.0	CHEMBL2431	Homo sapiens	Residual Activity	%	103.0
	12257152	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	89.0	CHEMBL2431	Homo sapiens	Residual Activity	%	89.0
	12257153	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	106.0	CHEMBL2431	Homo sapiens	Residual Activity	%	106.0
	12257154	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	99.0	CHEMBL2431	Homo sapiens	Residual Activity	%	99.0
	12257155	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	95.0	CHEMBL2431	Homo sapiens	Residual Activity	%	95.0
	12257156	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	93.0	CHEMBL2431	Homo sapiens	Residual Activity	%	93.0
	12257157	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	89.0	CHEMBL2431	Homo sapiens	Residual Activity	%	89.0
	12257158	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	99.0	CHEMBL2431	Homo sapiens	Residual Activity	%	99.0
	12257159	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	105.0	CHEMBL2431	Homo sapiens	Residual Activity	%	105.0
	12257160	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	97.0	CHEMBL2431	Homo sapiens	Residual Activity	%	97.0
	12257161	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	111.0	CHEMBL2431	Homo sapiens	Residual Activity	%	111.0
	12257162	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	94.0	CHEMBL2431	Homo sapiens	Residual Activity	%	94.0
	12257163	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	97.0	CHEMBL2431	Homo sapiens	Residual Activity	%	97.0
	12257164	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	105.0	CHEMBL2431	Homo sapiens	Residual Activity	%	105.0
	12257165	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	104.0	CHEMBL2431	Homo sapiens	Residual Activity	%	104.0
	12257166	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	88.0	CHEMBL2431	Homo sapiens	Residual Activity	%	88.0
	12257167	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	91.0	CHEMBL2431	Homo sapiens	Residual Activity	%	91.0
	12257168	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	110.0	CHEMBL2431	Homo sapiens	Residual Activity	%	110.0
	12257169	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	108.0	CHEMBL2431	Homo sapiens	Residual Activity	%	108.0
	12257170	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	110.0	CHEMBL2431	Homo sapiens	Residual Activity	%	110.0
	12257171	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	91.0	CHEMBL2431	Homo sapiens	Residual Activity	%	91.0
	12257172	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	114.0	CHEMBL2431	Homo sapiens	Residual Activity	%	114.0
	12257173	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	96.0	CHEMBL2431	Homo sapiens	Residual Activity	%	96.0
	12257174	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	86.0	CHEMBL2431	Homo sapiens	Residual Activity	%	86.0
	12257175	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	96.0	CHEMBL2431	Homo sapiens	Residual Activity	%	96.0
	12257176	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	84.0	CHEMBL2431	Homo sapiens	Residual Activity	%	84.0
	12257177	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	88.0	CHEMBL2431	Homo sapiens	Residual Activity	%	88.0
	12257178	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	89.0	CHEMBL2431	Homo sapiens	Residual Activity	%	89.0
	12257179	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	91.0	CHEMBL2431	Homo sapiens	Residual Activity	%	91.0
	12257180	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	84.0	CHEMBL2431	Homo sapiens	Residual Activity	%	84.0
	12257181	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	89.0	CHEMBL2431	Homo sapiens	Residual Activity	%	89.0
	12257182	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	90.0	CHEMBL2431	Homo sapiens	Residual Activity	%	90.0
	12257183	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	93.0	CHEMBL2431	Homo sapiens	Residual Activity	%	93.0
	12257184	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	86.0	CHEMBL2431	Homo sapiens	Residual Activity	%	86.0
	12257185	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	94.0	CHEMBL2431	Homo sapiens	Residual Activity	%	94.0
	12257186	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	86.0	CHEMBL2431	Homo sapiens	Residual Activity	%	86.0
	12257187	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	91.0	CHEMBL2431	Homo sapiens	Residual Activity	%	91.0
	12257188	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	86.0	CHEMBL2431	Homo sapiens	Residual Activity	%	86.0
	12257189	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	91.0	CHEMBL2431	Homo sapiens	Residual Activity	%	91.0
	12257190	CHEMBL2219394	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	28.0	CHEMBL2431	Homo sapiens	Residual Activity	%	28.0
	12257191	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	120.0	CHEMBL2431	Homo sapiens	Residual Activity	%	120.0
	12257192	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	77.0	CHEMBL2431	Homo sapiens	Residual Activity	%	77.0
	12257193	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	88.0	CHEMBL2431	Homo sapiens	Residual Activity	%	88.0
	12257194	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	98.0	CHEMBL2431	Homo sapiens	Residual Activity	%	98.0
	12257195	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	114.0	CHEMBL2431	Homo sapiens	Residual Activity	%	114.0
	12257196	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	114.0	CHEMBL2431	Homo sapiens	Residual Activity	%	114.0
	12257197	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	111.0	CHEMBL2431	Homo sapiens	Residual Activity	%	111.0
	12257198	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	93.0	CHEMBL2431	Homo sapiens	Residual Activity	%	93.0
	12257199	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	91.0	CHEMBL2431	Homo sapiens	Residual Activity	%	91.0
	12257200	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	96.0	CHEMBL2431	Homo sapiens	Residual Activity	%	96.0
	12257201	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	96.0	CHEMBL2431	Homo sapiens	Residual Activity	%	96.0
	12257202	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	88.0	CHEMBL2431	Homo sapiens	Residual Activity	%	88.0
	12257203	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	105.0	CHEMBL2431	Homo sapiens	Residual Activity	%	105.0
	12257204	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	96.0	CHEMBL2431	Homo sapiens	Residual Activity	%	96.0
	12257205	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	123.0	CHEMBL2431	Homo sapiens	Residual Activity	%	123.0
	12257206	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	99.0	CHEMBL2431	Homo sapiens	Residual Activity	%	99.0
	12257207	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	82.0	CHEMBL2431	Homo sapiens	Residual Activity	%	82.0
	12257208	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	53.0	CHEMBL2431	Homo sapiens	Residual Activity	%	53.0
	12257209	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	85.0	CHEMBL2431	Homo sapiens	Residual Activity	%	85.0
	12257210	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	99.0	CHEMBL2431	Homo sapiens	Residual Activity	%	99.0
	12257211	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	82.0	CHEMBL2431	Homo sapiens	Residual Activity	%	82.0
	12257212	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	93.0	CHEMBL2431	Homo sapiens	Residual Activity	%	93.0
	12257213	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	90.0	CHEMBL2431	Homo sapiens	Residual Activity	%	90.0
	12257214	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	107.0	CHEMBL2431	Homo sapiens	Residual Activity	%	107.0
	12257215	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	103.0	CHEMBL2431	Homo sapiens	Residual Activity	%	103.0
	12257216	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	97.0	CHEMBL2431	Homo sapiens	Residual Activity	%	97.0
	12257217	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	69.0	CHEMBL2431	Homo sapiens	Residual Activity	%	69.0
	12257218	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	80.0	CHEMBL2431	Homo sapiens	Residual Activity	%	80.0
	12257219	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	106.0	CHEMBL2431	Homo sapiens	Residual Activity	%	106.0
	12257220	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	76.0	CHEMBL2431	Homo sapiens	Residual Activity	%	76.0
	12257221	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	103.0	CHEMBL2431	Homo sapiens	Residual Activity	%	103.0
	12257222	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	89.0	CHEMBL2431	Homo sapiens	Residual Activity	%	89.0
	12257223	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	79.0	CHEMBL2431	Homo sapiens	Residual Activity	%	79.0
	12257224	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	93.0	CHEMBL2431	Homo sapiens	Residual Activity	%	93.0
	12257225	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	96.0	CHEMBL2431	Homo sapiens	Residual Activity	%	96.0
	12257226	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	88.0	CHEMBL2431	Homo sapiens	Residual Activity	%	88.0
	12257227	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	90.0	CHEMBL2431	Homo sapiens	Residual Activity	%	90.0
	12257228	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	107.0	CHEMBL2431	Homo sapiens	Residual Activity	%	107.0
	12257229	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	95.0	CHEMBL2431	Homo sapiens	Residual Activity	%	95.0
	12257230	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	95.0	CHEMBL2431	Homo sapiens	Residual Activity	%	95.0
	12257231	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	112.0	CHEMBL2431	Homo sapiens	Residual Activity	%	112.0
	12257232	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	105.0	CHEMBL2431	Homo sapiens	Residual Activity	%	105.0
	12257233	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	82.0	CHEMBL2431	Homo sapiens	Residual Activity	%	82.0
	12257234	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	70.0	CHEMBL2431	Homo sapiens	Residual Activity	%	70.0
	12257235	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	97.0	CHEMBL2431	Homo sapiens	Residual Activity	%	97.0
	12257236	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	89.0	CHEMBL2431	Homo sapiens	Residual Activity	%	89.0
	12257237	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	92.0	CHEMBL2431	Homo sapiens	Residual Activity	%	92.0
	12257238	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	93.0	CHEMBL2431	Homo sapiens	Residual Activity	%	93.0
	12257239	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	44.0	CHEMBL2431	Homo sapiens	Residual Activity	%	44.0
	12257240	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	90.0	CHEMBL2431	Homo sapiens	Residual Activity	%	90.0
	12257241	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	91.0	CHEMBL2431	Homo sapiens	Residual Activity	%	91.0
	12257242	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	91.0	CHEMBL2431	Homo sapiens	Residual Activity	%	91.0
	12257243	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	60.0	CHEMBL2431	Homo sapiens	Residual Activity	%	60.0
	12257244	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	80.0	CHEMBL2431	Homo sapiens	Residual Activity	%	80.0
	12257245	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	96.0	CHEMBL2431	Homo sapiens	Residual Activity	%	96.0
	12257246	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	89.0	CHEMBL2431	Homo sapiens	Residual Activity	%	89.0
	12257247	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	103.0	CHEMBL2431	Homo sapiens	Residual Activity	%	103.0
	12257248	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	98.0	CHEMBL2431	Homo sapiens	Residual Activity	%	98.0
	12257249	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	110.0	CHEMBL2431	Homo sapiens	Residual Activity	%	110.0
	12257250	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	80.0	CHEMBL2431	Homo sapiens	Residual Activity	%	80.0
	12257251	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	84.0	CHEMBL2431	Homo sapiens	Residual Activity	%	84.0
	12257252	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	46.0	CHEMBL2431	Homo sapiens	Residual Activity	%	46.0
	12257253	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	93.0	CHEMBL2431	Homo sapiens	Residual Activity	%	93.0
	12257254	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	81.0	CHEMBL2431	Homo sapiens	Residual Activity	%	81.0
	12257255	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	91.0	CHEMBL2431	Homo sapiens	Residual Activity	%	91.0
	12257256	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	88.0	CHEMBL2431	Homo sapiens	Residual Activity	%	88.0
	12257257	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	92.0	CHEMBL2431	Homo sapiens	Residual Activity	%	92.0
	12257258	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	77.0	CHEMBL2431	Homo sapiens	Residual Activity	%	77.0
	12258669	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	84.0	CHEMBL2431	Homo sapiens	Residual Activity	%	84.0
	12258670	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	109.0	CHEMBL2431	Homo sapiens	Residual Activity	%	109.0
	12258671	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	76.0	CHEMBL2431	Homo sapiens	Residual Activity	%	76.0
	12258672	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	85.0	CHEMBL2431	Homo sapiens	Residual Activity	%	85.0
	12258673	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	60.0	CHEMBL2431	Homo sapiens	Residual Activity	%	60.0
	12258674	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	77.0	CHEMBL2431	Homo sapiens	Residual Activity	%	77.0
	12258675	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	82.0	CHEMBL2431	Homo sapiens	Residual Activity	%	82.0
	12258676	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	84.0	CHEMBL2431	Homo sapiens	Residual Activity	%	84.0
	12258677	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	87.0	CHEMBL2431	Homo sapiens	Residual Activity	%	87.0
	12258678	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	33.0	CHEMBL2431	Homo sapiens	Residual Activity	%	33.0
	12258679	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	83.0	CHEMBL2431	Homo sapiens	Residual Activity	%	83.0
	12258680	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	2.0	CHEMBL2431	Homo sapiens	Residual Activity	%	2.0
	12258681	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	112.0	CHEMBL2431	Homo sapiens	Residual Activity	%	112.0
	12258682	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	105.0	CHEMBL2431	Homo sapiens	Residual Activity	%	105.0
	12258683	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	77.0	CHEMBL2431	Homo sapiens	Residual Activity	%	77.0
	12258684	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	106.0	CHEMBL2431	Homo sapiens	Residual Activity	%	106.0
	12258685	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	92.0	CHEMBL2431	Homo sapiens	Residual Activity	%	92.0
	12258686	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	114.0	CHEMBL2431	Homo sapiens	Residual Activity	%	114.0
	12258687	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	101.0	CHEMBL2431	Homo sapiens	Residual Activity	%	101.0
	12258688	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	79.0	CHEMBL2431	Homo sapiens	Residual Activity	%	79.0
	12258689	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	113.0	CHEMBL2431	Homo sapiens	Residual Activity	%	113.0
	12258690	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	92.0	CHEMBL2431	Homo sapiens	Residual Activity	%	92.0
	12258691	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	104.0	CHEMBL2431	Homo sapiens	Residual Activity	%	104.0
	12258692	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	123.0	CHEMBL2431	Homo sapiens	Residual Activity	%	123.0
	12258693	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	103.0	CHEMBL2431	Homo sapiens	Residual Activity	%	103.0
	12258694	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	120.0	CHEMBL2431	Homo sapiens	Residual Activity	%	120.0
	12258695	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	97.0	CHEMBL2431	Homo sapiens	Residual Activity	%	97.0
	12258696	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	112.0	CHEMBL2431	Homo sapiens	Residual Activity	%	112.0
	12258697	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	117.0	CHEMBL2431	Homo sapiens	Residual Activity	%	117.0
	12258698	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	116.0	CHEMBL2431	Homo sapiens	Residual Activity	%	116.0
	12258699	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	90.0	CHEMBL2431	Homo sapiens	Residual Activity	%	90.0
	12258700	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	124.0	CHEMBL2431	Homo sapiens	Residual Activity	%	124.0
	12258701	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	70.0	CHEMBL2431	Homo sapiens	Residual Activity	%	70.0
	12258702	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	22.0	CHEMBL2431	Homo sapiens	Residual Activity	%	22.0
	12258703	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	132.0	CHEMBL2431	Homo sapiens	Residual Activity	%	132.0
	12258704	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	92.0	CHEMBL2431	Homo sapiens	Residual Activity	%	92.0
	12258705	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	120.0	CHEMBL2431	Homo sapiens	Residual Activity	%	120.0
	12258706	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	95.0	CHEMBL2431	Homo sapiens	Residual Activity	%	95.0
	12258707	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	97.0	CHEMBL2431	Homo sapiens	Residual Activity	%	97.0
	12258708	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	86.0	CHEMBL2431	Homo sapiens	Residual Activity	%	86.0
	12258709	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	88.0	CHEMBL2431	Homo sapiens	Residual Activity	%	88.0
	12258710	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	85.0	CHEMBL2431	Homo sapiens	Residual Activity	%	85.0
	12258711	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	104.0	CHEMBL2431	Homo sapiens	Residual Activity	%	104.0
	12258712	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	92.0	CHEMBL2431	Homo sapiens	Residual Activity	%	92.0
	12258713	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	90.0	CHEMBL2431	Homo sapiens	Residual Activity	%	90.0
	12258714	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	80.0	CHEMBL2431	Homo sapiens	Residual Activity	%	80.0
	12258715	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	100.0	CHEMBL2431	Homo sapiens	Residual Activity	%	100.0
	12258716	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	84.0	CHEMBL2431	Homo sapiens	Residual Activity	%	84.0
	12258717	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	84.0	CHEMBL2431	Homo sapiens	Residual Activity	%	84.0
	12258718	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	95.0	CHEMBL2431	Homo sapiens	Residual Activity	%	95.0
	12258719	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	100.0	CHEMBL2431	Homo sapiens	Residual Activity	%	100.0
	12258720	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	71.0	CHEMBL2431	Homo sapiens	Residual Activity	%	71.0
	12258721	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	108.0	CHEMBL2431	Homo sapiens	Residual Activity	%	108.0
	12258722	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	97.0	CHEMBL2431	Homo sapiens	Residual Activity	%	97.0
	12258723	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	90.0	CHEMBL2431	Homo sapiens	Residual Activity	%	90.0
	12258724	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	95.0	CHEMBL2431	Homo sapiens	Residual Activity	%	95.0
	12258725	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	70.0	CHEMBL2431	Homo sapiens	Residual Activity	%	70.0
	12258726	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	91.0	CHEMBL2431	Homo sapiens	Residual Activity	%	91.0
	12258727	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	98.0	CHEMBL2431	Homo sapiens	Residual Activity	%	98.0
	12258728	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	104.0	CHEMBL2431	Homo sapiens	Residual Activity	%	104.0
	12258729	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	124.0	CHEMBL2431	Homo sapiens	Residual Activity	%	124.0
	12258730	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	100.0	CHEMBL2431	Homo sapiens	Residual Activity	%	100.0
	12258731	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	108.0	CHEMBL2431	Homo sapiens	Residual Activity	%	108.0
	12258732	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	107.0	CHEMBL2431	Homo sapiens	Residual Activity	%	107.0
	12258733	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	105.0	CHEMBL2431	Homo sapiens	Residual Activity	%	105.0
	12258734	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	94.0	CHEMBL2431	Homo sapiens	Residual Activity	%	94.0
	12258735	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	88.0	CHEMBL2431	Homo sapiens	Residual Activity	%	88.0
	12258736	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	103.0	CHEMBL2431	Homo sapiens	Residual Activity	%	103.0
	12258737	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	101.0	CHEMBL2431	Homo sapiens	Residual Activity	%	101.0
	12258738	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	100.0	CHEMBL2431	Homo sapiens	Residual Activity	%	100.0
	12258739	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	112.0	CHEMBL2431	Homo sapiens	Residual Activity	%	112.0
	12258740	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	98.0	CHEMBL2431	Homo sapiens	Residual Activity	%	98.0
	12258741	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	98.0	CHEMBL2431	Homo sapiens	Residual Activity	%	98.0
	12258742	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	36.0	CHEMBL2431	Homo sapiens	Residual Activity	%	36.0
	12258743	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	89.0	CHEMBL2431	Homo sapiens	Residual Activity	%	89.0
	12258744	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	61.0	CHEMBL2431	Homo sapiens	Residual Activity	%	61.0
	12258745	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	78.0	CHEMBL2431	Homo sapiens	Residual Activity	%	78.0
	12258746	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	80.0	CHEMBL2431	Homo sapiens	Residual Activity	%	80.0
	12258747	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	73.0	CHEMBL2431	Homo sapiens	Residual Activity	%	73.0
	12258748	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	18.0	CHEMBL2431	Homo sapiens	Residual Activity	%	18.0
	12258749	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	77.0	CHEMBL2431	Homo sapiens	Residual Activity	%	77.0
	12258750	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	81.0	CHEMBL2431	Homo sapiens	Residual Activity	%	81.0
	12258751	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	77.0	CHEMBL2431	Homo sapiens	Residual Activity	%	77.0
	12258752	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	61.0	CHEMBL2431	Homo sapiens	Residual Activity	%	61.0
	12258753	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	73.0	CHEMBL2431	Homo sapiens	Residual Activity	%	73.0
	12258754	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	81.0	CHEMBL2431	Homo sapiens	Residual Activity	%	81.0
	12258755	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	78.0	CHEMBL2431	Homo sapiens	Residual Activity	%	78.0
	12258756	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	78.0	CHEMBL2431	Homo sapiens	Residual Activity	%	78.0
	12258757	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	64.0	CHEMBL2431	Homo sapiens	Residual Activity	%	64.0
	12258758	CHEMBL2219395	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	15.0	CHEMBL2431	Homo sapiens	Residual Activity	%	15.0
	12649534	CHEMBL2329396	Inhibition of AKT2 (unknown origin) at 1 uM	B	CC(C)(C)[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1		CHEMBL2325895	=	Inhibition	%	-6.0	CHEMBL2431	Homo sapiens	INH	%	-6.0
	12649535	CHEMBL2329396	Inhibition of AKT2 (unknown origin) at 1 uM	B	C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1		CHEMBL2325894	=	Inhibition	%	-8.0	CHEMBL2431	Homo sapiens	INH	%	-8.0
	12649536	CHEMBL2329396	Inhibition of AKT2 (unknown origin) at 1 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C#N		CHEMBL2325906	=	Inhibition	%	3.0	CHEMBL2431	Homo sapiens	INH	%	3.0
	12649537	CHEMBL2329396	Inhibition of AKT2 (unknown origin) at 1 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C		CHEMBL2325903	=	Inhibition	%	-10.0	CHEMBL2431	Homo sapiens	INH	%	-10.0
	12649681	CHEMBL2329566	Inhibition of AKT2 (unknown origin) at 10 uM	B	C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1	Outside typical range	CHEMBL2325894	=	Inhibition	%	-13.0	CHEMBL2431	Homo sapiens	INH	%	-13.0
	12649682	CHEMBL2329566	Inhibition of AKT2 (unknown origin) at 10 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)O	Outside typical range	CHEMBL2325904	=	Inhibition	%	-12.0	CHEMBL2431	Homo sapiens	INH	%	-12.0
	12649683	CHEMBL2329566	Inhibition of AKT2 (unknown origin) at 10 uM	B	CC(C)NC(=O)c1c[nH]c2ncc(C3CC3)nc12		CHEMBL2325901	=	Inhibition	%	9.0	CHEMBL2431	Homo sapiens	INH	%	9.0
	12660679	CHEMBL2330799	Inhibition of Akt2 (unknown origin) at 1 uM	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Inhibition	%	75.0	CHEMBL2431	Homo sapiens	INH	%	75.0
	12662126	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	nM	8.0
	12662127	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	COCCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325740	=	IC50	nM	130.0	CHEMBL2431	Homo sapiens	IC50	nM	130.0
	12662128	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325739	=	IC50	nM	24.0	CHEMBL2431	Homo sapiens	IC50	nM	24.0
	12662129	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325738	=	IC50	nM	22.0	CHEMBL2431	Homo sapiens	IC50	nM	22.0
	12662130	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325737	=	IC50	nM	46.0	CHEMBL2431	Homo sapiens	IC50	nM	46.0
	12662131	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CS(=O)(=O)NCCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325736	=	IC50	nM	36.0	CHEMBL2431	Homo sapiens	IC50	nM	36.0
	12662132	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC(=O)C(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325730	=	IC50	nM	159.0	CHEMBL2431	Homo sapiens	IC50	nM	159.0
	12662133	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)N[C@@H](CCN2CCCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325729	=	IC50	nM	13.0	CHEMBL2431	Homo sapiens	IC50	nM	13.0
	12662134	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)N[C@@H](CCN2CCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325728	=	IC50	nM	31.0	CHEMBL2431	Homo sapiens	IC50	nM	31.0
	12662135	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCCN2CCCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325996	=	IC50	nM	30.0	CHEMBL2431	Homo sapiens	IC50	nM	30.0
	12662136	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCCN2CCOCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325995	=	IC50	nM	42.0	CHEMBL2431	Homo sapiens	IC50	nM	42.0
	12662137	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCCN2CCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325994	=	IC50	nM	96.0	CHEMBL2431	Homo sapiens	IC50	nM	96.0
	12662138	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CN(C)CCCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325993	=	IC50	nM	15.0	CHEMBL2431	Homo sapiens	IC50	nM	15.0
	12662139	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CN(C)CCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325992	=	IC50	nM	14.0	CHEMBL2431	Homo sapiens	IC50	nM	14.0
	12662140	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	COc1ccc(C(C)NC(=O)C2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1OC		CHEMBL2325991	=	IC50	nM	8578.0	CHEMBL2431	Homo sapiens	IC50	nM	8578.0
	12662141	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(S(C)(=O)=O)cc1		CHEMBL2325990	=	IC50	nM	805.0	CHEMBL2431	Homo sapiens	IC50	nM	805.0
	12662142	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccccn1		CHEMBL2325989	=	IC50	nM	16498.0	CHEMBL2431	Homo sapiens	IC50	nM	16498.0
	12662143	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1cccnc1		CHEMBL2325988	=	IC50	nM	8111.0	CHEMBL2431	Homo sapiens	IC50	nM	8111.0
	12662144	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(F)cc1		CHEMBL2325987	=	IC50	nM	344.0	CHEMBL2431	Homo sapiens	IC50	nM	344.0
	12662145	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccccc1		CHEMBL2325986	=	IC50	nM	709.0	CHEMBL2431	Homo sapiens	IC50	nM	709.0
	12662146	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(Cc2ccccc2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325985	=	IC50	nM	190.0	CHEMBL2431	Homo sapiens	IC50	nM	190.0
	12662147	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(c2ccccc2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325984	=	IC50	nM	210.0	CHEMBL2431	Homo sapiens	IC50	nM	210.0
	12662148	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(c2ccc(Cl)cc2)C2CC2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325983	=	IC50	nM	30.0	CHEMBL2431	Homo sapiens	IC50	nM	30.0
	12662149	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325982	=	IC50	nM	23.0	CHEMBL2431	Homo sapiens	IC50	nM	23.0
	12662150	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	C[C@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325743	=	IC50	nM	20.0	CHEMBL2431	Homo sapiens	IC50	nM	20.0
	12662151	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	C[C@@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325742	=	IC50	nM	836.0	CHEMBL2431	Homo sapiens	IC50	nM	836.0
	12662152	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325997	=	IC50	nM	40.0	CHEMBL2431	Homo sapiens	IC50	nM	40.0
	12662153	CHEMBL2330885	Inhibition of recombinant Akt2 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	IC50	nM	66.0	CHEMBL2431	Homo sapiens	IC50	nM	66.0
	12672923	CHEMBL2341629	Inhibition of recombinant PKB beta (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336379	=	Activity	%	103.0	CHEMBL2431	Homo sapiens	Activity	%	103.0
	12672924	CHEMBL2341629	Inhibition of recombinant PKB beta (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336377	=	Activity	%	111.0	CHEMBL2431	Homo sapiens	Activity	%	111.0
	12693257	CHEMBL2343942	Inhibition of AKT2 (unknown origin)	B	Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F		CHEMBL2333365	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	nM	10000.0
	12700060	CHEMBL2344121	Inhibition of recombinant AKT2 (unknown origin) by FRET-based Z'-LYTE assay	B	CN1C/C(=C\c2ccccn2)C(=O)[C@@H](Cc2ccccn2)C1		CHEMBL2338335	>	IC50	nM	100000.0	CHEMBL2431	Homo sapiens	IC50	uM	100.0
	12700072	CHEMBL2344121	Inhibition of recombinant AKT2 (unknown origin) by FRET-based Z'-LYTE assay	B	CN1C/C(=C\c2ccccn2)C(=O)[C@H](Cc2ccccn2)C1		CHEMBL2338334	>	IC50	nM	100000.0	CHEMBL2431	Homo sapiens	IC50	uM	100.0
	12700084	CHEMBL2344121	Inhibition of recombinant AKT2 (unknown origin) by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccn2)CSC/C1=C\c1ccccn1		CHEMBL2036343	=	IC50	nM	3300.0	CHEMBL2431	Homo sapiens	IC50	uM	3.3
	12700096	CHEMBL2344121	Inhibition of recombinant AKT2 (unknown origin) by FRET-based Z'-LYTE assay	B	CN1C/C(=C\c2ccccn2)C(=O)/C(=C/c2ccccn2)C1		CHEMBL2338333	=	IC50	nM	1900.0	CHEMBL2431	Homo sapiens	IC50	uM	1.9
	12700109	CHEMBL2344121	Inhibition of recombinant AKT2 (unknown origin) by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccn2)CNC/C1=C\c1ccccn1		CHEMBL574646	=	IC50	nM	20.0	CHEMBL2431	Homo sapiens	IC50	uM	0.02
	12700171	CHEMBL2344121	Inhibition of recombinant AKT2 (unknown origin) by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccc2F)CNC/C1=C\c1ccccc1F		CHEMBL379849	=	IC50	nM	720.0	CHEMBL2431	Homo sapiens	IC50	uM	0.72
	12727693	CHEMBL2350869	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	96.0	CHEMBL2431	Homo sapiens	Activity	%	96.0
	12728979	CHEMBL2350155	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	99.0	CHEMBL2431	Homo sapiens	Activity	%	99.0
	12730122	CHEMBL2350869	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	90.0	CHEMBL2431	Homo sapiens	Activity	%	90.0
	12730940	CHEMBL2350113	Inhibition of AKT2 (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	99.0	CHEMBL2431	Homo sapiens	Activity	%	99.0
	13282444	CHEMBL2378502	Inhibition of AKT2 (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3ncn4cc(F)cc(F)c34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376158	=	Inhibition	%	14.0	CHEMBL2431	Homo sapiens	INH	%	14.0
	13282445	CHEMBL2378502	Inhibition of AKT2 (unknown origin) at 10 uM relative to control	B	Cn1nc(-c2cnc3[nH]cc(C(=O)N[C@@H](C(=O)N4CC(C#N)C4)C4CC4)c3n2)c2ccc(Cl)cc21		CHEMBL2376154	=	Inhibition	%	96.0	CHEMBL2431	Homo sapiens	INH	%	96.0
	13282446	CHEMBL2378502	Inhibition of AKT2 (unknown origin) at 10 uM relative to control	B	CC[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376153	=	Inhibition	%	-3.0	CHEMBL2431	Homo sapiens	INH	%	-3.0
	13282447	CHEMBL2378502	Inhibition of AKT2 (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)cc(F)c34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376152	=	Inhibition	%	7.0	CHEMBL2431	Homo sapiens	INH	%	7.0
	13282448	CHEMBL2378502	Inhibition of AKT2 (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376144	=	Inhibition	%	6.0	CHEMBL2431	Homo sapiens	INH	%	6.0
	13282449	CHEMBL2378502	Inhibition of AKT2 (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3cn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376143	=	Inhibition	%	7.0	CHEMBL2431	Homo sapiens	INH	%	7.0
	13375948	CHEMBL2406108	Inhibition of AKT2 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	13416873	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Inhibition	%	85.0	CHEMBL2431	Homo sapiens	INH	%	85.0
	13416874	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=C(C1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1)N1CCOCC1		CHEMBL2420907	=	Inhibition	%	25.0	CHEMBL2431	Homo sapiens	INH	%	25.0
	13416875	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	CN(C)C(=O)C1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1		CHEMBL2420906	=	Inhibition	%	27.0	CHEMBL2431	Homo sapiens	INH	%	27.0
	13416876	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	CNC(=O)C1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1		CHEMBL2420905	=	Inhibition	%	41.0	CHEMBL2431	Homo sapiens	INH	%	41.0
	13416877	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	OCC1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1		CHEMBL2417586	=	Inhibition	%	38.0	CHEMBL2431	Homo sapiens	INH	%	38.0
	13416878	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=C(O)C1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1		CHEMBL2420904	=	Inhibition	%	17.0	CHEMBL2431	Homo sapiens	INH	%	17.0
	13416879	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	COC(=O)C1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1		CHEMBL2420903	=	Inhibition	%	19.0	CHEMBL2431	Homo sapiens	INH	%	19.0
	13416880	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(C2CCC3(CCN(c4ncnc5[nH]cnc45)CC3)NC2)cc1		CHEMBL2420902	=	Inhibition	%	41.0	CHEMBL2431	Homo sapiens	INH	%	41.0
	13416881	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCC3(CCN(c4ncnc5[nH]cnc45)CC3)NC2)cc1		CHEMBL2420901	=	Inhibition	%	36.0	CHEMBL2431	Homo sapiens	INH	%	36.0
	13416882	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420900	=	Inhibition	%	98.0	CHEMBL2431	Homo sapiens	INH	%	98.0
	13416883	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(C2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420899	=	Inhibition	%	89.0	CHEMBL2431	Homo sapiens	INH	%	89.0
	13416884	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCC2(CC1)CC(O)CCN2		CHEMBL2420898	=	Inhibition	%	13.0	CHEMBL2431	Homo sapiens	INH	%	13.0
	13416885	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	OC1CCNC2(CCN(c3ncnc4[nH]cnc34)CC2)C1		CHEMBL2420897	=	Inhibition	%	59.0	CHEMBL2431	Homo sapiens	INH	%	59.0
	13416886	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCC2(CCC(O)CN2)CC1		CHEMBL2420928	=	Inhibition	%	14.0	CHEMBL2431	Homo sapiens	INH	%	14.0
	13416887	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	OC1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1		CHEMBL2420927	=	Inhibition	%	59.0	CHEMBL2431	Homo sapiens	INH	%	59.0
	13416888	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCCOC3)CC2)c2nc[nH]c2n1		CHEMBL2420926	=	Inhibition	%	6.0	CHEMBL2431	Homo sapiens	INH	%	6.0
	13416889	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCCCO3)CC2)c2nc[nH]c2n1		CHEMBL2420925	=	Inhibition	%	10.0	CHEMBL2431	Homo sapiens	INH	%	10.0
	13416890	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCCCC3)CC2)c2nc[nH]c2n1		CHEMBL2420924	=	Inhibition	%	6.0	CHEMBL2431	Homo sapiens	INH	%	6.0
	13416891	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCCC12CCNCC2		CHEMBL2420923	=	Inhibition	%	13.0	CHEMBL2431	Homo sapiens	INH	%	13.0
	13416892	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCCC2(CCCNC2)C1		CHEMBL2420922	=	Inhibition	%	12.0	CHEMBL2431	Homo sapiens	INH	%	12.0
	13416893	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCCC2(CCNCC2)C1		CHEMBL2420921	=	Inhibition	%	17.0	CHEMBL2431	Homo sapiens	INH	%	17.0
	13416894	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCC2(CCNC2)CC1		CHEMBL2420920	=	Inhibition	%	17.0	CHEMBL2431	Homo sapiens	INH	%	17.0
	13416895	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCC2(CCCNC2)CC1		CHEMBL2420919	=	Inhibition	%	14.0	CHEMBL2431	Homo sapiens	INH	%	14.0
	13416896	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCC2(CCCN2)CC1		CHEMBL2420918	=	Inhibition	%	11.0	CHEMBL2431	Homo sapiens	INH	%	11.0
	13416897	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCC2(CCCCN2)CC1		CHEMBL2420917	=	Inhibition	%	10.0	CHEMBL2431	Homo sapiens	INH	%	10.0
	13416898	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	NC1(Cc2ccccc2)CCN(S(=O)(=O)c2cccc3cnccc23)CC1		CHEMBL2420916	=	Inhibition	%	13.0	CHEMBL2431	Homo sapiens	INH	%	13.0
	13416899	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCCC23CCNCC3)c2nc[nH]c2n1		CHEMBL2420915	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	13416900	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCCC3(CCCNC3)C2)c2nc[nH]c2n1		CHEMBL2420914	=	Inhibition	%	37.0	CHEMBL2431	Homo sapiens	INH	%	37.0
	13416901	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCCC3(CCNCC3)C2)c2nc[nH]c2n1		CHEMBL2420913	=	Inhibition	%	26.0	CHEMBL2431	Homo sapiens	INH	%	26.0
	13416902	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCNC3)CC2)c2nc[nH]c2n1		CHEMBL2420912	=	Inhibition	%	70.0	CHEMBL2431	Homo sapiens	INH	%	70.0
	13416903	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCCNC3)CC2)c2nc[nH]c2n1		CHEMBL2420911	=	Inhibition	%	87.0	CHEMBL2431	Homo sapiens	INH	%	87.0
	13416904	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCCN3)CC2)c2nc[nH]c2n1		CHEMBL2420910	=	Inhibition	%	72.0	CHEMBL2431	Homo sapiens	INH	%	72.0
	13416905	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCCCN3)CC2)c2nc[nH]c2n1		CHEMBL2420909	=	Inhibition	%	57.0	CHEMBL2431	Homo sapiens	INH	%	57.0
	13416906	CHEMBL2424336	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	NC1(Cc2ccccc2)CCN(c2ncnc3[nH]cnc23)CC1		CHEMBL2420908	=	Inhibition	%	74.0	CHEMBL2431	Homo sapiens	INH	%	74.0
	13421001	CHEMBL2424129	Inhibition of AKT2 (unknown origin) by microfluidic mobility shift assay	B	c1nc(N2CCC3(CCCNC3)CC2)c2nc[nH]c2n1		CHEMBL2420911	=	IC50	nM	9500.0	CHEMBL2431	Homo sapiens	IC50	uM	9.5
	13421002	CHEMBL2424129	Inhibition of AKT2 (unknown origin) by microfluidic mobility shift assay	B	c1nc(N2CCC3(CCCCN3)CC2)c2nc[nH]c2n1		CHEMBL2420909	=	IC50	nM	66000.0	CHEMBL2431	Homo sapiens	IC50	uM	66.0
	13439901	CHEMBL2428330	Competitive binding affinity to AKT2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	13440838	CHEMBL2429581	Inhibition of PKB-beta (unknown origin) at 1 uM by [33P]-ATP filter-binding assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc4c(N)ncnc43)cc2)cc1		CHEMBL2425144	=	Inhibition	%	-7.0	CHEMBL2431	Homo sapiens	INH	%	-7.0
	13445407	CHEMBL2428330	Competitive binding affinity to AKT2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	13448466	CHEMBL2428330	Competitive binding affinity to AKT2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	13451721	CHEMBL2428330	Competitive binding affinity to AKT2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	13453016	CHEMBL2429581	Inhibition of PKB-beta (unknown origin) at 1 uM by [33P]-ATP filter-binding assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cccnc3)cc2)cc1	Outside typical range	CHEMBL2425156	=	Inhibition	%	-38.0	CHEMBL2431	Homo sapiens	INH	%	-38.0
	13453064	CHEMBL2429581	Inhibition of PKB-beta (unknown origin) at 1 uM by [33P]-ATP filter-binding assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(C)c3)cc2)cc1	Outside typical range	CHEMBL2425145	=	Inhibition	%	-28.0	CHEMBL2431	Homo sapiens	INH	%	-28.0
	13464323	CHEMBL2433452	Inhibition of human PKBbeta assessed as residual activity at 1 uM relative to control	B	CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12		CHEMBL407002	=	Activity	%	94.0	CHEMBL2431	Homo sapiens	Activity	%	94.0
	13464350	CHEMBL2433484	Inhibition of human PKBbeta assessed as residual activity at 10 uM relative to control	B	CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12		CHEMBL407002	=	Activity	%	91.0	CHEMBL2431	Homo sapiens	Activity	%	91.0
	13465294	CHEMBL2433265	Inhibition of human PKBbeta assessed as residual activity at 25 uM relative to control	B	COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1		CHEMBL576349	=	Activity	%	90.0	CHEMBL2431	Homo sapiens	Activity	%	90.0
	13465317	CHEMBL2433484	Inhibition of human PKBbeta assessed as residual activity at 10 uM relative to control	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Activity	%	88.0	CHEMBL2431	Homo sapiens	Activity	%	88.0
	13465343	CHEMBL2433452	Inhibition of human PKBbeta assessed as residual activity at 1 uM relative to control	B	CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1		CHEMBL2430324	=	Activity	%	89.67	CHEMBL2431	Homo sapiens	Activity	%	89.67
	13465374	CHEMBL2433484	Inhibition of human PKBbeta assessed as residual activity at 10 uM relative to control	B	CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1		CHEMBL2430324	=	Activity	%	84.04	CHEMBL2431	Homo sapiens	Activity	%	84.04
	13465405	CHEMBL2433452	Inhibition of human PKBbeta assessed as residual activity at 1 uM relative to control	B	CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1		CHEMBL2430323	=	Activity	%	94.57	CHEMBL2431	Homo sapiens	Activity	%	94.57
	13465436	CHEMBL2433484	Inhibition of human PKBbeta assessed as residual activity at 10 uM relative to control	B	CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1		CHEMBL2430323	=	Activity	%	94.01	CHEMBL2431	Homo sapiens	Activity	%	94.01
Not Active	13475288	CHEMBL2439112	Inhibition of human wild type AKT2 at 1 uM by qPCR analysis	B	CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1		CHEMBL2436978		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	13508491	CHEMBL2447364	Inhibition of AKT2 (unknown origin) at 30 uM	B	O=C(Nc1ccc2c(c1)B(O)OC2)c1c(C(F)(F)F)ccc(Cl)c1F		CHEMBL2441375		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	13871782	CHEMBL3101243	Inhibition of human PKBbeta assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	87.0	CHEMBL2431	Homo sapiens	Activity	%	87.0
	13953278	CHEMBL3130712	Inhibition of human PKBbeta assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125727	=	Activity	%	98.0	CHEMBL2431	Homo sapiens	Activity	%	98.0
	13953316	CHEMBL3130712	Inhibition of human PKBbeta assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125728	=	Activity	%	93.0	CHEMBL2431	Homo sapiens	Activity	%	93.0
	13953342	CHEMBL3130712	Inhibition of human PKBbeta assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125726	=	Activity	%	90.0	CHEMBL2431	Homo sapiens	Activity	%	90.0
Not Active	13973391	CHEMBL3134655	Inhibition of AKT2 (unknown origin)using GSK3 (14 to 27) as substrate after 60 mins by scintillation counting	B	Oc1cccc(Nc2ccnc3[nH]c4ccccc4c23)c1		CHEMBL3133821		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	14582431	CHEMBL3240214	Inhibition of human AKT2 assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	153.5	CHEMBL2431	Homo sapiens	Activity	%	153.5
	14593772	CHEMBL3241188	Inhibition of human AKT2	B	Oc1cccc(Nc2ccnc3[nH]c4ccccc4c23)c1		CHEMBL3133821	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	14648062	CHEMBL3266632	Inhibition of human PKB-beta at 1 uM relative to control	B	CC(C)CCNc1ccc(-c2cnc3ccc(NC4CCN(C)CC4)nn23)cn1		CHEMBL2380687	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	14648063	CHEMBL3266632	Inhibition of human PKB-beta at 1 uM relative to control	B	N[C@H]1CC[C@H](Nc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1		CHEMBL3264059	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	14663199	CHEMBL3268842	Inhibition of AKT2 (unknown origin) at 1 uM relative to control	B	CCOC(=O)c1sc(-c2ccncc2)nc1O		CHEMBL3261228	=	Inhibition	%	96.0	CHEMBL2431	Homo sapiens	INH	%	96.0
	14663200	CHEMBL3268842	Inhibition of AKT2 (unknown origin) at 1 uM relative to control	B	NC(=O)c1sc(-c2ccnc(N)n2)nc1-c1ccc(Cl)cc1Cl		CHEMBL3261514	=	Inhibition	%	100.0	CHEMBL2431	Homo sapiens	INH	%	100.0
	14663201	CHEMBL3268842	Inhibition of AKT2 (unknown origin) at 1 uM relative to control	B	COc1ccc(-c2nc(-c3ccnc(N)n3)sc2C(N)=O)c(Cl)c1		CHEMBL3261517	=	Inhibition	%	100.0	CHEMBL2431	Homo sapiens	INH	%	100.0
	15014100	CHEMBL3361855	Inhibition of AKT2 (unknown origin) at 100 nM	B	O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1		CHEMBL3298678	=	Inhibition	%	5.6	CHEMBL2431	Homo sapiens	INH	%	5.6
	15037096	CHEMBL3368322	Inhibition of AKT2 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2cnc3[nH]cc(-c4ccc(OC)c(OC)c4)c3c2)cc1OC		CHEMBL3102948	=	Inhibition	%	100.0	CHEMBL2431	Homo sapiens	INH	%	100.0
	15037097	CHEMBL3368322	Inhibition of AKT2 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1cc(-c2c[nH]c3ncc(-c4cccc(N)c4)cc23)cc(OC)c1OC		CHEMBL3319457	=	Inhibition	%	100.0	CHEMBL2431	Homo sapiens	INH	%	100.0
	15037098	CHEMBL3368322	Inhibition of AKT2 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2c[nH]c3ncc(-c4ccc(C(=O)N5CCOCC5)c(N)c4)cc23)cc1OC		CHEMBL3319467	=	Inhibition	%	97.0	CHEMBL2431	Homo sapiens	INH	%	97.0
	15037099	CHEMBL3368322	Inhibition of AKT2 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2c[nH]c3ncc(-c4cc(OC)c(OC)c(OC)c4)cc23)cc1OC		CHEMBL3319468	=	Inhibition	%	100.0	CHEMBL2431	Homo sapiens	INH	%	100.0
	15037100	CHEMBL3368322	Inhibition of AKT2 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2cnc3[nH]cc(-c4ccc(OC)c(OC)c4)c3c2)cc1N		CHEMBL3319470	=	Inhibition	%	100.0	CHEMBL2431	Homo sapiens	INH	%	100.0
Not Active	15062578	CHEMBL3370291	Inhibition of human AKT2 by Off-chip mobility shift assay	B	O=C(Cc1c(F)cccc1Cl)Nc1onc(-c2ccc(F)cc2)c1-c1ccncn1		CHEMBL3310142		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	15072479	CHEMBL3380095	Inhibition of PKBbeta (unknown origin) assessed as remaining enzyme activity at 10 uM by radioactive [33P]-ATP filter binding assay	B	Cc1ccc(-c2cc(C(=O)Nc3ccnc(Cl)c3)nn2-c2ccc3ccccc3n2)cc1		CHEMBL3338802	=	Activity	%	83.0	CHEMBL2431	Homo sapiens	Activity	%	83.0
	15080992	CHEMBL3384752	Inhibition of Akt2 (unknown origin)	B	CC(C)(N)c1ccc(-c2nc3ccccc3nc2-c2ccccc2)cc1		CHEMBL362455	=	IC50	nM	23000.0	CHEMBL2431	Homo sapiens	IC50	uM	23.0
	15080993	CHEMBL3384753	Inhibition of Akt2 PH domain (unknown origin)	B	CC(C)(N)c1ccc(-c2nc3ccccc3nc2-c2ccccc2)cc1	Outside typical range	CHEMBL362455	>	IC50	nM	250000.0	CHEMBL2431	Homo sapiens	IC50	uM	250.0
	15107866	CHEMBL3385204	Inhibition of wild type AKT2 (unknown origin) incubated for 5 mins by HTRF assay	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C		CHEMBL3357634	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	nM	10000.0
	15190947	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1NC(=S)Nc1ccccc1		CHEMBL3408381	=	Inhibition	%	10.0	CHEMBL2431	Homo sapiens	INH	%	10.0
	15190948	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=c1\sc(-c2ccccc2)nn1-c1ccccc1		CHEMBL3408382	=	Inhibition	%	2.0	CHEMBL2431	Homo sapiens	INH	%	2.0
	15190949	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CC(=O)c1nn(-c2ccccc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1		CHEMBL3408383	=	Inhibition	%	12.0	CHEMBL2431	Homo sapiens	INH	%	12.0
	15190950	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CC(=O)c1nn(-c2ccc(C)cc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1		CHEMBL3408384	=	Inhibition	%	15.0	CHEMBL2431	Homo sapiens	INH	%	15.0
	15190951	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	COc1ccc(-n2nc(C(C)=O)s/c2=N\c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)cc1		CHEMBL3408385	=	Inhibition	%	26.0	CHEMBL2431	Homo sapiens	INH	%	26.0
	15190952	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CC(=O)c1nn(-c2ccc(Cl)cc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1		CHEMBL3408386	=	Inhibition	%	37.0	CHEMBL2431	Homo sapiens	INH	%	37.0
	15190953	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CCOC(=O)c1nn(-c2ccccc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1		CHEMBL3408387	=	Inhibition	%	56.0	CHEMBL2431	Homo sapiens	INH	%	56.0
	15190954	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CCOC(=O)c1nn(-c2ccc(C)cc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1		CHEMBL3408388	=	Inhibition	%	54.0	CHEMBL2431	Homo sapiens	INH	%	54.0
	15190955	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CCOC(=O)c1nn(-c2ccc(Cl)cc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1		CHEMBL3408389	=	Inhibition	%	43.0	CHEMBL2431	Homo sapiens	INH	%	43.0
	15190956	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=c1\sc(C(=O)Nc2ccccc2)nn1-c1ccccc1		CHEMBL3408390	=	Inhibition	%	21.0	CHEMBL2431	Homo sapiens	INH	%	21.0
	15190957	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=C1\SCC(=O)N1c1ccccc1		CHEMBL3408391	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	15190958	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=c1\scc(-c2ccccc2)n1-c1ccccc1		CHEMBL3408392	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	15190959	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=C1\S/C(=C2\SC(c3ccccc3)=NN2c2ccccc2)C(=O)N1c1ccccc1		CHEMBL3408393	=	Inhibition	%	15.0	CHEMBL2431	Homo sapiens	INH	%	15.0
	15190960	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CC(=O)C1=NN(c2ccccc2)/C(=C2/S/C(=N\c3nc(-c4ccccc4)cc(-c4ccccc4)c3C#N)N(c3ccccc3)C2=O)S1		CHEMBL3408394	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	15190961	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CCOC(=O)C1=NN(c2ccccc2)/C(=C2/S/C(=N\c3nc(-c4ccccc4)cc(-c4ccccc4)c3C#N)N(c3ccccc3)C2=O)S1		CHEMBL3408395	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	15190962	CHEMBL3412789	Inhibition of AKT2 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=C1\S/C(=C2\SC(C(=O)Nc3ccccc3)=NN2c2ccccc2)C(=O)N1c1ccccc1		CHEMBL3408396	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	15251882	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL443738	=	Activity	%	14.0	CHEMBL2431	Homo sapiens	Activity	%	14.0
	15251915	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427170	=	Activity	%	49.0	CHEMBL2431	Homo sapiens	Activity	%	49.0
	15252017	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427171	=	Activity	%	79.0	CHEMBL2431	Homo sapiens	Activity	%	79.0
	15252662	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427172	=	Activity	%	46.0	CHEMBL2431	Homo sapiens	Activity	%	46.0
	15252764	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)CS3)sc2c1		CHEMBL3427173	=	Activity	%	26.0	CHEMBL2431	Homo sapiens	Activity	%	26.0
	15252866	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)CS3)sc2c1		CHEMBL3427174	=	Activity	%	29.0	CHEMBL2431	Homo sapiens	Activity	%	29.0
	15253200	CHEMBL3430057	Inhibition of human PKBbeta	B	CCn1nc(C#Cc2cc(C(=O)Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)ccc2C)c2c(N)ncnc21		CHEMBL3426225	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	15253540	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427175	=	Activity	%	61.0	CHEMBL2431	Homo sapiens	Activity	%	61.0
	15253642	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427176	=	Activity	%	73.0	CHEMBL2431	Homo sapiens	Activity	%	73.0
	15253744	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427177	=	Activity	%	62.0	CHEMBL2431	Homo sapiens	Activity	%	62.0
	15254410	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427178	=	Activity	%	14.0	CHEMBL2431	Homo sapiens	Activity	%	14.0
	15254512	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@H]1C(=O)O		CHEMBL3427179	=	Activity	%	67.0	CHEMBL2431	Homo sapiens	Activity	%	67.0
	15254614	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@@H]1C(=O)O		CHEMBL3427180	=	Activity	%	44.0	CHEMBL2431	Homo sapiens	Activity	%	44.0
	15255305	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427181	=	Activity	%	86.0	CHEMBL2431	Homo sapiens	Activity	%	86.0
	15255407	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427182	=	Activity	%	85.0	CHEMBL2431	Homo sapiens	Activity	%	85.0
	15255510	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427183	=	Activity	%	103.0	CHEMBL2431	Homo sapiens	Activity	%	103.0
	15256241	CHEMBL3427820	Inhibition of PKBbeta (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427184	=	Activity	%	80.0	CHEMBL2431	Homo sapiens	Activity	%	80.0
	15654940	CHEMBL3599520	Inhibition of PKBbeta (unknown origin) at 0.5 uM relative to control	B	Nc1nccc(-c2c[nH]c3ccccc23)n1		CHEMBL48082	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	15654941	CHEMBL3599520	Inhibition of PKBbeta (unknown origin) at 0.5 uM relative to control	B	Nc1nccc(-c2cn(C(=O)N3CCOCC3)c3ccc(Br)cc23)n1		CHEMBL3133762	=	Inhibition	%	12.6	CHEMBL2431	Homo sapiens	INH	%	12.6
	15654942	CHEMBL3599520	Inhibition of PKBbeta (unknown origin) at 0.5 uM relative to control	B	Cc1noc(C)c1Cn1cc(-c2ccnc(N)n2)c2ccccc21		CHEMBL3133770	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	15665855	CHEMBL3602851	Inhibition of recombinant AKT2 (unknown origin) at 1 uM after 3 hrs	B	CS(=O)(=O)NCc1ccc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nn12		CHEMBL3601472	=	Inhibition	%	-1.0	CHEMBL2431	Homo sapiens	INH	%	-1.0
	15756118	CHEMBL3631610	Inhibition of AKT2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	21.57	CHEMBL2431	Homo sapiens	INH	%	21.57
	15757713	CHEMBL3631610	Inhibition of AKT2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	20.55	CHEMBL2431	Homo sapiens	INH	%	20.55
	15757981	CHEMBL3631610	Inhibition of AKT2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	18.94	CHEMBL2431	Homo sapiens	INH	%	18.94
256529	16260655	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccsc3)COc3cccc(F)c3-4)cc2)C1		CHEMBL3701722	=	IC50	nM	0.91	CHEMBL2431	Homo sapiens	IC50	nM	0.91
256547	16261119	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCOc1cccc2c1-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701739	=	IC50	nM	1.8	CHEMBL2431	Homo sapiens	IC50	nM	1.8
256554	16261523	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccncc3-4)cc2)C1		CHEMBL3701746	=	IC50	nM	0.78	CHEMBL2431	Homo sapiens	IC50	nM	0.78
256528	16262236	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccncc3)COc3cccc(F)c3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701721	=	IC50	nM	0.91	CHEMBL2431	Homo sapiens	IC50	nM	0.91
256565	16262358	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3nccnc3-4)cc2)C1		CHEMBL3701756	=	IC50	nM	4.0	CHEMBL2431	Homo sapiens	IC50	nM	4.0
256587	16264785	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(O)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cc(C(=O)O)ccc3-4)cc2)C1		CHEMBL3701778	=	IC50	nM	0.94	CHEMBL2431	Homo sapiens	IC50	nM	0.94
256585	16267064	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cc(C(N)=O)ccc3-4)cc2)C1		CHEMBL3701776	=	IC50	nM	0.4	CHEMBL2431	Homo sapiens	IC50	nM	0.4
256532	16269529	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cc(F)ccc3-4)cc2)C1		CHEMBL3701725	=	IC50	nM	2.0	CHEMBL2431	Homo sapiens	IC50	nM	2.0
256577	16272715	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CN(C)C(=O)c1ccc2c(c1)-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701768	=	IC50	nM	1.3	CHEMBL2431	Homo sapiens	IC50	nM	1.3
256538	16274266	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccncc3)COc3ccccc3-4)cc2)CCC1		CHEMBL3701731	=	IC50	nM	6.5	CHEMBL2431	Homo sapiens	IC50	nM	6.5
256544	16274540	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1ccc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(C)(O)C3)cc2)c1-c1ccccc1		CHEMBL3701736	=	IC50	nM	0.91	CHEMBL2431	Homo sapiens	IC50	nM	0.91
256570	16274653	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(C#N)cc3-4)cc2)C1		CHEMBL3701761	=	IC50	nM	0.97	CHEMBL2431	Homo sapiens	IC50	nM	0.97
256583	16275217	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(C(=O)NCCO)cc3-4)cc2)C1		CHEMBL3701774	=	IC50	nM	0.57	CHEMBL2431	Homo sapiens	IC50	nM	0.57
256549	16277397	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	Cc1ccc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(O)(C4CC4)C3)cc2)c1-c1ccccc1		CHEMBL3701741	=	IC50	nM	1.5	CHEMBL2431	Homo sapiens	IC50	nM	1.5
256553	16278949	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccnc3-4)cc2)C1		CHEMBL3701745	=	IC50	nM	4.6	CHEMBL2431	Homo sapiens	IC50	nM	4.6
256542	16279221	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1cccc2c1-c1nc(-c3ccc(C4(N)CC(O)(C5CC5)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701732	=	IC50	nM	2.0	CHEMBL2431	Homo sapiens	IC50	nM	2.0
219809	16281236	CHEMBL3707653	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	N=C(c1ccccc1)n1c(=N)ccc2nc(-c3ccc(C4(N)CC(F)(F)C4)cc3)c(-c3ccccc3)cc21		CHEMBL3679631	=	IC50	nM	140.0	CHEMBL2431	Homo sapiens	IC50	nM	140.0
256572	16288218	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(-c5cn[nH]c5)cc3-4)cc2)C1		CHEMBL3701763	=	IC50	nM	0.42	CHEMBL2431	Homo sapiens	IC50	nM	0.42
219806	16291736	CHEMBL3707653	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	N=C(c1ccccc1)n1c(=N)ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)cc21		CHEMBL3679633	=	IC50	nM	32.0	CHEMBL2431	Homo sapiens	IC50	nM	32.0
256546	16291973	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCOc1cccc2c1-c1nc(-c3ccc(C4(N)CC(O)(C5CC5)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701738	=	IC50	nM	1.7	CHEMBL2431	Homo sapiens	IC50	nM	1.7
256571	16293914	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(-c5ccn[nH]5)cc3-4)cc2)C1		CHEMBL3701762	=	IC50	nM	0.32	CHEMBL2431	Homo sapiens	IC50	nM	0.32
256555	16294749	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccncc3-4)cc2)C1		CHEMBL3701747	=	IC50	nM	1.1	CHEMBL2431	Homo sapiens	IC50	nM	1.1
256561	16295474	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ncccc3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701752	=	IC50	nM	0.91	CHEMBL2431	Homo sapiens	IC50	nM	0.91
256552	16296182	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccnc3-4)cc2)CCC1		CHEMBL3701744	=	IC50	nM	4.0	CHEMBL2431	Homo sapiens	IC50	nM	4.0
256533	16297581	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3c(F)cccc3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701726	=	IC50	nM	1.4	CHEMBL2431	Homo sapiens	IC50	nM	1.4
256573	16301208	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	Cc1cnc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(C)(O)C3)cc2)c1-c1ccccc1		CHEMBL3701764	=	IC50	nM	0.85	CHEMBL2431	Homo sapiens	IC50	nM	0.85
256536	16301644	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccccc3-4)cc2)CCC1		CHEMBL3701729	=	IC50	nM	2.8	CHEMBL2431	Homo sapiens	IC50	nM	2.8
256525	16304526	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccc(F)c3-4)cc2)C1		CHEMBL3701718	=	IC50	nM	0.5	CHEMBL2431	Homo sapiens	IC50	nM	0.5
256541	16304618	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1ccc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(O)(C4CC4)C3)cc2)c1-c1ccccc1		CHEMBL3701734	=	IC50	nM	0.6	CHEMBL2431	Homo sapiens	IC50	nM	0.6
256574	16305404	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1ccc2c(n1)-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701765	=	IC50	nM	1.1	CHEMBL2431	Homo sapiens	IC50	nM	1.1
256581	16305854	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cc(C(=O)NCCO)ccc3-4)cc2)C1		CHEMBL3701772	=	IC50	nM	0.7	CHEMBL2431	Homo sapiens	IC50	nM	0.7
256586	16306714	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(O)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(C(=O)O)cc3-4)cc2)C1		CHEMBL3701777	=	IC50	nM	0.91	CHEMBL2431	Homo sapiens	IC50	nM	0.91
256531	16306759	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(F)cc3-4)cc2)C1		CHEMBL3701724	=	IC50	nM	1.0	CHEMBL2431	Homo sapiens	IC50	nM	1.0
256537	16307147	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccsc3)COc3ccccc3-4)cc2)CCC1		CHEMBL3701730	=	IC50	nM	5.4	CHEMBL2431	Homo sapiens	IC50	nM	5.4
256563	16310794	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ncccc3-4)cc2)CCC1		CHEMBL3701754	=	IC50	nM	1.6	CHEMBL2431	Homo sapiens	IC50	nM	1.6
256530	16311271	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccncc3)COc3cccc(F)c3-4)cc2)C1		CHEMBL3701723	=	IC50	nM	1.1	CHEMBL2431	Homo sapiens	IC50	nM	1.1
256582	16312129	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCONC(=O)c1ccc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(C)(O)C3)cc2)c1-c1ccccc1		CHEMBL3701773	=	IC50	nM	0.53	CHEMBL2431	Homo sapiens	IC50	nM	0.53
256556	16312149	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccncc3-4)cc2)CCC1		CHEMBL3701748	=	IC50	nM	1.7	CHEMBL2431	Homo sapiens	IC50	nM	1.7
256543	16315231	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1ccc2c(c1)-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701735	=	IC50	nM	0.75	CHEMBL2431	Homo sapiens	IC50	nM	0.75
256576	16315984	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(C(N)=O)cc3-4)cc2)C1		CHEMBL3701767	=	IC50	nM	0.26	CHEMBL2431	Homo sapiens	IC50	nM	0.26
256557	16316043	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccncc3-4)cc2)C1		CHEMBL3701746	=	IC50	nM	2.1	CHEMBL2431	Homo sapiens	IC50	nM	2.1
256578	16318775	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCNC(=O)c1ccc2c(c1)-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701769	=	IC50	nM	0.31	CHEMBL2431	Homo sapiens	IC50	nM	0.31
256568	16318881	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cc(CO)ccc3-4)cc2)C1		CHEMBL3701759	=	IC50	nM	2.7	CHEMBL2431	Homo sapiens	IC50	nM	2.7
256560	16322406	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cnccc3-4)cc2)CCC1		CHEMBL3701751	=	IC50	nM	1.1	CHEMBL2431	Homo sapiens	IC50	nM	1.1
256558	16326441	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cnccc3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701749	=	IC50	nM	0.48	CHEMBL2431	Homo sapiens	IC50	nM	0.48
219810	16330981	CHEMBL3707653	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	C[C@]1(O)C[C@@](N)(c2ccc(-c3nc4ccc5nnc(C(F)F)n5c4cc3-c3ccccc3)cc2)C1		CHEMBL3679632	=	IC50	nM	1.7	CHEMBL2431	Homo sapiens	IC50	nM	1.7
256524	16331281	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccc(F)c3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701717	=	IC50	nM	0.29	CHEMBL2431	Homo sapiens	IC50	nM	0.29
256580	16331368	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CN(C)C(=O)c1ccc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(C)(O)C3)cc2)c1-c1ccccc1		CHEMBL3701771	=	IC50	nM	3.5	CHEMBL2431	Homo sapiens	IC50	nM	3.5
256526	16334605	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccc(F)c3-4)cc2)CCC1		CHEMBL3701719	=	IC50	nM	1.2	CHEMBL2431	Homo sapiens	IC50	nM	1.2
256569	16335924	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cc(C#N)ccc3-4)cc2)C1		CHEMBL3701760	=	IC50	nM	1.2	CHEMBL2431	Homo sapiens	IC50	nM	1.2
256534	16337184	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccccc3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701727	=	IC50	nM	1.0	CHEMBL2431	Homo sapiens	IC50	nM	1.0
256562	16337781	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ncccc3-4)cc2)C1		CHEMBL3701753	=	IC50	nM	0.97	CHEMBL2431	Homo sapiens	IC50	nM	0.97
256550	16337886	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccnc3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701742	=	IC50	nM	1.6	CHEMBL2431	Homo sapiens	IC50	nM	1.6
219805	16340040	CHEMBL3707653	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	N=c1ccc2nc(-c3ccc(C4(NC(=O)Cc5cccnc5)CCC4)cc3)c(-c3ccccc3)cc2n1C(N)=O		CHEMBL3679634	=	IC50	nM	200.0	CHEMBL2431	Homo sapiens	IC50	nM	200.0
256545	16341831	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccc(Cl)c3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701737	=	IC50	nM	0.3	CHEMBL2431	Homo sapiens	IC50	nM	0.3
256564	16341989	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3nccnc3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701755	=	IC50	nM	3.3	CHEMBL2431	Homo sapiens	IC50	nM	3.3
256584	16343116	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCONC(=O)c1ccc2c(c1)-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701775	=	IC50	nM	0.4	CHEMBL2431	Homo sapiens	IC50	nM	0.4
256567	16344759	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(CO)cc3-4)cc2)C1		CHEMBL3701758	=	IC50	nM	0.55	CHEMBL2431	Homo sapiens	IC50	nM	0.55
256548	16345783	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1cc(OC)c2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(O)(C4CC4)C3)cc2)c1-c1ccccc1		CHEMBL3701740	=	IC50	nM	0.27	CHEMBL2431	Homo sapiens	IC50	nM	0.27
256551	16347513	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccnc3-4)cc2)C1		CHEMBL3701743	=	IC50	nM	2.0	CHEMBL2431	Homo sapiens	IC50	nM	2.0
256527	16347910	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccsc3)COc3cccc(F)c3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701720	=	IC50	nM	0.71	CHEMBL2431	Homo sapiens	IC50	nM	0.71
256575	16349458	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CNC(=O)c1ccc2c(c1)-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701766	=	IC50	nM	0.28	CHEMBL2431	Homo sapiens	IC50	nM	0.28
219807	16350696	CHEMBL3707653	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	N=C(N)n1c(=N)ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)cc21		CHEMBL3679629	=	IC50	nM	24.0	CHEMBL2431	Homo sapiens	IC50	nM	24.0
256540	16350781	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1ccc2c(c1)-c1nc(-c3ccc(C4(N)CC(O)(C5CC5)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701733	=	IC50	nM	5.1	CHEMBL2431	Homo sapiens	IC50	nM	5.1
219808	16351056	CHEMBL3707653	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	CC(=N)n1c(=N)ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)cc21		CHEMBL3679630	=	IC50	nM	50.0	CHEMBL2431	Homo sapiens	IC50	nM	50.0
256566	16351593	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3nccnc3-4)cc2)C1		CHEMBL3701757	=	IC50	nM	7.0	CHEMBL2431	Homo sapiens	IC50	nM	7.0
256579	16354042	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CNC(=O)c1ccc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(C)(O)C3)cc2)c1-c1ccccc1		CHEMBL3701770	=	IC50	nM	0.49	CHEMBL2431	Homo sapiens	IC50	nM	0.49
256535	16355249	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccccc3-4)cc2)C1		CHEMBL3701728	=	IC50	nM	1.7	CHEMBL2431	Homo sapiens	IC50	nM	1.7
256559	16356454	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cnccc3-4)cc2)C1		CHEMBL3701750	=	IC50	nM	0.74	CHEMBL2431	Homo sapiens	IC50	nM	0.74
256539	16356481	CHEMBL3708023	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1cccc2c1-c1nc(-c3ccc(C4(N)CC(O)(C5CC5)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701732	=	IC50	nM	0.35	CHEMBL2431	Homo sapiens	IC50	nM	0.35
	16376434	CHEMBL3734458	Inhibition of recombinant human AKT2 using fluorescein-labeled peptide as substrate by fluorescence-electrophoretic mobility shift assay	B	Cl.NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O		CHEMBL3732044	=	Inhibition	%	8.0	CHEMBL2431	Homo sapiens	INH	%	8.0
	16397302	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1c(C(=O)c2coc3c2cc(O)c2ccccc23)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3740492	=	Inhibition	%	56.0	CHEMBL2431	Homo sapiens	INH	%	56.0
	16397303	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1c(C(=O)c2coc3ccc(O)cc23)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3741960	=	Inhibition	%	32.0	CHEMBL2431	Homo sapiens	INH	%	32.0
	16397304	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1-c1ccc(NC(=O)c2ccccc2)c(=O)o1		CHEMBL3740003	=	Inhibition	%	45.0	CHEMBL2431	Homo sapiens	INH	%	45.0
	16397305	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Oc1nnc(-c2c[nH]c(-c3ccccc3)c2-c2ccccc2)c2cn(-c3ccc(Cl)cc3)nc12		CHEMBL3742200	=	Inhibition	%	58.0	CHEMBL2431	Homo sapiens	INH	%	58.0
	16397306	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1ccc(-n2cc3c(-c4c[nH]c(-c5ccccc5)c4-c4ccccc4)nnc(O)c3n2)cc1		CHEMBL3739586	=	Inhibition	%	44.0	CHEMBL2431	Homo sapiens	INH	%	44.0
	16397307	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Oc1nnc(-c2c[nH]c(-c3ccccc3)c2-c2ccccc2)c2cn(-c3ccccc3)nc12		CHEMBL3740923	=	Inhibition	%	56.0	CHEMBL2431	Homo sapiens	INH	%	56.0
	16397308	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1-c1nnc(C)c2nn(-c3ccc(Cl)cc3)cc12		CHEMBL3741655	=	Inhibition	%	35.0	CHEMBL2431	Homo sapiens	INH	%	35.0
	16397309	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1ccc(-n2cc3c(-c4c(C)[nH]c(-c5ccccc5)c4-c4ccccc4)nnc(C)c3n2)cc1		CHEMBL3742060	=	Inhibition	%	32.0	CHEMBL2431	Homo sapiens	INH	%	32.0
	16397310	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1-c1nnc(C)c2nn(-c3ccccc3)cc12		CHEMBL3740582	=	Inhibition	%	21.0	CHEMBL2431	Homo sapiens	INH	%	21.0
	16397311	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1C(=O)c1cn(-c2ccccc2)nc1-c1ccccc1		CHEMBL3741069	=	Inhibition	%	32.0	CHEMBL2431	Homo sapiens	INH	%	32.0
	16397312	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1C(=O)c1cn(-c2ccc(Cl)cc2)nc1C(=O)Nc1ccccc1		CHEMBL3740385	=	Inhibition	%	69.0	CHEMBL2431	Homo sapiens	INH	%	69.0
	16397313	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1ccc(-n2cc(C(=O)c3c(C)[nH]c(-c4ccccc4)c3-c3ccccc3)c(C(=O)Nc3ccccc3)n2)cc1		CHEMBL3740713	=	Inhibition	%	44.0	CHEMBL2431	Homo sapiens	INH	%	44.0
	16397314	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1C(=O)c1cn(-c2ccccc2)nc1C(=O)Nc1ccccc1		CHEMBL3740930	=	Inhibition	%	86.0	CHEMBL2431	Homo sapiens	INH	%	86.0
	16397315	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	CCOC(=O)c1nn(-c2ccc(Cl)cc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3741526	=	Inhibition	%	8.0	CHEMBL2431	Homo sapiens	INH	%	8.0
	16397316	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	CCOC(=O)c1nn(-c2ccc(C)cc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3742349	=	Inhibition	%	34.0	CHEMBL2431	Homo sapiens	INH	%	34.0
	16397317	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	CCOC(=O)c1nn(-c2ccccc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3740131	=	Inhibition	%	36.0	CHEMBL2431	Homo sapiens	INH	%	36.0
	16397318	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	CC(=O)c1nn(-c2ccc(Cl)cc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3739587	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	16397319	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	CC(=O)c1nn(-c2ccc(C)cc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3740247	=	Inhibition	%	2.0	CHEMBL2431	Homo sapiens	INH	%	2.0
	16397320	CHEMBL3743111	Inhibition of AKT2 (unknown origin) at 30 uM by microfluidic assay relative to control	B	CC(=O)c1nn(-c2ccccc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3739750	=	Inhibition	%	3.0	CHEMBL2431	Homo sapiens	INH	%	3.0
	16413403	CHEMBL3743741	Inhibition of AKT2 (unknown origin)	B	O=C(O)C1CN(Cc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2)C1		CHEMBL3741589	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	16425279	CHEMBL3751105	Inhibition of AKT2 (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	-0.3	CHEMBL2431	Homo sapiens	INH	%	-0.3
	16431724	CHEMBL3749732	Inhibition of human AKT2 using [KGSGSGRPRTSSFAEG] as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	16450757	CHEMBL3762143	Inhibition of AKT2 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	8.8	CHEMBL2431	Homo sapiens	INH	%	8.8
Active	16460528	CHEMBL3760245	Inhibition of AKT2 phosphorylation in human HuH7 cells at 1 to 10 uM after 24 hrs by immunoblot analysis	B	CN(C)CCCNC(=O)c1cccc2nc3c(nc12)-c1ccccc1/C3=N\OCCCN(C)C.Cl		CHEMBL3759822		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	16485698	CHEMBL3773979	Inhibition of human recombinant AKT2 assessed as residual activity at 10 uM after 1 hr by qPCR analysis relative to control	B	Cc1c(Cl)cccc1NC(=O)c1sc2nc3c(cc2c1N)C(=O)CC3		CHEMBL3771285	=	Activity	%	72.0	CHEMBL2431	Homo sapiens	Activity	%	72.0
	16495181	CHEMBL3777509	Inhibition of human PKBbeta assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	-5.0	CHEMBL2431	Homo sapiens	Activity	%	-5.0
	16496100	CHEMBL3777509	Inhibition of human PKBbeta assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	-8.0	CHEMBL2431	Homo sapiens	Activity	%	-8.0
	16508287	CHEMBL3777509	Inhibition of human PKBbeta assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	-4.0	CHEMBL2431	Homo sapiens	Activity	%	-4.0
Not Active	16514097	CHEMBL3782145	Inhibition of partial length human AKT2 expressed in bacterial system at 1 uM	B	Cc1cnc(N)nc1OCC(C)(C)CO		CHEMBL3780032		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	16518657	CHEMBL3782582	Inhibition of human wild type partial length Akt2 expressed in bacterial system at 10 uM	B	CCOC(=O)c1cc2c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc3ccccc3n2c1-c1ccccc1		CHEMBL3781272	=	Inhibition	%	35.0	CHEMBL2431	Homo sapiens	INH	%	35.0
	16518658	CHEMBL3782582	Inhibition of human wild type partial length Akt2 expressed in bacterial system at 10 uM	B	CCOC(=O)c1cn2c(c(-c3ccc(CN4CCC(c5nc6ccc(F)cc6[nH]5)CC4)cc3)nc3ccccc32)c1-c1ccccc1		CHEMBL3780332	=	Inhibition	%	38.0	CHEMBL2431	Homo sapiens	INH	%	38.0
	16518660	CHEMBL3782580	Inhibition of Akt2 (unknown origin)	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	10.0	CHEMBL2431	Homo sapiens	IC50	nM	10.0
	16578376	CHEMBL3802248	Inhibition of partial length wild type human AKT2 expressed in bacterial system assessed as enzyme activity at 1 uM relative to control	B	CN(C)S(=O)(=O)Nc1ccc(F)c(Nc2ncccc2-c2ncnc3[nH]cnc23)c1F		CHEMBL3798256	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	16589173	CHEMBL3807597	Inhibition of Akt2 (unknown origin) at 0.5 uM by mobility shift assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)oc1Cl		CHEMBL3805228	=	Inhibition	%	98.6	CHEMBL2431	Homo sapiens	INH	%	98.6
	16589702	CHEMBL3807614	Inhibition of Akt2 (unknown origin) by mobility shift assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	16.0	CHEMBL2431	Homo sapiens	IC50	nM	16.0
	16593471	CHEMBL3812154	Inhibition of full length His-tagged human recombinant AKT2 expressed in baculovirus using Fluorescein-Crosstide as substrate at 100 nM	B	COC(=O)c1cc2cc(NCc3cc(NC(=O)c4cc(-n5cnc(C)c5)cc(C(F)(F)F)c4)ccc3C)cnc2[nH]1		CHEMBL3808884	<	Inhibition	%	40.0	CHEMBL2431	Homo sapiens	INH	%	40.0
	16594916	CHEMBL3812223	Inhibition of human Akt2 expressed in bacterial system assessed as enzyme activity at 10 uM by KINOMEScan assay	B	O=C1C2=C(C(=O)c3c(O)ccc(O)c31)[C@@H](O)[C@@H](O)[C@@H](O)C2		CHEMBL1987813	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	16595524	CHEMBL3811146	Inhibition of recombinant human N-terminal His6-tagged PKBbeta (120 to 481 residues) expressed in baculovirus infected Sf21 cells assessed as residual activity at 300 uM in presence of radiolabelled ATP by radiometric assay relative to control	B	CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)C(C)C		CHEMBL3809381	=	Activity	%	96.0	CHEMBL2431	Homo sapiens	Activity	%	96.0
	16595530	CHEMBL3811140	Inhibition of recombinant human N-terminal His6-tagged PKBbeta (120 to 481 residues) expressed in baculovirus infected Sf21 cells assessed as residual activity at 30 uM in presence of radiolabelled ATP by radiometric assay relative to control	B	CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)C(C)C)[C@@H](C)CC		CHEMBL3808687	=	Activity	%	18.0	CHEMBL2431	Homo sapiens	Activity	%	18.0
	16612666	CHEMBL3815506	Inhibition of human PKBbeta (120 to 481 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL405665	=	Activity	%	-9.0	CHEMBL2431	Homo sapiens	Activity	%	-9.0
	16612667	CHEMBL3815506	Inhibition of human PKBbeta (120 to 481 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCCCc1cc(-c2c[nH]c3ncccc23)nc(N)n1		CHEMBL3814340	=	Activity	%	-3.0	CHEMBL2431	Homo sapiens	Activity	%	-3.0
	16612668	CHEMBL3815506	Inhibition of human PKBbeta (120 to 481 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1		CHEMBL3814140	=	Activity	%	3.0	CHEMBL2431	Homo sapiens	Activity	%	3.0
	16612669	CHEMBL3815506	Inhibition of human PKBbeta (120 to 481 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCCCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1		CHEMBL3815046	=	Activity	%	-21.0	CHEMBL2431	Homo sapiens	Activity	%	-21.0
	16613762	CHEMBL3816555	Inhibition of human AKT2 at 1 uM using [KGSGSGRPRTSSFAEG] as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	1.0	CHEMBL2431	Homo sapiens	INH	%	1.0
	16618283	CHEMBL3817002	Inhibition of full length recombinant human His-tagged AKT2 expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	16628519	CHEMBL3820635	Inhibition of human recombinant AKT2 S474D mutant (120 to 481 residues) expressed in insect Sf21 cells at 1 uM using GRPRTSSFAEGKK as substrate after 30 mins	B	O=C(Nc1cc(Nc2c(Cl)cnc3c2OCO3)ccn1)C1CC1		CHEMBL3818173	<	Inhibition	%	80.0	CHEMBL2431	Homo sapiens	INH	%	80.0
	16632172	CHEMBL3824674	Inhibition of AKT2 (unknown origin)	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	>	Ki	nM	10000.0	CHEMBL2431	Homo sapiens	Ki	nM	10000.0
	16641965	CHEMBL3826118	Inhibition of His-tagged full-length human AKT2 expressed in baculovirus system at 100 nM by Z-lyte assay	B	O=C(CNC(=O)c1cccn(Cc2ccc(F)c(F)c2)c1=O)Nc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL3824119	=	Inhibition	%	-4.0	CHEMBL2431	Homo sapiens	INH	%	-4.0
	16654172	CHEMBL3830963	Inhibition of human PKBbeta assessed as remaining enzyme activity at 50 uM after 30 mins by 33P-ATP filter-binding assay	B	Cc1cc(=O)c2c(O)cc(O)c([C@H]3CCN(C)C[C@H]3O)c2o1		CHEMBL1077604	=	Activity	%	80.0	CHEMBL2431	Homo sapiens	Activity	%	80.0
	16837423	CHEMBL3876094	Inhibition of human recombinant full length His-tagged AKT2beta expressed in baculovirus expression system	B	CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21		CHEMBL3884319	=	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	nM	10000.0
	16881169	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccccc2C(F)(F)F)sc1Cl		CHEMBL3892820	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881170	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Br)c1-c1cc(C(=O)N[C@H](CN)Cc2ccccc2C(F)(F)F)sc1Cl		CHEMBL3890070	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881171	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cc1cnn(C)c1-c1cc(C(=O)N[C@H](CN)Cc2ccccc2C(F)(F)F)sc1Cl		CHEMBL3952025	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881172	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1nccc1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL3942525	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881173	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	CCc1sc(C(=O)N[C@H](CN)Cc2cccc(F)c2)cc1-c1c(Cl)cnn1C		CHEMBL3907254	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881174	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccccc2C(F)(F)F)oc1Cl		CHEMBL3904492	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881175	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cc1cnn(C)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)oc1Cl		CHEMBL3968297	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881176	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cc1sc(C(=O)N[C@H](CN)Cc2cccc(F)c2)cc1-c1c(Cl)cnn1C		CHEMBL3965875	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881177	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Br)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL3926382	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881178	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Br)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(C(F)(F)F)c2)sc1Cl		CHEMBL3923631	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881179	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Br)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)cc2)sc1Cl		CHEMBL3905729	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881180	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	COc1sc(C(=O)N[C@H](CN)Cc2cccc(F)c2)cc1-c1c(Cl)cnn1C		CHEMBL3963487	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881181	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)sc1Cl		CHEMBL3953883	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881182	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1nccc1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3929383	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881183	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	CCn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)cc2)sc1Cl		CHEMBL3932335	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881184	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cc1cnn(C)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL3935057	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881185	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	CCn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)sc1Cl		CHEMBL3971992	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881186	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	CCn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3903718	>=	IC50	nM	31.62	CHEMBL2431	Homo sapiens	pIC50		7.5
	16881187	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	=	IC50	nM	10.0	CHEMBL2431	Homo sapiens	pIC50		8.0
	16881188	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)oc1Cl		CHEMBL3953878	=	IC50	nM	15.85	CHEMBL2431	Homo sapiens	pIC50		7.8
	16881189	CHEMBL3880965	Inhibition of full length human AKT2 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	=	IC50	nM	15.85	CHEMBL2431	Homo sapiens	pIC50		7.8
282814	17665159	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CC(c4nnc(-c5ccccn5)[nH]4)C3)cc2)cc1		CHEMBL3667041	<	IC50	nM	500.0	CHEMBL2431	Homo sapiens	IC50	nM	500.0
282815	17665160	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CC(c5nnc(-c6ccccn6)[nH]5)C4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3667042	=	IC50	nM	65.0	CHEMBL2431	Homo sapiens	IC50	nM	65.0
282816	17665161	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1cnc2nc(-c3ccc(CN4CC(c5nnc(-c6ccccn6)[nH]5)C4)cc3)c(-c3ccccc3)cn12		CHEMBL3667043	<	IC50	nM	50.0	CHEMBL2431	Homo sapiens	IC50	nM	50.0
282817	17665162	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Clc1cnc2nc(-c3ccc(CN4CC(c5nnc(-c6ccccn6)[nH]5)C4)cc3)c(-c3ccccc3)cn12		CHEMBL3667044	=	IC50	nM	11.0	CHEMBL2431	Homo sapiens	IC50	nM	11.0
282818	17665163	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4nc5ccncc5[nH]4)CC3)cc2)cc1		CHEMBL3667045	=	IC50	nM	1220.0	CHEMBL2431	Homo sapiens	IC50	nM	1220.0
282819	17665164	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4nc5cccnc5[nH]4)CC3)cc2)cc1		CHEMBL3672010	=	IC50	nM	607.0	CHEMBL2431	Homo sapiens	IC50	nM	607.0
282820	17665165	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	N#Cc1ccc2nc(C3CCN(Cc4ccc(-c5nc6nccn6cc5-c5ccccc5)cc4)CC3)[nH]c2c1		CHEMBL3672011	=	IC50	nM	426.0	CHEMBL2431	Homo sapiens	IC50	nM	426.0
282821	17665166	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4cnc5ccccc5n4)CC3)cc2)cc1		CHEMBL3672012	=	IC50	nM	9.0	CHEMBL2431	Homo sapiens	IC50	nM	9.0
282822	17665167	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	N#Cc1ccc2nc(C3CCN(Cc4ccc(-c5nc6ccnn6cc5-c5ccccc5)cc4)CC3)[nH]c2c1		CHEMBL3672013	=	IC50	nM	316.0	CHEMBL2431	Homo sapiens	IC50	nM	316.0
282823	17665168	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5nc6ccc(F)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672014	=	IC50	nM	228.0	CHEMBL2431	Homo sapiens	IC50	nM	228.0
282824	17665169	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5nc6ccncc6[nH]5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672015	=	IC50	nM	5840.0	CHEMBL2431	Homo sapiens	IC50	nM	5840.0
282825	17665170	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3nccc3nc2-c2ccc(CN3CCC(c4nc5cccnc5[nH]4)CC3)cc2)cc1		CHEMBL3672016	=	IC50	nM	1080.0	CHEMBL2431	Homo sapiens	IC50	nM	1080.0
282826	17665171	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	FC(F)(F)c1ccc2nc(C3CCN(Cc4ccc(-c5nc6ccnn6cc5-c5ccccc5)cc4)CC3)[nH]c2c1		CHEMBL3672017	>	IC50	nM	20000.0	CHEMBL2431	Homo sapiens	IC50	nM	20000.0
282827	17665172	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc2nc(C3CCN(Cc4ccc(-c5nc6ccnn6cc5-c5ccccc5)cc4)CC3)[nH]c2c1		CHEMBL3672018	=	IC50	nM	1090.0	CHEMBL2431	Homo sapiens	IC50	nM	1090.0
282828	17665173	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3nc4ccnn4cc3-c3ccccc3)cc2)CC1		CHEMBL3672019	=	IC50	nM	332.0	CHEMBL2431	Homo sapiens	IC50	nM	332.0
282829	17665174	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5nc6ccc(C#N)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672020	=	IC50	nM	1010.0	CHEMBL2431	Homo sapiens	IC50	nM	1010.0
282830	17665175	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5nc6ccc(C(F)(F)F)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672021	=	IC50	nM	2500.0	CHEMBL2431	Homo sapiens	IC50	nM	2500.0
282831	17665176	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672022	=	IC50	nM	417.0	CHEMBL2431	Homo sapiens	IC50	nM	417.0
282832	17665177	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5nc6cccnc6[nH]5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672023	=	IC50	nM	759.0	CHEMBL2431	Homo sapiens	IC50	nM	759.0
282833	17665178	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672024	=	IC50	nM	435.0	CHEMBL2431	Homo sapiens	IC50	nM	435.0
282834	17665179	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5cnc6ccccc6n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672025	=	IC50	nM	9880.0	CHEMBL2431	Homo sapiens	IC50	nM	9880.0
282835	17665180	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6ncc(C)n6cc5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672026	=	IC50	nM	18.0	CHEMBL2431	Homo sapiens	IC50	nM	18.0
282836	17665181	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)cn2c1Br		CHEMBL3672027	=	IC50	nM	4.0	CHEMBL2431	Homo sapiens	IC50	nM	4.0
282837	17665182	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cnn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CC(c5n[nH]c(-c6cccc(C)n6)n5)C4)cc3)nc12		CHEMBL3672028	=	IC50	nM	115.0	CHEMBL2431	Homo sapiens	IC50	nM	115.0
282838	17665183	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cnn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc12		CHEMBL3672029	=	IC50	nM	761.0	CHEMBL2431	Homo sapiens	IC50	nM	761.0
282839	17665184	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CC(C)c1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672030	=	IC50	nM	35.0	CHEMBL2431	Homo sapiens	IC50	nM	35.0
282840	17665185	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CC(C)c1nc2nc(-c3ccc(CN4CCC(c5cnc6ccccc6n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672031	=	IC50	nM	509.0	CHEMBL2431	Homo sapiens	IC50	nM	509.0
282841	17665186	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C(C)C)nn6cc5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672032	=	IC50	nM	14.0	CHEMBL2431	Homo sapiens	IC50	nM	14.0
282842	17665187	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cnn2cc(-c3ccc(F)cc3F)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc12		CHEMBL3672033	=	IC50	nM	214.0	CHEMBL2431	Homo sapiens	IC50	nM	214.0
282843	17665188	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)cc1		CHEMBL3672034	=	IC50	nM	253.0	CHEMBL2431	Homo sapiens	IC50	nM	253.0
282844	17665189	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4cnc5ccccc5n4)CC3)cc2)cc1		CHEMBL3672035	=	IC50	nM	2290.0	CHEMBL2431	Homo sapiens	IC50	nM	2290.0
282845	17665190	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C)nn6cc5-c5ccc(F)cc5F)cc4)C3)n[nH]2)n1		CHEMBL3672036	=	IC50	nM	42.0	CHEMBL2431	Homo sapiens	IC50	nM	42.0
282846	17665191	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4cnc5ccccc5n4)CC3)cc2)cc1		CHEMBL3672012	=	IC50	nM	589.0	CHEMBL2431	Homo sapiens	IC50	nM	589.0
282847	17665192	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cn2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5cnc6ccccc6n5)CC4)cc3)nc2n1		CHEMBL3672037	=	IC50	nM	256.0	CHEMBL2431	Homo sapiens	IC50	nM	256.0
282848	17665193	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C)cn6cc5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672038	=	IC50	nM	16.0	CHEMBL2431	Homo sapiens	IC50	nM	16.0
282849	17665194	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C7CC7)nn6cc5-c5ccc(F)cc5)cc4)C3)n[nH]2)n1		CHEMBL3672039	=	IC50	nM	27.0	CHEMBL2431	Homo sapiens	IC50	nM	27.0
282850	17665195	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3nc(C4CC4)nc3nc2-c2ccc(CN3CCC(c4cnc5ccccc5n4)CC3)cc2)cc1		CHEMBL3672040	=	IC50	nM	273.0	CHEMBL2431	Homo sapiens	IC50	nM	273.0
282851	17665196	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C7CC7)nn6cc5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672041	=	IC50	nM	10.0	CHEMBL2431	Homo sapiens	IC50	nM	10.0
282852	17665197	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCc1cnn2cc(-c3ccccc3)c(-c3ccc(CN4CC(c5n[nH]c(-c6cccc(C)n6)n5)C4)cc3)nc12		CHEMBL3672042	=	IC50	nM	19.0	CHEMBL2431	Homo sapiens	IC50	nM	19.0
282853	17665198	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CC(C)Nc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672044	=	IC50	nM	11.0	CHEMBL2431	Homo sapiens	IC50	nM	11.0
282854	17665199	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)c(C)n2n1		CHEMBL3672045	=	IC50	nM	17.0	CHEMBL2431	Homo sapiens	IC50	nM	17.0
282855	17665200	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C)nn6c(C)c5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672046	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	nM	8.0
282856	17665201	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)c(NC3CCC3)n2n1		CHEMBL3672047	=	IC50	nM	374.0	CHEMBL2431	Homo sapiens	IC50	nM	374.0
282857	17665202	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5cccc(C)n5)n4)C3)cc2)nc2nc(C)nn12		CHEMBL3672048	=	IC50	nM	21.0	CHEMBL2431	Homo sapiens	IC50	nM	21.0
282858	17665203	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)c(NC(C)C)n2n1		CHEMBL3672049	=	IC50	nM	31.0	CHEMBL2431	Homo sapiens	IC50	nM	31.0
282859	17665204	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)c(NC(C)C)n2n1		CHEMBL3672049	=	IC50	nM	20.0	CHEMBL2431	Homo sapiens	IC50	nM	20.0
282860	17665205	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cnn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CCC(c5n[nH]c(-c6cccc(C)n6)n5)CC4)cc3)nc12		CHEMBL3672050	=	IC50	nM	82.0	CHEMBL2431	Homo sapiens	IC50	nM	82.0
282861	17665206	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cnn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)nc12		CHEMBL3672051	=	IC50	nM	203.0	CHEMBL2431	Homo sapiens	IC50	nM	203.0
282862	17665207	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CCN(Cc4ccc(-c5nc6nc(C)nn6cc5-c5cccc(F)c5)cc4)CC3)n[nH]2)n1		CHEMBL3672052	=	IC50	nM	37.0	CHEMBL2431	Homo sapiens	IC50	nM	37.0
282863	17665208	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3cccc(F)c3)cn2n1		CHEMBL3672053	=	IC50	nM	129.0	CHEMBL2431	Homo sapiens	IC50	nM	129.0
282864	17665209	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6cc(Cl)ccn6)n5)CC4)cc3)c(-c3ccc(F)cc3F)cn2n1		CHEMBL3672054	=	IC50	nM	97.0	CHEMBL2431	Homo sapiens	IC50	nM	97.0
282865	17665210	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CCN(Cc4ccc(-c5nc6nc(C)nn6cc5-c5ccc(F)cc5F)cc4)CC3)n[nH]2)n1		CHEMBL3672055	=	IC50	nM	108.0	CHEMBL2431	Homo sapiens	IC50	nM	108.0
282866	17665211	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6cnccn6)n5)CC4)cc3)c(-c3ccc(F)cc3F)cn2n1		CHEMBL3672056	=	IC50	nM	1100.0	CHEMBL2431	Homo sapiens	IC50	nM	1100.0
282867	17665212	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CCN(Cc4ccc(-c5nc6nc(C7CC7)nn6cc5-c5ccc(F)cc5)cc4)CC3)n[nH]2)n1		CHEMBL3672057	=	IC50	nM	46.0	CHEMBL2431	Homo sapiens	IC50	nM	46.0
282868	17665213	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3nc(C4CC4)nc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL3672058	=	IC50	nM	69.0	CHEMBL2431	Homo sapiens	IC50	nM	69.0
282869	17665214	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3nc(C4CC4)nc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5cc(Cl)ccn5)n4)CC3)cc2)cc1		CHEMBL3672059	=	IC50	nM	165.0	CHEMBL2431	Homo sapiens	IC50	nM	165.0
282870	17665215	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CCN(Cc4ccc(-c5nc6nccn6cc5-c5ccc(F)cc5)cc4)CC3)n[nH]2)n1		CHEMBL3672060	=	IC50	nM	17.0	CHEMBL2431	Homo sapiens	IC50	nM	17.0
282871	17665216	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL3672061	=	IC50	nM	32.0	CHEMBL2431	Homo sapiens	IC50	nM	32.0
282872	17665217	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5cnccn5)n4)CC3)cc2)cc1		CHEMBL3672062	=	IC50	nM	1440.0	CHEMBL2431	Homo sapiens	IC50	nM	1440.0
282873	17665218	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CCN(Cc4ccc(-c5nc6ncc(Br)n6cc5-c5ccc(F)cc5)cc4)CC3)n[nH]2)n1		CHEMBL3672063	=	IC50	nM	7.0	CHEMBL2431	Homo sapiens	IC50	nM	7.0
282874	17665219	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3c(Cl)cnc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL3672064	=	IC50	nM	33.0	CHEMBL2431	Homo sapiens	IC50	nM	33.0
282875	17665220	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CCN(Cc4ccc(-c5nc6nccn6cc5-c5ccccc5F)cc4)CC3)n[nH]2)n1		CHEMBL3672065	=	IC50	nM	17.0	CHEMBL2431	Homo sapiens	IC50	nM	17.0
282876	17665221	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Brc1cnc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)cn12		CHEMBL3672066	=	IC50	nM	14.0	CHEMBL2431	Homo sapiens	IC50	nM	14.0
282877	17665222	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cn2cc(-c3ccccc3)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc2n1		CHEMBL3672067	=	IC50	nM	47.0	CHEMBL2431	Homo sapiens	IC50	nM	47.0
282878	17665223	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C)c(Br)n6cc5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672068	=	IC50	nM	3.0	CHEMBL2431	Homo sapiens	IC50	nM	3.0
282879	17665224	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)nc2nccn12		CHEMBL3672069	=	IC50	nM	476.0	CHEMBL2431	Homo sapiens	IC50	nM	476.0
282880	17665225	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)nc2ncc(Br)n12		CHEMBL3672070	=	IC50	nM	128.0	CHEMBL2431	Homo sapiens	IC50	nM	128.0
282881	17665226	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)nc2nc(C)cn12		CHEMBL3672071	=	IC50	nM	55.0	CHEMBL2431	Homo sapiens	IC50	nM	55.0
282882	17665227	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5cccc(C)n5)n4)C3)cc2)nc2nc(C)cn12		CHEMBL3672072	=	IC50	nM	19.0	CHEMBL2431	Homo sapiens	IC50	nM	19.0
282883	17665228	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	OCc1cnn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc12		CHEMBL3672094	=	IC50	nM	801.0	CHEMBL2431	Homo sapiens	IC50	nM	801.0
282884	17665229	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1nn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc2c1CO		CHEMBL3672073	=	IC50	nM	118.0	CHEMBL2431	Homo sapiens	IC50	nM	118.0
282885	17665230	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1nn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CC(c5n[nH]c(-c6cccc(C)n6)n5)C4)cc3)nc2c1CO		CHEMBL3672074	=	IC50	nM	34.0	CHEMBL2431	Homo sapiens	IC50	nM	34.0
282886	17665231	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1nn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CCC(c5n[nH]c(-c6cccc(C)n6)n5)CC4)cc3)nc2c1CO		CHEMBL3672075	=	IC50	nM	108.0	CHEMBL2431	Homo sapiens	IC50	nM	108.0
282887	17665232	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1nn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)nc2c1CO		CHEMBL3672076	=	IC50	nM	97.0	CHEMBL2431	Homo sapiens	IC50	nM	97.0
282888	17665233	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cn2c(NC(C)C)c(-c3ccccc3)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc2n1		CHEMBL3672077	=	IC50	nM	39.0	CHEMBL2431	Homo sapiens	IC50	nM	39.0
282889	17665234	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C)cn6c(NC(C)C)c5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672078	=	IC50	nM	36.0	CHEMBL2431	Homo sapiens	IC50	nM	36.0
282890	17665235	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CC(C)Nc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)nc2nccn12		CHEMBL3672079	=	IC50	nM	53.0	CHEMBL2431	Homo sapiens	IC50	nM	53.0
282891	17665236	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)nc2nc(-c3ccccn3)nn12		CHEMBL3672080	=	IC50	nM	145.0	CHEMBL2431	Homo sapiens	IC50	nM	145.0
282892	17665237	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CC(C)Nc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)nc2nc(-c3ccccn3)nn12		CHEMBL3672081	=	IC50	nM	88.0	CHEMBL2431	Homo sapiens	IC50	nM	88.0
282893	17665238	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(-c7ccccn7)nn6c(NC(C)C)c5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672082	=	IC50	nM	16.0	CHEMBL2431	Homo sapiens	IC50	nM	16.0
282894	17665239	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3nc(C4CC4)nc3nc2-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)cc1		CHEMBL3639709	=	IC50	nM	5.0	CHEMBL2431	Homo sapiens	IC50	nM	5.0
282895	17665240	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CSc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6cccc(C)n6)n5)C4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672083	=	IC50	nM	4.0	CHEMBL2431	Homo sapiens	IC50	nM	4.0
282896	17665241	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CSc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672084	=	IC50	nM	100.0	CHEMBL2431	Homo sapiens	IC50	nM	100.0
282897	17665242	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CSc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672085	=	IC50	nM	12.0	CHEMBL2431	Homo sapiens	IC50	nM	12.0
282898	17665243	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CSc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ncccn6)n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672086	=	IC50	nM	222.0	CHEMBL2431	Homo sapiens	IC50	nM	222.0
282899	17665244	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CSc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6cnccn6)n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672087	=	IC50	nM	80.0	CHEMBL2431	Homo sapiens	IC50	nM	80.0
282900	17665245	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CSc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6cccc(C)n6)n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672088	=	IC50	nM	4.0	CHEMBL2431	Homo sapiens	IC50	nM	4.0
282901	17665246	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=O)(=O)c1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672089	=	IC50	nM	102.0	CHEMBL2431	Homo sapiens	IC50	nM	102.0
282902	17665247	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cn2cc(-c3ccccc3)c(-c3ccc(CN4CC(c5n[nH]c(-c6cccc(C)n6)n5)C4)cc3)nc2n1		CHEMBL3672090	=	IC50	nM	14.0	CHEMBL2431	Homo sapiens	IC50	nM	14.0
282903	17665248	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cn2cc(-c3ccccc3)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc2n1		CHEMBL3672091	=	IC50	nM	17.0	CHEMBL2431	Homo sapiens	IC50	nM	17.0
282904	17665249	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	OCc1cn2cc(-c3ccccc3)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc2n1		CHEMBL3672092	=	IC50	nM	124.0	CHEMBL2431	Homo sapiens	IC50	nM	124.0
282905	17665250	CHEMBL3705789	TR-FRET Assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx- KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlinn-Buch, Germany). For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3cc(F)ccc3F)cn2n1		CHEMBL3672093	=	IC50	nM	154.0	CHEMBL2431	Homo sapiens	IC50	nM	154.0
288121	17670485	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ncccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699664	=	IC50	nM	563.0	CHEMBL2431	Homo sapiens	IC50	nM	563.0
288122	17670486	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2n1		CHEMBL3699665	=	IC50	nM	153.0	CHEMBL2431	Homo sapiens	IC50	nM	153.0
288123	17670487	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(C5CC5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699666	=	IC50	nM	54.0	CHEMBL2431	Homo sapiens	IC50	nM	54.0
288124	17670488	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(-c5ccccc5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699667	=	IC50	nM	33.0	CHEMBL2431	Homo sapiens	IC50	nM	33.0
288125	17670489	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1ccccc1-c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2n1		CHEMBL3699668	=	IC50	nM	94.0	CHEMBL2431	Homo sapiens	IC50	nM	94.0
288126	17670490	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cnc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699669	=	IC50	nM	293.0	CHEMBL2431	Homo sapiens	IC50	nM	293.0
288127	17670491	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cnc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699670	=	IC50	nM	291.0	CHEMBL2431	Homo sapiens	IC50	nM	291.0
288128	17670492	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOc1cnc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699671	=	IC50	nM	328.0	CHEMBL2431	Homo sapiens	IC50	nM	328.0
288129	17670493	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ncc(-c5ccccc5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699672	=	IC50	nM	550.0	CHEMBL2431	Homo sapiens	IC50	nM	550.0
288130	17670494	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699673	=	IC50	nM	426.0	CHEMBL2431	Homo sapiens	IC50	nM	426.0
288131	17670495	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-n5cccn5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699674	=	IC50	nM	13.0	CHEMBL2431	Homo sapiens	IC50	nM	13.0
288132	17670496	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1cc(OC)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699675	=	IC50	nM	38.0	CHEMBL2431	Homo sapiens	IC50	nM	38.0
288133	17670497	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(C(N)=O)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699676	=	IC50	nM	9.0	CHEMBL2431	Homo sapiens	IC50	nM	9.0
288134	17670498	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CNC(=O)Nc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3699677	=	IC50	nM	146.0	CHEMBL2431	Homo sapiens	IC50	nM	146.0
288135	17670499	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(-n5ccccc5=O)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699678	=	IC50	nM	402.0	CHEMBL2431	Homo sapiens	IC50	nM	402.0
288136	17670500	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-n5cccn5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699679	=	IC50	nM	193.0	CHEMBL2431	Homo sapiens	IC50	nM	193.0
288137	17670501	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2n1		CHEMBL3699680	=	IC50	nM	120.0	CHEMBL2431	Homo sapiens	IC50	nM	120.0
288138	17670502	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(O)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699681	=	IC50	nM	564.0	CHEMBL2431	Homo sapiens	IC50	nM	564.0
288139	17670503	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCCOc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2n1		CHEMBL3699682	=	IC50	nM	148.0	CHEMBL2431	Homo sapiens	IC50	nM	148.0
288140	17670504	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699683	=	IC50	nM	313.0	CHEMBL2431	Homo sapiens	IC50	nM	313.0
288141	17670505	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3699684	=	IC50	nM	241.0	CHEMBL2431	Homo sapiens	IC50	nM	241.0
288142	17670506	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699685	=	IC50	nM	274.0	CHEMBL2431	Homo sapiens	IC50	nM	274.0
288143	17670507	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3699686	=	IC50	nM	52.0	CHEMBL2431	Homo sapiens	IC50	nM	52.0
288144	17670508	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699687	=	IC50	nM	229.0	CHEMBL2431	Homo sapiens	IC50	nM	229.0
288145	17670509	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3699688	=	IC50	nM	47.0	CHEMBL2431	Homo sapiens	IC50	nM	47.0
288146	17670510	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CNC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699689	=	IC50	nM	116.0	CHEMBL2431	Homo sapiens	IC50	nM	116.0
288147	17670511	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COCc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699690	=	IC50	nM	419.0	CHEMBL2431	Homo sapiens	IC50	nM	419.0
288148	17670512	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699691	=	IC50	nM	124.0	CHEMBL2431	Homo sapiens	IC50	nM	124.0
288149	17670513	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699692	=	IC50	nM	769.0	CHEMBL2431	Homo sapiens	IC50	nM	769.0
288150	17670514	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(CO)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699693	=	IC50	nM	357.0	CHEMBL2431	Homo sapiens	IC50	nM	357.0
288151	17670515	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(CO)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699694	=	IC50	nM	263.0	CHEMBL2431	Homo sapiens	IC50	nM	263.0
288152	17670516	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699696	=	IC50	nM	163.0	CHEMBL2431	Homo sapiens	IC50	nM	163.0
288153	17670517	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699697	=	IC50	nM	66.0	CHEMBL2431	Homo sapiens	IC50	nM	66.0
288154	17670518	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOc1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699698	=	IC50	nM	106.0	CHEMBL2431	Homo sapiens	IC50	nM	106.0
288155	17670519	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3699699	=	IC50	nM	53.0	CHEMBL2431	Homo sapiens	IC50	nM	53.0
288156	17670520	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5cn[nH]c5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699700	=	IC50	nM	22.0	CHEMBL2431	Homo sapiens	IC50	nM	22.0
288157	17670521	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699701	=	IC50	nM	204.0	CHEMBL2431	Homo sapiens	IC50	nM	204.0
288158	17670522	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COCCNCc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699702	=	IC50	nM	1958.0	CHEMBL2431	Homo sapiens	IC50	nM	1958.0
288159	17670523	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(CO)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699703	=	IC50	nM	385.0	CHEMBL2431	Homo sapiens	IC50	nM	385.0
288160	17670524	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1ccc(COc2ccn3c(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc3n2)cn1		CHEMBL3639985	=	IC50	nM	38.0	CHEMBL2431	Homo sapiens	IC50	nM	38.0
288161	17670525	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COCCOc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2n1		CHEMBL3699704	=	IC50	nM	416.0	CHEMBL2431	Homo sapiens	IC50	nM	416.0
288162	17670526	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(COc2ccn3c(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc3n2)ccn1		CHEMBL3699705	=	IC50	nM	165.0	CHEMBL2431	Homo sapiens	IC50	nM	165.0
288163	17670527	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(C)Oc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2n1		CHEMBL3699707	=	IC50	nM	139.0	CHEMBL2431	Homo sapiens	IC50	nM	139.0
288164	17670528	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(OC5CCCCC5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699708	=	IC50	nM	138.0	CHEMBL2431	Homo sapiens	IC50	nM	138.0
288165	17670529	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(Oc5ccccc5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699709	=	IC50	nM	85.0	CHEMBL2431	Homo sapiens	IC50	nM	85.0
288166	17670530	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCc1cnc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699710	=	IC50	nM	161.0	CHEMBL2431	Homo sapiens	IC50	nM	161.0
288167	17670531	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5ccc(F)cc5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699711	=	IC50	nM	50.0	CHEMBL2431	Homo sapiens	IC50	nM	50.0
288168	17670532	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3699712	=	IC50	nM	64.0	CHEMBL2431	Homo sapiens	IC50	nM	64.0
288169	17670533	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699713	=	IC50	nM	198.0	CHEMBL2431	Homo sapiens	IC50	nM	198.0
288170	17670534	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(C5CC5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699714	=	IC50	nM	101.0	CHEMBL2431	Homo sapiens	IC50	nM	101.0
288171	17670535	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699715	=	IC50	nM	192.0	CHEMBL2431	Homo sapiens	IC50	nM	192.0
288172	17670536	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(Br)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699716	=	IC50	nM	162.0	CHEMBL2431	Homo sapiens	IC50	nM	162.0
288173	17670537	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(Br)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699717	=	IC50	nM	46.0	CHEMBL2431	Homo sapiens	IC50	nM	46.0
288174	17670538	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL2035022	=	IC50	nM	50.0	CHEMBL2431	Homo sapiens	IC50	nM	50.0
288175	17670539	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(C(=O)N5CCCC5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699718	=	IC50	nM	519.0	CHEMBL2431	Homo sapiens	IC50	nM	519.0
288176	17670540	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOC(=O)c1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699719	=	IC50	nM	233.0	CHEMBL2431	Homo sapiens	IC50	nM	233.0
288177	17670541	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(F)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699720	=	IC50	nM	277.0	CHEMBL2431	Homo sapiens	IC50	nM	277.0
288178	17670542	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(Cl)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699721	=	IC50	nM	216.0	CHEMBL2431	Homo sapiens	IC50	nM	216.0
288179	17670543	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(F)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699722	=	IC50	nM	385.0	CHEMBL2431	Homo sapiens	IC50	nM	385.0
288180	17670544	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(C5CC5)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699723	=	IC50	nM	253.0	CHEMBL2431	Homo sapiens	IC50	nM	253.0
288181	17670545	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	C=Cc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699724	=	IC50	nM	422.0	CHEMBL2431	Homo sapiens	IC50	nM	422.0
288182	17670546	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	C=Cc1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699725	=	IC50	nM	1592.0	CHEMBL2431	Homo sapiens	IC50	nM	1592.0
288183	17670547	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(-c5cn[nH]c5)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699726	=	IC50	nM	231.0	CHEMBL2431	Homo sapiens	IC50	nM	231.0
288184	17670548	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C(=O)O)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699727	=	IC50	nM	67.0	CHEMBL2431	Homo sapiens	IC50	nM	67.0
288185	17670549	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(Br)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699728	=	IC50	nM	17.0	CHEMBL2431	Homo sapiens	IC50	nM	17.0
288186	17670550	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(C)NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699729	=	IC50	nM	279.0	CHEMBL2431	Homo sapiens	IC50	nM	279.0
288187	17670551	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C(=O)NCCF)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699730	=	IC50	nM	144.0	CHEMBL2431	Homo sapiens	IC50	nM	144.0
288188	17670552	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C(=O)NCCO)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699731	=	IC50	nM	482.0	CHEMBL2431	Homo sapiens	IC50	nM	482.0
288189	17670553	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COCCNC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699732	=	IC50	nM	515.0	CHEMBL2431	Homo sapiens	IC50	nM	515.0
288190	17670554	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C(=O)NC5CC5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699733	=	IC50	nM	295.0	CHEMBL2431	Homo sapiens	IC50	nM	295.0
288191	17670555	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C(=O)NCC5CC5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699734	=	IC50	nM	239.0	CHEMBL2431	Homo sapiens	IC50	nM	239.0
288192	17670556	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C(=O)NO)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699735	=	IC50	nM	118.0	CHEMBL2431	Homo sapiens	IC50	nM	118.0
288193	17670557	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1cc(Cl)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699736	=	IC50	nM	116.0	CHEMBL2431	Homo sapiens	IC50	nM	116.0
288194	17670558	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CN(C)C(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699737	=	IC50	nM	1483.0	CHEMBL2431	Homo sapiens	IC50	nM	1483.0
288195	17670559	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCNC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699738	=	IC50	nM	154.0	CHEMBL2431	Homo sapiens	IC50	nM	154.0
288196	17670560	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C5CC5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699739	=	IC50	nM	154.0	CHEMBL2431	Homo sapiens	IC50	nM	154.0
288197	17670561	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(OCCN5CCCC5=O)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699740	=	IC50	nM	777.0	CHEMBL2431	Homo sapiens	IC50	nM	777.0
288198	17670562	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)C1(COc2ccn3c(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc3n2)CC1		CHEMBL3699741	=	IC50	nM	338.0	CHEMBL2431	Homo sapiens	IC50	nM	338.0
288199	17670563	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(Cl)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699742	=	IC50	nM	60.0	CHEMBL2431	Homo sapiens	IC50	nM	60.0
288200	17670564	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(F)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699743	=	IC50	nM	79.0	CHEMBL2431	Homo sapiens	IC50	nM	79.0
288201	17670565	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(-c5ccc(F)cc5)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699744	=	IC50	nM	521.0	CHEMBL2431	Homo sapiens	IC50	nM	521.0
288202	17670566	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(-c5cccc(F)c5)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699745	=	IC50	nM	480.0	CHEMBL2431	Homo sapiens	IC50	nM	480.0
288203	17670567	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cncc(-c2cccn3c(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc23)c1		CHEMBL3699746	=	IC50	nM	267.0	CHEMBL2431	Homo sapiens	IC50	nM	267.0
288204	17670568	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(-c5ccn[nH]5)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699747	=	IC50	nM	170.0	CHEMBL2431	Homo sapiens	IC50	nM	170.0
288205	17670569	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(-c5ccc6cn[nH]c6c5)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699748	=	IC50	nM	749.0	CHEMBL2431	Homo sapiens	IC50	nM	749.0
288206	17670570	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(C)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699749	=	IC50	nM	56.0	CHEMBL2431	Homo sapiens	IC50	nM	56.0
288207	17670571	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1Cl		CHEMBL3699750	=	IC50	nM	210.0	CHEMBL2431	Homo sapiens	IC50	nM	210.0
288208	17670572	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(F)cc(F)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699751	=	IC50	nM	73.0	CHEMBL2431	Homo sapiens	IC50	nM	73.0
288209	17670573	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(Cl)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699752	=	IC50	nM	160.0	CHEMBL2431	Homo sapiens	IC50	nM	160.0
288210	17670574	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOC(=O)c1cc(Br)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699753	=	IC50	nM	102.0	CHEMBL2431	Homo sapiens	IC50	nM	102.0
288211	17670575	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(Cl)cc(Cl)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699754	=	IC50	nM	62.0	CHEMBL2431	Homo sapiens	IC50	nM	62.0
288212	17670576	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1C#N		CHEMBL3699755	=	IC50	nM	108.0	CHEMBL2431	Homo sapiens	IC50	nM	108.0
288213	17670577	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(Cl)c(Cl)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699756	=	IC50	nM	93.0	CHEMBL2431	Homo sapiens	IC50	nM	93.0
288214	17670578	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1c(Cl)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1Br		CHEMBL3699757	=	IC50	nM	15.0	CHEMBL2431	Homo sapiens	IC50	nM	15.0
288215	17670579	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(Br)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699758	=	IC50	nM	109.0	CHEMBL2431	Homo sapiens	IC50	nM	109.0
288216	17670580	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1c(Cl)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1-c1ccc(F)cc1		CHEMBL3699760	=	IC50	nM	516.0	CHEMBL2431	Homo sapiens	IC50	nM	516.0
288217	17670581	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1c(Cl)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1-c1ccn[nH]1		CHEMBL3699761	=	IC50	nM	392.0	CHEMBL2431	Homo sapiens	IC50	nM	392.0
288218	17670582	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1c(-c2ccn[nH]2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1C		CHEMBL3699762	=	IC50	nM	55.0	CHEMBL2431	Homo sapiens	IC50	nM	55.0
288219	17670583	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2cccnc2)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699763	=	IC50	nM	410.0	CHEMBL2431	Homo sapiens	IC50	nM	410.0
288220	17670584	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2ccn[nH]2)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699765	=	IC50	nM	736.0	CHEMBL2431	Homo sapiens	IC50	nM	736.0
288221	17670585	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2cn[nH]c2)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699766	=	IC50	nM	203.0	CHEMBL2431	Homo sapiens	IC50	nM	203.0
288222	17670586	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cc(Br)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699767	=	IC50	nM	41.0	CHEMBL2431	Homo sapiens	IC50	nM	41.0
288223	17670587	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cc(Br)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699768	=	IC50	nM	24.0	CHEMBL2431	Homo sapiens	IC50	nM	24.0
288224	17670588	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(C(N)=O)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699769	=	IC50	nM	1375.0	CHEMBL2431	Homo sapiens	IC50	nM	1375.0
288225	17670589	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cc(-c2cn[nH]c2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699770	=	IC50	nM	50.0	CHEMBL2431	Homo sapiens	IC50	nM	50.0
288226	17670590	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cc(-c2ccn[nH]2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699771	=	IC50	nM	119.0	CHEMBL2431	Homo sapiens	IC50	nM	119.0
288227	17670591	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cc(-c2cccnc2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699772	=	IC50	nM	112.0	CHEMBL2431	Homo sapiens	IC50	nM	112.0
288228	17670592	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1c(C(N)=O)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1C		CHEMBL3699773	=	IC50	nM	91.0	CHEMBL2431	Homo sapiens	IC50	nM	91.0
288229	17670593	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(C(N)=O)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699774	=	IC50	nM	36.0	CHEMBL2431	Homo sapiens	IC50	nM	36.0
288230	17670594	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2cn[nH]c2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699775	=	IC50	nM	100.0	CHEMBL2431	Homo sapiens	IC50	nM	100.0
288231	17670595	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2ccn[nH]2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699776	=	IC50	nM	190.0	CHEMBL2431	Homo sapiens	IC50	nM	190.0
288232	17670596	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2cccnc2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699777	=	IC50	nM	129.0	CHEMBL2431	Homo sapiens	IC50	nM	129.0
288233	17670597	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2cc(C)c3nc(-c4ccc(C5(N)CCC5)cc4)c(-c4ccccc4)n3c2)[nH]n1		CHEMBL3699778	=	IC50	nM	475.0	CHEMBL2431	Homo sapiens	IC50	nM	475.0
288234	17670598	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccccn4c3-c3ccccc3)cc2)CCC1		CHEMBL2035021	=	IC50	nM	435.0	CHEMBL2431	Homo sapiens	IC50	nM	435.0
288235	17670599	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703102	=	IC50	nM	70.0	CHEMBL2431	Homo sapiens	IC50	nM	70.0
288236	17670600	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	C=Cc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703103	=	IC50	nM	621.0	CHEMBL2431	Homo sapiens	IC50	nM	621.0
288237	17670601	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5ccncc5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703104	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	nM	8.0
288238	17670602	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5cccnc5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703105	=	IC50	nM	7.0	CHEMBL2431	Homo sapiens	IC50	nM	7.0
288239	17670603	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5ccccn5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703106	=	IC50	nM	19.0	CHEMBL2431	Homo sapiens	IC50	nM	19.0
288240	17670604	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5cc[nH]n5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703107	=	IC50	nM	23.0	CHEMBL2431	Homo sapiens	IC50	nM	23.0
288241	17670605	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5ncc[nH]5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703108	=	IC50	nM	8.0	CHEMBL2431	Homo sapiens	IC50	nM	8.0
288242	17670606	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5cnc[nH]5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703109	=	IC50	nM	22.0	CHEMBL2431	Homo sapiens	IC50	nM	22.0
288243	17670607	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cn1cncc1-c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703110	=	IC50	nM	13.0	CHEMBL2431	Homo sapiens	IC50	nM	13.0
288244	17670608	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5nn[nH]n5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703111	=	IC50	nM	9.0	CHEMBL2431	Homo sapiens	IC50	nM	9.0
288245	17670609	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOC(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703112	=	IC50	nM	22.0	CHEMBL2431	Homo sapiens	IC50	nM	22.0
288246	17670610	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(C(=O)O)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703113	=	IC50	nM	29.0	CHEMBL2431	Homo sapiens	IC50	nM	29.0
288247	17670611	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CNC(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703114	=	IC50	nM	53.0	CHEMBL2431	Homo sapiens	IC50	nM	53.0
288248	17670612	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)/C=C/c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703115	=	IC50	nM	52.0	CHEMBL2431	Homo sapiens	IC50	nM	52.0
288249	17670613	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)/C=C/c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703116	=	IC50	nM	44.0	CHEMBL2431	Homo sapiens	IC50	nM	44.0
288250	17670614	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)CCc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703117	=	IC50	nM	75.0	CHEMBL2431	Homo sapiens	IC50	nM	75.0
288251	17670615	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCNC(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703118	=	IC50	nM	46.0	CHEMBL2431	Homo sapiens	IC50	nM	46.0
288252	17670616	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(C(=O)NO)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703119	=	IC50	nM	48.0	CHEMBL2431	Homo sapiens	IC50	nM	48.0
288253	17670617	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703120	=	IC50	nM	55.0	CHEMBL2431	Homo sapiens	IC50	nM	55.0
288254	17670618	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5cnc[nH]5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703121	=	IC50	nM	369.0	CHEMBL2431	Homo sapiens	IC50	nM	369.0
288255	17670619	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5ncc[nH]5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703122	=	IC50	nM	504.0	CHEMBL2431	Homo sapiens	IC50	nM	504.0
288256	17670620	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5cc[nH]n5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703123	=	IC50	nM	596.0	CHEMBL2431	Homo sapiens	IC50	nM	596.0
288257	17670621	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5cn[nH]c5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703124	=	IC50	nM	115.0	CHEMBL2431	Homo sapiens	IC50	nM	115.0
288258	17670622	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cn1cncc1-c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703125	=	IC50	nM	97.0	CHEMBL2431	Homo sapiens	IC50	nM	97.0
288259	17670623	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cn1cc(-c2ccc3nc(-c4ccc(C5(N)CCC5)cc4)c(-c4ccccc4)n3c2)cn1		CHEMBL3703126	=	IC50	nM	210.0	CHEMBL2431	Homo sapiens	IC50	nM	210.0
288260	17670624	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5nn[nH]n5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703127	=	IC50	nM	56.0	CHEMBL2431	Homo sapiens	IC50	nM	56.0
288261	17670625	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5ccncc5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703128	=	IC50	nM	288.0	CHEMBL2431	Homo sapiens	IC50	nM	288.0
288262	17670626	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5cccnc5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703129	=	IC50	nM	159.0	CHEMBL2431	Homo sapiens	IC50	nM	159.0
288263	17670627	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5ccccn5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703130	=	IC50	nM	462.0	CHEMBL2431	Homo sapiens	IC50	nM	462.0
288264	17670628	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(Br)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699695	=	IC50	nM	101.0	CHEMBL2431	Homo sapiens	IC50	nM	101.0
288265	17670629	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(Cl)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703131	=	IC50	nM	88.0	CHEMBL2431	Homo sapiens	IC50	nM	88.0
288266	17670630	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)/C=C/c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703132	=	IC50	nM	203.0	CHEMBL2431	Homo sapiens	IC50	nM	203.0
288267	17670631	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)/C=C/c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703133	=	IC50	nM	134.0	CHEMBL2431	Homo sapiens	IC50	nM	134.0
288268	17670632	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703134	=	IC50	nM	142.0	CHEMBL2431	Homo sapiens	IC50	nM	142.0
288269	17670633	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703135	=	IC50	nM	69.0	CHEMBL2431	Homo sapiens	IC50	nM	69.0
288270	17670634	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(Cl)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3703136	=	IC50	nM	51.0	CHEMBL2431	Homo sapiens	IC50	nM	51.0
288271	17670635	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(OC)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703137	=	IC50	nM	64.0	CHEMBL2431	Homo sapiens	IC50	nM	64.0
288272	17670636	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCc1cc(OC)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703138	=	IC50	nM	50.0	CHEMBL2431	Homo sapiens	IC50	nM	50.0
288273	17670637	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(-c2cnc[nH]2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3703139	=	IC50	nM	49.0	CHEMBL2431	Homo sapiens	IC50	nM	49.0
288274	17670638	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(-c2ncc[nH]2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3703140	=	IC50	nM	51.0	CHEMBL2431	Homo sapiens	IC50	nM	51.0
288275	17670639	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cn1cc(-c2ccn3c(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc3c2)cn1		CHEMBL3703141	=	IC50	nM	35.0	CHEMBL2431	Homo sapiens	IC50	nM	35.0
288276	17670640	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Nc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703142	=	IC50	nM	711.0	CHEMBL2431	Homo sapiens	IC50	nM	711.0
288277	17670641	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(=O)Nc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703143	=	IC50	nM	95.0	CHEMBL2431	Homo sapiens	IC50	nM	95.0
288278	17670642	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)Nc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703144	=	IC50	nM	92.0	CHEMBL2431	Homo sapiens	IC50	nM	92.0
288279	17670643	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CON(C)C(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703145	=	IC50	nM	305.0	CHEMBL2431	Homo sapiens	IC50	nM	305.0
288280	17670644	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Nc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703146	=	IC50	nM	586.0	CHEMBL2431	Homo sapiens	IC50	nM	586.0
288281	17670645	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(=O)Nc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703147	=	IC50	nM	92.0	CHEMBL2431	Homo sapiens	IC50	nM	92.0
288282	17670646	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)Nc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703148	=	IC50	nM	221.0	CHEMBL2431	Homo sapiens	IC50	nM	221.0
288283	17670647	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CNC(=O)Nc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703149	=	IC50	nM	308.0	CHEMBL2431	Homo sapiens	IC50	nM	308.0
288284	17670648	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CS(=O)(=O)Nc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703150	=	IC50	nM	313.0	CHEMBL2431	Homo sapiens	IC50	nM	313.0
288285	17670649	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	C=Cc1cc(OC)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703151	=	IC50	nM	76.0	CHEMBL2431	Homo sapiens	IC50	nM	76.0
288286	17670650	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	N[C@]1(c2ccc(-c3nc4nc(O)ccn4c3-c3ccccc3)cc2)C[C@H](O)C1		CHEMBL3703152	=	IC50	nM	871.0	CHEMBL2431	Homo sapiens	IC50	nM	871.0
288287	17670651	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(O)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703154	=	IC50	nM	459.0	CHEMBL2431	Homo sapiens	IC50	nM	459.0
288288	17670652	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(O)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703155	=	IC50	nM	704.0	CHEMBL2431	Homo sapiens	IC50	nM	704.0
288289	17670653	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3703156	=	IC50	nM	154.0	CHEMBL2431	Homo sapiens	IC50	nM	154.0
288290	17670654	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cc(Cl)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703157	=	IC50	nM	28.0	CHEMBL2431	Homo sapiens	IC50	nM	28.0
288291	17670655	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	C#Cc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703158	=	IC50	nM	703.0	CHEMBL2431	Homo sapiens	IC50	nM	703.0
288292	17670656	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)CCc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703159	=	IC50	nM	417.0	CHEMBL2431	Homo sapiens	IC50	nM	417.0
288293	17670657	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCC(=O)CCc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703160	=	IC50	nM	1318.0	CHEMBL2431	Homo sapiens	IC50	nM	1318.0
288294	17670658	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703161	=	IC50	nM	82.0	CHEMBL2431	Homo sapiens	IC50	nM	82.0
288295	17670659	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703162	=	IC50	nM	132.0	CHEMBL2431	Homo sapiens	IC50	nM	132.0
288296	17670660	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	CN(C)C(=O)COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703163	=	IC50	nM	97.0	CHEMBL2431	Homo sapiens	IC50	nM	97.0
288297	17670661	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	[C-]#[N+]COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703164	=	IC50	nM	135.0	CHEMBL2431	Homo sapiens	IC50	nM	135.0
288298	17670662	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)COc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703165	=	IC50	nM	486.0	CHEMBL2431	Homo sapiens	IC50	nM	486.0
288299	17670663	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	[C-]#[N+]COc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703166	=	IC50	nM	134.0	CHEMBL2431	Homo sapiens	IC50	nM	134.0
288300	17670664	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(O)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703167	=	IC50	nM	2026.0	CHEMBL2431	Homo sapiens	IC50	nM	2026.0
288301	17670665	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5cccnc5O)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703168	=	IC50	nM	616.0	CHEMBL2431	Homo sapiens	IC50	nM	616.0
288302	17670666	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2ccc3nc(-c4ccc(C5(N)CCC5)cc4)c(-c4ccccc4)n3c2)[nH]n1		CHEMBL3640020	=	IC50	nM	686.0	CHEMBL2431	Homo sapiens	IC50	nM	686.0
288303	17670667	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(-c2cn[nH]c2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3703169	=	IC50	nM	30.0	CHEMBL2431	Homo sapiens	IC50	nM	30.0
288304	17670668	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n12		CHEMBL3703170	=	IC50	nM	1093.0	CHEMBL2431	Homo sapiens	IC50	nM	1093.0
288305	17670669	CHEMBL3705585	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1cc(Cl)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703171	=	IC50	nM	397.0	CHEMBL2431	Homo sapiens	IC50	nM	397.0
290728	17672965	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4ccnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL2035019	=	IC50	nM	1439.0	CHEMBL2431	Homo sapiens	IC50	nM	1439.0
290729	17672966	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cn2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)cc2n1		CHEMBL3639713	=	IC50	nM	20000.0	CHEMBL2431	Homo sapiens	IC50	nM	20000.0
290730	17672967	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cnc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn12		CHEMBL3672479	=	IC50	nM	1726.0	CHEMBL2431	Homo sapiens	IC50	nM	1726.0
290731	17672968	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	N#Cc1cccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)c1		CHEMBL3672480	=	IC50	nM	82.0	CHEMBL2431	Homo sapiens	IC50	nM	82.0
290732	17672969	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=O)(=O)c1ccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)cc1		CHEMBL3672481	=	IC50	nM	278.0	CHEMBL2431	Homo sapiens	IC50	nM	278.0
290733	17672970	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	N#Cc1ccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)cc1		CHEMBL3672482	=	IC50	nM	136.0	CHEMBL2431	Homo sapiens	IC50	nM	136.0
290734	17672971	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)c1		CHEMBL3672483	=	IC50	nM	58.0	CHEMBL2431	Homo sapiens	IC50	nM	58.0
290735	17672972	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(F)cc5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672484	=	IC50	nM	81.0	CHEMBL2431	Homo sapiens	IC50	nM	81.0
290736	17672973	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1ccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)cc1		CHEMBL3672485	=	IC50	nM	277.0	CHEMBL2431	Homo sapiens	IC50	nM	277.0
290737	17672974	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5cccc(CO)c5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672486	=	IC50	nM	37.0	CHEMBL2431	Homo sapiens	IC50	nM	37.0
290738	17672975	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(CO)cc5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672487	=	IC50	nM	123.0	CHEMBL2431	Homo sapiens	IC50	nM	123.0
290739	17672976	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(S(N)(=O)=O)cc5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672488	=	IC50	nM	151.0	CHEMBL2431	Homo sapiens	IC50	nM	151.0
290740	17672977	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(Br)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672489	=	IC50	nM	264.0	CHEMBL2431	Homo sapiens	IC50	nM	264.0
290741	17672978	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(F)c(CO)c5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672490	=	IC50	nM	92.0	CHEMBL2431	Homo sapiens	IC50	nM	92.0
290742	17672979	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC(=O)c1ccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)cc1		CHEMBL3672491	=	IC50	nM	118.0	CHEMBL2431	Homo sapiens	IC50	nM	118.0
290743	17672980	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC(=O)c1cccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)c1		CHEMBL3672492	=	IC50	nM	68.0	CHEMBL2431	Homo sapiens	IC50	nM	68.0
290744	17672981	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5cn[nH]c5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672493	=	IC50	nM	67.0	CHEMBL2431	Homo sapiens	IC50	nM	67.0
290745	17672982	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(O)nc5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672494	=	IC50	nM	431.0	CHEMBL2431	Homo sapiens	IC50	nM	431.0
290746	17672983	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1ccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)cn1		CHEMBL3672495	=	IC50	nM	115.0	CHEMBL2431	Homo sapiens	IC50	nM	115.0
290747	17672984	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccn[nH]5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672496	=	IC50	nM	70.0	CHEMBL2431	Homo sapiens	IC50	nM	70.0
290748	17672985	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc6cn[nH]c6c5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672497	=	IC50	nM	22.0	CHEMBL2431	Homo sapiens	IC50	nM	22.0
290749	17672986	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOC(=O)c1cncc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)c1		CHEMBL3672498	=	IC50	nM	110.0	CHEMBL2431	Homo sapiens	IC50	nM	110.0
290750	17672987	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cncc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)c1		CHEMBL3672499	=	IC50	nM	46.0	CHEMBL2431	Homo sapiens	IC50	nM	46.0
290751	17672988	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn2c1-c1cccc(C(N)=O)c1		CHEMBL3672500	=	IC50	nM	16764.0	CHEMBL2431	Homo sapiens	IC50	nM	16764.0
290752	17672989	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn2c1-c1ccc(F)c(CO)c1		CHEMBL3672501	=	IC50	nM	16725.0	CHEMBL2431	Homo sapiens	IC50	nM	16725.0
290753	17672990	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn2c1-c1ccc(F)cc1		CHEMBL3672503	=	IC50	nM	5107.0	CHEMBL2431	Homo sapiens	IC50	nM	5107.0
290754	17672991	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn2c1-c1ccc(C(N)=O)cc1		CHEMBL3672504	=	IC50	nM	4823.0	CHEMBL2431	Homo sapiens	IC50	nM	4823.0
290755	17672992	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn2c1-c1ccn[nH]1		CHEMBL3672505	=	IC50	nM	5228.0	CHEMBL2431	Homo sapiens	IC50	nM	5228.0
290756	17672993	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cc(-c2c(C)nc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)[nH]n1		CHEMBL3672506	=	IC50	nM	17150.0	CHEMBL2431	Homo sapiens	IC50	nM	17150.0
290757	17672994	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(F)cc5)c(Br)nc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672507	=	IC50	nM	41.0	CHEMBL2431	Homo sapiens	IC50	nM	41.0
290758	17672995	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(F)cc5)c(Cl)nc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672508	=	IC50	nM	106.0	CHEMBL2431	Homo sapiens	IC50	nM	106.0
290759	17672996	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC(=O)/C=C/c1cnc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn12		CHEMBL3672509	=	IC50	nM	222.0	CHEMBL2431	Homo sapiens	IC50	nM	222.0
290760	17672997	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	C=Cc1cnc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn12		CHEMBL3672510	=	IC50	nM	326.0	CHEMBL2431	Homo sapiens	IC50	nM	326.0
290761	17672998	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn2c1/C=C/C(N)=O		CHEMBL3672511	=	IC50	nM	20000.0	CHEMBL2431	Homo sapiens	IC50	nM	20000.0
290762	17672999	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)/C=C/c1c(C)nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn12		CHEMBL3672512	=	IC50	nM	10120.0	CHEMBL2431	Homo sapiens	IC50	nM	10120.0
290763	17673000	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	C=Cc1c(C)nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn12		CHEMBL3672513	=	IC50	nM	16689.0	CHEMBL2431	Homo sapiens	IC50	nM	16689.0
290764	17673001	CHEMBL3706238	TR-FRET assay: Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased form Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCc1c(C)nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn12		CHEMBL3672514	=	IC50	nM	20000.0	CHEMBL2431	Homo sapiens	IC50	nM	20000.0
381894	17755440	CHEMBL3888208	Akt2 TR-FRET assay: His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased from Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.2 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a TR-FRET reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	NC1(c2ccc(-c3nc4c(O)nccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3982161	=	IC50	nM	970.0	CHEMBL2431	Homo sapiens	IC50	nM	970.0
381895	17755441	CHEMBL3888208	Akt2 TR-FRET assay: His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased from Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.2 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a TR-FRET reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	Cc1cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c(C)n1		CHEMBL3944710	=	IC50	nM	220.0	CHEMBL2431	Homo sapiens	IC50	nM	220.0
381896	17755442	CHEMBL3888208	Akt2 TR-FRET assay: His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased from Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.2 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a TR-FRET reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	COc1nc(Br)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3977365	=	IC50	nM	33.0	CHEMBL2431	Homo sapiens	IC50	nM	33.0
381897	17755443	CHEMBL3888208	Akt2 TR-FRET assay: His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased from Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.2 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a TR-FRET reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	CCc1cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c(OC)n1		CHEMBL3895917	=	IC50	nM	34.0	CHEMBL2431	Homo sapiens	IC50	nM	34.0
381898	17755444	CHEMBL3888208	Akt2 TR-FRET assay: His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased from Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.2 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a TR-FRET reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	CCOC(=O)c1cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2cn1		CHEMBL3968885	=	IC50	nM	130.0	CHEMBL2431	Homo sapiens	IC50	nM	130.0
381899	17755445	CHEMBL3888208	Akt2 TR-FRET assay: His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased from Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.2 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a TR-FRET reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	NC(=O)c1cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2cn1		CHEMBL3932688	=	IC50	nM	97.0	CHEMBL2431	Homo sapiens	IC50	nM	97.0
381900	17755446	CHEMBL3888208	Akt2 TR-FRET assay: His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased from Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.2 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a TR-FRET reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	COC(=O)c1cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c(OC)n1		CHEMBL3956697	=	IC50	nM	86.0	CHEMBL2431	Homo sapiens	IC50	nM	86.0
381901	17755447	CHEMBL3888208	Akt2 TR-FRET assay: His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased from Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.2 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a TR-FRET reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	COc1nc(C(N)=O)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3931748	=	IC50	nM	14.0	CHEMBL2431	Homo sapiens	IC50	nM	14.0
Inactive	17882960	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882961	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Active	17882962	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Kd	nM	356.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	356.0
Inactive	17882963	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882964	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882965	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882966	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882967	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882968	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882969	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882970	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882971	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882972	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882973	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882974	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882975	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882976	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882977	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882978	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882979	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882980	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882981	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882982	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882983	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882984	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882985	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882986	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882987	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882988	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17882989	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	=	Kd	nM	891.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	891.0
Inactive	17882990	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882991	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882992	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882993	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882994	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882995	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882996	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882997	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882998	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882999	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883000	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883001	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883002	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883003	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883004	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883005	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883006	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883007	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883008	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883009	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883010	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883011	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Active	17883012	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	Kd	nM	2490.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	2490.0
Inactive	17883013	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883014	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883015	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883016	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883017	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883018	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883019	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883020	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883021	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883022	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883023	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883024	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883025	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883026	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883027	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883028	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883029	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883030	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883031	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883032	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Active	17883033	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	=	Kd	nM	21.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	21.0
Inactive	17883034	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883035	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883036	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883037	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883038	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883039	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883040	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883041	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883042	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883043	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883044	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883045	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883046	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883047	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883048	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883049	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883050	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883051	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883052	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883053	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883054	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883055	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883056	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883057	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883058	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883059	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883060	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883061	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17883062	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	=	Kd	nM	2800.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	2800.0
Inactive	17883063	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883064	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883065	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883066	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883067	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883068	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883069	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883070	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883071	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883072	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883073	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883074	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883075	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883076	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883077	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883078	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883079	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883080	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883081	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883082	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883083	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883084	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883085	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883086	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883087	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883088	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883089	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883090	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883091	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883092	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883093	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883094	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883095	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883096	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883097	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883098	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883099	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883100	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883101	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883102	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883103	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883104	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883105	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883106	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883107	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883108	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883109	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883110	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883111	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883112	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883113	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883114	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883115	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883116	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883117	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883118	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883119	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883120	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883121	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883122	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883123	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883124	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883125	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883126	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883127	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883128	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883129	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883130	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883131	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883132	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883133	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883134	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883135	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883136	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883137	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883138	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883139	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883140	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883141	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883142	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883143	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883144	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883145	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883146	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883147	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883148	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883149	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883150	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883151	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883152	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883153	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883154	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883155	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883156	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883157	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883158	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883159	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883160	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883161	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883162	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883163	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883164	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883165	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883166	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883167	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883168	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883169	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883170	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883171	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883172	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883173	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883174	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883175	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883176	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883177	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883178	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883179	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883180	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883181	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883182	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883183	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883184	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883185	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883186	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883187	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883188	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883189	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883190	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883191	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883192	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883193	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883194	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883195	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883196	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883197	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883198	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883199	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883200	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883201	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17883202	CHEMBL3991624	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL2431	Homo sapiens	Kd apparent	nM	30000.0
	17964872	CHEMBL3994981	Inhibition of human AKT2 expressed in bacterial expression system assessed as residual activity at 1 uM by KINOMEscan assay relative to control	B	CNc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)c(C)c2)ncn1		CHEMBL4060295	=	Activity	%	49.0	CHEMBL2431	Homo sapiens	Activity	%	49.0
	18065597	CHEMBL4014235	Inhibition of PKBbeta (unknown origin) in presence of [33P-gamma]ATP by scintillation counting	B	Cc1n[nH]c(C)c1-c1ccccc1		CHEMBL540487	=	IC50	nM	72000.0	CHEMBL2431	Homo sapiens	IC50	uM	72.0
	18065598	CHEMBL4014235	Inhibition of PKBbeta (unknown origin) in presence of [33P-gamma]ATP by scintillation counting	B	Cc1n[nH]c(N)c1-c1ccccc1		CHEMBL1609052	=	IC50	nM	660000.0	CHEMBL2431	Homo sapiens	IC50	uM	660.0
	18102176	CHEMBL4022196	Inhibition of recombinant human full length His-tagged AKT2 expressed in baculovirus expression system using ser/thr 6 as substrate after 1 hr by FRET-based Z'-Lyte assay	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	=	IC50	nM	402.0	CHEMBL2431	Homo sapiens	IC50	nM	402.0
	18114487	CHEMBL4025007	Inhibition of wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	95.0	CHEMBL2431	Homo sapiens	Activity	%	95.0
	18153354	CHEMBL4034251	Inhibition of AKT2 (unknown origin) labeling at ATP binding loop at 10 uM relative to control	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	-1.7	CHEMBL2431	Homo sapiens	INH	%	-1.7
	18203397	CHEMBL4043818	Inhibition of wild-type human partial length AKT2 expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	92.0	CHEMBL2431	Homo sapiens	Activity	%	92.0
	18211654	CHEMBL4045632	Inhibition of AKT2 labeling at ATP binding site (GTFGKVILVR) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	20.5	CHEMBL2431	Homo sapiens	INH	%	20.5
	18211779	CHEMBL4045875	Inhibition of AKT2 labeling at ATP binding site (GTFGKVILVR) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	17.1	CHEMBL2431	Homo sapiens	INH	%	17.1
	18232101	CHEMBL4050401	Inhibition of human PKBb assessed as residual activity at 1 uM in presence of [33P]ATP by filter binding assay relative to control	B	NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4077554	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	18248572	CHEMBL4053855	Inhibition of AKT2 (unknown origin) at 1 uM relative to control	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4104658	=	Inhibition	%	1.0	CHEMBL2431	Homo sapiens	INH	%	1.0
	18253723	CHEMBL4055146	Inhibition of wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	18253724	CHEMBL4055146	Inhibition of wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	88.0	CHEMBL2431	Homo sapiens	Activity	%	88.0
	18265738	CHEMBL4057188	Inhibition of AKT2 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	-2.0	CHEMBL2431	Homo sapiens	INH	%	-2.0
	18265954	CHEMBL4057404	Inhibition of AKT2 (unknown origin) at 0.49 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1		CHEMBL4088455	=	Inhibition	%	3.0	CHEMBL2431	Homo sapiens	INH	%	3.0
	18266170	CHEMBL4057620	Inhibition of AKT2 (unknown origin) at 0.078 uM relative to control	B	COC(=O)Nc1noc2cc(-c3c(-c4ccccn4)n[nH]c3C)ccc12		CHEMBL4066592	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	18282052	CHEMBL4120007	Inhibition of recombinant full length His-tagged human AKT2 expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	3.1	CHEMBL2431	Homo sapiens	INH	%	3.1
	18282371	CHEMBL4120007	Inhibition of recombinant full length His-tagged human AKT2 expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	-0.3	CHEMBL2431	Homo sapiens	INH	%	-0.3
	18282712	CHEMBL4120297	Inhibition of AKT2 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	-2.0	CHEMBL2431	Homo sapiens	INH	%	-2.0
	18282898	CHEMBL4120483	Inhibition of AKT2 (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	1.0	CHEMBL2431	Homo sapiens	INH	%	1.0
	18283112	CHEMBL4120697	Inhibition of AKT2 (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12		CHEMBL4129737	=	Inhibition	%	1.3	CHEMBL2431	Homo sapiens	INH	%	1.3
	18440073	CHEMBL4156897	Binding affinity to wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	92.0	CHEMBL2431	Homo sapiens	Activity	%	92.0
	18449811	CHEMBL4178048	Inhibition of human PKBbeta (120 to 481 residues) assessed as residual activity at 500 nM in presence of 33P-ATP by filter binding assay relative to control	B	Cc1cccc(-c2nc(N)sc2-c2ccc3ncccc3n2)c1		CHEMBL4209540	=	Activity	%	127.0	CHEMBL2431	Homo sapiens	Activity	%	127.0
	18457626	CHEMBL4179662	Inhibition of human AKT2 at 1 uM by filter binding assay relative to control	B	CS(=O)(=O)N1CCN(Cc2cc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3n2)CC1		CHEMBL4212439	<	Inhibition	%	25.0	CHEMBL2431	Homo sapiens	INH	%	25.0
	18457627	CHEMBL4179662	Inhibition of human AKT2 at 1 uM by filter binding assay relative to control	B	CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3n2)CC1		CHEMBL4217392	<	Inhibition	%	25.0	CHEMBL2431	Homo sapiens	INH	%	25.0
	18457628	CHEMBL4179662	Inhibition of human AKT2 at 1 uM by filter binding assay relative to control	B	CS(=O)(=O)N1CCN(Cc2cn3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1		CHEMBL4208064	<	Inhibition	%	25.0	CHEMBL2431	Homo sapiens	INH	%	25.0
	18457629	CHEMBL4179662	Inhibition of human AKT2 at 1 uM by filter binding assay relative to control	B	CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)c(Cl)n3n2)CC1		CHEMBL4205584	<	Inhibition	%	25.0	CHEMBL2431	Homo sapiens	INH	%	25.0
	18463783	CHEMBL4181199	Inhibition of recombinant human N-terminal His6-tagged PKBbeta (120 to 481 residue) S474D mutant expressed in baculovirus Sf21 insect cells at 10 uM by filter binding radioactive ATP transferase assay relative to control	B	C=C(C)n1c(=O)n(C(C)=O)c2cc(Br)cnc21		CHEMBL4212680	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	18484513	CHEMBL4185676	Binding affinity to wild-type human partial length AKT2 expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	18485108	CHEMBL4185676	Binding affinity to wild-type human partial length AKT2 expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	95.0	CHEMBL2431	Homo sapiens	Activity	%	95.0
	18489487	CHEMBL4187228	Inhibition of wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	Fc1cc(F)cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1		CHEMBL4207079	=	Activity	%	91.0	CHEMBL2431	Homo sapiens	Activity	%	91.0
	18507656	CHEMBL4191135	Inhibition of recombinant human PKBbeta (120 to end residues) at 1 uM using GRPRTSSFAEGKK as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1	Outside typical range	CHEMBL4207014	=	Inhibition	%	-13.0	CHEMBL2431	Homo sapiens	INH	%	-13.0
Active	18584153	CHEMBL4223163	Inhibition of AKT2 phosphorylation in human PC3 cells at 14 uM after 12 to 24 hrs by Western blot analysis	B	CSc1c(C(=O)c2ccc(Br)cc2)c(N)c2ccccc2c1C#N		CHEMBL4225101		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	18653777	CHEMBL4230015	Inhibition of AKT2 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	18653778	CHEMBL4230015	Inhibition of AKT2 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	-10.0	CHEMBL2431	Homo sapiens	INH	%	-10.0
	18655644	CHEMBL4230576	Binding affinity to wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	18663902	CHEMBL4232866	Inhibition of human AKT2 expressed in bacterial expression system assessed as residual activity at 5 uM by KINOMEscan assay relative to control	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	18663979	CHEMBL4232963	Binding affinity to human AKT2 expressed in bacterial expression system by KINOMEscan assay	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	>=	Kd	nM	5000.0	CHEMBL2431	Homo sapiens	Kd	uM	5.0
	18665495	CHEMBL4233285	Inhibition of AKT2 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4251324	>	IC50	nM	5000.0	CHEMBL2431	Homo sapiens	IC50	nM	5000.0
	18665567	CHEMBL4233285	Inhibition of AKT2 (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	nM	10000.0
	18674529	CHEMBL4235310	Inhibition of Akt2 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	>	Ki	nM	10000.0	CHEMBL2431	Homo sapiens	Ki	nM	10000.0
	18674530	CHEMBL4235310	Inhibition of Akt2 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242	>	Ki	nM	10000.0	CHEMBL2431	Homo sapiens	Ki	nM	10000.0
	18674531	CHEMBL4235310	Inhibition of Akt2 (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525	>	Ki	nM	10000.0	CHEMBL2431	Homo sapiens	Ki	nM	10000.0
	18693958	CHEMBL4253411	Inhibition of recombinant full length human His-tagged AKT2 expressed in baculovirus expression system at 0.1 uM by TR-FRET assay relative to control	B	CC1=Nc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc2C12CCCC2		CHEMBL4277900	=	Inhibition	%	1.0	CHEMBL2431	Homo sapiens	INH	%	1.0
	18694040	CHEMBL4253493	Inhibition of recombinant full length human His-tagged AKT2 expressed in baculovirus expression system at 1 uM by TR-FRET assay relative to control	B	CC1=Nc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc2C12CCCC2		CHEMBL4277900	=	Inhibition	%	9.0	CHEMBL2431	Homo sapiens	INH	%	9.0
	18697608	CHEMBL4254281	Inhibition of wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCNc1cc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2C(F)(F)F)ccn1		CHEMBL4281348	=	Activity	%	80.0	CHEMBL2431	Homo sapiens	Activity	%	80.0
	18708948	CHEMBL4256668	Inhibition of AKT2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	Nc1ccc[nH]c1=O		CHEMBL4286709	=	Inhibition	%	77.0	CHEMBL2431	Homo sapiens	INH	%	77.0
	18708994	CHEMBL4256668	Inhibition of AKT2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	Cn1cc(-c2c[nH]c(=O)c(N)c2)cn1		CHEMBL4288628	=	Inhibition	%	97.0	CHEMBL2431	Homo sapiens	INH	%	97.0
	18709006	CHEMBL4256668	Inhibition of AKT2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	Nc1cc(-c2ccncc2)c[nH]c1=O		CHEMBL12856	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	18709038	CHEMBL4256668	Inhibition of AKT2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	COc1ncc(-c2ccncc2)cc1N		CHEMBL4291350	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	18709067	CHEMBL4256668	Inhibition of AKT2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	Nc1cc(-c2ccnc3ccccc23)c[nH]c1=O		CHEMBL4280308	=	Inhibition	%	9.0	CHEMBL2431	Homo sapiens	INH	%	9.0
	18709096	CHEMBL4256668	Inhibition of AKT2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	CNc1nccc(-c2c[nH]c(=O)c(N)c2)n1		CHEMBL4292538	=	Inhibition	%	93.0	CHEMBL2431	Homo sapiens	INH	%	93.0
	18709125	CHEMBL4256668	Inhibition of AKT2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	Nc1cc(-c2ccnc(NC3CC3)n2)c[nH]c1=O		CHEMBL4282263	=	Inhibition	%	18.0	CHEMBL2431	Homo sapiens	INH	%	18.0
	18709172	CHEMBL4256668	Inhibition of AKT2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	Cc1nc(O)c(N)cc1-c1ccncc1		CHEMBL302219	=	Inhibition	%	17.0	CHEMBL2431	Homo sapiens	INH	%	17.0
	18709202	CHEMBL4256694	Inhibition of AKT2 (unknown origin) at 30 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	O=C(Nc1cc(-c2ccncc2)c[nH]c1=O)c1ccccc1		CHEMBL1738828	=	Inhibition	%	4.0	CHEMBL2431	Homo sapiens	INH	%	4.0
	18709231	CHEMBL4256668	Inhibition of AKT2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	COc1cccc(C(=O)Nc2cc(-c3ccncc3)c[nH]c2=O)c1		CHEMBL4285109	=	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	18709273	CHEMBL4256694	Inhibition of AKT2 (unknown origin) at 30 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	CN1CCN(c2ccc(C(=O)Nc3cc(-c4ccncc4)c[nH]c3=O)cc2)CC1		CHEMBL4286130	=	Inhibition	%	13.0	CHEMBL2431	Homo sapiens	INH	%	13.0
	18709306	CHEMBL4256694	Inhibition of AKT2 (unknown origin) at 30 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	O=C(Nc1cc(-c2ccnc(NC3CC3)n2)c[nH]c1=O)c1ccccc1		CHEMBL4291472	=	Inhibition	%	91.0	CHEMBL2431	Homo sapiens	INH	%	91.0
	18728883	CHEMBL4259713	Inhibition of AKT2 (unknown origin) at 10 nM after 40 mins by scintillation counting method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4285143	=	Inhibition	%	38.0	CHEMBL2431	Homo sapiens	INH	%	38.0
	18751078	CHEMBL4263727	Inhibition of AKT2 (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	3.0	CHEMBL2431	Homo sapiens	INH	%	3.0
	18752049	CHEMBL4264165	Binding affinity to wild-type human partial length AKT2 expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	88.0	CHEMBL2431	Homo sapiens	Activity	%	88.0
	18761565	CHEMBL4266616	Inhibition of human PKBbeta at 1 uM relative to control	B	CN(C)[C@H]1CC[C@H](Nc2ncnc3[nH]cc([C@H]4CC[C@H](C(N)=O)CC4)c23)CC1		CHEMBL4279192	=	Inhibition	%	12.0	CHEMBL2431	Homo sapiens	INH	%	12.0
	18761836	CHEMBL4266616	Inhibition of human PKBbeta at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C(C)C)c34)CC2)CC1		CHEMBL4278882	=	Inhibition	%	3.0	CHEMBL2431	Homo sapiens	INH	%	3.0
	18761999	CHEMBL4266616	Inhibition of human PKBbeta at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C5CCOCC5)c34)CC2)CC1		CHEMBL4290222	=	Inhibition	%	34.0	CHEMBL2431	Homo sapiens	INH	%	34.0
	18764461	CHEMBL4267056	Inhibition of human PKBbeta at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)cc3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4288103	<	Inhibition	%	70.0	CHEMBL2431	Homo sapiens	INH	%	70.0
	18764462	CHEMBL4267056	Inhibition of human PKBbeta at 100 nM	B	CN1CCC(c2nc(-c3cccc(S(C)(=O)=O)c3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4286880	<	Inhibition	%	70.0	CHEMBL2431	Homo sapiens	INH	%	70.0
	18764463	CHEMBL4267056	Inhibition of human PKBbeta at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)c(NS(C)(=O)=O)c3)c(-c3ccnc(NCC4CC4)n3)s2)CC1		CHEMBL4286841	<	Inhibition	%	70.0	CHEMBL2431	Homo sapiens	INH	%	70.0
Not Active	18847345	CHEMBL4304875	Inhibition of wild-type human partial length AKT2 expressed in bacterial expression system at 1 uM by Kinomescan method	B	O=C(Nc1ccc2[nH]nc(-c3ccc4[nH]ccc4c3)c2c1)c1c(Cl)cccc1Cl		CHEMBL4517719		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	18857784	CHEMBL4307682	Binding affinity to wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
Not Active	18883542	CHEMBL4312749	Activity at human PKBbeta at 10 uM	B	CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F		CHEMBL4585668		Activity			CHEMBL2431	Homo sapiens	Activity		
	18892684	CHEMBL4314565	Inhibition of recombinant full-length human PKBbeta S474D mutant (120 to end residues) assessed as residual activity at 10 uM using GRPRTSSFAEGKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	113.5	CHEMBL2431	Homo sapiens	Activity	%	113.5
	18919491	CHEMBL4322847	Binding affinity to recombinant human N-terminal GST-tagged AKT2 (120 to 481 residues) expressed in baculovirus expression system using crosstide as substrate incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	365.0	CHEMBL2431	Homo sapiens	Kd	nM	365.0
	18919679	CHEMBL4322847	Binding affinity to recombinant human N-terminal GST-tagged AKT2 (120 to 481 residues) expressed in baculovirus expression system using crosstide as substrate incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	357.0	CHEMBL2431	Homo sapiens	Kd	nM	357.0
	18937693	CHEMBL4327576	Inhibition of human AKT2 assessed as residual activity at 1 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	100.06	CHEMBL2431	Homo sapiens	Activity	%	100.06
	18937694	CHEMBL4327576	Inhibition of human AKT2 assessed as residual activity at 1 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	95.13	CHEMBL2431	Homo sapiens	Activity	%	95.13
	18938417	CHEMBL4327937	Inhibition of human AKT2 assessed as residual activity at 100 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL2431	Homo sapiens	Activity	%	65.0
	18938782	CHEMBL4328301	Inhibition of human AKT2 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	41.5	CHEMBL2431	Homo sapiens	IC50	10'-8M	4.15
	18953670	CHEMBL4331947	Inhibition of PKBb (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(NC3CCCCC3)c12		CHEMBL4440433	=	Inhibition	%	24.0	CHEMBL2431	Homo sapiens	INH	%	24.0
	18953736	CHEMBL4331947	Inhibition of PKBb (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(Nc3ccccc3F)c12		CHEMBL4449552	=	Inhibition	%	15.0	CHEMBL2431	Homo sapiens	INH	%	15.0
	18953861	CHEMBL4331947	Inhibition of PKBb (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(OC3CCCCC3)c12		CHEMBL4524629	=	Inhibition	%	28.0	CHEMBL2431	Homo sapiens	INH	%	28.0
	18953953	CHEMBL4332006	Inhibition of PKBb (unknown origin) at 1 uM relative to control	B	CC(C)n1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cn1		CHEMBL4589022	=	Inhibition	%	27.0	CHEMBL2431	Homo sapiens	INH	%	27.0
	18954017	CHEMBL4332006	Inhibition of PKBb (unknown origin) at 1 uM relative to control	B	c1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cc(N2CCOCC2)n1		CHEMBL4460272	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	18954084	CHEMBL4331947	Inhibition of PKBb (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(Nc3ccc4ncsc4c3)c12		CHEMBL4588446	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	18958687	CHEMBL4333276	Binding affinity to wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	93.0	CHEMBL2431	Homo sapiens	Activity	%	93.0
	18964588	CHEMBL4335235	Inhibition of recombinant human PKBbeta S474D mutant (120 to end residues) assessed as residual activity at 1 uM using GRPRTSSFAEGKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	111.0	CHEMBL2431	Homo sapiens	Activity	%	111.0
	18964589	CHEMBL4335235	Inhibition of recombinant human PKBbeta S474D mutant (120 to end residues) assessed as residual activity at 1 uM using GRPRTSSFAEGKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	102.0	CHEMBL2431	Homo sapiens	Activity	%	102.0
	18972048	CHEMBL4337058	Inhibition of recombinant human PKBbeta S474D mutant (120 to end residues) assessed as residual activity at 10 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	61.0	CHEMBL2431	Homo sapiens	Activity	%	61.0
	18989191	CHEMBL4340733	Inhibition of recombinant human N-terminal GST-His6-fused AKT2 C-terminal domain (A107 to E481 residues) expressed in Sf9 insect cells using GSK3(14-27)tide as substrate measured after 60 mins in presence of [gamma-33P]-ATP by scintillation counting method	B	CN(CCc1ccc(-c2ccccc2)cc1)Cc1cn(C)c2ccc(C(=O)Nc3ccc(F)cc3)cc12		CHEMBL4446681	=	IC50	nM	21000.0	CHEMBL2431	Homo sapiens	IC50	uM	21.0
	18989214	CHEMBL4340756	Inhibition of recombinant human full-length N-terminal GST-His6-fused AKT2 (M1 to E481 residues) expressed in Sf9 insect cells using GSK3-derived peptide as substrate measured after 60 mins in presence of [gamma-33P]-ATP by scintillation counting method	B	CN(CCc1ccc(-c2ccccc2)cc1)Cc1cn(C)c2ccc(C(=O)Nc3ccc(F)cc3)cc12		CHEMBL4446681	>	IC50	nM	100000.0	CHEMBL2431	Homo sapiens	IC50	uM	100.0
	19035285	CHEMBL4350381	Inhibition of human AKT2 assessed as residual activity at 10 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	B	O=C1NC2(CCCCC2)n2c1c(Cl)cc(Nc1ccncn1)c2=O		CHEMBL4439094	=	Activity	%	96.0	CHEMBL2431	Homo sapiens	Activity	%	96.0
Not Active	19040106	CHEMBL4352010	Inhibition of recombinant full-length human PKBbeta S474D mutant (120 to end residues) at 10 uM using GRPRTSSFAEGKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	19041002	CHEMBL4352263	Inhibition of human AKT2 at 10 uM using KGSGSGRPRTSSFAEG as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	19059453	CHEMBL4357754	Binding affinity to wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	19090026	CHEMBL4365600	Inhibition of wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	19091805	CHEMBL4366279	Inhibition of human AKT2 at 100 nM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	28.06	CHEMBL2431	Homo sapiens	INH	%	28.06
	19144752	CHEMBL4377768	Inhibition of recombinant human pkb-beta S474D mutant (120 to end residues) at 1 uM using GRPRTSSFAEGKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	23.0	CHEMBL2431	Homo sapiens	INH	%	23.0
	19147992	CHEMBL4379238	Inhibition of recombinant human PKBbeta S474D mutant (120 to end residues) using GRPRTSSFAEGKK as substrate incubated for 40 mins in presence of [gamma33P]ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL2431	Homo sapiens	IC50	uM	10.0
	19159281	CHEMBL4382385	Binding affinity to wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	94.0	CHEMBL2431	Homo sapiens	Activity	%	94.0
	19180957	CHEMBL4387167	Inhibition of recombinant full length human His-tagged AKT2 expressed in baculovirus expression system at 0.1 uM using serine/threonine-06 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	3.0	CHEMBL2431	Homo sapiens	INH	%	3.0
	19181183	CHEMBL4387167	Inhibition of recombinant full length human His-tagged AKT2 expressed in baculovirus expression system at 0.1 uM using serine/threonine-06 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	9.5	CHEMBL2431	Homo sapiens	INH	%	9.5
	19191244	CHEMBL4389581	Inhibition of wild-type human partial length AKT2 expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	100.0	CHEMBL2431	Homo sapiens	INH	%	100.0
	19191726	CHEMBL4389104	Inhibition of wild-type human partial length AKT2 expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	100.0	CHEMBL2431	Homo sapiens	INH	%	100.0
	19200015	CHEMBL4391207	Binding affinity to wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	80.0	CHEMBL2431	Homo sapiens	Activity	%	80.0
	19266302	CHEMBL4405252	Inhibition of wild-type human partial length AKT2 expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL2431	Homo sapiens	INH	%	50.0
	19273874	CHEMBL4407364	Inhibition of human Akt2 by mobile shift assay	B	CNC(=O)C[C@@H]1C[C@@H](c2ccc(F)c(F)c2)[C@H](NC(=O)c2cc(-c3c(Cl)cnn3C)c(Cl)o2)CN1		CHEMBL4440965	=	IC50	nM	1.2	CHEMBL2431	Homo sapiens	IC50	nM	1.2
	19273875	CHEMBL4407364	Inhibition of human Akt2 by mobile shift assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CCO)C[C@H]2c2ccc(F)c(F)c2)oc1Cl		CHEMBL4441825	=	IC50	nM	0.54	CHEMBL2431	Homo sapiens	IC50	nM	0.54
	19273876	CHEMBL4407364	Inhibition of human Akt2 by mobile shift assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)oc1Cl.O=C(O)[C@H](O)[C@@H](O)C(=O)O		CHEMBL4457064	<	IC50	nM	0.64	CHEMBL2431	Homo sapiens	IC50	nM	0.64
	19273877	CHEMBL4407364	Inhibition of human Akt2 by mobile shift assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	=	IC50	nM	1.0	CHEMBL2431	Homo sapiens	IC50	nM	1.0
	19276095	CHEMBL4408098	Inhibition of recombinant human PKBbeta (120 to end residues) at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	19319993	CHEMBL4417587	Inhibition of N-terminal GST tagged human AKT2 catalytic domain (120 to 481 AA) expressed in baculovirus at 10 uM using FAM-labelled peptide as substrate pre-incubated for 10 mins followed by substrate addition by mobility shift assay relative to control	B	COc1ccc(OC)c(Nc2cc(NC(=O)Nc3c(Cl)cccc3Cl)ncn2)c1		CHEMBL4548481	=	Inhibition	%	12.65	CHEMBL2431	Homo sapiens	INH	%	12.65
	19471309	CHEMBL4478654	Inhibition of full length active AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate/PDK1/MAPKAPK2/DOPS/DOPC/PtdIns(3,4,5)P3 addition measured after 30 mins by Alphascreen assay	B	Cl.Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4523032	=	IC50	nM	4.5	CHEMBL2431	Homo sapiens	IC50	uM	0.0045
	19471310	CHEMBL4478654	Inhibition of full length active AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate/PDK1/MAPKAPK2/DOPS/DOPC/PtdIns(3,4,5)P3 addition measured after 30 mins by Alphascreen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1.Cl		CHEMBL4519558	=	IC50	nM	3.2	CHEMBL2431	Homo sapiens	IC50	uM	0.0032
	19471311	CHEMBL4478654	Inhibition of full length active AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate/PDK1/MAPKAPK2/DOPS/DOPC/PtdIns(3,4,5)P3 addition measured after 30 mins by Alphascreen assay	B	Cl.Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL4574111	=	IC50	nM	2.8	CHEMBL2431	Homo sapiens	IC50	uM	0.0028
	19471312	CHEMBL4478654	Inhibition of full length active AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate/PDK1/MAPKAPK2/DOPS/DOPC/PtdIns(3,4,5)P3 addition measured after 30 mins by Alphascreen assay	B	Cl.Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4544109	=	IC50	nM	36.0	CHEMBL2431	Homo sapiens	IC50	uM	0.036
	19471338	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cc1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL4535365	=	IC50	nM	20000.0	CHEMBL2431	Homo sapiens	IC50	uM	20.0
	19471339	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	CC(C)(C)c1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL2177840	=	IC50	nM	16000.0	CHEMBL2431	Homo sapiens	IC50	uM	16.0
	19471340	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL4517839	=	IC50	nM	9300.0	CHEMBL2431	Homo sapiens	IC50	uM	9.3
Not Determined	19471341	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cc1ccnc2c1nc(-c1cccnc1N)n2-c1ccc(CN)cc1.Cl		CHEMBL4568743		IC50			CHEMBL2431	Homo sapiens	IC50		
	19471342	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cc1cnc2c(c1)nc(-c1cccnc1N)n2-c1ccc(CN)cc1.Cl		CHEMBL4565210	=	IC50	nM	5300.0	CHEMBL2431	Homo sapiens	IC50	uM	5.3
Not Determined	19471343	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cc1cc2nc(-c3cccnc3N)n(-c3ccc(CN)cc3)c2nc1C.Cl		CHEMBL4543768		IC50			CHEMBL2431	Homo sapiens	IC50		
	19471344	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3ccc(Cl)nc32)cc1		CHEMBL4545250	=	IC50	nM	1900.0	CHEMBL2431	Homo sapiens	IC50	uM	1.9
Not Determined	19471345	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3cc(Br)cnc32)cc1		CHEMBL4558319		IC50			CHEMBL2431	Homo sapiens	IC50		
	19471346	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3ccc(-c4ccccc4)nc32)cc1		CHEMBL4513257	=	IC50	nM	33.0	CHEMBL2431	Homo sapiens	IC50	uM	0.033
	19471347	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CN)cc4)c3n2)c1.Cl		CHEMBL4546484	=	IC50	nM	24.0	CHEMBL2431	Homo sapiens	IC50	uM	0.024
	19471348	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	CC(=O)Nc1ccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CN)cc4)c3n2)cc1.Cl		CHEMBL4586184	=	IC50	nM	79.0	CHEMBL2431	Homo sapiens	IC50	uM	0.079
	19471349	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3ccc(-c4cn[nH]c4)nc32)cc1		CHEMBL4576518	=	IC50	nM	14.0	CHEMBL2431	Homo sapiens	IC50	uM	0.014
	19471350	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3cc(-c4cccnc4)cnc32)cc1		CHEMBL4550916	=	IC50	nM	3500.0	CHEMBL2431	Homo sapiens	IC50	uM	3.5
Not Determined	19471351	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	CC(C)(N)c1ccc(-n2c(-c3cccnc3N)nc3ccc(-c4ccccc4)nc32)cc1		CHEMBL4528363		IC50			CHEMBL2431	Homo sapiens	IC50		
	19471352	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4523032	=	IC50	nM	14.0	CHEMBL2431	Homo sapiens	IC50	uM	0.014
Not Determined	19471353	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	CC(=O)NC1(c2ccc(-n3c(-c4cccnc4N)nc4ccc(-c5ccccc5)nc43)cc2)CCC1		CHEMBL4553900		IC50			CHEMBL2431	Homo sapiens	IC50		
Not Determined	19471354	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	COC(=O)C1(c2ccc(-n3c(-c4cccnc4N)nc4ccc(-c5ccccc5)nc43)cc2)CCC1		CHEMBL4526693		IC50			CHEMBL2431	Homo sapiens	IC50		
Not Determined	19471355	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	NC(=O)C1(c2ccc(-n3c(-c4cccnc4N)nc4ccc(-c5ccccc5)nc43)cc2)CCC1		CHEMBL4517319		IC50			CHEMBL2431	Homo sapiens	IC50		
	19471356	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1.Cl		CHEMBL4519558	=	IC50	nM	7.1	CHEMBL2431	Homo sapiens	IC50	uM	0.0071
	19471357	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL4574111	=	IC50	nM	5.4	CHEMBL2431	Homo sapiens	IC50	uM	0.0054
	19471358	CHEMBL4478657	Inhibition of full length unphosphorylated AKT2 (1 to 481 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4544109	=	IC50	nM	2.5	CHEMBL2431	Homo sapiens	IC50	uM	0.0025
	19476544	CHEMBL4479692	Inhibition of full-length recombinant human His-tagged AKT2 expressed in baculovirus expression system by Z'-LYTE assay	B	O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1		CHEMBL4569508	=	IC50	nM	23000.0	CHEMBL2431	Homo sapiens	IC50	nM	23000.0
	19476644	CHEMBL4479692	Inhibition of full-length recombinant human His-tagged AKT2 expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1		CHEMBL4550702	>	IC50	nM	100000.0	CHEMBL2431	Homo sapiens	IC50	nM	100000.0
	19476744	CHEMBL4479692	Inhibition of full-length recombinant human His-tagged AKT2 expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1		CHEMBL4568087	=	IC50	nM	430.0	CHEMBL2431	Homo sapiens	IC50	nM	430.0
	19476844	CHEMBL4479692	Inhibition of full-length recombinant human His-tagged AKT2 expressed in baculovirus expression system by Z'-LYTE assay	B	Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12		CHEMBL4552628	=	IC50	nM	2500.0	CHEMBL2431	Homo sapiens	IC50	nM	2500.0
	20600460	CHEMBL4603289	Inhibition of recombinant full length human His-tagged AKT2 expressed in baculovirus expression system using Ser/Thr-06 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL2431	Homo sapiens	IC50	uM	100.0
	20642204	CHEMBL4613506	Inhibition of PKBbeta (unknown origin)	B	O=C(/C=C/c1nc2ccccc2[nH]1)c1c(O)nc2ccc(Cl)cc2c1-c1ccccc1		CHEMBL190313	=	IC50	nM	1640.0	CHEMBL2431	Homo sapiens	IC50	uM	1.64
	20642209	CHEMBL4613506	Inhibition of PKBbeta (unknown origin)	B	Cc1ccc2[nH]c(/C=C/C(=O)c3c(-c4ccccc4)c4cc(Cl)ccc4[nH]c3=O)nc2c1		CHEMBL4637800	=	IC50	nM	1640.0	CHEMBL2431	Homo sapiens	IC50	uM	1.64
	20642214	CHEMBL4613506	Inhibition of PKBbeta (unknown origin)	B	O=C(/C=C/c1nc2cc(Br)ccc2[nH]1)c1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL4648204	=	IC50	nM	1640.0	CHEMBL2431	Homo sapiens	IC50	uM	1.64
	20642219	CHEMBL4613506	Inhibition of PKBbeta (unknown origin)	B	O=C(/C=C/c1nc2cc(F)ccc2[nH]1)c1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL4644882	=	IC50	nM	1640.0	CHEMBL2431	Homo sapiens	IC50	uM	1.64
	20642224	CHEMBL4613506	Inhibition of PKBbeta (unknown origin)	B	O=C(/C=C/c1nc2ccccc2[nH]1)c1c(-c2ccccc2)c2ccccc2[nH]c1=O		CHEMBL4646965	=	IC50	nM	1640.0	CHEMBL2431	Homo sapiens	IC50	uM	1.64
	20642229	CHEMBL4613506	Inhibition of PKBbeta (unknown origin)	B	O=C(/C=C/c1nc2ccccc2[nH]1)c1c(-c2ccccc2)c2cc(Br)ccc2[nH]c1=O		CHEMBL4636228	=	IC50	nM	1640.0	CHEMBL2431	Homo sapiens	IC50	uM	1.64
	20642234	CHEMBL4613506	Inhibition of PKBbeta (unknown origin)	B	Cc1ccc2[nH]c(=O)c(C(=O)/C=C/c3nc4ccccc4[nH]3)c(-c3ccccc3)c2c1		CHEMBL4643610	=	IC50	nM	1640.0	CHEMBL2431	Homo sapiens	IC50	uM	1.64
	20642239	CHEMBL4613506	Inhibition of PKBbeta (unknown origin)	B	Cn1c(=O)c(C(=O)/C=C/c2nc3cc(F)ccc3[nH]2)c(-c2ccccc2)c2cc(Cl)ccc21		CHEMBL4646743	=	IC50	nM	1640.0	CHEMBL2431	Homo sapiens	IC50	uM	1.64
	20642244	CHEMBL4613506	Inhibition of PKBbeta (unknown origin)	B	O=C(/C=C/c1nc2cc(F)ccc2[nH]1)c1c(-c2ccc(F)cc2)c2cc(F)ccc2[nH]c1=O		CHEMBL4638124	=	IC50	nM	1640.0	CHEMBL2431	Homo sapiens	IC50	uM	1.64
	20642249	CHEMBL4613506	Inhibition of PKBbeta (unknown origin)	B	O=C(/C=C/c1nc2cc(F)c(F)cc2[nH]1)c1c(-c2ccc(F)cc2)c2cc(F)ccc2[nH]c1=O		CHEMBL4645387	=	IC50	nM	1640.0	CHEMBL2431	Homo sapiens	IC50	uM	1.64
	20642254	CHEMBL4613506	Inhibition of PKBbeta (unknown origin)	B	O=C(/C=C/c1nc2cc(F)c(F)cc2[nH]1)c1c(-c2ccc(F)cc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL4633766	=	IC50	nM	1640.0	CHEMBL2431	Homo sapiens	IC50	uM	1.64
	20642259	CHEMBL4613506	Inhibition of PKBbeta (unknown origin)	B	O=C(/C=C/c1nc2cc(F)c(F)cc2[nH]1)c1c(-c2ccc(F)c(F)c2)c2cc(F)ccc2[nH]c1=O		CHEMBL4649562	=	IC50	nM	1640.0	CHEMBL2431	Homo sapiens	IC50	uM	1.64
	22392008	CHEMBL4667103	Inhibition of recombinant human His-tagged full length AKT2 expressed in baculovirus expression system using Ser/Thr 06 as substrate at 10 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	7.5	CHEMBL2431	Homo sapiens	INH	%	7.5
	22423847	CHEMBL4674499	Inhibition of human AKT2 using KGSGSGRPRTSSFAEG as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	94.24	CHEMBL2431	Homo sapiens	Activity	%	94.24
	22423848	CHEMBL4674499	Inhibition of human AKT2 using KGSGSGRPRTSSFAEG as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	99.21	CHEMBL2431	Homo sapiens	Activity	%	99.21
	22470459	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCN(C(=O)N(C)C)C4)CC1)c1ccc(Cl)cc1		CHEMBL4744557	=	Activity	%	95.0	CHEMBL2431	Homo sapiens	Activity	%	95.0
	22470460	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCC4)CC1)c1ccccc1Cl		CHEMBL4744717	=	Activity	%	101.0	CHEMBL2431	Homo sapiens	Activity	%	101.0
	22470461	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	COc1ccc(C(CNC(C)C)C(=O)N2CCN(c3ncnc4sc5c(c34)CCC5)CC2)cc1		CHEMBL4776972	=	Activity	%	86.0	CHEMBL2431	Homo sapiens	Activity	%	86.0
	22470462	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCC4)CC1)c1ccc(Br)cc1		CHEMBL4787195	=	Activity	%	67.0	CHEMBL2431	Homo sapiens	Activity	%	67.0
	22470463	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCC4)CC1)c1ccc(F)cc1		CHEMBL4753482	=	Activity	%	104.0	CHEMBL2431	Homo sapiens	Activity	%	104.0
	22470464	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	O=C(C(CNC1CCCCC1)c1ccc(Cl)cc1)N1CCN(c2ncnc3sc4c(c23)CCC4)CC1		CHEMBL4745768	=	Activity	%	51.0	CHEMBL2431	Homo sapiens	Activity	%	51.0
	22470465	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	O=C(C(CNC1CCCC1)c1ccc(Cl)cc1)N1CCN(c2ncnc3sc4c(c23)CCC4)CC1		CHEMBL4757904	=	Activity	%	63.0	CHEMBL2431	Homo sapiens	Activity	%	63.0
	22470466	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CCCCNCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCC4)CC1)c1ccc(Cl)cc1		CHEMBL4781445	=	Activity	%	56.0	CHEMBL2431	Homo sapiens	Activity	%	56.0
	22470467	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CCNCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCC4)CC1)c1ccc(Cl)cc1		CHEMBL4793499	=	Activity	%	58.0	CHEMBL2431	Homo sapiens	Activity	%	58.0
	22470468	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCOC4)CC1)c1ccc(Cl)cc1		CHEMBL4749173	=	Activity	%	81.0	CHEMBL2431	Homo sapiens	Activity	%	81.0
	22470469	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCC4)CC1)c1ccc(Cl)cc1		CHEMBL4785199	=	Activity	%	57.0	CHEMBL2431	Homo sapiens	Activity	%	57.0
	22470470	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCCC4)CC1)c1ccc(Cl)cc1		CHEMBL4750379	=	Activity	%	72.0	CHEMBL2431	Homo sapiens	Activity	%	72.0
	22470471	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCN(C)C4)CC1)c1ccccc1Cl		CHEMBL4800620	=	Activity	%	83.0	CHEMBL2431	Homo sapiens	Activity	%	83.0
	22470472	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	COc1ccc(C(CNC(C)C)C(=O)N2CCN(c3ncnc4sc5c(c34)CCN(C)C5)CC2)cc1		CHEMBL4781839	=	Activity	%	78.0	CHEMBL2431	Homo sapiens	Activity	%	78.0
	22470473	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	Cc1ccc(C(CNC(C)C)C(=O)N2CCN(c3ncnc4sc5c(c34)CCN(C)C5)CC2)cc1		CHEMBL4776552	=	Activity	%	73.0	CHEMBL2431	Homo sapiens	Activity	%	73.0
	22470474	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCN(C)C4)CC1)c1ccc(Br)cc1		CHEMBL4747290	=	Activity	%	86.0	CHEMBL2431	Homo sapiens	Activity	%	86.0
	22470475	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCN(C)C4)CC1)c1ccc(F)cc1		CHEMBL4797537	=	Activity	%	111.0	CHEMBL2431	Homo sapiens	Activity	%	111.0
	22470476	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CN1CCc2c(sc3ncnc(N4CCN(C(=O)C(CNC5CCCCC5)c5ccc(Cl)cc5)CC4)c23)C1		CHEMBL4754428	=	Activity	%	88.0	CHEMBL2431	Homo sapiens	Activity	%	88.0
	22470477	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CN1CCc2c(sc3ncnc(N4CCN(C(=O)C(CNC5CCCC5)c5ccc(Cl)cc5)CC4)c23)C1		CHEMBL4756067	=	Activity	%	81.0	CHEMBL2431	Homo sapiens	Activity	%	81.0
	22470478	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CCCCNCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCN(C)C4)CC1)c1ccc(Cl)cc1		CHEMBL4762720	=	Activity	%	93.0	CHEMBL2431	Homo sapiens	Activity	%	93.0
	22470479	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CCNCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCN(C)C4)CC1)c1ccc(Cl)cc1		CHEMBL4787253	=	Activity	%	107.0	CHEMBL2431	Homo sapiens	Activity	%	107.0
	22470480	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCN(C(C)C)C4)CC1)c1ccc(Cl)cc1		CHEMBL4762457	=	Activity	%	81.0	CHEMBL2431	Homo sapiens	Activity	%	81.0
	22470481	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCN(C2CC2)C4)CC1)c1ccc(Cl)cc1		CHEMBL4783415	=	Activity	%	71.0	CHEMBL2431	Homo sapiens	Activity	%	71.0
	22470482	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCN(Cc2ccccc2)C4)CC1)c1ccc(Cl)cc1		CHEMBL4788316	=	Activity	%	77.0	CHEMBL2431	Homo sapiens	Activity	%	77.0
	22470483	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CCCN1CCc2c(sc3ncnc(N4CCN(C(=O)C(CNC(C)C)c5ccc(Cl)cc5)CC4)c23)C1		CHEMBL4742710	=	Activity	%	89.0	CHEMBL2431	Homo sapiens	Activity	%	89.0
	22470484	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CCN1CCc2c(sc3ncnc(N4CCN(C(=O)C(CNC(C)C)c5ccc(Cl)cc5)CC4)c23)C1		CHEMBL4755498	=	Activity	%	82.0	CHEMBL2431	Homo sapiens	Activity	%	82.0
	22470485	CHEMBL4685025	Inhibition of full length human Akt2 S474D mutant assessed as remaining activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method relative to control	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCN(C)C4)CC1)c1ccc(Cl)cc1		CHEMBL4758396	=	Activity	%	91.0	CHEMBL2431	Homo sapiens	Activity	%	91.0
	22470519	CHEMBL4685028	Inhibition of full length human Akt2 S474D mutant using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177390	=	IC50	nM	32.0	CHEMBL2431	Homo sapiens	IC50	uM	0.032
	22470520	CHEMBL4685028	Inhibition of full length human Akt2 S474D mutant using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method	B	CC(C)NCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCC4)CC1)c1ccc(Br)cc1	Outside typical range	CHEMBL4787195	=	IC50	nM	136000.0	CHEMBL2431	Homo sapiens	IC50	uM	136.0
	22470521	CHEMBL4685028	Inhibition of full length human Akt2 S474D mutant using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method	B	O=C(C(CNC1CCCCC1)c1ccc(Cl)cc1)N1CCN(c2ncnc3sc4c(c23)CCC4)CC1	Outside typical range	CHEMBL4745768	=	IC50	nM	130000.0	CHEMBL2431	Homo sapiens	IC50	uM	130.0
	22470522	CHEMBL4685028	Inhibition of full length human Akt2 S474D mutant using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method	B	O=C(C(CNC1CCCC1)c1ccc(Cl)cc1)N1CCN(c2ncnc3sc4c(c23)CCC4)CC1		CHEMBL4757904	=	IC50	nM	1710.0	CHEMBL2431	Homo sapiens	IC50	uM	1.71
	22470523	CHEMBL4685028	Inhibition of full length human Akt2 S474D mutant using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method	B	CCCCNCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCC4)CC1)c1ccc(Cl)cc1		CHEMBL4781445	=	IC50	nM	3780.0	CHEMBL2431	Homo sapiens	IC50	uM	3.78
	22470524	CHEMBL4685028	Inhibition of full length human Akt2 S474D mutant using GRPRTSSFAEGKK as substrate incubated for 40 mins by scintillation counting method	B	CCNCC(C(=O)N1CCN(c2ncnc3sc4c(c23)CCC4)CC1)c1ccc(Cl)cc1		CHEMBL4793499	=	IC50	nM	3050.0	CHEMBL2431	Homo sapiens	IC50	uM	3.05
Not Determined	22752737	CHEMBL4700191	Inhibition of human AKT2 by kinase-profiling analysis	B	C#Cc1nc(Nc2ccc(S(N)(=O)=O)cc2)nc2[nH]cnc12		CHEMBL4074015		IC50			CHEMBL2431	Homo sapiens	IC50		
	22752738	CHEMBL4700191	Inhibition of human AKT2 by kinase-profiling analysis	B	C#Cc1nc(Nc2ccccc2)nc2[nH]cnc12		CHEMBL4094562	=	IC50	nM	55400.0	CHEMBL2431	Homo sapiens	IC50	uM	55.4
	22759635	CHEMBL4701763	Inhibition of human AKT2 at 1 uM using fluorescently labeled peptide substrate measured after 3 hrs by microfluidic mobility shift assay relative to control	B	CN(C)C(=O)c1ccc(Oc2nc(-c3cnc(N)s3)nc(N3CCOCC3)n2)cc1		CHEMBL4782133	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	22784729	CHEMBL4708151	Inhibition of Akt-2 (unknown origin)	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	IC50	nM	7.0	CHEMBL2431	Homo sapiens	IC50	nM	7.0
	22784749	CHEMBL4708163	Binding affinity to Akt2 (unknown origin)	B	COc1cc2cc(COCc3c(-c4ccc(F)cc4)nc(N(C)S(C)(=O)=O)nc3C(C)C)oc(=O)c2cc1OC		CHEMBL4759850	=	Activity	kcal/mol	-10.6	CHEMBL2431	Homo sapiens	Activity	kcal/mol	-10.6
	22784750	CHEMBL4708163	Binding affinity to Akt2 (unknown origin)	B	COc1cc2c(cc1OC)/C(=C/COCc1c(-c3ccc(F)cc3)nc(N(C)S(C)(=O)=O)nc1C(C)C)OC2=O		CHEMBL4756388	=	Activity	kcal/mol	-9.9	CHEMBL2431	Homo sapiens	Activity	kcal/mol	-9.9
	22784751	CHEMBL4708163	Binding affinity to Akt2 (unknown origin)	B	COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1		CHEMBL53463	=	Activity	kcal/mol	-8.6	CHEMBL2431	Homo sapiens	Activity	kcal/mol	-8.6
	22820552	CHEMBL4716278	Inhibition of recombinant N-terminal His6-tagged human PKBbeta S474D mutant (120 to 481 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	Activity	%	70.0	CHEMBL2431	Homo sapiens	Activity	%	70.0
	22820553	CHEMBL4716278	Inhibition of recombinant N-terminal His6-tagged human PKBbeta S474D mutant (120 to 481 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCNC2		CHEMBL4782674	=	Activity	%	102.0	CHEMBL2431	Homo sapiens	Activity	%	102.0
	22843850	CHEMBL4720836	Inhibition of human AKT2 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	21.5	CHEMBL2431	Homo sapiens	IC50	10^-8M	2.15
	22844326	CHEMBL4721189	Inhibition of human AKT2 assessed as residual activity using KGSGSGRPRTSSFAEG as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	91.42	CHEMBL2431	Homo sapiens	Activity	%	91.42
	22844612	CHEMBL4721287	Inhibition of wild-type human partial length AKT2 expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	97.08	CHEMBL2431	Homo sapiens	Activity	%	97.08
Not Active	22889483	CHEMBL4729002	Inhibition of wild-type human partial length AKT2 expressed in bacterial expression system at 1 uM by Kinomescan method	B	COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4748740		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	22909856	CHEMBL4734046	Inhibition of recombinant full length human His-tagged AKT2 using serine/threonine-06 peptide as substrate at 10 uM incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	c1ccc(CSc2ncnc3[nH]cnc23)cc1		CHEMBL397434		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	22909857	CHEMBL4734046	Inhibition of recombinant full length human His-tagged AKT2 using serine/threonine-06 peptide as substrate at 10 uM incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	Clc1cccc(CSc2ncnc3[nH]cnc23)c1		CHEMBL4754930		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	22909858	CHEMBL4734046	Inhibition of recombinant full length human His-tagged AKT2 using serine/threonine-06 peptide as substrate at 10 uM incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	Brc1ccccc1CSc1ncnc2[nH]cnc12		CHEMBL4776788		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
	22952955	CHEMBL4766892	Inhibition of recombinant human PKBbeta (120 to end residues) assessed as residual activity at 10 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	107.0	CHEMBL2431	Homo sapiens	Activity	%	107.0
	23120160	CHEMBL4804339	Inhibition of AKT2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	IC50	nM	19000.0	CHEMBL2431	Homo sapiens	IC50	uM	19.0
	23120161	CHEMBL4804339	Inhibition of AKT2 in human NCI-H929 cells by mass spectroscopic analysis	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	IC50	nM	14900.0	CHEMBL2431	Homo sapiens	IC50	uM	14.9
	23120162	CHEMBL4804339	Inhibition of AKT2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4859660	=	IC50	nM	-1300.0	CHEMBL2431	Homo sapiens	IC50	uM	-1.3
	23121205	CHEMBL4804521	Inhibition of AKT2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	23121206	CHEMBL4804521	Inhibition of AKT2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	23121207	CHEMBL4804521	Inhibition of AKT2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	Inhibition	%	0.0	CHEMBL2431	Homo sapiens	INH	%	0.0
	23122439	CHEMBL4804790	Inhibition of human AKT2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	100.0	CHEMBL2431	Homo sapiens	Activity	%	100.0
	23123134	CHEMBL4805378	Inhibition of human AKT2 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	89.0	CHEMBL2431	Homo sapiens	Activity	%	89.0
	23123751	CHEMBL4805995	Inhibition of DNA-tagged human AKT2 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	82.0	CHEMBL2431	Homo sapiens	Activity	%	82.0
	23124249	CHEMBL4806322	Inhibition of AKT2 (unknown origin) at 10 uM relative to control	B	Cn1cc(-n2cnc3c(NCc4nc5cc(Cl)c(Cl)cc5[nH]4)nc(N4CCOCC4)nc32)cn1		CHEMBL4877117	=	Inhibition	%	2.0	CHEMBL2431	Homo sapiens	INH	%	2.0
	23124358	CHEMBL4806395	Inhibition of human AKT2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	86.0	CHEMBL2431	Homo sapiens	Activity	%	86.0
	23124359	CHEMBL4806395	Inhibition of human AKT2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	99.0	CHEMBL2431	Homo sapiens	Activity	%	99.0
	23127804	CHEMBL4807743	Inhibition of AKT2 (107 to 481) (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	>	Activity	%	75.0	CHEMBL2431	Homo sapiens	Activity	%	75.0
	23127805	CHEMBL4807743	Inhibition of AKT2 (107 to 481) (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL2431	Homo sapiens	Activity	%	75.0
	23127806	CHEMBL4807743	Inhibition of AKT2 (107 to 481) (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL2431	Homo sapiens	Activity	%	75.0
	23158841	CHEMBL4812093	Inhibition of human N-terminal His-tagged full length AKT2 expressed in Sf9 cells at 10 uM preincubated for 10 mins followed by peptide substrate addition relative to control	B	CC(C)(C)OC(=O)c1ccc(NC(=O)c2ccc(Cl)c(S(N)(=O)=O)c2)cc1		CHEMBL4860361	=	Inhibition	%	3.38	CHEMBL2431	Homo sapiens	INH	%	3.38
	23246259	CHEMBL4830025	Inhibition of N-terminal GST-tagged human AKT2 (120 to 481 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	CNC(=O)C[C@@H]1C[C@@H](c2ccc(F)c(F)c2)[C@H](NC(=O)c2cc(-c3c(Cl)cnn3C)c(Cl)o2)CN1		CHEMBL4440965	=	IC50	nM	0.2	CHEMBL2431	Homo sapiens	IC50	nM	0.2
	23246260	CHEMBL4830025	Inhibition of N-terminal GST-tagged human AKT2 (120 to 481 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)cc1		CHEMBL4460756	=	IC50	nM	6.0	CHEMBL2431	Homo sapiens	IC50	nM	6.0
	23246261	CHEMBL4830025	Inhibition of N-terminal GST-tagged human AKT2 (120 to 481 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177390	=	IC50	nM	3.8	CHEMBL2431	Homo sapiens	IC50	nM	3.8
Not Determined	23246262	CHEMBL4830025	Inhibition of N-terminal GST-tagged human AKT2 (120 to 481 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cc(F)cc(F)c2)c(Cl)c1		CHEMBL4875495		IC50			CHEMBL2431	Homo sapiens	IC50		
	23246263	CHEMBL4830025	Inhibition of N-terminal GST-tagged human AKT2 (120 to 481 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cc(F)cc(F)c2)c(F)c1		CHEMBL4866810	=	IC50	nM	8.8	CHEMBL2431	Homo sapiens	IC50	nM	8.8
	23246264	CHEMBL4830025	Inhibition of N-terminal GST-tagged human AKT2 (120 to 481 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cc(F)cc(F)c2)cc1F		CHEMBL4874391	=	IC50	nM	7.1	CHEMBL2431	Homo sapiens	IC50	nM	7.1
Not Determined	23246265	CHEMBL4830025	Inhibition of N-terminal GST-tagged human AKT2 (120 to 481 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(Cl)c1		CHEMBL4858782		IC50			CHEMBL2431	Homo sapiens	IC50		
	23246266	CHEMBL4830025	Inhibition of N-terminal GST-tagged human AKT2 (120 to 481 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(F)c1		CHEMBL4556790	=	IC50	nM	97.5	CHEMBL2431	Homo sapiens	IC50	nM	97.5
Not Determined	23246267	CHEMBL4830025	Inhibition of N-terminal GST-tagged human AKT2 (120 to 481 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.O=C(N[C@@H]1CNCC[C@H]1c1ccc(F)c(F)c1)c1ccc(-c2ccn[nH]2)cc1F		CHEMBL4854839		IC50			CHEMBL2431	Homo sapiens	IC50		
Not Determined	23246268	CHEMBL4830025	Inhibition of N-terminal GST-tagged human AKT2 (120 to 481 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	CCn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(F)c1.Cl		CHEMBL4847466		IC50			CHEMBL2431	Homo sapiens	IC50		
	23250048	CHEMBL4830972	Inhibition of His-tagged full length human recombinant AKT2 expressed in baculovirus expression system at 1 uM by Z'-LYTE assay	B	COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccc(NCc3ccc(S(=O)(=O)F)cc3)cc2)n1		CHEMBL4866162	=	Inhibition	%	90.0	CHEMBL2431	Homo sapiens	INH	%	90.0
Not Active	23250049	CHEMBL4830972	Inhibition of His-tagged full length human recombinant AKT2 expressed in baculovirus expression system at 1 uM by Z'-LYTE assay	B	COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2cccc(NC(C)=O)c2)n1		CHEMBL4856343		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Active	23250102	CHEMBL4830999	Inhibition of His-tagged full length human recombinant AKT2 expressed in baculovirus expression system at 100 nM by Z'-LYTE assay	B	C#CCNC(=O)c1cc(Nc2cc(C3CC3)[nH]n2)nc(N2CCN(Cc3ccc(S(=O)(=O)F)cc3)CC2)n1		CHEMBL4855850		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	23250103	CHEMBL4830999	Inhibition of His-tagged full length human recombinant AKT2 expressed in baculovirus expression system at 100 nM by Z'-LYTE assay	B	COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccc(NCc3ccc(S(=O)(=O)F)cc3)cc2)n1		CHEMBL4866162		Inhibition	%		CHEMBL2431	Homo sapiens	INH		
Not Active	23317274	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	88.0	CHEMBL2431	Homo sapiens	% Control	%	88.0
Not Active	23317742	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	84.0	CHEMBL2431	Homo sapiens	% Control	%	84.0
Not Active	23318416	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	81.0	CHEMBL2431	Homo sapiens	% Control	%	81.0
Not Active	23318892	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	78.0	CHEMBL2431	Homo sapiens	% Control	%	78.0
Not Active	23319532	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23320004	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23320682	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23321150	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	98.0	CHEMBL2431	Homo sapiens	% Control	%	98.0
Not Active	23321780	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23322248	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23322937	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23323405	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	96.0	CHEMBL2431	Homo sapiens	% Control	%	96.0
Not Active	23324097	CHEMBL4880716	PKBbeta (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	-5.0	CHEMBL2431	Homo sapiens	% inhibition	%	-5.0
Not Active	23324259	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23324894	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	88.0	CHEMBL2431	Homo sapiens	% Control	%	88.0
Not Active	23325362	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23326009	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23326477	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23327177	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23327645	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23328232	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	98.0	CHEMBL2431	Homo sapiens	% Control	%	98.0
Not Active	23328700	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	98.0	CHEMBL2431	Homo sapiens	% Control	%	98.0
Not Active	23329478	CHEMBL4881185	PKBbeta (h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	109.0	CHEMBL2431	Homo sapiens	% residual kinase activity	%	109.0
Not Active	23329646	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23330114	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23330870	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	90.0	CHEMBL2431	Homo sapiens	% Control	%	90.0
Not Active	23331338	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	96.0	CHEMBL2431	Homo sapiens	% Control	%	96.0
Not Active	23331925	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	88.4	CHEMBL2431	Homo sapiens	% Control	%	88.4
Not Active	23332393	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	82.5	CHEMBL2431	Homo sapiens	% Control	%	82.5
Not Active	23333109	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23333748	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	72.0	CHEMBL2431	Homo sapiens	% Control	%	72.0
Not Active	23334216	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	90.0	CHEMBL2431	Homo sapiens	% Control	%	90.0
Not Active	23334934	CHEMBL4881556	PKBbeta (h) Upstate kinase activity assay	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		Inhibition	%	85.0	CHEMBL2431	Homo sapiens	% inhibition	%	85.0
Not Active	23335195	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	98.0	CHEMBL2431	Homo sapiens	% Control	%	98.0
Not Active	23335663	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23336290	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23336758	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	98.0	CHEMBL2431	Homo sapiens	% Control	%	98.0
Not Active	23337512	CHEMBL4881883	AKT2 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	98.0	CHEMBL2431	Homo sapiens	% Ctrl	%	98.0
Not Active	23337839	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	84.0	CHEMBL2431	Homo sapiens	% Control	%	84.0
Not Active	23338307	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23338919	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	94.0	CHEMBL2431	Homo sapiens	% Control	%	94.0
Not Active	23339387	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	93.0	CHEMBL2431	Homo sapiens	% Control	%	93.0
Not Active	23340024	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	92.0	CHEMBL2431	Homo sapiens	% Control	%	92.0
Not Active	23340492	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23341149	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	99.0	CHEMBL2431	Homo sapiens	% Control	%	99.0
Not Active	23341617	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	91.0	CHEMBL2431	Homo sapiens	% Control	%	91.0
Not Active	23342233	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	89.0	CHEMBL2431	Homo sapiens	% Control	%	89.0
Not Active	23342701	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	72.0	CHEMBL2431	Homo sapiens	% Control	%	72.0
Not Active	23343331	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23343799	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	96.0	CHEMBL2431	Homo sapiens	% Control	%	96.0
Not Active	23344437	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23345010	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	89.0	CHEMBL2431	Homo sapiens	% Control	%	89.0
Not Active	23345478	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	85.0	CHEMBL2431	Homo sapiens	% Control	%	85.0
Not Active	23346055	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23346524	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23347134	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23347615	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23348194	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23348662	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23349249	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	99.0	CHEMBL2431	Homo sapiens	% Control	%	99.0
Not Active	23349867	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	93.0	CHEMBL2431	Homo sapiens	% Control	%	93.0
Not Active	23350335	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	93.0	CHEMBL2431	Homo sapiens	% Control	%	93.0
Not Active	23350940	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	95.0	CHEMBL2431	Homo sapiens	% Control	%	95.0
Not Active	23351408	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	92.0	CHEMBL2431	Homo sapiens	% Control	%	92.0
Not Active	23351961	CHEMBL4882654	AKT2 (PKB beta) Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	5.529	CHEMBL2431	Homo sapiens	% Inhibition	%	5.5295
Not Active	23352432	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23352900	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	89.0	CHEMBL2431	Homo sapiens	% Control	%	89.0
Not Active	23353782	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	95.0	CHEMBL2431	Homo sapiens	% Control	%	95.0
Not Active	23354250	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23354982	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23355450	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23356086	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	84.0	CHEMBL2431	Homo sapiens	% Control	%	84.0
Not Active	23356554	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23357163	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	87.0	CHEMBL2431	Homo sapiens	% Control	%	87.0
Not Active	23357810	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	81.0	CHEMBL2431	Homo sapiens	% Control	%	81.0
Not Active	23358278	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23358864	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	93.3	CHEMBL2431	Homo sapiens	% Control	%	93.3
Not Active	23359462	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23359930	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	93.0	CHEMBL2431	Homo sapiens	% Control	%	93.0
Not Active	23360515	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23360983	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23361556	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	87.0	CHEMBL2431	Homo sapiens	% Control	%	87.0
Not Active	23362092	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23362560	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	81.0	CHEMBL2431	Homo sapiens	% Control	%	81.0
Not Active	23364202	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	80.0	CHEMBL2431	Homo sapiens	% Control	%	80.0
Not Active	23364670	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23365409	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23365952	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	67.0	CHEMBL2431	Homo sapiens	% Control	%	67.0
Not Active	23366542	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	96.0	CHEMBL2431	Homo sapiens	% Control	%	96.0
Not Active	23367010	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23367468	CHEMBL4883821	AKT2 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	121.0	CHEMBL2431	Homo sapiens	% Residual activity with Skepinone-L	%	121.0
Not Active	23367888	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23368356	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	96.0	CHEMBL2431	Homo sapiens	% Control	%	96.0
Not Active	23368955	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23369423	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	95.0	CHEMBL2431	Homo sapiens	% Control	%	95.0
Not Active	23370194	CHEMBL4884436	PKBbeta (h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	105.0	CHEMBL2431	Homo sapiens	% residual kinase activity	%	105.0
Not Active	23370391	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	95.0	CHEMBL2431	Homo sapiens	% Control	%	95.0
Not Active	23370859	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23371668	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	93.0	CHEMBL2431	Homo sapiens	% Control	%	93.0
Not Active	23372136	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
	23372657	CHEMBL4884622	Akt2 [PKBbeta(AKT2CGY1)] Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL2431	Homo sapiens	pIC50		6.0
	23373066	CHEMBL4884913	Akt2 [PKBbeta(AKT2CGY1)] Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL2431	Homo sapiens	pIC50		6.0
	23373427	CHEMBL4885204	Akt2 [PKBbeta(AKT2CGY1)] Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL2431	Homo sapiens	pIC50		6.0
Active	23374888	CHEMBL4885857	TR-FRET (AKT2, 10 uM ATP)	B	NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1		CHEMBL4751394		IC50	nM	18.0	CHEMBL2431	Homo sapiens	IC50	nM	18.0
Active	23374889	CHEMBL4885858	TR-FRET (AKT2, 2 mM ATP)	B	NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1		CHEMBL4751394		IC50	nM	36.0	CHEMBL2431	Homo sapiens	IC50	nM	36.0
Not Active	23374893	CHEMBL4885862	TR-FRET (delta PH domain AKT2)	B	NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1	Non standard unit for type	CHEMBL4751394	>	IC50	µM	20.0	CHEMBL2431	Homo sapiens	IC50	µM	20.0
Active	23374905	CHEMBL4885874	NanoBRET (AKT2)	B	NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1		CHEMBL4751394		IC50	nM	10.7	CHEMBL2431	Homo sapiens	IC50	nM	10.7
Not Active	23374907	CHEMBL4885874	NanoBRET (AKT2)	B	NC1(c2ccc(-c3nc4c(O)ccnn4c3-c3ccccc3)cc2)CCC1	Non standard unit for type	CHEMBL5016886		IC50	µM	10.4	CHEMBL2431	Homo sapiens	IC50	µM	10.4
Not Active	23374909	CHEMBL4885876	Biochemical assay (AKT2)	B	NC1(c2ccc(-c3nc4c(O)ccnn4c3-c3ccccc3)cc2)CCC1	Non standard unit for type	CHEMBL5016886		IC50	µM	3.84	CHEMBL2431	Homo sapiens	IC50	µM	3.84
Not Active	23374913	CHEMBL4885907	AKT2 Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	7.5	CHEMBL2431	Homo sapiens	% Inhibition	%	7.5
Not Active	23375406	CHEMBL4886388	v-akt murine thymoma viral oncogene homolog 2  Millipore kinase panel	B	COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1	Outside typical range	CHEMBL2180408		Inhibition	%	-15.0	CHEMBL2431	Homo sapiens	% inhibition	%	-15.0
Not Active	23375563	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	82.0	CHEMBL2431	Homo sapiens	% Control	%	82.0
Not Active	23376031	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	89.0	CHEMBL2431	Homo sapiens	% Control	%	89.0
Not Active	23376609	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23377078	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	92.0	CHEMBL2431	Homo sapiens	% Control	%	92.0
Not Active	23377936	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	80.0	CHEMBL2431	Homo sapiens	% Control	%	80.0
Not Active	23378404	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	99.0	CHEMBL2431	Homo sapiens	% Control	%	99.0
Not Active	23379571	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	73.0	CHEMBL2431	Homo sapiens	% Control	%	73.0
Not Active	23380039	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	84.0	CHEMBL2431	Homo sapiens	% Control	%	84.0
Not Active	23380733	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23381381	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23381849	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL2431	Homo sapiens	% Control	%	100.0
Not Active	23382473	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	77.0	CHEMBL2431	Homo sapiens	% Control	%	77.0
Not Active	23382941	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	82.0	CHEMBL2431	Homo sapiens	% Control	%	82.0
Not Active	23383696	CHEMBL4887349	AKT2 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	95.0	CHEMBL2431	Homo sapiens	% Ctrl	%	95.0
Not Active	23384060	CHEMBL4887658	PKB-BETA DUNDEE kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	98.1	CHEMBL2431	Homo sapiens	% Ctrl	%	98.1
Not Active	23384415	CHEMBL4888010	PKBbeta(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	3.52	CHEMBL2431	Homo sapiens	% inhibition	%	3.52
Not Active	23384628	CHEMBL4888154	AKT2 (PKB beta) SelectScreen Kinase panel (LifeTechnologies)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		Inhibition	%	96.0	CHEMBL2431	Homo sapiens	% Inhibition	%	96.0
Active	23384726	CHEMBL4888141	Homogeneous Time Resolved Fluorescence (HTRF) assay (AKT2)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		IC50	nM	59.0	CHEMBL2431	Homo sapiens	IC50	nM	59.0
Active	23384729	CHEMBL4888144	NanoBRET assay (AKT2)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		IC50	nM	68.0	CHEMBL2431	Homo sapiens	IC50	nM	68.0
Not Active	23384740	CHEMBL4888144	NanoBRET assay (AKT2)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5ccc6c(c5)NC(=O)CO6)cc4)CC3)c2c1	Non standard unit for type	CHEMBL4802051		IC50	µM	8.3	CHEMBL2431	Homo sapiens	IC50	µM	8.3
Not Active	23384856	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	99.0	CHEMBL2431	Homo sapiens	% Control	%	99.0
Not Active	23385323	CHEMBL4879580	KinomeScan assay: inhibition of AKT2	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	91.0	CHEMBL2431	Homo sapiens	% Control	%	91.0
